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Alkaptonuria (AKU) is a rare inherited inborn error of tyrosine metabolism, 
resulting from a defect in homogentisate 1,2-dioxygenase. The major 
metabolic consequence of this is the accumulation of homogentisic acid 
(HGA) in circulation, and significant excretion in urine. Dating as far back as 
1500 B.C. in the Egyptian mummy Harwa, HGA was shown to be central to 
the pathophysiology of AKU through its deposition in collagenous tissues in a 
process termed ochronosis. Clinical manifestations are typically observed 
from the third decade of life and significantly affect the quality of life. 
Treatment measures available to patients are typically supportive and 
palliative, and in the last decade a major focus has been on the disease 
modifying agent nitisinone. This has been shown to be highly efficacious in 
reducing HGA, and it is hoped this will reduce ochronosis. Its use however 
has its own impact on metabolism as it leads to marked hypertyrosinaemia, 
the consequences of which are poorly understood.  
 
Presented herein is a comprehensive evaluation of the impact of nitisinone 
treatment on the metabolome in AKU. Unique insights into the wider 
metabolic consequences of treatment are shown through the application of 
liquid chromatography and mass spectrometry based techniques for the 
analysis of (i) serum and urine from AKU patients and (ii) urine, plasma, 
cerebrospinal fluid (CSF) and brain tissue from AKU mice. Novel changes 
have been demonstrated in relation to tyrosine, tryptophan and purine 
metabolism, and original observations have been made in relation to the 
abundance of several metabolites that are associated with oxidative stress.  
 
Importantly the work presented also addresses uncertainty around the impact 
of hypertyrosinaemia on neurotransmitter metabolism through (i) the 
quantitative measurement of urinary monoamine neurotransmitter 
metabolites and their related amino acids in serum from AKU patients, and 
(ii) the qualitative assessment of monoamine neurotransmitters in CSF and 
brain tissue from AKU mice. Experiments confirm that hypertyrosinaemia 
does affect the peripheral metabolism of monoamine metabolites in patients 
xi 
and mice. Psychometric data collected from AKU patients suggest that 
hypertyrosinaemia does not lead to depression. Interesting the level of 
tyramine in brain tissue of AKU mice was shown to increase, whilst dopamine 
and serotonin levels were unchanged.  
 
The work presented provides a unique example of where studying 
metabolism can help understand the metabolic consequences of treating a 
disease. It is hoped that this work will provide a platform for future clinical 
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complications in alkaptonuria. J Inherit Metab Dis 39(2):203-21. 
3 
1.1 History of Alkaptonuria 
 
Alkaptonuria (AKU, OMIM 203500) is a rare inherited metabolic disorder of 
the tyrosine metabolic pathway, which is characterised by a marked increase 
in circulating and urinary homogentisic acid (HGA). Elevated urinary HGA is 
diagnostic of AKU and is central to its pathophysiology.  
 
There are several reports of this ancient disease in Egyptian mummies, 
including Harwa, which is currently housed in the Field Museum in Chicago 
and dates from 1500 B.C. (Stenn et al., 1977). Scribonius (1584) provided 
the earliest record of someone with AKU; a school boy that passed urine “as 
dark as ink”. Twenty-five years later Schenck (1609) reported a similar 
phenomenon in a Carmelite monk. Similar cases were reported over the next 
200 years. 
 
The name alkaptonuria was first introduced by Boedeker who analysed urine 
from a 44-year old man with lumbar spine pain and poor mobility (Boedeker, 
1859). He identified a substance that reduced alkaline copper solutions, but 
the patient did not have any symptoms of diabetes, and unlike glucose the 
urinary substance would not reduce alkaline bismuth. He also observed that 
when left to stand the urine darkened. He further described that this occurred 
from the surface of the solution downwards and that this darkening 
accelerated on addition of alkali substances and quickly took up a large 
volume of oxygen. He described this new substance “alkapton”. 
 
Virchow later provided the first description of pigmented tissues in AKU and 
coined the term ‘ochronosis’ because of how HGA pigment appeared to be 
‘ochre’ under microscopy (Virchow, 1866). Black pigmentation was observed 
in large weight-bearing joints including intervertebral discs, menisci, laryngeal 
and tracheal cartilage. The ligaments and synovial tissues displayed 
pigmentation to a lesser extent than cartilage. When the black pigmentation 
was observed macroscopically it appeared yellow. 
4 
The chemical structure of ‘alkapton’ was identified in 1891 and named HGA 






Figure 1.1. Chemical structures and associated pKa’s (denoted in blue) 
of (A) Gentisic acid and (B) Homogentisic acid. Information on chemical 
structures from: https://chemicalize.com. 
 
 
It was in 1902 that Albrecht made the connection between ochronosis of 
tissues, ochronotic arthritis and AKU. Later in 1904, Osler was the first 
person to publish evidence to document the diagnosis of AKU in living 
individuals. The sufferer in question displayed pigmentation of the ears and 
the sclera, the latter being termed ‘Osler’s sign’. 
  
At this time the disorder was described as the result of an alternative course 
of metabolism; harmless, usually congenital, and lifelong (Garrod, 2002). 
Most famously Garrod presented his work at the Croonian lectures in 1908, 
whereby he introduced the concept of ‘inborn errors of metabolism’ to 
demonstrate that albinism, AKU, cystinuria and pentosuria were all resultant 
of Mendelian inheritance, causing variation in metabolism of normal 
metabolites within normal pathways (Scriver, 2008). Fifty years later, 
homogentisate 1,2-dioxygenase (HGD, E.C.1.13.11.5), an enzyme involved 
in the metabolism of tyrosine was identified as the enzymatic defect 




Figure 1.2. Tyrosine metabolic pathway – highlighting the site of the 
enzyme defect observed in AKU. Adapted from Taylor et al. (2018). 
 
 
1.2 Genetic basis of AKU 
 
The HGD gene was first cloned and sequenced from Aspergillus nidulans 
(Fernández-Cañón et al., 1996). The gene maps to the human chromosome 
3q13.33 (Gene ID: 3081, http://www.ncbi.nlm.nih.gov/gene) and is a single-
copy gene spanning 54 363 bp of genomic sequence, with 14 exons coding 
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for a protein of 445 amino acids that assembles into a functional hexamer 
arranged as a dimer of trimers (Titus et al., 2000). Hepatocytes and renal 
proximal tubular cells are the major sites of HGD activity. AKU arises from 
homozygous or compound heterozygous mutations in the HGD gene. There 
have been 212 unique AKU mutations identified (HGD mutation database: 
http://hgddatabase.cvtisr.sk, accessed 07/01/2020) of which the most 
frequent are missense variants (67 %), followed by splicing (12.2 %) and 
frameshift (12.2 %). 
  
AKU mutations are distributed throughout the entire HGD gene with some 
prevalence in exons 3, 6, 7, 8 and 13 (Zatkova, 2011). Haplotype analysis 
has been used to trace the migration of specific AKU alleles through human 
history. The 3 most widespread AKU mutations in Europe, M368V, V300G, 
and P230S (20, 5, and 5 % of European AKU mutations, respectively) appear 
to be ancient mutations that were introduced into Europe with the founder 
populations (Zatkova, 2011). Some HGD mutations are found with 
widespread distribution, examples include S59fs, which was one of the first 
identified AKU mutations, V300G, as well as the most frequent European 
mutation M368V (Zatkova 2011). On the other hand, there are mutations 
rather unique to specific regions; for example c.87+1G>A 
(p.(Tyr6_Gln29del)) for the Narikuravar gypsy community in India (Sakthivel 
et al., 2014), A122V in Jordan (Nemethova et al., 2016) and C120W for the 
Dominican Republic (Goicoechea De Jorge et al., 2002). The largest number 
of AKU cases (>200) have been reported in Slovakia (Srsen et al., 2002), the 
majority clustering in a small region in the north west of the country. To date, 
there is no explanation for this massive increase in the incidence of AKU 
causing mutations in this region; it cannot be explained by a classical founder 
effect. In contrast, the high incidence of AKU in the Dominican Republic 
arose through a classical founder effect with C120W as the mutation 
(Goicoechea De Jorge et al., 2002). 
 
As yet, no relationship between specific mutations and clinical manifestations 
has been established (Ascher et al., 2019), although several AKU mutations 
have been identified, which have been shown to have residual catalytic 
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activity in functional assays. Interestingly, for 8 AKU patients no HGD 
mutations were identified, and in 22 cases only 1 mutant allele was found 
(Nemethova et al., 2016). 
 
Recently a large genomic deletion of exon 2 including intronic sequences 
was reported in 1 case from Lebanon (Zouheir Habbal et al., 2014) and has 
also been identified in 2 siblings from Israel (Nemethova et al., 2016). It is 
possible that, in addition to deep intronic mutations, large deletions 
encompassing 1 or more exons might be occurring in cases where genomic 
sequencing does not lead to mutation identification. 
 
 
1.3 Animal models 
 
In 1994, an AKU mouse model generated by n-ethyl-n-nitrosourea (ENU) 
mutagenesis was identified by Montagutelli et al. (1994) due to the presence 
of darkened cage bedding caused by elevated HGA in the urine. The AKU 
mutation was backcrossed onto the BALB/cByJ and C57BL/6J murine 
backgrounds. The murine HGD gene was cloned and the mutation identified 
to be a splice mutation that results in a truncated HGD protein (Manning et 
al., 1999). This mouse model harbours a recessive splice site mutation, 
c.1006+2T>A, in exon 10 of the HGD gene (GenBank NM_013547) located 
on mouse chromosome 16. This mutation leads to skipping of 1 or 2 exons 
and the generation of a premature stop codon. Initially it was reported that 
the AKU mouse model had the metabolic defects of AKU, but that the tissues 
did not demonstrate signs of ochronosis. Several theories were suggested 
including the short life span of the mouse (~2 years) and the endogenous 
production of ascorbic acid. However, it was subsequently demonstrated that 
this AKU model (BALB/c HGD-/-) had relatively stable elevated plasma HGA 
concentrations and extensive chondrocyte pigmentation, via a modified 
Schmorl’s stain (Taylor et al., 2012). This model showed that initial 
pigmentation early in life is pericellular, progressing linearly with age to the 
intracellular compartment. Treatment with a drug called nitisinone (Figure 
1.2) from birth, which inhibits hydroxyphenylpyruvate dioxygenase (HPPD, 
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EC 1.13.11.27) forming HGA (Figure 1.2), was shown to completely prevent 
chondrocyte pigmentation in mice (Preston et al., 2014; Keenan et al., 2015). 
 
This HGD-/- AKU mouse model has greatly contributed to our knowledge of 
AKU, in terms of both the disease pathology and treatment, however ENU 
mutagenesis is not a targeted approach to create a model of genetic disease. 
Due to the high frequency of DNA mutations that ENU causes there could 
potentially be other unknown and uncharacterised mutations in this 
mutagenesis model affecting the disease phenotype. To overcome this 
uncertainty, a new targeted mouse model of AKU has been raised in the 
C57BL/6 background using a mutant knockout-first allele obtained from the 
KOMP repository (www.komp.org). In addition to being targeted, the 
knockout-first model harbours a lacZ/lacZ transgene for localising gene 
expression and can be manipulated via FLP/FRT and Cre/LoxP 
recombination to obtain an inducible and tissue specific knockout. The 
conditional allele can be used to investigate the effect of partial HGD 
knockout on the AKU phenotype. With gene therapy becoming a likely tool in 
the future, this conditional mouse model provides an insight into the level and 
location of HGD expression that could rescue the AKU phenotype in humans. 
 
 
1.4 Clinical manifestations observed in patients 
 
Helliwell et al. (2008) demonstrated at autopsy the plethora of features 
observed in AKU confirming the true multisystem nature of the disease 
(Figure 1.3). There are few signs and symptoms in the young (Srsen et al., 
1982) with symptoms appearing around age 30 years and progressively 
increasing in severity with age, apart from dark urine which is present from 
birth (Cox et al., 2011; Ranganath et al., 2011; Ranganath et al., 2013). The 
various clinical features in AKU can be appreciated from the Alkaptonuria 
Severity Score Index (AKUSSI) (Table 1.1). This incorporates multiple, 
clinically meaningful outcomes that can be described in a single score, 
including kidney and prostate stones, aortic stenosis, bone fractures, 
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tendon/ligament/muscle ruptures, kyphosis, scoliosis, joint replacements and 





Figure 1.3. Clinical features frequently observed in AKU that should 
alert a clinician to its possible diagnosis. (A) Pigmentation of the sclera of 
the eye; (B) Extensive osteoarthritis of the large joints, this is an image of a 
knee joint at surgery showing pigmentation and fragmentation of the articular 














Feature Test Feature Test 
CLINICAL AKUSSI 
Eye ochronosis: 







Left eye nasal* 










Prostate stones:  




 (4 per episode) 
Ultrasound/ 
History 




Aortic sclerosis: (6), aortic stenosis: (mild, 




(8 per fracture) 
History 
Muscle rupture:                            




(8 per rupture) 
 
History 
Tendon rupture:  
(8 per rupture) 
 
History 
Joint pain score:  
(1 for each large joint area; 14 large joint areas) 
History 
Scintigraphic scan joint score:  
(2 for each large joint; 14 large joint areas) 
18F
PET-CT 
Number of arthroscopies: (2 each) History 
Number of joint replacements: (4 each) History 
SPINE AKUSSI 
Spinal pain score:  
(2 each for cervical, thoracic, lumbar, sacroiliac) 
History 
Scintigraphic scan spine score:  
(6 areas; 4 points for each area; pubic symphysis, 
costochondral, lumbar, thoracic, cervical, sacroiliac) 
18F
PET-CT 
Kyphosis: (4) X-ray 
Scoliosis: (4) X-ray 
ALL AKUSSI (CLINICAL + JOINT + SPINE) 
 
Table 1.1. Summary of Alkaptonuria Severity Score Index. The various 
clinical features observed in AKU are scored in the manner indicated above. 
Assessments include subjective pain scoring, photographs, history, 
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ultrasound abdomen, echocardiogram, computed tomography bone mineral 
densitometry (CT-BMD), x-ray spine and positron emission tomography–
computed tomography (18FPET-CT) scan. *Eye pigmentation: 1, 2 and 3 
points for slight, moderate and marked conjunctival pigmentation and 4, 6 
and 8 points for scleral pigmentation; **Ear pigmentation: 2 and 4 points for 
slight and marked pigmentation (Cox et al., 2011; Ranganath et al., 2011; 
Ranganath et al., 2013). 
 
 
1.5 Biochemical consequences 
 
AKU is a biochemical defect that arises in the tyrosine degradation pathway 
(Figure 1.2), whereby deficiency of HGD results in significantly elevated 
serum and urine HGA (La Du, 1958; Phornphutkul et al., 2002; Suwannarat 
et al., 2005; Introne et al., 2011; Ranganath et al., 2016; Milan et al., 2017; 
Sloboda et al., 2019). With advancements in analytical methodologies HGA 
has been quantified to be present in millimolar concentrations in urine from 
AKU patients (Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne et 
al., 2011; Ranganath et al., 2016; Milan et al., 2017; Sloboda et al., 2019), 
this is in contrast to healthy individuals where urinary HGA has been reported 
as <2.92 µmol/day (Davison et al., 2015). Circulating concentrations of HGA 
have been shown to be in micromolar quantities, an order of magnitude lower 
than excreted concentrations (Phornphutkul et al., 2002; Suwannarat et al., 
2005; Introne et al., 2011; Ranganath et al., 2016; Milan et al., 2017). Of 
note, although AKU is a defect in the tyrosine degradation pathway, serum 
and urine tyrosine are within normal reference range prior to administration of 
nitisinone (Phornphutkul et al., 2002; Introne et al., 2011; Ranganath et al., 







1.6 Management and treatment of AKU 
 
1.6.1 Current treatments available for AKU patients 
There is still no approved disease-modifying therapy in AKU. Gene and 
enzyme replacement therapies are still some way off and currently treatment 
remains supportive and palliative (Table 1.2). Low protein diet has been used 
with little effect (de Haas et al., 1998; Phornphutkul et al., 2002) and ascorbic 
acid used as an anti-oxidant to prevent the conversion of HGA to ochronotic 
pigment, has unproven efficacy (Phornphutkul et al., 2002). Lifestyle 
counselling and physiotherapy can be beneficial to patients, but are 
underutilised. 
  
Supportive analgesia and palliative arthroplasty are crucial to managing the 
severe musculoskeletal pain in AKU (Rynes et al., 1975; Phornphutkul et al., 
2002; Ranganath et al., 2013; Gil et al., 2016). Local anaesthetic patches 
such as lidocaine are also beneficial. Intermittent colchicine has also been 
used to control episodic pain (Rynes et al., 1975). Transcutaneous electrical 
nerve stimulation and acupuncture are widely used to control pain in patients 
attending the National AKU Centre (NAC). Neuromuscular blocks and trigger 
point injections can also provide long-term analgesia in AKU. Joint 
replacement is inevitable, and highly effective. Spinal decompression surgery 
is needed when spinal compression complicates AKU (Akeda et al., 2008; Gil 
et al., 2016; Donaldson et al., 2019). Aortic valve disease is highly prevalent 
and is almost universal by age 60 years in AKU (Pettit et al., 2011). Aortic 
valve surgery is better carried out electively before left ventricular 
decompensation ensues, but is technically challenging in ochronotic aortic 
tissue and sometimes fatal. Stone disease is also common in AKU due to 
increased HGA. To minimise the formation of renal stones and prevent renal 







Treatment modality Mechanism of action Nature 
Joint replacements Replacing damaged organ Palliative 
Acupuncture 




Relief from pain depending 
on drug 
Supportive 
Parenteral Analgesia Mainly opioid effect Supportive 
Physiotherapy 



















Low protein diet Reduction in tyrosine intake 




Table 1.2. Supportive and palliative treatment modalities available for 
AKU. Adapted from Davison et al. (2020). 
 
 
1.6.2 Disease modifying therapy through inhibition of HPPD 
Nitisinone (2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione, 
C14H10F3NO5, MW 329.2, Figure 1.4) is a reversible competitive inhibitor of 
HPPD (half-life ~52-54 h) in the tyrosine metabolic pathway (Figure 1.2) 
(Lock et al., 1998). Developed as an herbicide, nitisinone was found to be 
highly efficacious in hereditary tyrosinemia type 1 (HT1, OMIM 276700), and 
is now standard first-line therapy (Lindstedt et al., 1992; Lock et al., 1998; 
McKiernan, 2013). The mode of action of nitisinone led to the recognition that 
it could be effective in AKU. Decreasing circulating concentrations of HGA, 
through the inhibition of HPPD should in principle decrease ochronosis, thus 
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preventing the progression of disease in AKU. As nitisinone changes the 
main metabolic abnormality responsible for AKU, it should prevent or reduce 
its associated morbidity, if started before the symptomatic phase, and alter 
progression in those already symptomatic. There are several key studies 
which have looked at the key metabolites in the tyrosine pathway, both 





Figure 1.4. Chemical structure and associated pKa (denoted in blue) of 
nitisinone. Information on chemical structure from: https://chemicalize.com. 
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Trial design n 
Pre-nitisinone 
concentrations 













 39.3±15.5  
[HGA]
U
 2.4-73  
[Tyrosine]
S
 79±18  
0.35-1.4 mg 
twice daily 
9 and 10 
days 












et al., 2002 
Open-label, 
uncontrolled, proof of 
concept.  
Reduced protein 




 10.2±6.2  
[HGA]
U
 23.9±10.6  
[Tyrosine]
S
 68±18  
0.35-1.05 mg 
twice daily 
15 weeks  
(n=5) 









to ~97 % when 
protein restricted 
(<40 g/day)  





et al., 2005 
Randomised, parallel 








 33.8±11.8  
[Tyrosine]
S
 60±13  
No treatment, 2 
mg daily 
36 months 

















 14.4-69.5  
  
No treatment, 1, 
2, 4, 8 mg once 
daily 
4 weeks 
98.8 % reduction in 
[HGA]
U









et al., 2016 
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 30.0±12.9  
[HGA]
U





2 mg daily after 
3 months  
(2 mg given 
every other day 
up to 3 months) 
24 months 




at 3 months and 2 
years. 
83.2 % reduction in 
[HGA]
S
 at 2 years 
Serum nitisinone 
1.58±0.52 µmol/L 
at 2 years 
Milan  
et al., 2017 






0.2 mg daily.  
Over duration of 
study this varied 
as 1 patient was 
pregnant and 1 














et al., 2019 
 
Table 1.3. Summary of clinical studies that have evaluated nitisinone for the treatment of AKU. # - only 2/58 received 
nitisinone; LLOQ – lower limit of quantification; HPPA – 3-(4-hydroxyphenyl)pyruvic acid. [HGA]S – serum HGA concentration; 
[HGA]U – urinary HGA concentration; [Tyrosine]S – serum tyrosine concentration; [Tyrosine]U – urinary tyrosine concentration. All 
serum and urine HGA and tyrosine concentrations, except where ** displayed, are expressed in µmol/L and mmol/24 h, respectively 
and as mean ± SD where data were available, otherwise a range is quoted. ** – [HGA]U expressed as mmol/mol creatinine. 
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1.6.3 Clinical trials of nitisinone in the USA 
In the earliest study of AKU (Phornphutkul et al., 2002) 2 women were given 
nitisinone at a 30-fold lower dose than that used in HT1 (McKiernan, 2013). 
Urine and plasma HGA, and serum tyrosine concentrations were measured 
in all patients pre- and post-treatment. Within this study, there were also 10 
patients on ascorbic acid with doses ranging from 0.25-4 g/day 
(recommended daily dose is 0.065-0.09 g/day, with an upper limit of 2 g). 
Notable in this study was that there was no correlation between urine HGA 
excretion and the genetic mutation (Phornphutkul et al., 2002). High dose 
ascorbic acid treatment has not been proven efficacious (Sealock et al., 
1940; Wolff et al., 1989; Phornphutkul et al., 2002). The mean urinary HGA in 
those on high dose ascorbic acid was not significantly different from the 
untreated AKU patients. In addition, those on a low protein diet also showed 
no difference in urinary HGA excretion. 
 
Another open-label study at the National Institute for Health (USA) which, 
employed nitisinone (2.1 mg daily), demonstrated a 95 % decrease in urinary 
HGA excretion in 9 AKU adult patients over a 4 month period (Suwannarat et 
al., 2005). This study also confirmed that a strict protein restriction (1 week 
only) produced an additional decrease in urine HGA concentrations (Table 
1.3). Various definitions of protein restriction led to some of the ambiguity in 
effects with the recommended daily allowance (RDA) defined as 0.8 g 
protein/kg of body weight; approximately 56 or 46 g/day for the average 
sedentary male or female, respectively. Where a reduction in urinary HGA 
has been quantitated, protein has been restricted to <40 g/day and as low as 
20 g/day (Suwannarat et al., 2005), which is not sustainable long-term and 
would lead to detrimental effects on muscle strength, a side-effect which 
would worsen these patients’ symptoms. 
  
In a third study, a 3-year single-blind clinical trial of 20 patients, the nitisinone 
group (2 mg/day) showed a sustained decrease in mean urinary HGA from 
30.3 to 0.74 mmol/day (Introne et al., 2011). Mean plasma HGA 
concentrations fell from 34.1 to 1.82 µmol/L after treatment. Urine and 
plasma HGA decreased by 98 and 95 %, respectively, but despite this the 
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study was reported as inconclusive as the clinical primary and secondary 
outcome measures failed to show benefit from the treatment. 
  
1.6.4 Clinical trials of nitisinone in the UK and Europe 
The impetus for continued clinical development of nitisinone use in AKU 
came from Liverpool in the UK. A 2-pronged strategy was adopted: (1) 
licencing of nitisinone for AKU through clinical trials and (2) use of nitisinone 
off-label to determine its efficacy and safety in AKU. The first clinical trial was 
a dose-ranging study (part of a programme called DevelopAKUre, funded by 
the European Commission as part of the Framework Programme 7) called 
SONIA-1 (Suitability Of Nitisinone In Alkaptonuria-1) and concluded that 
nitisinone 8 mg was the dose that decreased urine HGA most efficaciously 
(Ranganath et al., 2016). Nitisinone (10 mg capsule once daily) was then 
trialled in SONIA-2 (Suitability Of Nitisinone In Alkaptonuria-2, 
ClinicalTrials.gov Identifier: NCT01916382); this 4-year outcome study was 
completed in 2019 where the clinical phase data has led to an application 
being prepared for submission to the European Medicines Agency in 
February 2020 to approve the use of nitisinone in AKU. 
 
1.6.5 Off-label use of nitisinone 
In 2012, NHS England Highly Specialised Services designated Liverpool as 
the NAC, and approved the use of a 2 mg daily dose of nitisinone. This off-
label use of nitisinone in AKU is supported by a multidisciplinary team of 
healthcare professionals to ensure the efficacy and safety of nitisinone is 
monitored. The NAC service is ‘protocolised’ to allow collection of high-
quality data on the use of nitisinone as required by NHS England. The 3-year 
data on the use of nitisinone in the NAC shows partial reversal of ochronosis 
and slower progression of the disease (Ranganath et al., 2018; Griffin et al., 
2018). This is the first time that the disease process and clinical outcomes in 
AKU have been beneficially modified by any therapy. 
 
Recently Sloboda et al. (2019) reported the off-licence use of nitisinone over 
3-5 years in 3 patients aged between 3-28 years old. Interestingly these 
patients were given a very low dose of nitisinone, 0.2 mg/day in an attempt to 
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reduce HGA and limit hypertyrosinaemia. Remarkably in these patients 
urinary HGA was reduced by >90 %, and mean serum tyrosine 
concentrations ranged from 305-416 µmol/L. While these patients were not 
part of a clinical trial or indeed attending a specialist centre like the NAC in 
the UK, they had strict monitoring of their protein intake (0.5 g/kg/day – 
patient 1; 1.1 g/kg/day – patient 2 (pregnant during period reported) and 1.6-
2.5 g/kg/day – patient 3 (child)). Unique to this report is treatment through 
pregnancy and during childhood.  
 
1.6.6 Nitisinone-induced hypertyrosinaemia  
1.6.6.1 Magnitude of hypertyrosinaemia 
The universal metabolic complication of nitisinone therapy is 
hypertyrosinaemia; reported in both AKU (Phornphutkul et al., 2002; 
Suwannarat et al., 2005; Introne et al., 2011; Ranganath et al., 2016; Milan et 
al., 2017; Davison et al., 2018a; Sloboda et al., 2019) and HT1 (Lindstedt et 
al., 1992; van Ginkel et al., 2016; Zeybek et al., 2017). The dose of nitisinone 
used in AKU trials is significantly lower compared with that used in HT1; 
mg/day compared with 1-2 mg/kg body weight in HT1; however the increase 
in tyrosine is comparable (Table 1.3). 
 
Introne et al. (2011) demonstrated that the average serum tyrosine was 
approximately 800 µmol/L with the highest measured being 1500 µmol/L on a 
2 mg daily dose (no dietary restriction). Ranganath et al. (2016) added to this 
with SONIA-1 trial whereby a short-term study examined the effects of 
varying nitisinone doses (1-8 mg daily) on the metabolic profile. A dose-
dependent decrease in urine HGA excretion was measured with a 98.8 % 
reduction at 8 mg/day. This dose dependence was not reflected in serum 
tyrosine concentrations; although a 10-fold increase was observed. This 
supports the findings of Introne et al. (2011), with all patients having serum 
tyrosine >500 µmol/L and the highest 1117 µmol/L (on 4 mg daily dose). 
Data from the NAC corroborates findings from previous studies; with the 
longitudinal monitoring of tyrosine metabolites, whilst treated with a 2 mg 
daily dose of nitisinone, showing a 94 % reduction in urine HGA maintained 
at 2 years with a concurrent reduction in serum HGA (83.2 %) (Milan et al., 
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2017). Mean serum tyrosine at 2 years was 594 µmol/L with a large variation 
reflecting the dietary protein contribution. In contrast Sloboda et al. (2019) 
demonstrated mean serum tyrosine concentrations between 305-416 µmol/L 
on a 0.2 mg daily dose of nitisinone with a mean reduction of HGA >90 %. 
This report demonstrates that tyrosine can be kept under 500 µmol/L, on 
nitisinone therapy; however this was in a small number of patients, one of 
which was on protein restriction. Furthermore, urinary HGA levels remained 
relatively elevated compared to previous studies which, is a big limitation in 
this study. 
 
1.6.6.2 Hypertyrosinaemia and neurotransmitter metabolism 
Tyrosine has several metabolic fates beyond that of being metabolised in  
the tyrosine metabolic pathway (Figure 1.2) depicted in Figure 1.5. 
It is a precursor for the biosynthesis of catecholamine neurotransmitters, 




Figure 1.5. The metabolic fate of tyrosine in catecholamine biosynthesis and its potential association with tryptophan 
metabolism in the presence of hypertyrosinaemia. The major neurotransmitters are in red (serotonin and dopamine). PAH – 
phenylalanine hydroxylase; TyH – tyrosine hydroxylase; COMT – catechol-O-methyltransferase; MAO – monoamine oxidase; PNMT 
– phenylethanolamine-N-methyltransferase; DBH – dopamine-β-hydroxylase; TPH – tryptophan hydroxylase; AADC – aromatic L-
amino acid decarboxylase; AFAH – aryl-formylamine amidohydrolase; ALDH – aldehyde dehydrogenase; KAT – kynurenine 
aminotransferase; KH – kynurenine hydroxylase; TDO – tryptophan dioxygenase; IDO – indole dioxygenase; KN – kynureninase; 
NMT – N-methyltransferase; L-DOPA – L-3,4-dihydroxyphenylalanine;--- - indicates rate limiting steps in tyrosine and tryptophan 
metabolism.
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Much of the interest in hypertyrosinaemia comes from studying HT1 and has 
centred around the direct impact it may have on catecholamine metabolism, 
specifically dopamine (DP), and the indirect impact it may have on serotonin 
metabolism (Figure 1.5), respectively. The reason for this interest is that both 
DP and serotonin play a pivotal role in cognitive function and mood.  
 
In HT1 treatment with nitisinone is commenced from an early age despite the 
potential risk of cognitive impairment because it has dramatically improved 
survival rates (Thimm et al., 2012; Pohorecka et al., 2012; Bendadi et al., 
2014). Typically serum tyrosine concentrations are regularly monitored and 
as a guide the aim should be to keep tyrosine concentrations between 200-
400 μmol/L up to the age of about 12 years. This is not easy to achieve and 
some centres allow plasma tyrosine concentrations up to 500 μmol/L (de 
Laet et al., 2013). There are several mechanisms proposed for the altered 
cognition observed in HT1, these include: increased transport of tyrosine into 
the brain; decreased transport of other amino acids into the brain (specifically 
tryptophan); increased central nervous system (CNS) DP; decreased CNS 
serotonin, oxidative damage from δ-aminolevulinic acid and succinylacetone 
or modification of neuronal proteins (Thimm et al., 2011; Hillgartner et al., 
2016). It has also been suggested that altered serotonin metabolism may be 
due to direct inhibition of tryptophan hydroxylase (TPH; EC 1.14.16.4) activity 
by tyrosine (Figure 1.5) (Thimm et al., 2011; Hillgartner et al., 2016). Barone 
et al. (2019) demonstrated that human tyrosine hydroxylase isoform 1 and 
human tryptophan hydroxylase 2, expressed in Escherichia coli (BL21), 
exhibited prominent substrate inhibition kinetics and that enzyme activity 
decreased at elevated tyrosine levels. This supports the earlier hypothesis, 
but in this study no downstream metabolites were measured (i.e. dopamine 
or serotonin). There is no direct evidence of altered cognition or 
neurotransmitter metabolism in AKU patients with hypertyrosinaemia. 
 
In a recent study in patients with phenylketonuria (PKU) cerebrospinal fluid 
(CSF) concentrations of 5-hydroxyindole acetic acid (5-HIAA) and 5-
hydroxytryptophan (5-HTP) were shown to be significantly lower compared to 
non-PKU controls. Moreover, significant negative correlations were observed 
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between CSF 5-HIAA, homovanillic acid (HVA), 5-HTP and phenylalanine 
(Pilotto et al., 2019). Lower 5-HIAA and 5-HTP concentrations were also 
correlated with precuneus and frontal atrophy, and lower HVA concentrations 
with occipital atrophy, respectively. This study provides further support to the 
supposition that an excess of large neural aromatic amino acids like 
phenylalanine can impair the transport of other large aromatic amino acids 
(i.e. tryptophan and tyrosine) into the CNS leading to low neurotransmitter 
concentrations. This study is unique in that metabolites were measured in 
CSF, thus providing a true reflection of neurotransmitter concentration in the 
CNS. For this reason, both CSF and brain tissue are ideal for the 
assessment of neurotransmitter concentrations (Rajkowska et al., 2013; 
Paterson et al., 2014). However the collection of CSF via lumbar puncture 
and brain tissue via biopsy are impractical, and so alternative sample types 
have been used to assess neurotransmitter concentrations with some degree 
of success, including plasma (Pan et al., 2018) and urine (Roy et al., 1986a; 
Roy et al., 1986b; Grossman et al., 1999; Hughes et al., 2004). For example, 
Pan et al. (2018) conducted a study into patients with major depressive 
disorders and assessed a panel of 19 neurotransmitter metabolites in plasma 
using mass spectrometry based techniques, and showed nine were 
significantly changed in the major depressive subjects compared to controls. 
These metabolites were involved in GABAergic, catecholaminergic and 
serotonergic systems.  
 
As AKU is a rare disease there has been very little reported on the 
assessment of neurotransmitters or their respective metabolites in the 
context of depression and altered cognitive function until recently where a 
short-term study demonstrated increased urinary excretion of the DP 
metabolite, 3-methoxytyramine (3-MT) and decreased urinary 
normetadrenaline (NMA) over a 4 week period (Davison et al., 2018b). The 
increased urinary 3-MT was confirmed in patients attending the NAC over a 2 
year period with concentrations increasing 2-fold of the normal reference 
range (Davison et al., 2018c). The marked increase in 3-MT excretion 
suggests nitisinone alters peripheral metabolism of catecholamines, more 
specifically DP. Metabolism of catecholamine neurotransmitters is complex 
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due to the multiple origins and notably urine concentrations will reflect 
circulating concentrations, renal uptake and renal synthesis (Eisenhofer et 
al., 1996). Of interest in this larger cohort there was no concurrent change in 
Beck’s depression inventory-II (BDI-II) scores associated with these patients 
supporting the renal synthesis hypothesis (Davison et al., 2018c). 
Fascinatingly, the previous change in NMA was not seen over this longer 
time period; with the increased patient numbers and monitoring of patients 
over 2 years the NAC data is likely to reflect changes in those on long term 
therapy. Reassuringly a study using mass spectrometry imaging 
demonstrated that monoamine neurotransmitter patterns in brain tissue from 
a murine model of AKU did not change following short term treatment with 
nitisinone (Davison et al., 2019a). 
 
1.6.6.3 Reported clinical manifestations of hypertyrosinaemia 
Despite careful use of nitisinone, tyrosine ocular keratopathy, as well as skin 
rash are observed in approximately 5 % of patients treated with the 2 mg 
dose (Introne et al., 2011; Stewart et al., 2014; Ranganath et al., 2016; Khedr 
et al., 2018; White et al., 2018). With circulating tyrosine concentrations >800 
µmol/L, the solubility of tyrosine is exceeded, and corresponds to ocular 
tyrosine concentrations of 3500 µmol/L (Lock et al., 2006), the point at which 
tyrosine crystallises in the cornea leading to corneal keratopathy; similar 
critical tyrosine thresholds for cutaneous and brain effects have not been 
described. Published cases have demonstrated that eye symptoms resolve 
upon cessation of nitisinone and either a lower dose and or protein restriction 
enables the patient to re-start nitisinone. In HT1, studies have also 
demonstrated ocular keratopathy (~9 %) in patients on nitisinone treatment 
(Holme et al., 1998; Gissen et al., 2003). 
 
1.6.7 Rationale for treatment of hypertyrosinaemia 
Limiting phenylalanine and tyrosine amino acid intake should mitigate 
hypertyrosinaemia. The minimum dietary recommendations for optimal health 
are phenylalanine and tyrosine intakes of 15 mg/kg/day, with an optimal 
dietary ratio of phenylalanine and tyrosine in mass units of 60:40, similar to 
the phenylalanine to tyrosine ratio seen in human tissue (Pencharz et al., 
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2007). The effectiveness of dietary restriction of both tyrosine and 
phenylalanine has been demonstrated in a murine model of AKU (plasma 
tyrosine <400 µmol/L after 3 days of restriction) and in patients attending the 
NAC (4 out of 10 patients had serum tyrosine <700 µmol/L following 
restriction) (Hughes et al., 2020). 
 
Tackling hypertyrosinaemia by switching to elemental amino acid 
administration free of phenylalanine and tyrosine is impractical. Instead, the 
emphasis is on decreasing dietary protein intake to manage 
hypertyrosinaemia. It is necessary to ensure the reference nutrient intake 
(RNI) for protein intake is met, the RNI for protein is 0.75 g/kg of body weight 
in the UK (COMA, 1991) and the RDA for protein is 0.8 g/kg of body weight in 
the USA (FNB, 2005; WHO, 2007). Meeting these targets for protein should 
ensure that the requirement for limiting amino acids such as lysine, 
methionine, threonine and tryptophan are met; such an approach will 
guarantee adequate provision of other amino acids including phenylalanine 
and tyrosine. 
 
There is a lack of guidance in the management of hypertyrosinaemia in 
adults, although there is some guidance in children with HT1 (Pencharz et 
al., 2007; de Laet et al., 2013). The goal in these children is to maintain 
serum tyrosine between 200-400 µmol/L and to avoid levels >500 µmol/L (de 
Laet et al., 2013). Such stringent goals are difficult to achieve in adults with 
AKU as they have been used to consuming a relatively normal protein intake. 
At the NAC a pragmatic algorithm-based approach is employed, consistent 
with existing knowledge and recommendations, where the goal is to maintain 
circulating tyrosine as low as possible <900 µmol/L. Values of circulating 
tyrosine of <500 µmol/L are considered desirable and protein intake of 1 g/kg 
is considered acceptable. Action thresholds for tyrosine have been devised 
between 500 and 700, and between 700 and 900 µmol/L, invoking lower 
protein intakes of 0.9 and 0.8 g/kg body weight, respectively (Ranganath et 
al., 2016; Ranganath et al., 2018), while meeting minimum daily 
requirements. Concentrations >900 µmol/L require in addition 
phenylalanine/tyrosine-free meal exchanges. 
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1.7 Depression and Beck’s depression inventory-II 
 
In 2015, the World Health Organization (WHO) reported that 4.4 % of the 
global population were living with depression (WHO, 2017). Individuals with 
chronic disease are more likely to experience depressive symptoms (Katon, 
2002) and it is well documented in patients with cancer, stroke, heart 
disease, diabetes, and respiratory disease compared to the general 
population (Clarke et al., 2009). AKU is a chronic painful debilitating disease 
making patients more susceptible to depression. Additionally, as alluded to 
earlier (section 1.6.6.2) there are unsubstantiated concerns about whether 
nitisinone induced hypertyrosinaemia may lead to altered mood or 
depression. As a consequence, patients attending the NAC that receive a  
2 mg daily dose of nitisinone undergo annual assessments through the 
Department of Psychology at The University of Liverpool. Assessments 
include the self-reporting BDI-II questionnaire (Beck et al., 1961; Beck et al., 
1996). Whilst this is not a formal assessment of depression like Hamilton 
Depression Rating Scale or Montgomery-Asberg Depression Rating Scale, it 
is a widely accepted tool in clinical practice that is cost effective and provides 
a reasonable quantifiable standard to be compared against (Solomon et al., 
2015). It must however be borne in mind that this approach is very subjective 
in nature as it requires a patient to critically and honestly assess their own 
behaviour. The BDI-II (Beck et al., 1961; Beck et al., 1996) questionnaire 
consists of 21 questions where each has 4 alternative statements ranked in 
order of severity from 0-3. The questionnaire evaluates a number of emotions 
including: mood, pessimism, sense of failure, self-dissatisfaction, guilt, 
punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, 
social withdrawal, insomnia, and loss of appetite. Conventional total score 
cut-offs are: 0–13 for minimal depression, 14–19 for mild depression, 20–28 
for moderate depression and 29–63 for severe depression, with a maximum 
score of 63. This approach allows the assessment of the severity and 
directionality of symptoms, and meets the Diagnostic and Statistical Manual 
of Mental Disorders DSM-IV criteria (American Psychiatric Association, 
1994). 
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1.8 Acute metabolic complications associated with AKU 
 
Much of the literature on AKU focuses on the chronic metabolic 
consequences of the disease, and its response to treatment with nitisinone. It 
is however clear that the metabolic burden of AKU can manifest acutely. 
There are 11 cases in the literature reporting the acute fatal metabolic 
complications that can occur in AKU (Table 1.4). These include 5 patients 
that had oxidative haemolysis and methaemoglobinaemia (Abero et al., 1983; 
Suehiro et al., 2007; Isa et al., 2014; Mullan et al., 2015; Freeman et al., 
2018); 4 patients with methaemoglobinaemia only (Liu et al., 2001; Uchiyama 
et al., 2010; Miyasaka et al., 2013; Hugar et al., 2019) and 2 patients with 
oxidative haemolysis (Heng et al., 2010; Bataille et al., 2014). In all cases the 
outcome was death. 
  
Common to all of these cases is that all patients had acute kidney injury 
(AKI), in some cases this was a new presentation and in others it occurred on 
a background of chronic kidney disease (CKD). Six of 11 patients also 
presented with sepsis (Liu et al., 2001; Suehiro et al., 2007; Uchiyama et al., 
2010; Miyasaka et al., 2013; Mullan et al., 2015; Hugar et al., 2019). As 
previously mentioned the kidney plays a critical role in the elimination of HGA 
from the body, and thus it is reasonable to expect significant increases in the 
circulating concentration of HGA when kidney function is impaired. In all 11 
cases reported HGA was not measured, but is presumed to have been 
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Table 1.4. Cases of the acute haematological complications observed in patients with AKU reported in the literature. CKD – 
chronic kidney disease; AKI – acute kidney injury; COAD – chronic obstructive airways disease; MetHb – methaemoglobin; ESRF – 
end stage renal failure. Methaemoglobin reference range <1.5 %. 
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Introne et al. (2002) reported on a patient with AKU and CKD, where an 
increased plasma concentration of HGA was observed along with worsening 
clinically apparent ochronosis. Three months post renal transplantation the 
concentration of HGA was decreased from 126.3 to 43.7 µmol/L 
demonstrating the importance of kidney function in the elimination of HGA. 
  
Interestingly, no acute oxidative haemolysis or methaemoglobinaemia was 
reported despite the very high concentrations of plasma HGA. This is in 
keeping with others where CKD has been reported in AKU and no fatal 
metabolic complications have been observed (Venkataseshan et al., 1992; 
Kazancioglu et al., 2004; Faria et al., 2012). This suggests that an elevated 
concentration of HGA alone is not responsible for the fatal metabolic 
complications that have been observed in other reported cases (Abero et al., 
1983; Liu et al., 2001; Suehiro et al., 2007; Heng et al., 2010; Uchiyama et 
al., 2010; Miyasaka et al., 2013; Bataille et al., 2014; Isa et al., 2014; Mullan 
et al., 2015; Freeman et al., 2018; Hugar et al., 2019). It is hypothesised that 
multiple ‘insults’ to anti-oxidant defence mechanisms have a cumulative 
effect and are responsible for the reported haematological complications. 
 
In all published cases where fatal metabolic complications were observed 
treatments utilised were unsuccessful (Table 1.4). The reasons for this are 
not entirely clear. Treatments were based around renal replacement therapy 
(haemodialysis and haemofiltration), blood transfusion, and anti-oxidant 
therapies including; vitamin C, N-acetyl cysteine (NACys) and methylene 
blue. Some of these therapies can act as pro-oxidant molecules, thus 








1.9 Pathophysiology of acute haematological complications     
observed in AKU 
 
1.9.1 Mechanisms maintaining the pro- and anti-oxidant balance 
Oxidative stress is an imbalance between the pro-oxidant reactions and anti-
oxidant defence mechanisms, which favours the former. Under healthy 
physiological conditions, pro-oxidant reactions do not predominate as red 
blood cells (RBCs) have greater than 250 times more reducing capacity than 
oxidizing potential (Burak et al., 2008). Some of the consequences of a pro-
oxidant environment include damage to DNA, membrane ion transport 
systems, enzymes, proteins, and lipid peroxidation (Al-Omar et al., 2004; 
Masella et al., 2005). 
 
Oxidative stress can lead to the generation of free radicals. These are 
chemical entities that possess an unpaired electron and are formed from a 1 
or 2 electron reduction of oxygen. Reactive oxygen species (ROS) include 
the non-radical hydrogen peroxide and singlet oxygen, as well as the 
radicals: superoxide anion, hydroxyl radical and nitric oxide (Burak et al., 
2008) (Figure 1.6). 
  
Enzymatic systems, principally found within RBCs, act as defence 
mechanisms against oxidative stress (Figures 1.6 and 1.7). Key enzymes 
include: glutathione peroxidase, glutathione reductase, catalase, cytochrome 
b5 reductase, superoxide dismutase, glucose-6-phosphate dehydrogenase 
(G6PD) and thioredoxin reductase. Non-enzymatic factors that contribute to 
maintaining the redox state of the body include: (a) vitamins A and E, 
ubiquinone and melatonin, all of which are lipophilic, and (b) vitamin C, 
glutathione, uric acid, caeruloplasmin, transferrin and haptoglobin all of which 




Figure 1.6. Exogenous and endogenous factors influencing the 
oxidation of haemoglobin. This includes the potential role of HGA and 
‘soluble melanins’ and the biological mechanisms responsible for the 
reduction of methaemoglobin. ROS – reactive oxygen species; H2O2 – 
hydrogen peroxide; O2 – singlet oxygen; O2
.- – superoxide anion; HO. – 
hydroxyl radical; NO – nitric oxide; PPP – pentose phosphate pathway; 
NADH – nicotinamide adenine dinucleotide; NADPH – nicotinamide adenine 
dinucleotide phosphate; G6PD – glucose-6-phosphate dehydrogenase; FAD+ 





Figure 1.7. Enzymatic systems in the red blood cell responsible for 
maintaining the redox state of the body. The pathways detailed 
demonstrate the role of the glutathione, thioredoxin and superoxide 
dismutase in reducing oxidative species generated in the red blood cell. H2O2 
– hydrogen peroxide; O2 – singlet oxygen; O2
.- – superoxide anion; HO. – 
hydroxyl radical; NO – nitric oxide; PPP– pentose phosphate pathway; NADH 
– nicotinamide adenine dinucleotide; NADPH – nicotinamide adenine 
dinucleotide phosphate; G6PD – glucose-6-phosphate dehydrogenase. Red 
flat ended arrows indicate an inhibitory action. 
 
 
1.9.2 Disturbance of the pro- and anti-oxidant balance in AKU 
Circulating HGA is present at very high concentrations in individuals with 
AKU (Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne et al., 2011; 
Ranganath et al., 2016; Milan et al., 2017; Sloboda et al., 2019). 
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HGA undergoes auto-oxidation to form benzoquinone acetic acid polymers, 
also referred to as ‘soluble melanins’ (Hegedus et al., 1994). The latter are 
purported to have pro-oxidant properties. It is proposed that the oxidative 
stress associated with these melanins and their associated metabolites/free 
radicals (i.e. of oxygen radicals such as superoxide anion, hydroxyl radical, 
and hydrogen peroxide) are a potential ‘trigger’ for oxidative haemolysis. 
Adding vitamin C and glutathione to cultured cells has been shown to reverse 
oxidative haemolysis (Hegedus et al., 1994). 
 
Increasing evidence to support HGA induced oxidative stress has been 
reported in vitro in serum (Braconi et al., 2011) and cellular models (Braconi 
et al., 2010), and in patients with AKU (Millucci et al., 2014). Recently a study 
involving 21 patients with AKU showed that in addition to elevated HGA, 
urinary total antioxidant capacity and markers of lipid peroxidation (oxidative 
degradation products of thiobarbituric acid-reactive substances) were 
significantly elevated compared to controls supporting that increased 
oxidative stress is observed in AKU. Furthermore, this study reinforced the 
complexity of oxidative mechanisms occurring in AKU (Albatayneh et al., 
2019). 
 
CKD has been shown to reduce the anti-oxidant capacity of the body 
(Olszewska, 2004; Stepniewska et al., 2005; Stepniewska et al., 2006). 
However, when kidney function is stable in CKD, acute complications are not 
frequently observed. Rapid decline of renal function resulting from an acute 
insult to the body, for example due to an infection or drug toxicity, can lead to 
AKI (Table 1.4). It is thought that this may predispose an individual to acute 
oxidative haemolysis. 
 
When AKI occurs in AKU it is proposed that there is a significant retention of 
HGA, owing to the reduced excretory capacity of the kidney. This in turn may 
mean that more HGA is oxidised to ‘soluble melanins’, and an excess of ROS 
are generated. Together these exceed the anti-oxidant capacity of the body 
by consuming the substrates required for the anti-oxidant defence 
mechanisms (e.g. NADH, NADPH, vitamin C). This may be exacerbated 
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further by underlying deficiencies in anti-oxidant defence mechanisms; these 
may have a genetic (e.g. reduced enzyme activity) and or an environmental 
basis (e.g. poor nutrition). Together these factors are likely to contribute to 
oxidative haemolysis and or methaemoglobin (MetHb) (Figures 1.6 and 1.7), 
both of which can be fatal as they reduce oxygen carriage to tissues and lead 
to cyanosis. It is also important to consider that while AKI can occur as a 
consequence of oxidative stress it can result from massive haemolysis (e.g. 
G6PD deficiency). 
 
Secondary amyloidosis is another important consideration. It is reported by 
one group to be a complication of AKU and is suggested to contribute to the 
decline of renal function in AKU (Millucci et al., 2012; Millucci et al., 2014; 
Millucci et al., 2015). Amyloid A protein is responsible for amyloid A 
amyloidosis, which occurs in long term inflammatory conditions (Urieli-Shoval 
et al., 2000). The N-terminal fragment of serum amyloid A is an 
apolipoprotein synthesised by the liver under the transcriptional regulation of 
inflammatory cytokines (Simons et al., 2013). In a minority of patients, a 
sustained inflammatory stimulus and the overproduction of amyloid A protein 
can lead to protein mis-folding and amyloid deposition (secondary 
amyloidosis), which may result in kidney damage (Simons et al., 2013; 
Millucci et al., 2014; Millucci et al., 2015). 
 
In considering the impact of CKD on the pro- and anti-oxidant balance we 
can get an appreciation of why, when AKI occurs, specifically in patients with 
AKU the outcome can be fatal. It is clear that there appears to be no single 
factor that is responsible, rather an intricate interplay of several factors. 
 
In CKD (Olszewska, 2004; Stepniewska et al., 2005; Stepniewska et al., 
2006) and AKI (Himmelfarb et al., 2004) the anti-oxidant capacity of the body 
is reduced. Uraemic toxins, observed in CKD have been shown to be 
associated with enhanced oxidative stress. This occurs indirectly by carbonyl 
compounds which are generated from the metabolism of carbohydrates and 
lipids to form advanced glycation and lipid end products, and by the carbonyl 
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modification of proteins (Ingani et al., 1999; Miyata et al., 2001). The 
consequences of this are observed in dialysis related amyloidosis. 
Treatment of uraemic patients with haemofiltration or haemodialysis has also 
been shown to increase oxidative stress and to reduce the concentration of 
anti-oxidants in the blood (Olszewska, 2004; Stepniewska et al., 2005; 
Stepniewska et al., 2006). In addition, lack of vitamins A and E, selenium, 
blood transfusion and parenteral iron administration have been shown to 
promote a pro-oxidant environment (Agarwal et al., 2004; Olszewska, 2004; 
Stepniewska et al., 2005; Stepniewska et al., 2006; Karkouti, 2012). More 
specifically it has been shown that in the RBCs of patients with CKD the 
pentose phosphate pathway (PPP) does not generate adequate supplies of 
reductive equivalents (i.e. NADPH) necessary to restore reduced glutathione 
(GSH) (Stepniewska et al., 2006), an important free radical scavenger, thus 
increasing oxidative stress. 
 
Furthermore, as haemodialysis causes a significant loss of glucose, which is 
essential for the PPP, significant changes in the anti-oxidant system of the 
blood of patients with CKD occurs. It has been demonstrated that the activity 
of RBC glutathione peroxidase decreases with the duration of dialysis, thus 
potentiating the effects of oxidative stress (Stepniewska et al., 2006). Lower 
RBC concentrations of selenium in dialysed patients have also been shown 
to correlate with lower glutathione peroxidase activities (Stepniewska et al., 
2006). 
 
RBCs in patients with CKD are also exposed to an increased activity of free 
radicals. The net consequence of this is that peroxidation of lipids and 
proteins in RBC membrane occurs (Ceballos-Picot et al., 1996). This reduces 
the stability of the RBC and increases the likelihood of haemolysis. Advanced 
oxidation protein and glycation end products also contribute to this and 
increase the likelihood of haemolysis (Ceballos-Picot et al., 1996). 
 
Disturbances of anti-oxidant enzyme activity in other metabolic pathways can 
also occur. These include reactions that involve superoxide dismutase, 
glutathione peroxidase, catalase and glutathione reductase (Figure 1.7). The 
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extent to which these pathways are altered is determined by the stage of 
CKD and efficiency of treatment (Stepniewska et al., 2005). Of particular note 
is that the energy production in RBCs depends largely on glycolysis, with 
glucose as the principal substrate. Both glycolysis and the PPP generate 
NADH and NADPH, respectively to reduce MetHb, which is being 
continuously produced. If aberrations occur in these systems a pro-oxidant 
environment will dominate and MetHb will be present at higher 
concentrations (normal reference range <1.5 %, fatal >70 %). 
 
In health there are 2 main mechanisms to minimise the formation of MetHb 
(Skold et al., 2011). The first is to minimise the formation of ROS and the 
second to reduce ferric (Fe3+) iron back to its ferrous (Fe2+) state. The main 
enzyme in RBCs that does this is cytochrome b5 reductase, which utilises 
NADH to reduce cytochrome b5 which in turn reduces MetHb (Skold et al., 
2011). 
 
A second enzyme called flavin reductase also contributes to maintaining 
haemoglobin in the ferrous state through its utilisation of NADPH and the co-
factor methylene blue, to form leukomethylene blue. Riboflavin, flavin 
adenine dinucleotide and flavin mononucleotide also act as electron 
acceptors to reduce MetHb back to its ferrous state. 
 
A very important consideration in RBC oxidative stress is the activity of the 
enzyme G6PD. This enzyme is central to the formation of the reducing 
equivalents NADH and NADPH. A deficiency in G6PD can lead to 
inadequate formation of NADPH and NADH, the consequence of which is 
that the demands of anti-oxidant regulatory pathways are not met. This 
predisposes an individual to an increased risk of haemolytic anaemia and or 
methaemoglobinaemia (Cappellini et al., 2008). In all cases reported (Table 
1.4) the activity of G6PD was not documented, and may have been an 
independent risk factor for the development of the fatal metabolic 




1.9.3 Treatment options employed for haemolysis in AKU 
All therapeutic strategies employed in the 11 cases reported (see Table 1.4) 
failed to demonstrate therapeutic benefit, as all patients died. It is important 
to consider why this is the case. Treatments included vitamin C, NACys, 
methylene blue, blood transfusion and renal replacement therapy (i.e. 
haemodialysis and or haemofiltration). Regardless of treatment it is clear that 
the supply of reducing equivalents were inadequate to meet the cellular 
demands to minimise oxidative stress, thus oxidative haemolysis and or the 
formation of MetHb occurred. 
 
Increased oxidative stress from the generation of ‘soluble melanins’ (pro-
oxidants) may have saturated anti-oxidant mechanisms causing depletion of 
NADPH and thus when these treatments were given they were ineffective. 
Both vitamin C and NACys (Figure 1.7) are key co-factors in the recycling of 
thioredoxin and glutathione, respectively. Vitamin C is a self-limiting anti-
oxidant mechanism in humans as they cannot synthesise it endogenously. 
Moreover, vitamin C when given at high concentrations has been shown to 
induce haemolysis in patients with G6PD deficiency (Cappellini et al., 2008). 
No patients were reported to have G6PD deficiency; however this may have 
been a contributing factor in the lack of therapeutic response to anti-oxidant 
therapy. 
 
The use of NACys is entrenched in the medical literature for the treatment of 
oxidative liver damage observed in paracetamol overdose. This is because of 
its role in the recycling of glutathione. While its use in AKU has not been 
assessed for clinical efficacy, it has been used based on its purported 
benefits as an anti-oxidant (Heng et al., 2010; Mullan et al., 2015). It is likely 
that therapeutic benefit has not been demonstrated in patients with AKU due 
to the magnitude of pro-oxidant species present. 
 
Methylene blue has a number of clinical uses, but at first glance seems 
counter intuitive as therapy for the treatment of oxidative stress in AKU as it 
can behave as a pro-oxidant at higher concentrations, thus potentially 
exacerbating oxidative stress. In addition, there are concerns over its use in 
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patients that have G6PD deficiency as it can lead to life threatening 
haemolytic anaemia (Beutler et al., 1963). It is proposed that leukomethylene 
blue can diffuse into G6PD deficient RBCs resulting in haemolysis (Beutler et 
al., 1963). 
 
Haemodialysis and or haemofiltration were used as treatments in 8 of the 11 
cases reported (Suehiro et al., 2007; Heng et al., 2010; Miyasaka et al., 
2013; Bataille et al., 2014; Isa et al., 2014; Mullan et al., 2015; Freeman et 
al., 2018; Hugar et al., 2019). While this in principle may have facilitated the 
removal of HGA, thus potentially reducing the formation of ‘soluble melanins’ 
and oxidative stress, it is known that haemodialysis increases oxidative 
stress as anti-oxidant defences are reduced by pro-oxidant haemodialysis 
factors, which is more profound in patients with renal anaemia (Olszewska, 
2004; Stepniewska et al., 2005; Stepniewska et al., 2006). 
 
As a consequence of haemolysis the majority of patients (Table 1.4) were 
given blood transfusions. This is a lifesaving treatment during haemolysis; 
however it is known that transfusions can harm the kidney. The exact 
mechanism of how this occurs is not fully understood. It is known that RBCs 
during storage undergo biochemical and morphological change and it is 
thought that after transfusion these changes promote a pro-inflammatory 
state impairing oxygen delivery to tissues and promoting oxidative stress 
(Karkouti et al., 2012). 
 
It is clear that there were limitations to all medical therapies given in the 
cases reported. In principle renal transplantation could serve to reduce the 
circulating concentration of HGA (Introne et al., 2002) and thus reduce the 
risk of oxidative haemolysis and or the formation of MetHb, however this is 
not a treatment that could be implemented rapidly and has its own challenges 
(i.e. risk of graft rejection). A potentially lifesaving therapy could be the 
utilisation of a therapy that decreases the production of HGA and this can be 
achieved by a drug, namely nitisinone. 
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If the additional ‘insult’ for the haematological complications in AKU is the 
formation of pro-oxidants as a consequence of HGA accumulating and being 
metabolised to ‘soluble melanins’ then the inhibition of the formation of HGA 
through the use of nitisinone would be a highly suitable treatment. Moreover, 
the drop in HGA concentrations is rapid, with approximately 60 % decrease 
in circulating HGA within 48 h on 2 mg dose (unpublished data, Ranganath 
LR) and thus is an efficacious treatment. Published trials have demonstrated 
a significant dose response decrease in urinary HGA in AKU with 8 mg daily 
dose reducing urinary HGA to 98.8 % of baseline concentrations (Ranganath 
et al., 2016, Milan et al., 2019). 
 
It is postulated that treatment with nitisinone should be made available earlier 
even if renal function is normal rather than waiting for decline in renal 
function and the presentation of haematological complications. This approach 
is also recommended as there may be delays in obtaining nitisinone quickly, 
in what could be a rapidly fatal event.  
 
It is clear from the literature that the metabolic consequences of AKU as a 
chronic disease entity, and the impact of treatment with nitisinone has largely 
focused on the targeted measurement of circulating and urinary HGA and 
tyrosine in a clinical trial setting. Moreover, in reported cases where acute 
fatal metabolic complications have been observed much of the literature 
relates to inference based metabolic changes that are observed in other 
disease states that are known to have increased oxidative stress. It is 
therefore clear that much is still not know about the wider metabolic 
consequences of AKU and treatment with nitisinone (i.e. the impact of 
hypertyrosinaemia on neurotransmitter metabolism), and what metabolic 
changes occur with respect to oxidative stress. It is essential that the wider 
metabolic consequences of AKU, and nitisinone therapy are investigated 







Metabolomics is defined as “global unbiased analysis of the small-molecule 
metabolites present within a biological system in an identified and quantified 
manner” (Fiehn, 2002). Small molecule metabolites are typically regarded as 
having a molecular weight of <1500 Da. 
 
Metabolomics can be split into targeted and untargeted. The targeted 
approach encompasses the quantitative measurement of a selection of 
known metabolites from a biochemical pathway, in contrast untargeted 
metabolomics is defined as the global unbiased analysis of all small 
molecules that constitute the metabolome (Fiehn, 2002; Patti et al., 2012; 
Naz et al., 2014; Tzoulaki et al., 2014; Cajka et al., 2016). Non-targeted 
methodologies can also be subdivided into metabolic profiling, which focuses 
on specific classes of compounds, and metabolic fingerprinting, which 
represents a global approach based on the measurement of metabolic 
patterns (Dettmer et al., 2007). 
 
Metabolomics has seen huge growth in the last decade and its application 
offers real promise to clinicians as it has the potential to provide predictive, 
prognostic, diagnostic, and surrogate markers of disease and the potential to 
inform on the underlying molecular mechanisms of disease (Berger et al., 
2016). Ultimately in the clinical environment one of the key aims of 
metabolomic studies is biomarker discovery, with the hope that new 
biomarker(s) have the clinical utility to allow specific treatment(s) and or 
further investigations to be carried out for a patient, providing so called 
‘personalised medicine’. 
 
The WHO defined a biomarker as “almost any measurement reflecting an 
interaction between a biological system and a potential hazard, which may be 
chemical, physical or biological. The measured response may be functional 
and physiological, biochemical at the cellular level, or a molecular interaction” 
(WHO, 1993). Numerous factors can influence the metabolome (Figure 1.8, 
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adapted from Beger et al., 2016) and should be borne in mind when 









1.11 Analytical techniques used in metabolomics 
 
Numerous analytical platforms have been utilised for metabolomic 
applications. These include nuclear magnetic resonance (NMR), fourier 
transform infrared spectroscopy and high resolution accurate mass 
spectrometry (HRAMS) coupled to separation techniques like gas or liquid 
chromatography, capillary electrophoresis and fourier transform. HRAMS can 
also be used to evaluate the metabolome of tissue samples, where ions 
liberated from tissue during the ionisation process (e.g. desorption ionisation, 
electrospray ionisation, DESI) are drawn into the mass spectrometer for 
analysis. The focus hereafter will be on 1D proton (1H) NMR and HRAMS as 
these techniques were used in the work presented herein. For a detailed 
review of other techniques see a recent review by Zhang et al. (2012). 
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There are key advantages and disadvantages to using NMR and HRAMS for 
metabolomics, these are summarised in Table 1.5 (information taken from 
Emwas, 2015). In addition to the challenges encountered with the analytical 
platform chosen, study design (Kirwan et al., 2018), quality control 
(Broadhurst et al., 2018) and the validation of analytical and chemometric 
methodologies require careful consideration (Beckonert et al., 2007; 














Intrinsically quantitative High sensitivity (pg-ng) 
Minimal sample preparation High resolution 




Can use for direct analysis 
of any sample type 
(including tissue) 
Can be combined with a 
variety of hyphenated 
techniques (e.g. 
LC/GC/CE) 
Can measure all 
metabolites under same 
conditions as long as 
above NMR sensitivity 
threshold 
Small sample volume 
required 
Limitations 
Moderate resolution due to 
signal overlap 
Destructive method  
 
Low sensitivity (µg) 
Moderate reproducibility 
with salty mixtures due 
to ion suppression 
Low metabolite detection 
(40-200) 
Detection bias  





conditions to detect 
different metabolite 
classes 
 Sample preparation can 
be complex 
 
Table 1.5. Comparison between NMR and MS based methodologies for 
use in metabolomics experiments. GC – gas chromatography; LC – liquid 




1.11.1 High resolution accurate mass spectrometry 
HRAMS provides the ability to screen a sample, whether it be human serum 
or urine, or even tissue culture media on the basis of exact mass, allowing 
measurement of the mass to charge ratio (m/z) of an ion to the 4th or 5th 
decimal place. This level accuracy enables isobaric compounds of the same 
‘nominal’, but differing exact masses to be distinguished. However this 
technique alone cannot distinguish isomers, often this is addressed through 
the use of hyphenated chromatographic techniques (Wood, 2019).  
 
The International Union of Pure and Applied Chemistry defines resolution in 
mass spectrometry in 2 different ways (Murray et al., 2013), herein the 
favoured definition for HRAMS (Barrow et al., 2005) is presented and defines 
it as m/Δm, where m is the mass of the ion of interest and Δm is the peak 
width (typically at 50 % of peak height) (Figure 1.9). The resolving power of 
HRAMS instruments these days is typically ≥10000 m/△m (Table 1.6) 





Figure 1.9. Definition of mass resolution. m – mass of the ion of interest; 
Δm – peak width at 50 % of peak height. 
48 
A number of different analytical platforms are available to perform HRAMS, 
typically time of flight (TOF) and orbitrap analysers are used in metabolomics 
studies. Table 1.6 summarises technical specifications and characteristics of 
TOF and orbitrap (García-Reyes et al., 2017) and Table 1.7 their major 
advantages and disadvantages, respectively (Wood, 2019). From this point 
forward the focus relating to HRAMS will be on TOF mass spectrometry 











[FWHM at defined 
(m/z)] 

























MicroOTOF-QII 20,000 (922) <2 <5 50-20,000 20 
MaXis impact 40,000 (386) <1 <3 50-20,000 50 




XEVO G2  
Q-TOF 
22,500 (956) <1 - 20-16,000 30 
Synapt G2-S 
HDMS 
50,000 (956) <1 - 20-100,000 30 
Agilent  6500 Q-TOF 42,000 (922) <1 - 50-10,000 50 
Sciex  
TripleTOF 4600 30,000 (full-range) <0.5 <1 5-40,000 100 
TripleTOF 5600 35,000 (full-range) <0.5 <2 5-40,000 100 
TripleTOF 6600 40,000 (full-range) <0.5 <2 5-4000 100 






<1 <5 50-4000 12 at RP 17,500 
Q-Orbitrap Q-Exactive 140,000 (200) <1 <5 50-4000 12 at RP 17,500 




500,000 (200) <1 <3 50-6000 18 at RP 17,500 
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Table 1.6. Technical specifications and characteristics of TOF and orbitrap mass analysers. RP – resolving power; FWHM – 
full width at half maximum; HDMS – high-definition mass spectrometry; IT-TOF – ion trap time-of-flight; LTQ-Orbitrap – linear ion 
trap orbitrap; MS – mass spectrometry; MS/MS – tandem mass spectrometry. Adapted from Garcia-Reyes et al. (2017). Bold text 
indicates mass spectrometers that were used in Chapters 2, 3, 7 and 8.
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Resolving power is independent of acquisition 
rate providing excellent compatibility with the 
flow rates used in ultra-high-performance liquid 
chromatography and capillary electrophoresis 
 
Resolving power constant across mass range 
 
High sensitivity (superior to triple quadrupole in 
full scan mode – no loss of ions associated with 
“scanning” technologies) 
 
Mass range of the analyser is unlimited in 
principle, as this is based on the time it takes 
the ion of interest to reach the detector 
 
Parallel detection of all the ions over the 
complete mass range is relatively 
straightforward 
 




Ion source and 







Superior resolving power than TOF at slow scan 
speeds (resolving power is inversely 
proportional to scan speed) 
 
High sensitivity (superior to triple quadrupole in 







More expensive than 
TOF 
 




1.11.1.1 Theory of TOF 
The concept of TOF was first described in the 1940’s (Stephens et al., 1946) 
and it is based on determining the m/z by measuring the time it takes an ion 
to travel over a fixed distance (i.e. from ion pulser plate to the detector via a 
field free flight tube and reflectron). For a comprehensive mathematical 
description of the theory of TOF see Boesl, (2017). In brief this can be 





Figure 1.10. Mathematical denotation of TOF.  – kinetic energy;  – 
mass;  – velocity;  – electric charge;  – accelerating voltage;  – 
elementary charge constant;  – potential energy;  – charge number;  – 
time;  – distance;  – constant encompassing terms  and ;  – constant 
encompassing a corrected time zero as measured time zero may not 
correspond to true time zero. Adapted from de Hoffmann, (2007). 
 
 
Equation 1 denotes the relationship between an ion with mass  and total 
charge  which is accelerated by accelerating voltage , essentially this 
shows that electrical potential energy   is converted to kinetic energy . 
Equation 2 denotes the velocity of the ion leaving the ion pulser plate. After 
ions are accelerated into the field free flight tube they travel at a constant 
velocity over a fixed distance (via a reflectron) to the detector. The time  
required to cover this distance  is denoted in equation 3. Replacing  by its 
original value gives the denotation on equation 4, which combines the terms 
relating to time and energy required to accelerate ions. As the goal of 
analysis is to determine the m/z it is important to rearrange equation 4 to 
make this the subject as per equation 5. This equation can be simplified to 
what is denoted in equation 6 as distance  and accelerating voltage  are 
constant for a given TOF instrument, and the relationship between  
and  is linear, thus can be simplified into a constant, . A second constant  
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can be added to correct for time delays as the measured time zero will not 
correspond to the true time zero due to (1) the time the control electronics 
send a start pulse to the time that high voltage is present on the rear ion 
pulsar plate and (2) the time an ion reaches the front of the ion detector plate 
surface until the signal generated by the ion is digitised by the acquisition 
electronics. 
 
Figure 1.11 shows the schematic representation of the Agilent 6550 QTOF-
MS utilised in the work presented herein. The beginning of the analytical 
process in this system starts with the introduction of the liquid 
chromatography (LC) eluent (containing the sample) into the spray chamber 
via a nebulizer into the MS where ions undergo electrospray ionisation (ESI). 
For mechanistic aspects of ESI see Bruins (1998). In brief, ionic species are 
transferred from solution into gaseous phase. In the Agilent 6550 system 
(Agilent 6200 Series TOF and 6500 Series Q-TOF LC/MS System Concepts 
Guide, 2014) this begins as LC eluent is sprayed at atmospheric pressure 
through the nebuliser (held at ground state) at a right angle to the capillary, 
which is raised to a high voltage. The spray is thermally focused by the dual 
jet spray technology (heated nitrogen gas). This together with the strong 
electrostatic field generated from the voltage applied to the capillary, causes 
the LC eluent to break up into small droplets and the preferential migration of 








Figure 1.11. Schematic of Agilent 6550 quadrupole TOF mass 
spectrometer (García-Reyes et al., 2017). 
 
 
As the heated nitrogen gas is sprayed solvent evaporation starts to occur  
resulting in the formation of smaller droplet sizes forcing the predominantly 
like surface-charges closer together. This process continues until coulombic 
repulsion equals the surface tension of the droplet and the droplet explodes 
to produce smaller droplets, which are subject to further evaporation. This 
occurs until the charge density reaches the critical limit of ~108 V/cm3, and 
ion evaporation occurs. The ejected ions are then drawn into the hexabore 
capillary (held at ~4 kV) and transferred into the dual ion funnels, which 
remove excess gas and neutral species and captures charged species. Ions 
are initially transmitted into the first funnel held at high pressure (7-14 Torr), 
and then into the second funnel held at a lower pressure (1-3 Torr). Radio 
frequency (RF) and direct current voltages are applied to the funnels to focus 
the ions to the centre of the funnel and accelerate them towards the exit and 
the octopole, respectively. This region of the mass spectrometer exists under 
high vacuum. Ions are focused by the octopole due to a RF voltage applied 
to the parallel rods that repel ions above a particular mass range toward the 
centre of the rod set. Ions then progress through focusing lenses into the 
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quadrupole mass filter, which optimises ion transmission and spectral 
resolution through application of RF frequency, and into the hexapole 
collision cell containing nitrogen (only active during fragmentation 
experiments when a collision energy voltage is applied over the accelerating 
linear voltage to generate fragments or product ions).  
 
Ions are then focused via an ion beam compressor (octopole) to enter the ion 
transfer region which contains an orthogonal ion pulser which consists of a 
stack of ion plates. As ions progress into this stack with vertical and 
horizontal momentum a high voltage potential is applied to the back plate to 
accelerate ions through the stack towards the detector. Ions travel through 
the flight tube (field free) towards a 2-stage mirror called a reflectron. This 
enables the refocusing of ions, and the effective doubling of the distance ions 
travel.  
 
As ions reach the detector they will strike its surface which contains a series 
of small tubes that span from the front to the rear of the plate. As ions strike 
they cause electrons to be released and start a process of electrical signal 
amplification (10 times more electrons leave the plate than enter). As 
electrons leave the microchannel plate they are focused onto a scintillator, 
which produces a photon of light. This is then focused through 2 small lenses 
onto a photomultiplier tube, which produces the electrical signal read by the 
data system allowing the calculation of exact mass. 
 
1.11.2  Hyphenated techniques used with HRAMS 
The use of hyphenated techniques with HRAMS is commonplace and 
provides an additional dimension of specificity to analysis. This is a vast area 
and as such the brief focus will be on the approaches used in the work 
presented herein, specifically LC for liquid biological samples and DESI for 
tissue imaging. 
 
1.11.2.1 Liquid chromatography 
LC is central to metabolomic experiments for the analysis of biological 
material including serum (Dunn et al., 2011), urine (Want et al., 2010) and 
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cell culture media (Want et al., 2013). Common to all of these approaches is 
the use of reversed and normal phase chromatography. Using this common 
2-pronged strategy facilitates the maximum coverage of non-polar and polar 
metabolites, respectively. This is because LC delays the transit of 
metabolites into the mass spectrometer, and provides an orthogonal 
mechanism of separation. This is vitally important when trying to identify a 
metabolite, especially when the compound is isomeric. Typical 
chromatographic conditions used for the analysis of serum (Dunn et al., 
2011) and urine (Want et al., 2010) are: 
 
1. Reversed phase chromatography - conditions include water and 
methanol as a mobile phase pair, containing a buffer (e.g. ammonium 
formate) and a C18 analytical column. This chromatographic approach 
is for the separation of less polar compounds. 
 
2. Normal phase chromatography - conditions include water and 
acetonitrile as a mobile phase pair, containing a buffer (e.g. 
ammonium formate) and a hydrophobic interaction liquid 
chromatography (HILIC) column. This chromatographic approach is 
for the separation of polar compounds. 
 
Both approaches tend to utilise analytical columns with a sub 2 µm particle 
size operated under high pressure facilitating improved resolution and peak 
capacity. 
 
1.11.2.2 Mass spectrometry imaging  
Mass spectrometry imaging (MSI) is a unique approach to the analysis of 
complex matrices (e.g. tissue) that provides both chemical and spatial 
information, which can be processed to generate chemical images (Wu et al., 
2013; Perez et al., 2019). Ambient ionisation is a subfield of MSI that enables 
the analysis of a native sample under atmospheric conditions with minimal or 
no sample preparation; ionisation occurs outside of the mass spectrometer 
before ions are drawn into the mass spectrometer for analysis (Figure 1.12). 
The major benefit of this approach is that it facilitates soft desorption and 
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ionization of analytes, and enables more rapid analysis owing to minimal or 
no sample pre-treatment (Perez et al., 2019). There are many variants of 
MSI; the work presented herein (Chapter 7) utilised DESI coupled to HRAMS 
for the analysis of neurotransmitter metabolites, which has the capability of 
generating imaging resolutions of 100-200 μm (Perez et al., 2019), more 
recently Shariatgorji et al. (2019) published on the comprehensive mapping of 
neurotransmitter networks using matrix-assisted laser desorption ionization 
(MALDI) coupled to HRAMS. This particular approach employs a 
fluoromethylpyridinium based reactive matrix to facilitate the covalent charge 
tagging of molecules containing primary or secondary amine groups enabling 





Figure 1.12. Desorption electrospray ionization. Adapted from Shariatgorji 




1.11.3  NMR 
Proton (1H) NMR can provide information on the structure and energetics of a 
molecule (metabolite), and has been utilised in the field of metabolomics for 
over 50 years (Wishart, 2019). The work presented herein utilised 1H NMR 
as a complementary technique to HRAMS, and it exploits the magnetic 
properties of a proton (nuclear spin) (Bothwell et al., 2011), which are very 
sensitive to the surroundings in which they weakly interact (Hore, 2017). It is 
these properties that make NMR highly suited to understanding the atomic 
structure of a molecule. NMR spectra from molecules in a liquid can reveal 5 
important pieces of information (Hore, 2017): 
 
1. The intensities of individual resonances (influenced by the number of 
nuclei responsible). 
2. Chemical shifts - interaction of nuclear spins with an applied magnetic 
field. 
3. Spin-spin coupling - interaction with one another. 
4. Spin relaxation - restoration of thermal equilibration. 
5. Chemical exchange - effects of conformation and chemical equilibria. 
 
This information is obtained by placing a sample into a strong magnetic field 
(Figure 1.13) and exposing it to electromagnetic radiation in the form of RF 
pulses. The latter excites protons (depending on the structure of the 
molecule), and as they relax back to their unexcited state the energy emitted 
is recorded as an oscillating electromagnetic signal, referred to as free 
induction decay (FID). This represents a complex wave function (intensity 
versus time) that requires fourier transformation (Ernst et al., 1966) to 
generate a spectrum of intensity versus frequency. Data in the NMR 
spectrum are represented as a series of peaks with chemical shift (δ), in 
parts per million (ppm), on the x-axis and intensity along the y-axis. The 
chemical shift is the resonant frequency of the specific nucleus compared to 
the nucleus of an internal standard, typically tetramethylsilane (TMS). The 
distance between the resonant frequency observed and the TMS signal 
depends on the chemical environment of the proton (i.e. the molecular 
structure). Protons that exist in different parts of the molecule have a different 
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chemical shift which gives rise to a unique pattern of peaks with respect to 
chemical shift and peak intensity. In certain sample types, for example serum 
TMS is not used as an internal standard due to interference from high protein 
concentrations (Bell et al., 1988; Nicholson et al., 1989; Chatham et al., 
1999; Nagana et al., 2014). In this situation spectra can be aligned to a 






Figure 1.13. Schematic representation of a 1H NMR spectrometer 
(Rankin et al., 2014). This shows a superconducting magnet in its centre. 
This is kept at 4 K by a sleeve of liquid helium – evaporation of this is 
prevented by a vacuum and a jacket containing liquid nitrogen. The RF coil 
contained in the sample probe sits in the bottom of the magnet within its 
bore. Sample analysis is performed within the NMR tube; here the 
superconducting magnet (e.g. 16.5 tesla, 700 MHz – Bruker Advance III) 
causes protons to spin. The RF coil sends a RF pulse sequence to excite 
them and collects the free-induction decay as they relax back to equilibrium. 
Pulse sequences are programmed using a computer and sent to the console, 
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which acts both as a RF transmitter and receiver. The signals are amplified 
on transmission and receipt. The FIDs are fourier transformed to produce 1H 
NMR spectra of intensity versus chemical shift (δ), typically between 0-10 





Figure 1.14. 1H nuclei chemical shifts due to different chemical 
environments (Fuloria et al., 2012). 
 
 
Typically the Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence is employed 
to identify smaller metabolites in the presence of more complex structures 
like proteins and lipoproteins (Meiboom et al., 1958). This is possible 
because there is a long delay between the excitatory pulse and the 
acquisition period. This means larger molecules (e.g. lipids and proteins) will 
have stopped spinning, when smaller molecules are still spinning producing a 
FID signal. The mathematical principles that underpin 1H NMR are complex, 





1.12 Challenges in metabolomic studies 
 
A major challenge in NMR or HRAMS based metabolomic experiments is 
mining information from the vast volume of experimental data generated, and 
integrating it into a meaningful biological context (Goodacre, 2005; Barupal et 
al., 2018). Much of the data generated are redundant, in part this is a 
reflection of signals that are generated from entities that are not present in 
the sample (i.e. contaminants) and originate from sample collection and 
preparation processes (Table 1.8). Data redundancy in the context of 
metabolomics also relates to the high degree of related signals within a data 
set (Chen et al., 2017). For example, raw unprocessed LC-MS data includes 
m/z retention time pairs not only for the native entity, but also related signals 
representing the same entity (i.e. associated isotopes and adducts). It is 
essential therefore that sample collection, preparation and analysis, as well 
as data processing are rigorous and reproducible. There are a number of 
factors that can influence this which are summarised in Table 1.9. 
 
Huge efforts are being made to standardise study design, which is complex 
(Jacyna et al., 2019), and the analysis of raw data (Ren et al., 2015). Data 
sharing is also strongly encouraged (Considine et al., 2019) in the 
metabolomics community, and vast progress in this area can be seen by the 
number of entries in the Human Metabolome Database (~115 000) (Wishart 
et al., 2018). Moreover, there is an increasing availability of spectral data for 
small molecules in public libraries like METLIN, KEGG, MIST-MS, 
ChemSpider, LipidMaps and PubChem (Milman et al., 2016). The major 
limitation to all of these is that data are generated using a variety of analytical 
platforms with different configurations (e.g. different LC and mass 
spectrometer source parameters) so are not entirely transferable. For this 
reason, there are benefits in establishing in-house metabolite libraries that 









Confounding factors (e.g. gender, 
genetic make-up, age, diet, 
lifestyle) 
 
Power study to ensure enough  
samples per group 
 
Analytical greater than biological 
variability 
Control and limit confounding factors; 
admission to clinic to restrict 
environmental influences 
 
Appropriate number of samples based 
on pilot study; biological replicates  
 
Regular injection of QCs, blanks, 
labelled IS; sample randomisation 




Blaise et al., 2016  
 
 
Broadhurst et al., 2018  
Begou et al., 2018 
Beger, 2018 
Metabolome changes: 
– Arterial vs venous blood 
– Circadian rhythm 
– Pre- vs post-prandial status 
– Sample type/preservatives 
– Time between sampling and 
storage 
Use protocols describing sampling 
procedures (matrix, sampling site, 
containers, storage conditions, time of 
day, fasting) 
 
Reproducible sampling conditions 
Kohler et al., 2016 
Sample 
storage 
Chemical and enzymatic 
degradation and/or 
interconversion, altering both 
qualitative/quantitative information 
Immediate quenching (e.g. 60–100 % 
MeOH) and snap-freezing in liquid 
nitrogen 
 
Sample storage in adequate containers 
at -80 °C, preferably up to 6 months; 3 
freeze–thaw cycles maximum 
 
Use preservatives if needed  
 
Kohler et al., 2016 












Automate sample preparation; use 
labelled IS; work in temperature 
regulated rooms 
 
Single batch preparation of samples or 
division of samples into several 
batches, use of QCs 
Kohler et al., 2016 
Metabolite coverage 
Keep the sample preparation as simple 
as possible but still fit-for-purpose 
Beckonert et al., 2007 
Want et al., 2010 
Dunn et al., 2011 
Want et al., 2013  
Separation 
RPLC: poor retention of polar 
compounds 
 
HILIC: poor repeatability; large 
peak shape 
RPLC: use HILIC or CE for polar 
compounds 
 
HILIC: adequate equilibration; 
reproducible buffers; high proportion of 
ACN in sample 
Want et al., 2010 
Dunn et al., 2011 
Want et al., 2013 
Ionisation 
ESI: matrix effects 
(suppression/enhancement) 
 
ESI: systematic evaluation of matrix 
effects during method development; 
use IS 
Matuszewski et al., 1998 
Annesley, 2003 
Chamberlain et al., 2019 
Detection 
Mass spectrometry: 
Stereoisomers: same m/z and 
fragmentation patterns 
Stereoisomers: use ion mobility 
spectrometry; chiral stationary phase  
Kohler et al., 2012 
NMR: 
Low sensitivity, relatively high 
sample volume 
 
Chemical shifts due to pH 
differences 
 
Use of strong superconductive 
magnets and cryoprobes; microtubes 
 
Addition of buffer; post analysis 
alignment 
Beckonert et al., 2007 
Kohler et al., 2016 
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Challenging peak identification Simultaneous recording of 2D-J 
resolved spectra; apply STOCSY 
Data analysis 
Selection of the most adequate 




Misleading class separation in PCA 
and PLS-DA modelling 
 
Confidence in metabolite 
identification and 
biological interpretation 
PQN normalization and UV scaling; 
systematic data alignment; careful 
peak picking (adequate S:N ratio, peak 
width, number of features) 
 
Systematic use of internal cross-
validation methods 
 
MSI guidelines (see Table 1.10); fusion 
with other omics data; biomarker 
validation 
Kohl et al., 2012 
Ren et al., 2015 







Sumner et al., 2007 
Biomarker 
discovery 
Biomarker validation  
 
 
Clinical utility and application of 
novel biomarkers 
Validation criteria based on predictive, 
prognosis, or diagnostic purpose 
 
Fit for purpose validation (internal and 
external, clinical trials, continued 
surveillance) 
Kohler et al., 2016 
Barupal et al., 2018 
 
Table 1.8. Summary of potential confounding factors in a clinical metabolomics experiment/study and potential solutions. 
IS – internal standard; MSI – metabolomics standards initiative; PQN – probabilistic quotient normalisation; RPLC – reversed phase 
liquid chromatography; HILIC – hydrophobic interaction liquid chromatography; MeOH – methanol; ACN – acetonitrile; S:N – signal 
to noise; ESI – electrospray ionisation; CE – capillary electrophoresis; NMR – nuclear magnetic resonance; PCA – principal 
component analysis; PLS-DA – partial least squares discriminant analysis; STOCSY – statistical total correlation spectroscopy; QC 
– quality control; UV – unit variance. Adapted from Kohler et al. (2016). 
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In addition, efforts have been made to standardise the reporting of metabolite 





Description Requisite analytical data 
1 ‘Identified 
metabolites’ 
Two orthogonal analytical techniques 
applied to the analysis of both the 
metabolite of interest and to a chemical 
reference standard of suspected 
structural equivalence, with all analyses 
performed under identical analytical 
conditions within the same laboratory. 
Examples of appropriate orthogonal 
data:  
(1) accurate mass via MS with retention 
time 
(2) accurate mass MS and 
fragmentation data or isotopic pattern 
(3) 2D NMR spectra, full 1H and/or 13C 
NMR spectra 
2 ‘Putatively annotated 
compounds’ 
As for levels 3 and 4, including spectral 
(NMR and/or MS) similarity with public 




As for level 4, plus spectral and/or 
physicochemical properties consistent 
with a particular class of organic 
compounds 
4 ‘Unknown’ A discernible spectral signal (NMR, MS 
or other) that can be reproducibly 
detected and quantified 
 
Table 1 9. Proposed minimum reporting standards for chemical analysis 








1.13 Metabolomics and alkaptonuria 
 
Gertsman et al. (2015a) was the first to report on the use of HRAMS to 
evaluate the serum metabolome of patients with AKU taking nitisinone (2-8 
mg daily) over a period of 6 months to 3.5 years. This small study revealed 
the expected decrease in HGA and increase in tyrosine following treatment 
with nitisinone. This untargeted analysis also revealed significant increases in 
N-acetyl-L-tyrosine and -glutamyltyrosine, which is not surprising due to the 
significant hypertyrosinaemia that is observed following treatment with 
nitisinone. In a related publication (Gertsman et al., 2015b) novel 
disturbances in tryptophan metabolism following treatment with nitisinone 
were also reported. Specifically, indole-carboxyaldehyde, indole-3-pyruvate 
and indole-3-lactate (I-3-L) were shown to increase 5-fold. It was proposed 
the tyrosine metabolite HPPA, which increases significantly following 
nitisinone therapy, up regulates tryptophan aminotransferase activity 
resulting in downstream changes in the concentration of tryptophan 
metabolites and not tryptophan itself. The significance of this is unknown, it 
has been suggested that aromatic keto acids increase the affinity of 
tryptophan transaminase for tryptophan (Lees et al., 1973), thus altering its 
metabolism. 
 
Davison et al. (2019b) also reported increases in serum N-acetyl-L-tyrosine 
and -glutamyltyrosine following treatment with nitisinone using HRAMS, but 
interestingly only observed a change in I-3-L. This study did show increases 
in other tryptophan metabolites including trigonelline and quinoline carboxylic 
acid. Novel changes were also observed in metabolites relating to the citric 
acid cycle (decrease in succinate and α-ketoglutarate) and xanthine 
metabolism (decrease in uridine and inosine). It was suggested that these 
changes along with those observed in N-acetyl-L-tyrosine and -
glutamyltyrosine relate to changes in the redox state of the cell following 
treatment with the HGA lowering agent nitisinone. 
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Increases in 4-hydroxyphenylacetic acid and 4-hydroxybenzaldehyde, and a 
decrease in benzaldehyde were also reported following nitisinone treatment. 
The significance of the latter 2 metabolites is uncertain, but was suggested 
that they relate to the ochronotic pigment observed in AKU. The increase in  
4-hydroxyphenylacetic acid is thought to result from increased activity of gut 
microbiota following treatment with nitisinone due to the presence of less 
oxidative stress. 
 
Norman et al. (2019a) has also reported novel changes in urinary tryptophan 
and related metabolites in patients with AKU treated with nitisinone. In this 
study urinary indoxyl sulphate, tryptophan and kynurenine decreased whilst 
xanthurenic acid increased following treatment. This study supports the 
changes reported in 4-hydroxybenzaldehyde and 4-hydroxyphenylacetic acid 
(Davison et al., 2019b), but also reported novel changes in 4-coumarate, 
tyramine, mandelic acid and phenylacetic acid. Interestingly a number of 
changes were also observed in purine metabolism. Importantly many of 
these changes reported in patients were also observed in a murine model of 
AKU treated with nitisinone that was used in this study reinforcing that the 
changes observed were a consequence of nitisinone therapy. 
 
 
1.14 Aims of research 
 
There were 2 main aims to the research presented in this thesis. The first 
was to establish a methodological approach for the comprehensive 
evaluation of the metabolome in serum and urine samples obtained from 
patients with AKU, before and after treatment with nitisinone. The rationale 
for this is that the knowledge of the impact of nitisinone treatment on the 
metabolome is very limited; published literature has focused on a limited 
number of metabolites, primarily HGA and tyrosine. A better understanding of 
the wider metabolic consequences of nitisinone therapy is essential for its 
use in the treatment of AKU, particularly in relation to neurotransmitter 
metabolism, oxidative stress and ochronosis. In this thesis a comprehensive 
targeted metabolomic profiling strategy using LC-QTOF-MS is presented and 
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applied for the analysis of urine (Chapter 2) and serum (Chapter 3) from 
patients with AKU treated with nitisinone. Additionally, in Chapter 3 a 
methodological approach utilising NMR for the evaluation of the serum 
metabolome is presented. 
 
The second aim was more specific, and focused on whether  nitisinone-
induced hypertyrosinaemia alters neurotransmitter metabolism and the 
metabolism of other amino acids. Whilst changes to neurotransmitter and 
amino metabolism were evaluated when performing comprehensive targeted 
metabolomic profiling using LC-QTOF-MS for the analysis of urine (Chapter 
2) and serum (Chapter 3) data acquired were qualitative, and no internal 
standards were used. As such additional targeted quantitative analysis of 
urinary neurotransmitter metabolites was performed using liquid 
chromatography tandem mass spectrometry in samples collected from 
patients following treatment with nitisinone (Chapters 5 and 6). Quantitative 
analysis of serum amino acids using liquid chromatography (Chapter 4) was 
also performed to determine if amino acid metabolism beyond that of tyrosine 
was affected by treatment with nitisinone. Data from the analysis of urinary 
neurotransmitter metabolites and serum aromatic amino acids were also 
correlated with psychometric data (BDI-II Scores, Chapter 6) collected from 
patients to assess if changes in biochemical parameters could be related to 
changes in mood in patients following treatment with nitisinone. 
 
Due to the limitations of measuring neurotransmitters and their related 
metabolites in serum and urine, and the subjective nature of psychometric 
data analysis; patterns of neurotransmitters were also assessed directly in 
brain tissue from a murine model of AKU following treatment with nitisinone 
(Chapter 7). Analysis of CSF from the same murine model of AKU following 
treatment with nitisinone was also performed using LC-QTOF-MS to provide 
a direct assessment of neurotransmitter metabolism in the CNS (Chapter 8).  
 
The integration of biochemical and psychometric data from human subjects, 
and biochemical data from the murine model of AKU following nitisinone 
therapy has provided a new insight into the impact of nitisinone therapy on 
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the serum and urine metabolome in AKU, and more specifically the impact of 
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Chapter 2  
 
A comprehensive LC-QTOF-MS metabolic phenotyping 
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Background: Identification of unknown chemical entities is a major 
challenge in metabolomics. To address this challenge, we developed a 
comprehensive targeted profiling strategy, combining 3 complementary liquid 
chromatography (LC) quadrupole time-of-flight mass spectrometry (QTOF-
MS) techniques and in-house accurate mass retention time (AMRT) 
databases established from commercial standards. This strategy was used to 
evaluate the effect of nitisinone on the urinary metabolome of patients and 
mice with alkaptonuria (AKU). As hypertyrosinaemia is a known 
consequence of nitisinone therapy, we investigated the wider metabolic 
consequences beyond this. 
Materials and methods: 619 standards (molecular weight 45-1354 Da) 
covering a range of primary metabolic pathways were analyzed using 3 LC 
methods, 2 reversed phase and 1 normal phase, coupled to QTOF-MS. 
Separate AMRT databases were generated for the 3 methods, comprising 
chemical name, formula, theoretical accurate mass and measured retention 
time. Databases were used to identify chemical entities acquired from non-
targeted analysis of AKU urine; match window theoretical accurate mass ±10 
ppm and retention time ±0.3 min.  
Results: Application of the AMRT databases to data acquired from analysis 
of urine from 25 patients with AKU (pre-treatment and after 3, 12 and 24 
months on nitisinone) and 18 HGD-/- mice (pre-treatment and after 1 week on 
nitisinone) revealed 31 previously unreported statistically significant changes 
in metabolite patterns and abundance, indicating alterations to tyrosine, 
tryptophan and purine metabolism post-nitisinone. 
Conclusions: The comprehensive targeted profiling strategy described here 
has the potential of enabling discovery of novel pathways associated with 









Metabolic profiling has potential to advance knowledge of disease beyond 
established biochemical pathways and will play a major role in precision 
medicine (Fiehn et al., 2002; Holmes et al., 2008; Baker et al., 2011; 
Nicholson et al., 2012; Beger et al., 2016). However, metabolite identification 
is a major challenge in untargeted profiling studies using mass spectrometry 
(MS) (Wishart et al., 2011; Dunn et al., 2013) since they produce many 
chemical signals representing ‘unknowns’. To address this challenge, we 
generated 3 accurate mass/retention time (AMRT) databases from 619 
metabolite standards using liquid chromatography-quadrupole time-of-flight-
mass spectrometry (LC-QTOF-MS). We applied this strategy to the inborn 
error of metabolism alkaptonuria (AKU, OMIM 203500). In AKU, bi-allelic 
mutations in the homogentisate 1,2-dioxygenase (HGD) gene result in a lack 
of homogentisate 1,2-dioxygenase (HGD, E.C.1.12.11.5) (Zatkova et al., 
2011), leading to increased homogentisic acid (HGA), a metabolite of 
tyrosine catabolism (Figure 2.1). HGA accumulates in connective tissue, 
particularly cartilage, where it is deposited as a dark pigment, a process 
termed ochronosis. Ochronosis underlies a range of clinical features in AKU, 
the most debilitating of which is severe, early-onset osteoarthropathy that 
alters the physico-mechanical properties of cartilage (Taylor et al., 2011; 
Ranganath et al., 2013). 
 
Nitisinone has emerged as a promising therapeutic agent in AKU because it 
reduces circulating HGA concentrations (Phornphutkul et al., 2002; 
Suwannarat et al., 2005; Introne et al., 2011; Ranganath et al., 2016; Milan et 
al., 2017) by reversibly inhibiting 4-hydroxyphenylpyruvate dioxygenase (E.C. 
1.13.11.27). Nitisinone has been shown to completely inhibit ochronosis in an 
HGD-/- mouse model of AKU (Preston et al., 2014). Although not currently 
licenced for AKU, nitisinone is being used to treat patients attending the 
National Alkaptonuria Centre (NAC) in the UK. One of the major metabolic 
consequences of nitisinone is hypertyrosinaemia (Lindstedt et al., 1992; 
Suwannarat et al., 2005; Introne et al., 2011; McKiernan et al., 2015; Olsson 
et al., 2015; Ranganath et al., 2016; Milan et al., 2017; Davison et al., 2018a; 
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Davison et al., 2018b; Davison et al., 2018c) (Figure 2.1). The objective of 
our study was to apply the developed profiling strategy to urine from patients 
with AKU and BALB/c (HGD-/-) mice to understand the wider metabolic 





Figure 2.1.Tyrosine catabolic pathway with reference to its defect in 
alkaptonuria and treatment with nitisinone. Lack of the enzyme 
homogentisate 1,2-dioxygenase increases concentrations of circulating HGA 
by preventing its conversion to maleylacetoacetic acid. It is previously 
established that nitisinone has the upstream consequence of increased 
concentrations of tyrosine, 3-(4-hydroxyphenyl)pyruvic acid and 3-(4-
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2.3 Materials and methods 
 
2.3.1 Metabolite standards library preparation 
619 standards (IROA Technology MS metabolite library of standards; 
molecular weight 45-1354 Da, Supplementary Table 2.1) were purchased 
from Sigma-Aldrich (UK) in 7 deep well plates. Each compound was present 
at 5 µg/well (>95 % purity). The standards covered a broad range of primary 
and intermediary metabolism, including the following compound classes: 
carboxylic acids, amino acids, biogenic amines, polyamines, nucleotides, 
coenzymes, vitamins, carbohydrates, fatty acids, lipids, steroids and 
hormones (Supplementary Table 2.1).  
 
Prior to analysis, plates were thawed (stored at -80 °C) at ambient 
temperature (18 °C) and compounds reconstituted in 15 µL methanol (LC/MS 
grade, Sigma-Aldrich) followed by 285 µL deionized water (DIRECT-Q 3UV 
Millipore water purification system). Plates 1-5 were left to stand for 1 h 
following addition of water and methanol. Plates 6 and 7 (primarily non-polar 
compounds) were left to stand for 2 h at room temperature following addition 
of methanol to ensure solubilisation; water was then added. Plates were 
agitated on a plate shaker (MTS 2/4m IKA, Germany) at 600 rpm for 10 min. 
Compounds were pooled across rows of each plate (12 wells/row). 20 µL 
was removed from each well and pooled into 1 well (12 compounds analyzed 
per injection). Fifty-six injections were performed in positive and negative 
polarity across all plates (112 injections for each LC-QTOF-MS method; 
Supplementary Figure 2.1). The total volume of each pool was 240 µL with 




2.3.2 Evaluation of LC-QTOF-MS strategy and effect of nitisinone on 
the metabolome using AKU urine 
Acidified 24 h urine collections (2.5 L bottles containing 30 mL of 5N H2SO4) 
were obtained from 25 patients with AKU attending the NAC (12 male, 
mean(±SD) age 51±15 years). Samples were collected before nitisinone, 
then at 3 (2 mg nitisinone every other day), 12 and 24 (2 mg nitisinone daily) 
months and stored at -80 °C. Samples were diluted 1:3 with deionized water 
and stored at -80 °C as 3 separate aliquots for analysis by methods 1-3. 
Metabolomic analysis was part of the diagnostic service to patients being 
seen at the NAC and with approval from the Royal Liverpool and Broadgreen 
University Hospital Trusts Audit Committee (Audit no ACO3836). 
 
Mouse urine (non-acidified) was from 18 (9 male, mean age 27±12 weeks) 
HGD-/- BALB/c mice (Preston et al., 2014) bred from laboratory stocks at the 
University of Liverpool. Samples were obtained on a single-collection basis 
before treatment then after 1 week on nitisinone, administered in all drinking 
water (4 mg/L), supplied ad libitum. Mouse urine was collected onto cling 
film, pipetted into sample tubes and stored at -80 °C. Analysis was performed 
following dilution of 1:9 with deionized water. Mouse breeding and dosing 
was authorized under the Animals (Scientific Procedures) Act, UK. 
 
Samples were pooled for quality assurance in profiling experiments. For each 
sampling time point, a representative pool was created by pooling  
20 µL of each individual urine sample. An additional overall pool was created 
separately for human and mouse experiments by pooling equal proportions 
of the pooled urine groups detailed above. Pooled human and mouse 
samples were stored and treated as above prior to analysis. 
 
2.3.3 Analytical conditions 
2.3.3.1 Chemicals 
Water for mobiles phases was purified as per section 2.3.1. Methanol, 
acetonitrile, isopropanol (Sigma-Aldrich), formic acid (Biosolve, Netherlands) 




Sample analysis was performed on an Agilent 1290 Infinity LC coupled to an 
Agilent 6550 QTOF-MS equipped with a dual AJS electrospray ionization 
source (Agilent, Cheadle, UK). 
 
2.3.3.3 Chromatographic conditions 
Three chromatographic methods were designed to separate different 
compound classes. Method 1: non-polar compounds. Method 2: a range of 
polar/non-polar compounds. Method 3: polar compounds. Metabolite 
standards were analyzed using all 3 LC-QTOF-MS methods.  
 
Method 1 
A Zorbax Eclipse Plus C18 column (2.1 x 100 mm, 1.8 µm, Agilent, Cheadle, 
UK) was maintained at 60 °C (flow rate 0.4 mL/min). Mobile phases were (A) 
water and (B) methanol both containing 5 mmol/L ammonium formate and 
0.1 % formic acid. The elution gradient started at 5 % B at 0-1 min increasing 
linearly to 100 % by 12 min, held at 100 % B until 14 min, returning to 95 % A 
for 5 min.  
 
Method 2 
Method 2 employed the same conditions and elution gradient as method 1, 
but with an Atlantis dC18 column (3.0 x 100 mm, 3 µm, Waters, UK). 
 
Method 3 
A BEH amide column (3.0 x 150 mm, 1.7 µm, Waters) was maintained at 40 
°C (flow rate 0.6 mL/min). Mobile phases were (A) water and (B) acetonitrile 
(both containing 0.1 % formic acid). The elution gradient started at 99 % B 
decreasing linearly to 30 % from 1-12 min, held at 30 % B until 12.6 min, 
returning to 99 % B for 3.4 min. 
 
Sample injection volume was 1 µL for metabolite standards and human urine, 
and 2 µL for mouse urine. The autosampler was maintained at 4 °C and the 
needle was washed with a solution of water:methanol:isopropanol (45:45:10 
v/v) between injections. 
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2.3.4 Design of urine metabolic profiling experiments 
Human and mouse urine was analyzed separately. Human samples were 
analyzed batch-wise using all 3 methods, negative followed by positive 
polarity. Mouse samples were analyzed by method 2 only due to limited 
sample volume, in 1 batch comprising both polarities.  
 
The analytical sequence of each profiling batch was designed according to 
published guidance (Vorkas et al., 2015). Each run commenced with 20 
replicate injections of the overall pooled sample to condition the system. The 
order of individual samples was randomized computationally. Pooled 
samples were interspersed throughout the analytical sequence, every 10th 
injection. Injections of each sample group pool and the overall pooled sample 
were also placed at the start (post-conditioning) and end of each analytical 
sequence. 
 
2.3.5 Data acquisition and processing 
Data acquisition and processing were performed using the MassHunter suite 
(Agilent, Cheadle, UK). Data were acquired with Data Acquisition (Build 
06.00). Metabolite standards and urine samples were analyzed in both 
polarities, mass range 50-1700 on an Agilent 1290 Infinity LC coupled to an 
Agilent 6550 QTOF-MS equipped with a dual AJS electrospray ionization 
source (Agilent, Cheadle, UK). The mass spectrometer was tuned and 
calibrated according to protocols recommended by the manufacturer. 
Acquisition was performed in 2 GHz mode, positive and negative ionisation 
polarity and mass range 50-1700. The capillary voltage was 4000 V and 
fragmentor voltage 380 V. The desolvation gas temperature was 200 °C with 
flow rate at 15 L/min. The sheath gas temperature was 300 °C with flow rate 
at 12 L/min. The nebulizer pressure was 40 psi and nozzle voltage 1000 V 
(for positive and negative ionisation modes). The acquisition rate was 3 
spectra/s. 
 
A reference mass correction solution was prepared in 95:5 methanol:water 
containing 5 mmol/L purine (CAS No. 120-73-0), 100 mmol/L trifluoroacetic 
acid ammonium salt (TFA, CAS No. 3336-58-1) and 2.5 mmol/L hexakis(1H, 
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1H, 3H-tetrafluoropropoxy)phosphazine (HP-0921, CAS No. 58943-98-9) 
(Agilent, Cheadle, UK). The solution was continually infused at a flow rate of 
0.5 mL/min by a separate isocratic pump for constant mass correction 
[positive ionisation: purine (m/z 121.0509), HP-0921 (m/z 922.0098); 
negative ionisation: TFA (m/z 112.9856), purine (m/z 119.0363), HP-0921 
(HP-0921 + formate adduct: m/z 966.0007)]. 
 
Quality checks and processing of raw data were performed with Qualitative 
Analysis (Build 07.00) (See Supplementary Figure 2.2). Extracted ion 
chromatograms of reference masses were performed to check mass 
accuracy remained <5 ppm throughout the run. Binary pump pressure curves 
for injections across each analytical sequence were overlaid to check 
chromatographic reproducibility.  
 
Compound signals were extracted from the standards data in Qualitative 
Analysis (Build 07.00) by molecular formula using the ‘find by formula’ 
algorithm; mass window of theoretical accurate mass (calculated from 
molecular formula) ±5 ppm. Allowed ion species were: H+ and Na+ and 
additionally NH4
+ for methods 1 and 2 (positive polarity); and H- and 
additionally CHO2
- for methods 1 and 2 (negative polarity). Charge state 
range was 1-2. Dimers were allowed.  
 
Separate AMRT databases were created for each method for compounds 
that were retained and detected using personal compound database and 
library (PCDL) Manager (Build 08.00).This included theoretical monoisotopic 
mass, retention time (RT), molecular formula and chemical name (see 
Supplementary Tables 2.2-2.4 for these data, except for molecular formula 
which can be found in the complete databases online (Norman et al., 
2019b)). METLIN metabolites accurate mass database (Build 07.00) was 
used as the basis for each AMRT database (contained entries for 30,232 
small molecules; comprising chemical name, empirical formula, theoretical 
monoisotopic mass and where available deposited mass spectra). 
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Urine profiling data were mined for signals matching AMRT database 
compounds using ‘targeted feature extraction’ (Profinder, Build 08.00). This 
uses the molecular formulae to extract and group spectral signals (i.e. 
adducts, multimers and isotopes), corresponding to individual database 
compounds. Feature extraction window; theoretical accurate mass ±10 ppm 
and database RT ±0.3 min. Allowed ion species were the same as specified 
above.  
 
2.3.6 Detection of non-AMRT database compounds in urine  
Urine data were also mined using Profinder for compounds not included in 
generated AMRT databases, but of interest for their predicted role in 
AKU/nitisinone metabolism. These compounds were associated with (a) 
increased tyrosine: N-acetyl-L-tyrosine, -glutamyl-L-tyrosine and tyramine-
sulfate; (b) ochronotic pigment: 2,5-dihydroxybenzaldehyde, hipposudoric 
acid and norhipposudoric acid; or (c) nitisinone metabolism: hydroxy-
nitisinone, nitisinone and 2-nitro-4-trifluoromethylbenzoic acid. For non-
AMRT compounds, the same RT (range <0.3 min) was required across 
samples. Compound identifications were based on theoretical accurate mass 
±10 ppm.  
 
2.3.7 Data quality control and statistical analyses 
Several quality control (QC) filters were applied to AMRT matched entities 
from each profiling batch. First, entities were retained if observed in at least 2 
samples per experimental group (i.e. sampling time point). Data files were 
then exported from Profinder and imported into Mass Profiler Professional 
(MPP, Build 14.5). 24 h urinary creatinine measurements (Jaffe alkaline 
picrate reaction, Roche Diagnostics, Germany) were used as an external 
scalar for individual human urine samples (average values across each 
sampling time point used for pooled samples). Quantitative measurement of 
creatinine was not possible in mouse samples due to small sample volumes; 
the signal identified as creatinine by matched AMRT was used as external 
scalar for each sample using the peak area of the 13C [M+H]+ ion (13C 
because 12C creatinine signal was saturated) calculated in MassHunter 
Quantitative analysis (Build 06.00). 
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Entities were then further filtered in MPP based on data from pooled samples 
from each experiment. Entities were retained if observed in 100 % of 
replicate injections for at least one sample group pool, and with peak area 
coefficient of variation (CV) <25 % across replicate injections of all sample 
group pools. 
 
Statistical analyses were performed in MPP based on peak area. Human 
urine profiles at 3, 12 and 24 months (following nitisinone treatment) were 
compared with baseline (pre-nitisinone) by one-way repeated-measures 
ANOVA. Mouse urine profiles were compared pre-nitisinone and 1 week on 
nitisinone by paired t-test. Benjamini-Hochberg false-discovery rate 
adjustment was used in all statistical significance testing. Fold changes 
(FC’s) were calculated based on raw peak area. Principal component 
analyses employing 4-component models were also performed on each 





2.4.1 Analysis of metabolite standards 
Signals representing the chemical formulae for standards in each injection 
were extracted from the data by theoretical accurate mass ±5 ppm. Only 
standards with RT >0.3 min after the column void volume were considered. 
519/619 (83.8 %) of the standards were retained sufficiently to be detected 
by at least 1 method (Supplementary Tables 2.2-2.4 shows the matches 
obtained by methods 1-3). 116/619 (18.7 %) and 226/619 (36.5 %) of the 
compounds were retained sufficiently and detected by 1 or 2 methods only, 
respectively, demonstrating the utility of combining data from the 3 
chromatographic methods (Figure 2.2 (A)). RT, accurate mass and charge 
state were entered into an AMRT metabolite database for each method for 
matching unknowns against.  
 
Figure 2.2 (B-D) shows the mass/RT distribution for compounds detected by 
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each method and highlights differences in selectivity for compounds from 3 
example compound groups with different chemical properties: carbohydrates, 
amino acids and lipids. Method 3 retained and separated highly polar 





Figure 2.2. Summary of the data acquired from analysis of metabolite 
standards. (A) Venn diagram summarizing the number of compounds 
retained and detected by methods 1-3, both alone (non-overlapping sections) 
and in combination (overlapping sections). (B-D) Mass/RT scatter plots for 
metabolite standards detected with the 3 analytical methods, showing the 




In methods 1 and 2, the same carbohydrates were weakly retained; for 
method 1 all carbohydrates detected eluted within the initial column void 
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(24/26 detected, RT range 0.58-0.68 min) and for method 2 all carbohydrates 
detected eluted close to the initial void (23/26 detected, RT range 1.3-1.4 
min). Method 1 showed some evidence of improved suitability for analysis of 
lipid-like compounds (11/11 detected, RT range 7.7-13.7 min) compared to 
methods 2 (8/11 detected, RT range 9.3-14.3 min) and 3 (7/11 detected, RT 
range 1.5-8.3 min), which detected fewer of these compounds within a 
narrower RT range overall. All 3 methods enabled detection of the amino 
acids, with method 3 appearing to show the most useful chromatographic 
resolution and retention (19/21 detected, RT range 5.4-8.1 min) compared to 
methods 1 (21/21 detected, RT range 0.6-2.8 min) and 2 (21/21 detected, RT 
range 1.0-4.6 min). 
 
2.4.2 Identification of metabolites in pooled urine by AMRT 
Unknown chemical entities were matched against the respective AMRT 
database generated for each method: accurate mass ±10 ppm, RT ±0.3 min. 
For data presented here, analysis comprised 2 replicate injections of the 
overall pooled urine from patients with AKU from the start and end of each 
analytical run (n=4). Only unknowns obtained from both injections in positive 
or negative polarity and with single AMRT compound matches were retained 
in this analysis. Additional QC filters were then applied to ensure 
reproducibility across the run: CV <25 % for peak area and RT between the 2 
replicate injections. Table 2.1 summarizes matches retained for each 
method. No compounds were filtered out due to RT CV >25 %. The 
maximum RT CV percentage change between the replicate injections across 
all analytical runs (each comprised 205 injections) was 4.1 %. 
 
Figure 2.3 (A) shows that 203 unique compound matches were obtained from 
urine. Fourteen AMRT matches were obtained by all 3 methods. An 
additional 61 AMRT matches were obtained by 2 methods, and 128 matches 
by only 1 of the methods, further supporting the increased coverage from the 
3 methods in combination. Figure 2.3 (B-D) shows the mass/RT distribution 
of the AMRT match.
85 
 
Table 2.1. Number of accurate mass retention time (AMRT) matches obtained by the 3 methods and retained following 
quality control filtering and decreasing AMRT window size during feature extraction. RT, retention time; +VE – positive 




Number of urine AMRT matches 
Method 1 Method 2 Method 3 
+VE -VE +VE -VE +VE -VE 
Accurate mass 
10 ppm, RT 0.3 min 
None 274 153 248 105 111 74 
  (1) Unique AMRT's only, manual curation 80 38 121 43 70 37 
  
(2) Abundance QC: peak area CV <25 % between 
replicates 
75 36 107 35 59 30 
  (3) RT shift QC: RT CV   <25 % between replicates  75 36 107 35 59 30 
Accurate mass             
5 ppm, RT 0.15 min 
Steps (1) - (3) 44 31 65 25 38 22 
Accurate mass          
2.5 ppm, RT 0.075 min 
Steps (1) - (3) 17 21 22 12 14 13 
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Table 2.1 and Supplementary Figure 2.3 show the number of AMRT matches 
obtained with narrower AMRT matching windows. For each method, >50 % 
of matches obtained with ±10 ppm and ±0.3 min post-QC remained with ±5 





Figure 2.3. Summary of compounds identified from analysis of urine by 
accurate mass retention time (ARMT). (A) Venn diagram summarizing the 
number of AMRT matches obtained for methods 1-3. (B-D) Mass/RT scatter 
plots for AMRT compound matches obtained from analysis of urine by the 3 




2.4.3 Application of strategy to AKU: effect of nitisinone therapy on the 
urine metabolome 
Figures 2.4 (A) and (B) show the overall study design and a representative 
example of AMRT compound signals extracted from the data respectively. 
Representative principal component analysis plots (Figure 2.4 (C)) show 
clear separation between the AMRT matched profiles of urine pre- vs post-






Figure 2.4. Application of the profiling strategy to AKU. (A) Urine was 
obtained from patients with AKU and HGD-/- mice pre- then post-nitisinone 
therapy. (B) Representative urine profiles (top) and extracted signals (bottom) 
for compounds identified by AMRT. (C) Principal component analysis 
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showing alteration to human (left) and mouse (right) urine metabolomes post-
nitisinone. x, y and z axes represent components 1, 2 and 3, respectively. 
Thirty-five metabolites showed statistically significant changes (p<0.05, 
FC>2) in abundance after 3, 12 or 24 months nitisinone in humans or 1 week 
on nitisinone in mice (Table 2.2). A FC >2 was chosen in order to limit false 
discovery and focus on clear changes. In patients with AKU, 13 metabolites 
increased and 14 decreased. In HGD-/- mice, 12 metabolites increased and 6 
decreased. Ten metabolites changed in the same direction in humans and 
mice (Table 2.2). Together, the majority of these metabolite changes could 
































3-(4-Hydroxyphenyl)lactic acid1       84 √ 
 
<0.0001 
3-(4-Hydroxyphenyl)pyruvic acid1  16 √ 
 
<0.0001 
3-Methoxytyramine1                         3.3 √ 
 
<0.0001 
4-Coumarate1                                       37 √ 
 
<0.0001 
4-Hydroxybenzaldehyde1                    58 √ 
 
<0.0001 
4-Hydroxyphenylacetic acid 1 2.1 √ 
 
<0.0001 
L-Tyrosine1 100+ √ 
 
<0.0001 
Mandellic acid1 7.0 √ 
 
<0.0001 
Phenylacetic acid1  16.0 √ 
 
<0.0001 
Tyramine1 9.1 √ 
 
<0.0001 
Homogentisic acid1                    5.3 
 
√ <0.0001 






Xanthurenic acid2 2.4 √ 
 
<0.0001 
4-Quinolinecarboxylic acid2 4.8 √ 
 
<0.0001 
Indoxyl sulfate2                                 11.0 
 
√ <0.0001 
L-Kynurenine2                                     4.8 
 
√ <0.0001 
L-Tryptophan2                                     4.2 
 
√ <0.0001 
Caffeate3 2.3 √ 
 
<0.0001 
3,5-Cyclic AMP3                                 4.3 
 
√ <0.0001 
3-Ureidopropionate3                        100+ 
 
√ <0.0001 
Adenine3                                             4.6 
 
√ <0.0001 
Allantoin3                                            100+ 
 
√ <0.0001 
Xanthosine3                                        4.6 
 
√ <0.0001 
5-Valeroclactone4 6.6 √ 
 
<0.0001 
Ethylmalonic acid4 5.2 √ 
 
<0.0001 
Creatine4 2.1 √ 
 
<0.0001 
α-ketoglutaric acid4 2.2 √ 
 
<0.0001 
Isocitric acid4 3.0 √ 
 
0.002 
Maleimide4 2.8 √ 
 
0.004 
2-Hydroxybutyric acid4                      1.7 
 
√ <0.0001 
2-Hydroxy-4-(methylthio)butyric acid4                                        100+ 
 
√ <0.0001 
L-Threonine4                                       7.3 
 
√ <0.0001 







Table 2.2. Urinary metabolite changes identified post-nitisinone in 
alkaptonuria by application of the profiling strategy. Fold changes were 
calculated from raw peak area. Bold indicates change observed in human 
and mouse data; italics indicate change observed in mouse data only; p 
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value <0.05 deemed significant. Metabolic pathway affected denoted by a 
number: 1 – tyrosine metabolism; 2- tryptophan metabolism; 3 – purine 
metabolism; 4 – other metabolic processes.  
 
 
Interestingly, mouse data also showed clear separation by gender (principal 
component 1; x-axis Figure 2.4 (C)). Histamine was the primary driver of this 
separation in positive polarity (principal component 1 loading; 0.42), which 
captured the effect of gender and explained 43 % of the variation in the 
dataset. Histamine was significantly increased in female mice (p<0.0001, 
FC=16).  
 
2.4.5 Alterations to non-AMRT database compounds post-nitisinone 
Data showed alteration (p<0.05, FC>2) to metabolites with a predicted 
association to AKU/nitisinone metabolism that were not from AMRT 
databases (Supplementary Table 2.5). 2,5-Dihydroxybenzaldehyde, probably 
associated with ochronotic pigment, was decreased post-nitisinone. The 
tyrosine metabolites N-acetyl-L-tyrosine and -glutamyl-L-tyrosine and the 
nitisinone metabolite hydroxy-nitisinone were increased. These changes 





We have developed a strategy for comprehensive LC-QTOF-MS profiling 
with compound identification by 3 AMRT databases generated from 
metabolite standards. Application of this strategy enabled: (a) identification of 
unknown chemical entities in complex biological matrix by AMRT; and (b) 
identification of previously unreported changes to urinary metabolites and 
metabolic pathways following nitisinone treatment in AKU.  
 
A limitation of LC-MS compound identification by public databases (Smith et 
al., 2005; Horai et al., 2010; Kanehisa et al., 2010; Milman et al., 2016; 
Wishart et al., 2018) is that data were acquired using different analytical 
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techniques and parameters. The Metabolomics Standards Initiative (MSI) has 
established levels of metabolite identification confidence (Sumner et al., 
2007; Dunn et al., 2013). Only identification strategies, as reported here, that 
compared 2 or more orthogonal chemical properties (e.g. AMRT) with an 
authentic standard under identical analytical conditions achieved the highest 
identification confidence level. Identifications by public databases in which 
data were acquired under different analytical conditions can only achieve the 
second level of confidence (‘putative identification’), even with 2 matched 
orthogonal chemical properties. 
 
Combining data from 3 LC techniques enhanced the number of unique urine 
AMRT matches obtained, improving coverage of the metabolome. Methods 1 
and 2 showed some similarity in analyte retention (Figure 2.2 (B-D)). Method 
2 was used because the Atlantis dC18 column was previously shown to 
chromatographically resolve metabolites of the tyrosine pathway in patients 
with AKU (Hughes et al., 2014; Hughes et al., 2015). It also provided greater 
overall retention of polar metabolites compared to a standard C18 column due 
to endcapping of bi-functionally bonded C18 stationary phase. Method 1 was 
included here to improve peak capacity owing to the increased theoretical 
plates provided by the smaller 2.1 µm column particle size. Moreover, 
methods 1 and 2 yielded 39 and 57 AMRT matches, respectively that were 
exclusive to each method (Figure 2.3 (A)). 
 
The congenital defect that causes AKU directly affects tyrosine catabolism. 
However, AKU is multi-systemic (Ranganath et al., 2013) and the wider 
metabolic consequences of the disease and nitisinone treatment have not 
been systematically studied. The strategy was applied to AKU, but given the 
range of primary and intermediary metabolism covered by the AMRT 
compounds, it could be applied to study metabolism in any disease. The data 
show that nitisinone alters tyrosine and tryptophan metabolism, and support 
alteration to the purine metabolic pathway. The changes observed comprise 
increased and decreased metabolite abundance within the same pathways, 
suggesting that nitisinone has complex, wide-ranging effects on metabolism. 
Nitisinone is licenced to treat patients with hereditary tyrosinaemia type 1 
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(HT1, OMIM 276700), another congenital disease of tyrosine metabolism, 
and is a promising HGA reducing agent in AKU. In nitisinone-treated HT1 
and AKU it is established that circulating tyrosine increases markedly 
(Lindstedt et al., 1992; Suwannarat et al., 2005; Introne et al., 2011; 
McKiernan et al., 2015; Olsson et al., 2015; Ranganath et al., 2016; Milan et 
al., 2017; Davison et al., 2018a; Davison et al., 2018b; Davison et al., 2018c). 
Tyrosine is the precursor for catecholamines, thyroid hormones and melanin 
(Figure 2.1), suggesting that increased tyrosine substrate has potential to 
dysregulate these pathways. In HT1 there are concerns that 
hypertyrosinaemia may contribute to neurodevelopmental delay (Masurel-
Paulet et al., 2008; De Laet et al., 2011; Thimm et al., 2012; Bendadi et al., 
2014; McKiernan et al., 2015). 
 
Application of our profiling strategy identified a number of previously 
unreported metabolite changes post-nitisinone. Increased 3-(4-
hydroxyphenyl)lactic acid (HPLA) is probably directly related to elevated 
tyrosine and/or its clearance in urine. Changes to (a) homovanillic acid and 
the trace amine tyramine and (b) L-tryptophan represent further alterations to 
dopamine (DP) and tryptophan-serotonin metabolism, respectively compared 
to those previously reported. L-Tryptophan is the precursor for serotonin, and 
a post-nitisinone decrease in the serotonin metabolite 5-hydroxyindoleacetic 
acid was previously reported in HT1 cerebrospinal fluid (Thimm et al., 2011) 
and AKU urine (Davison et al., 2018b), although not observed here. 
Xanthurenic acid and L-kynurenine were increased and decreased 
respectively, indicating for the first time that the kynurenine pathway, 
originating from tryptophan, is altered by nitisinone. Also, indoxyl sulfate, a 
metabolite of the indolepyruvate pathway from tryptophan, was decreased. 
Alterations to indolepyruvate metabolism are previously reported in 
nitisinone-treated AKU plasma; carboxaldehyde, indole-3-lactate and indole-
3-pyruvate increased, and in vitro studies indicated this as a direct 
consequence of increased 3-(4-hydroxyphenyl)pyruvic acid (HPPA) (Lees et 
al., 1973; Gertsman et al., 2015b). This is the first report of alterations to 
purine metabolism following treatment with nitisinone. Decreased 3,5-cyclic-
AMP and xanthosine were unexpected but replicated in mice. 
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The remaining metabolite changes have been previously reported following 
nitisinone treatment; decreased HGA and increased tyrosine, N-acetyl-L-
tyrosine, -glutamyl-tyrosine, HPPA and 3-methoxytyramine (3-MT). 
Decreased HGA and increased tyrosine are well-known consequences of 
nitisinone, and observation of these changes in each analytical run (tyrosine 
in positive and HGA in negative polarity) supports the analysis, data 
extraction workflow, and validity of the data. Increased N-acetyl-L-tyrosine 
and -glutamyl-tyrosine have been previously reported in nitisinone-treated 
AKU and were proportional to tyrosine elevation (Gertsman et al., 2015a). 
Increased 3-MT was previously reported in AKU urine (Davison et al., 2018b; 
Davison et al., 2018c); it is a metabolite of DP metabolism and derived from 
tyrosine via decarboxylation of dihydroxyphenylalanine to DP.  
 
Ten AMRT-matched metabolite changes were observed in human and 
mouse: 4-hydroxyphenylacetic acid, HPLA, HPPA, L-tyrosine, phenylacetic 
acid and tyramine increased post-nitisinone; 2-hydroxy-4-(methylthio)butyric 
acid, 3,5-cyclic AMP, HGA and xanthosine decreased post-nitisinone. The 
concordance between human and mouse data supports the approach and 
validity of the data. For mice, it was possible to control potentially 
confounding factors that could affect metabolism, such as diet and genetic 
diversity. This increases likelihood that observed changes are attributable to 
nitisinone. Reduced phenotypic variation could explain the prominent gender 
difference observed for mouse only; histamine was particularly elevated in 
urine from females, as previously reported in the literature for rats (Kim et al., 
1959; Netter et al., 1961), but not mice to our knowledge. 
 
The limitations of this study are as follows. Firstly, there is a relatively small 
sample size for a clinical metabolomics study (25 patients). However, AKU is 
a rare disease and the repeated-measures design enhanced statistical 
power. Secondly, data represent changes observed in urine not serum, which 
more closely reflects internal homeostasis. The urine metabolome is a 
composite of products from endogenous metabolism, diet, drugs and the gut 
microbiome. Urine does however give a valuable indication of the metabolic 
fate of the increased circulating tyrosine post-nitisinone. Further metabolomic 
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analyses on fluids and tissues from other biological locations are required to 
achieve more detailed, compartment-specific data, for example cerebrospinal 
fluid to directly study the impact of nitisinone-induced tyrosinaemia on the 
central nervous system. Thirdly, 3 chromatographic methods were used, 
however this may not always be feasible. For large-scale studies, it may be 
pragmatic to use 2 of the methods to reduce analytical and processing time. 
 
 
2.6 Conclusion  
 
We have developed a targeted LC-QTOF-MS strategy for comprehensive 
coverage of the metabolome with compound structure identification using 3 
AMRT databases, which are publicly available. Application of the approach to 
AKU has advanced our knowledge of the wider metabolic consequences of 
nitisinone, demonstrating the potential of our method as a metabolic 

















2.7 Supplementary material  




Supplementary Figure 2.1. Summary of experiment workflow for 
preparation and LC-QTOF-MS analysis of the 619 metabolite standards. 
Compounds were pooled across rows (A1-A12, B1-12 etc) in each of the 7 
96-well plates. Analysis comprised 112 injections of compound pools 




Supplementary Figure 2.2. Representative data from quality checks performed on data acquired from LC-QTOF-MS 
analysis using methods 1 and 3. Each analytical sequence consisted of 209 urine samples. The upper panels represent overlaid 
reference ion signal in positive polarity (A1 and A2) and negative polarity (B1 and B2), extracted ion chromatograms of reference 
masses were performed to check mass accuracy remained <5 ppm throughout the run. The lower panels represent overlaid binary 




Supplementary Figure 2.3. Summary of the number of accurate mass 
retention time matches obtained by methods 1-3 with accurate mass 



















Compound name Formula Mass 
1 A1 Nicotinamide adenine dinucleotide C21H27N7O14P2 663.11 
1 A2 L-Glutamine C5H10N2O3 146.07 
1 A3 Hypotaurine C2H7NO2S 109.02 
1 A4 Inosine 5'-phosphate C10H13N4O8P 348.05 
1 A5 Citrate C6H8O7 192.03 
1 A6 L-Threonine C4H9NO3 119.06 
1 A7 Purine C5H4N4 120.04 
1 A8 N-Acetylneuraminate C11H19NO9 309.11 
1 A9 L-Kynurenine C10H12N2O3 208.08 
1 A12 Pyrimidine C4H4N2 80.04 
1 A11 D-Aspartate C4H7NO4 133.04 
1 A12 Urate C5H4N4O3 168.03 
1 B1 Cytidine C9H13N3O5 243.09 
1 B2 L-Serine C3H7NO3 105.04 
1 B3 L-Cysteine C3H7NO2S 121.02 
1 B4 Citrulline C6H13N3O3 175.1 
1 B5 Taurine C2H7NO3S 125.01 
1 B6 D-Glucono-1,5-lactone C6H12O7 178.05 
1 B7 Nicotinate C6H5NO2 123.03 
1 B8 Inosine C10H12N4O5 268.08 
1 B9 4-Aminobutanoate C4H9NO2 103.06 
1 B10 Cytosine C4H5N3O 111.04 
1 B11 L-Isoleucine C6H13NO2 131.09 
1 B12 Pyrazole C3H3N2 67.03 
1 C1 L-Glutamic acid C5H9NO4 147.05 
1 C2 Ascorbate C6H8O6 176.03 
1 C3 β-Alanine C3H7NO2 89.05 
1 C4 N-Acetyl-D-glucosamine C8H15NO6 221.09 
1 C5 Glycolate C2H4O3 76.02 
1 C6 Sarcosine C3H7NO2 89.05 
1 C7 Gluconic acid C6H12O7 196.06 
1 C8 Quinate C7H12O6 192.06 
1 C9 (S)-Dihydroorotate C5H6N2O4 158.03 
1 C10 Malonate C3H4O4 104.01 
1 C11 Pipecolate C6H11NO2 129.08 
1 C12 Formamide CH3NO 45.02 
1 D1 Glycine C2H5NO2 75.03 
1 D2 L-Methionine C5H11NO2S 149.05 
1 D3 Tetrahydrofolate C19H23N7O6 445.17 
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1 D4 Adenine C5H5N5 135.05 
1 D5 5'-Methylthioadenosine C11H15N5O3S 297.09 
1 D6 Thymidine C10H14N2O5 242.09 
1 D7 Glycerate C3H6O4 106.03 
1 D8 Orotate C5H4N2O4 156.02 
1 D9 Ethanolamine phosphate C2H8NO4P 141.02 
1 D10 Xanthine C5H4N4O2 152.03 
1 D11 Dihydrofolate C19H21N7O6 443.16 
1 D12 L-Cystine C6H12N2O4S2 240.02 
1 E1 L-Alanine C3H7NO2 89.05 
1 E2 L-Tryptophan C11H12N2O2 204.09 
1 E3 Uridine-5-monophosphate C9H13N2O9P 324.04 
1 E4 L-Proline C5H9NO2 115.06 
1 E5 Thymine C5H6N2O2 126.04 
1 E6 Succinate semialdehyde C4H6O3 102.03 
1 E7 (S)-Lactate C3H6O3 90.03 
1 E8 Uridine C9H12N2O6 244.07 
1 E9 Fructose-1,6-biphosphate C6H14O12P2 340.116 
1 E10 Carnosine C9H14N4O3 226.11 
1 E11 Nicotinamide C6H6N2O 122.05 
1 E12 Shikimate C7H10O5 174.05 
1 F1 Succinate C4H6O4 118.03 
1 F2 L-Phenylalanine C9H11NO2 165.08 
1 F3 Uracil C4H4N2O2 112.03 
1 F4 (S)-Malate C4H6O5 134.02 





1 F7 Hypoxanthine C5H4N4O 136.04 
1 F8 Creatine C4H9N3O2 131.07 
1 F9 3,4-Dihydroxy-L-phenylalanine C9H11NO4 197.07 
1 F10 Guanosine C10H13N5O5 283.09 
1 F11 5,6-Dihydrouracil C4H6N2O2 114.04 
1 F12 (R)-Malate C4H6O5 134.02 
1 G1 L-Lysine C6H14N2O2 146.11 
1 G2 L-Tyrosine C9H11NO3 181.07 
1 G3 Glycerol C3H8O3 92.05 
1 G4 L-Asparagine C4H8N2O3 132.05 
1 G5 L-Valine C5H11NO2 117.08 
1 G6 Guanine C5H5N5O 151.05 
1 G7 Homoserine C4H9NO3 119.06 
1 G8 Pyridoxine C8H11NO3 169.07 
1 G9 D-AMP C10H14N5O6P 331.07 
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1 G10 (R,R)-Tartaric acid C4H6O6 150.02 
1 G11 Nicotinamide mononucleotide C11H15N2O8P 334.06 
1 G12 Folic acid C19H19N7O6 441.14 
1 H1 Isocitric acid C6H8O7 257.97 
1 H2 Thiourea CH4N2S 76.01 
1 H3 Diethanolamine C4H11NO2 105.08 
1 H4 3-Aminoisobutanoate C4H9NO2 103.06 
1 H5 Cys-Gly C5H10N2O3S 178.04 
1 H6 L-2-Phosphoglyceric acid C3H7O7P 229.96 
1 H7 Guanidinoacetate C3H7N3O2 117.05 
1 H8 Creatinine C4H7N3O 113.06 
1 H9 N-Acetyl-D-tryptophan C13H14N2O3 246.1 
1 H10 Trans-aconitate C6H6O6 174.02 
1 H11 N-Acetyl-D-mannosamine C8H15NO6 221.09 
1 H12 D-Glucose-6-phosphate C6H13O9P 282.01 
2 A1 L-2,6-Diaminoheptanedioate C7H14N2O4 190.1 
2 A2 α-Aminoadipate C6H11NO4 161.07 
2 A3 Deoxycytidine C9H13N3O4 227.09 
2 A4 Noradrenaline C8H11NO3 169.07 
2 A5 D-Glucosamine 6-phosphate C6H14NO8P 281.03 
2 A6 (S,S)-Tartaric acid C4H6O6 150.02 
2 A7 3-Dehydroshikimate C7H8O5 172.04 
2 A8 Bis(3-Aminopropyl)amine C6H17N3 131.14 
2 A9 Homocysteine C4H9NO2S 135.04 
2 A12 Theophylline C7H8N4O2 180.06 
2 A11 Leucine C6H13NO2 131.09 
2 A12 D-(+)-Trehalose C12H22O11 378.14 
2 B1 Βine C5H11NO2 117.08 
2 B2 D-Tryptophan C11H12N2O2 204.09 
2 B3 3-Sulfino-L-alanine C3H7NO4S 153.01 
2 B4 O-Succinyl-L-homoserine C8H13NO6 219.07 
2 B5 Allantoin C4H6N4O3 158.04 
2 B6 Glyceraldehyde C3H6O3 90.03 
2 B7 D-Glucuronolactone C6H10O7 176.03 
2 B8 (2-Aminoethyl)phosphonate C2H8NO3P 125.02 
2 B9 Selenomethionine C5H11NO2Se 196.106 
2 B10 Maleimide C4H3NO2 97.02 
2 B11 Formate CH2O2 46.01 
2 B12 D-(+)-Glucosamine C6H13NO5 215.06 
2 C1 Paraxanthine C7H8N4O2 180.06 
2 C2 Adenosine 5'-diphosphate C10H15N5O10P2 450.02 
2 C3 2-Deoxy-D-glucose C6H12O5 164.07 
2 C4 N-(Pai)-Methyl-L-histidine C7H11N3O2 169.09 
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2 C5 Galactitol C6H14O6 182.08 
2 C6 5-Oxo-D-proline C5H7NO3 129.04 
2 C7 4-Pyridoxate C8H9NO4 183.05 
2 C8 Pyridine-2,3-dicarboxylate C7H5NO4 167.02 
2 C9 Methylguanidine C2H7N3 73.06 
2 C10 Caffeine C8H10N4O2 194.08 
2 C11 
DL-3-Hydroxy-3-methylglutaryl 




2 C12 D-Glucuronic acid C6H10O7 234.04 
2 D1 1-Methyladenosine C11H15N5O4 281.11 
2 D2 Deoxyuridine C9H12N2O5 228.07 
2 D3 Trans-4-hydroxyproline C5H9NO3 131.06 
2 D4 Urocanate C6H6N2O2 138.04 
2 D5 Kynurenine C10H12N2O3 208.08 
2 D6 5-Oxo-L-proline C5H7NO3 129.04 
2 D7 4-Acetamidobutanoate C6H11NO3 145.07 
2 D8 Trans-Cyclohexane-1,2-diol C6H12O2 116.08 
2 D9 Melanin C18H10N2O4 318.06 
2 D10 Dopamine C8H11NO2 189.06 
2 D11 Putrescine C4H12N2 88.1 
2 D12 L-Lysine C6H14N2O2 182.08 
2 E1 Cytidine 5'-diphosphocholine C14H26N4O11P2 532.09 
2 E2 1,3-Diaminopropane C3H10N2 74.08 





2 E5 5-Hydroxymethyluracil C5H6N2O3 142.04 
2 E6 L-Cystathionine C7H14N2O4S 222.07 
2 E7 L-Norvaline C5H11NO2 117.08 
2 E8 3-Hydroxy-3-methylglutarate C6H10O5 162.05 
2 E9 Phosphonoacetate C2H5O5P 139.99 
2 E10 Picolinic acid C6H5NO2 123.03 
2 E11 Ethanolamine C2H7NO 61.05 
2 E12 L-Arginine C6H14N4O2 210.09 
2 F1 4-Hydroxy-L-proline C5H9NO3 131.06 
2 F2 6-Deoxy-L-galactose C6H12O5 164.07 
2 F3 Homocystine C8H16N2O4S2 268.06 
2 F4 N-Methyl-L-glutamate C6H11NO4 161.07 
2 F5 D-Ornithine C5H12N2O2 168.07 
2 F6 Xanthosine C10H12N4O6 284.08 
2 F7 3-Methylcrotonyl-CoA C26H42N7O17P3S 849.16 
2 F8 Thyrotropin releasing hormone C16H22N6O4 362.17 
2 F9 5’-Cytidine monophosphate C9H14N3O8P 323.05 
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2 F10 N-Methyl-D-aspartic acid C5H9NO4 147.05 
2 F11 Galactarate C6H10O8 210.04 
2 F12 L-Histidine C6H9N3O2 208.05 
2 G1 
Nicotinic acid adenine 
dinucleotide phosphate 
C21H27N6O18P3 766.04 
2 G2 N-α-Acetyl-L-asparagine C6H10N2O4 174.06 
2 G3 L-Pipecolic acid C6H11NO2 129.08 





2 G6 Carbamoyl phosphate CH4NO5P 184.95 
2 G7 Isopentenyl pyrophosphate C5H12O7P2 297.09 





2 G10 Agmatine sulfate C5H14N4 228.09 





2 H1 N-Acetylglycine C4H7NO3 117.04 
2 H2 N-Acetyl-L-aspartic acid C6H9NO5 175.05 













2 H7 S-(5’-Adenosyl)-L-methionine C15H22N6O5S 570.16 
2 H8 6-Phosphogluconic acid C6H13O10P 344.99 
2 H9 α-Hydroxyisobutyric acid C4H8O3 104.05 
2 H10 L-Cysteic acid C3H7NO5S 187.02 
2 H11 Adenosine 5’-monophosphate C10H14N5O7P 391.03 
2 H12 D-Gluconate C6H12O7 218.04 
3 A1 Putrescine C4H12N2 88.15 





3 A4 Mevalolactone C6H12O4 130.06 
3 A5 Uridine 5’-diphosphoglucose C15H24N2O17P2 610.02 
3 A6 Isopentenyl pyrophosphate C5H12O7P2 297.09 
3 A7 2’-Deoxyuridine 5’-triphosphate C9H15N2O14P3 489.96 
3 A8 Phosphocholine C5H14NO4P 329.03 
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3 A9 Uridine 5’-triphosphate C9H15N2O15P3 484.14 
3 A12 6-Hydroxydopamine C8H11NO3 205.05 





3 B1 5-Methylcytosine hydrochloride C5H7N3O 161.04 





3 B4 Nε,Nε,Nε-Trimethyllysine C9H20N2O2 223.12 
3 B5 Phospho(enol)pyruvic acid C3H5O6P 251.94 
3 B6 Guanosine 5’-diphosphoglucose C16H25N5O16P2 628.07 
3 B7 α-D-Galactose 1-phosphate C6H13O9P 425.99 
3 B8 Pyridoxal 5’-phosphate C8H10NO6P 265.04 
3 B9 Dihydroxyacetone phosphate C3H7O6P 182.01 
3 B10 Phospho(enol)pyruvic acid C3H5O6P 205.94 
3 B11 D-Mannose 6-phosphate C6H13O9P 413.93 





3 C2 Phosphate C2H8NO4P 141.02 
3 C3 O-Acetyl-L-serine C5H9NO4 183.03 





3 C6 Adenosine-5’-diphosphoglucose C16H25N5O15P2 633.05 
3 C7 D-Fructose 6-phosphate C6H13O9P 322.0 
3 C8 Adenosine 3’,5’-diphosphate C10H15N5O10P2 470.99 
3 C9 3-Nitro-L-tyrosine C9H10N2O5 226.06 
3 C10 Octopamine C8H11NO2 189.06 
3 C11 N-α-Acetyl-L-lysine C8H16N2O3 188.12 
3 C12 Uridine 5’-diphosphogalactose C15H24N2O17P2 610.02 
3 D1 Spermidine C7H19N3 253.09 
3 D2 Pyridoxamine C8H12N2O2 240.04 





3 D5 Adenosine 5’-triphosphate C10H16N5O13P3 550.96 
3 D6 D-Ribulose 1,5-bisphosphate C5H12O11P2 350.99 
3 D7 Xanthosine 5’-monophosphate C10H13N4O9P 408.01 
3 D8 Flavin adenine dinucleotide C27H33N9O15P2 847.13 
3 D9 2’-Deoxyguanosine C10H13N5O4 285.11 
3 D10 Orotic acid C5H4N2O4 174.03 
3 D11 Lauroylcarnitine C19H37NO4 343.5 
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3 D12 1-Methylnicotinamide C7H9N2O 172.04 
3 E1 Spermine C10H26N4 346.12 
3 E2 N-Acetyl-DL-methionine C7H13NO3S 191.06 






















3 E9 L-Homocysteine thiolactone C4H7NOS 153 
3 E10 O-Phospho-DL-serine C3H8NO6P 185.01 
3 E11 S-(5’-Adenosyl)-L-homocysteine C14H20N6O5S 384.12 
3 E12 L-Ornithine C5H12N2O2 168.07 
3 F1 Adenine C5H5N5 170.02 





3 F4 Guanosine 5’-diphosphate C10H15N5O11P2 466.01 





3 F7 2,3-Diphospho-D-glyceric acid C3H8O10P2 375.87 
3 F8 Cytidine 5’-diphosphate C9H15N3O11P2 443.01 
3 F9 Selenocystamine C4H12N2Se2 283.91 
3 F10 Histamine C5H9N3 182.03 
3 F11 Indoxyl sulfate C8H7NO4S 249.96 
3 F12 Ethyl 3-ureidopropionate C6H12N2O3 160.08 
3 G1 Deoxyribose C5H10O4 134.06 
3 G2 Phytic acid C6H18O24P6 697.82 





3 G5 S-Hexyl-glutathione C16H29N3O6S 391.18 
3 G6 Glyoxylic acid C2H2O3 92.01 
3 G7 Guanosine 5’-monophosphate C10H14N5O8P 425.03 
3 G8 N-Acetyl-L-alanine C5H9NO3 131.06 
3 G9 4-Guanidinobutanoate C5H11N3O2 145.09 
3 G10 Hydroxypyruvate C3H4O4 141.97 
3 G11 D-Mannosamine C6H13NO5 215.06 
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3 G12 Cytochrome C C42H52FeN8O6S2 884.28 
3 H1 O-Acetyl-L-carnitine C9H17NO4 239.09 
3 H2 Riboflavin C17H20N4O6 376.14 
3 H3 Methyl β-D-galactoside C7H14O6 194.08 
3 H4 Glutaric acid C5H8O4 132.04 
3 H5 Dihydroxyfumaric acid C4H4O6 166.01 





3 H8 5’-Deoxyadenosine C10H13N5O3 251.1 
3 H9 Glutathione C10H17N3O6S 307.08 
3 H10 Erythritol C4H10O4 122.06 
3 H11 Glucosaminate C6H13NO6 195.07 
3 H12 Uridine 5’-triphosphate C9H15N2O15P3 483.97 
4 A1 2’-Deoxyadenosine C10H13N5O3 269.11 
4 A2 N-Acetylputrescine C6H14N2O 166.09 
4 A3 N-Acetyl-D-galactosamine C8H15NO6 221.09 
4 A4 N-Acetyl-DL-glutamic acid C7H11NO5 189.06 
4 A5 2,4-Dihydroxypteridine C6H4N4O2 164.03 
4 A6 6-Hydroxynicotinate C6H5NO3 139.03 
4 A7 N-Acetyl-L-cysteine C5H9NO3S 162.02 
4 A8 Inosine 5’-monophosphate C10H13N4O8P 392.01 
4 A9 D-Pantothenic acid C9H17NO5 476.17 
4 A12 2-Amino-2-methylpropanoate C4H9NO2 103.06 
4 A11 Aniline-2-sulfonic acid C6H7N 173.01 
4 A12 S-Carboxymethyl-L-cysteine C5H9NO4S 179.03 
4 B1 L-Rhamnose C6H12O5 182.08 
4 B2 Thiamine pyrophosphate C12H18N4O7P2S 460.01 
4 B3 L-Histidinol C6H11N3O 212.04 
4 B4 Thymidine 5’-monophosphate C10H15N2O8P 322.06 
4 B5 3-Ureidopropionate C4H8N2O3 132.05 
4 B6 5-Aminopentanoate C5H11NO2 117.08 
4 B7 Norleucine C6H13NO2 131.09 
4 B8 N-Formylglycine C3H5NO3 103.03 
4 B9 Adenosine C10H13N5O4 267.1 
4 B10 D-(+)-Raffinose C18H32O16 594.22 





4 C1 D-Saccharic acid C6H10O8 247.99 
4 C2 Adenosine 5’-triphosphate C10H16N5O13P3 568.97 
4 C3 3-Methoxy-L-tyrosine C10H13NO4 247.11 
4 C4 D-Lactose C12H22O11 360.13 
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4 C5 3-Hydroxybutanoic acid C4H8O3 104.05 
4 C6 4-Imidazoleacetic acid C5H6N2O2 161.01 
4 C7 D-(+)-Galacturonic acid C6H10O7 212.05 
4 C8 Cytidine 5’-triphosphate C9H16N3O14P3 526.95 
4 C9 3’,5’-Cyclic AMP C10H12N5O6P 329.05 
4 C10 L-Methionine sulfoximine C5H12N2O3S 180.06 
4 C11 Cis-4-Hydroxy-D-proline C5H9NO3 131.06 
4 C12 N-1-Acetylspermine C12H28N4O 352.16 





4 D3 3-Methylhistamine C6H11N3 197.05 
4 D4 Maleamate C4H5NO3 115.03 
4 D5 Choline C5H14NO 104.11 
4 D6 4-Aminobutanoate C4H9NO2 139.04 
4 D7 Formyl-L-methionyl peptide C6H11NO3S 177.05 
4 D8 Acetylcholine C7H16NO2 181.09 
4 D9 Oxalic Acid C2H2O4 126.02 
4 D10 5-Hydroxy-L-tryptophan C11H12N2O3 220.08 
4 D11 D-Alanine C3H7NO2 89.05 
4 D12 Theobromine C7H8N4O2 180.06 
4 E1 N-Amidino-L-aspartate C5H9N3O4 175.06 
4 E2 L-Histidine C6H9N3O2 155.07 
4 E3 L-Allothreonine C4H9NO3 119.06 
4 E4 Creatine phosphate C4H10N3O5P 327.04 
4 E5 Spermidine C7H19N3 145.16 
4 E6 Adenosine 5’-diphosphoribose C15H23N5O14P2 581.05 
4 E7 2-Methoxyethanol C3H8O2 76.05 
4 E8 Citramalate C5H8O5 223.95 
4 E9 L-Anserine C10H16N4O3 303.12 
4 E10 Biliverdin C33H34N4O6 618.22 
4 E11 Dl-5-Hydroxylysine C6H14N2O3 198.08 
4 E12 Cysteamine C2H7NS 77.03 
4 F1 Ophthalmic acid C11H19N3O6 289.13 
4 F2 L-2,3-Diaminopropionic acid C3H8N2O2 140.04 
4 F3 Trigonelline C7H7NO2 173.02 
4 F4 Adrenaline C9H13NO3 183.09 
4 F5 3,4-Dihydroxyphenyl glycol C8H10O4 170.06 
4 F6 Cadaverine C5H14N2 174.07 
4 F7 2-Hydroxybutyric acid C4H8O3 126.03 
4 F8 Coenzyme A C21H36N7O16P3S 790.1 
4 F9 Oxalomalic acid C6H6O8 271.95 
4 F10 Inosine 5’-triphosphate C10H15N4O14P3 573.93 
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4 F11 Sn-Glycero-3-phosphocholine C8H20NO6P 440.94 
4 F12 2,5-Dimethylpyrazine C6H8N2 108.07 
4 G1 Stachyose C24H42O21 666.22 
4 G2 2’-Deoxycytidine 5'-diphosphate C9H15N3O10P2 410.01 
4 G3 (2r,3r)-(-)-2,3-Butanediol C4H10O2 90.07 
4 G4 D-Ribose 5-phosphate C5H11O8P 291.99 
4 G5 3-Hydroxykynurenine C10H12N2O4 224.08 





4 G8 Sn-Glycerol 3-phosphate C3H9O6P 370.22 
4 G9 Vitamin B12 C63H88CoN14O1P 1354.57 
4 G10 4-Hydroxy-L-phenylglycine C8H9NO3 167.06 
4 G11 N-Acetyl-DL-serine C5H9NO4 147.05 
4 G12 Uridine 5'-diphosphate C9H14N2O12P2 467.99 
4 H1 Glycerol 2-phosphate C3H9O6P 233.99 
4 H2 α-D-Glucose 1-phosphate C6H13O9P 322.00 
4 H3 D-Glucosamine 6-sulfate C6H13NO8S 259.04 
5 A1 3-Methyglutaric acid C6H10O4 146.06 
5 A2 Sorbate C6H8O2 150.01 
5 A3 Mono-ethyl malonate C3H4O4 132.04 
5 A4 Dimethyl sulfide C2H6S 62.02 
5 A5 4-Hydroxybenzoate C7H6O3 138.03 
5 A6 Tyramine C8H11NO 137.08 
5 A7 Cortisol C21H30O5 362.21 
5 A8 Prenol C5H10O 86.07 
5 A9 3-Hydroxybenzaldehyde C7H6O2 122.04 
5 A12 Xanthurenic acid C10H7NO4 205.04 
5 A11 2-Methylpropanal oxime C4H9NO 87.07 
5 A12 Propionate C3H6O2 96.02 
5 B1 Trimethylamine C3H9N 95.05 
5 B2 Melatonin C13H16N2O2 232.12 
5 B3 Maleic acid C4H4O4 116.01 
5 B4 Pentanoate C5H10O2 102.07 
5 B5 Propanoate C3H6O2 74.04 
5 B6 Bilirubin C33H36N4O6 584.26 
5 B7 (S)-Nicotine C10H14N2 162.12 





5 B10 2-Methylpropanoate C4H8O2 88.05 
5 B11 3-Hydroxybenzyl alcohol C7H8O2 124.05 
5 B12 Aniline C6H7N 93.06 
108 
5 C1 4-Hydroxyphenylacetic acid C8H8O3 152.05 
5 C2 3,5-Diiodo-L-tyrosine C9H9I2NO3 468.89 
5 C3 Mandelic acid C8H8O3 152.05 
5 C4 Tryptamine C10H12N2 160.1 
5 C5 Benzoate C7H6O2 122.04 
5 C6 Glutarate C5H8O4 132.04 
5 C7 Indole-3-acetate C10H9NO2 175.06 
5 C8 Caffeate C9H8O4 180.04 
5 C9 Lumichrome C12H10N4O2 242.08 
5 C10 6-Carboxyhexanoate C7H12O4 160.07 
5 C11 N-Acetyl-L-phenylalanine C11H13NO3 207.09 
5 C12 Amylose C14H26O11 167.04 
5 D1 L-Tryptophanamide C11H13N3O 238.07 
5 D2 Phenol C6H6O 94.04 
5 D3 N-Ω-Methyltryptamine C11H14N2 173.11 
5 D4 Oxaloacetate C4H4O5 132.01 
5 D5 2,3-Dihydroxybenzoate C7H6O4 154.03 
5 D6 Propenoate C3H4O2 72.02 
5 D7 Indole-3-ethanol C10H11NO 161.08 
5 D8 Ferulate C10H10O4 194.06 
5 D9 Glycocholate C26H43NO6 465.31 
5 D10 Phenylethanolamine C8H11NO 137.08 





5 E1 Propanal C3H6O 58.04 
5 E2 Benzoate C7H5NaO2 144.02 
5 E3 3-Amino-5-hydroxybenzoic acid C7H7NO3 189.02 
5 E4 Catechol C6H6O2 110.04 
5 E5 3,4-Dihydroxybenzoate C7H6O4 154.03 
5 E6 Cyclopentanone C5H8O 84.06 
5 E7 Pantolactone C6H10O3 130.06 
5 E8 Guaiacol C7H8O2 124.05 
5 E9 2-Hydroxyphenylacetic acid C8H8O3 152.05 





5 E12 2-Hydroxypyridine C5H5NO 95.04 
5 F1 3,4 Dihydroxyphenylacetate C8H8O4 168.04 
5 F2 N-6-(δ-2-Isopentenyl) adenine C10H13N5 203.12 
5 F3 Methyl vanillate C8H8O4 182.06 
5 F4 2-Oxobutanoate C4H6O3 102.03 
5 F5 Lipoamide C8H15NOS2 205.06 
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5 F6 3-Hydroxyanthranilate C7H7NO3 153.04 
5 F7 3-(4-Hydroxyphenyl)pyruvate C9H8O4 180.04 
5 F8 Hexanoate C6H12O2 116.08 
5 F9 Methylmalonate C4H6O4 118.03 
5 F10 
Serotonin creatinine sulfate 
complex 
C14H23N5O7S 405.13 
5 F11 Cortisol 21-acetate C23H32O6 404.22 
5 F12 Indole-3-acetamide C10H10N2O 174.08 
5 G1 Hippurate C9H9NO3 179.06 
5 G2 Ethylmalonic acid C5H8O4 132.04 
5 G3 3,5-Diiodo-L-thyronine C15H13I2NO4 524.89 
5 G4 Fumarate C4H4O4 116.01 
5 G5 Benzaldehyde C7H6O 106.04 
5 G6 4-Hydroxybenzaldehyde C7H6O2 122.04 
5 G7 3-(2-Hydroxyphenyl)propanoate C9H10O3 166.06 
5 G8 3-Methoxytyramine C9H13NO2 203.07 
5 G9 Benzylamine C7H9N 107.07 
5 G10 2-Quinolinecarboxylic acid C10H7NO2 173.05 
5 G11 Serotonin C10H12N2O 211.06 
5 G12 Pterin C6H5N5O 163.05 
5 H1 4-Aminobenzoate C7H7NO2 137.05 
5 H2 2-Aminophenol C6H7NO 109.05 
5 H3 Acetoin C4H8O2 88.05 
5 H4 Indole-3-pyruvic acid C11H9NO3 203.06 
5 H5 Dehydro-L-(+)-ascorbic acid dimer C6H6O6 348.03 
5 H6 3-Amino-4-hydroxybenzoic acid C7H7NO3 153.04 
5 H7 Dihydroxymandelic acid C8H8O5 184.04 
5 H8 Anthranilate C7H7NO2 137.05 
5 H9 Thioacetate C2H4OS 76.00 
5 H10 Butanoate C4H8O2 88.05 
5 H11 Indole-3-acetic acid C10H9NO2 196.04 
5 H12 5-Valerolactone C5H8O2 100.05 
6 A1 2,5-Dihydroxybenzoate C7H6O4 154.03 
6 A2 2-Methylmaleate C5H6O4 130.03 
6 A3 Hydroquinone C6H6O2 110.04 
6 A4 Dethiobiotin C10H18N2O3 214.13 
6 A5 3-Methyl-2-oxovaleric acid C6H10O3 130.06 
6 A6 α-Ketoglutaric acid C5H6O5 167.00 
6 A7 N-Acetylserotonin C12H14N2O2 218.11 
6 A8 3-Methylbutanal C5H10O 86.07 
6 A9 Itaconate C5H6O4 130.03 
6 A12 Azelaic acid C9H16O4 188.1 
6 A11 Mono-methyl glutarate C6H10O4 146.06 
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6 A12 2-Methylglutaric acid C6H10O4 146.06 
6 B1 Phenylacetaldehyde C8H8O 120.06 
6 B2 2-Methylbutanal C5H10O 86.07 
6 B3 Phenyl acetate C8H8O2 136.05 
6 B4 Diacetyl C4H6O2 86.04 
6 B5 Pyruvate C3H4O3 88.02 
6 B6 Trans-Cinnamaldehyde C9H8O 132.06 
6 B7 2,6-Dihydroxypyridine C5H5NO2 147.01 
6 B8 Phenethylamine C8H11N 121.09 
6 B9 Methyl acetoacetate C5H8O3 116.05 
6 B10 Suberic acid C8H14O4 174.09 
6 B11 Adipic acid C6H10O4 146.06 
6 B12 Geranyl ayrophosphate C10H20O7P2 368.17 
6 C1 N-Acetyl-L-leucine C8H15NO3 173.11 
6 C2 2',4'-Dihydroxyacetophenone C8H8O3 152.05 
6 C3 Benzyl alcohol C7H8O 108.06 
6 C4 2-Oxoadipate C6H8O5 160.04 
6 C5 Methyl indole-3-acetate C11H11NO2 189.08 
6 C6 (R)-Mevalonic acid lithium salt C6H11O4 · xLi+ 147.15 
6 C7 3-Methoxy-4-hydroxymandelate C9H10O5 198.05 
6 C8 Homovanillate C9H10O4 182.06 
6 C9 4-Quinolinecarboxylic acid C10H7NO2 173.05 
6 C10 (S)-1-Phenylethanol C8H10O 122.07 
6 C11 Tetrahydroisoquinoline C10H13NO2 258.01 
6 C12 Salicylamide C7H7NO2 137.05 
6 D1 3-Hydroxybenzoate C7H6O3 138.03 









6 D5 Homogentisate C8H8O4 168.04 





6 D8 3-Hydroxyphenylacetate C8H8O3 152.05 
6 D9 4-Methylcatechol C7H8O2 124.05 
6 D10 Pyridoxal C8H9NO3 203.03 
6 D11 Salicylate C7H6O3 138.03 
6 D12 3-Methylbutanol C5H12O 88.09 
6 E1 3-Methyl-2-oxindole C9H9NO 147.07 
6 E2 3-Methyladenine C6H7N5 149.07 
6 E3 3-(4-Hydroxyphenyl)lactic acid C9H10O4 182.06 
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6 E4 Biotin C10H16N2O3S 244.09 
6 E5 Mercaptopyruvate C3H4O3S 141.97 
6 E6 Pyruvic aldehyde C3H4O2 72.02 
6 E7 Pyrrole-2-carboxylate C5H5NO2 110.02 
6 E8 5-Hydroxyindoleacetate C10H9NO3 191.06 
6 E9 Phenylacetic acid C8H8O2 136.05 
6 E10 Resorcinol monoacetate C8H8O3 152.05 
6 E11 Acetoacetate C4H6O3 108.04 
6 E12 Acetyl phosphate C2H5O5P 183.95 
6 F1 Ethyl 3-indoleacetate C12H13NO2 203.09 
6 F2 Dehydroascorbate C6H6O6 174.02 
6 F6 D-Fructose C6H12O6 180.063 
6 F7 L-Sorbose C6H12O6 180.063 
6 F7 Xylitol C5H12O5 152.068 
6 F9 Ribitol C5H12O5 152.068 
6 F10 Myoinositol C6H12O6 180.063 
6 F11 Mannose C6H12O6 180.063 
6 F12 Arabinose C5H10O5 150.052 
6 G1 D-Xylose C5H10O5 150.052 
6 G2 Sucrose C12H22O11 342.116 
6 G3 D-Galactose C6H12O6 180.063 
6 G4 α-D-Glucose C6H12O6 180.063 
6 G5 Allose C6H12O6 180.063 
6 G6 Mannitol C6H14O6 182.079 
6 G7 Melibiose C12H22O11 342.116 
6 G8 D-Sorbitol C6H14O6 180.063 
6 G9 Maltose C12H22O11 342.116 
6 G10 D-Tagatose C6H12O6 180.063 
6 G11 D-Gulonic acid -lactone C6H12O7 178.047 
6 G12 D-(-)-Arabinose C5H10O5 150.052 
6 H1 D-(+)-Cellobiose C12H22O11 342.116 
6 H2 D-Psicose C6H12O6 180.063 
6 H3 L-Arabitol C5H12O5 152.068 
6 H4 D-Lyxose C5H10O5 150.052 
6 H5 D-Ribose C5H10O5 150.052 
6 H6 Palatinose C12H22O11 342.116 
7 A1 Vitamin D2 C28H44O 396.339 
7 A2 Squalene C30H50 410.391 
7 A3 4-Coumarate C9H8O3 164.047 
7 A4 Nonanoate C9H18O2 158.13 
7 A5 Chenodeoxycholate C24H40O4 392.292 
7 A6 Caprylic Acid C8H16O2 144.115 
7 A7 Cholesteryl acetate C29H48O2 428.365 
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7 A8 Petroselinic acid C18H34O2 282.255 
7 A9 1,2-Dipalmitoyl-Sn-glycerol C35H68O5 568.506 
7 A12 3α,12α-Dihydroxy-5β-cholanate C24H40O4 392.292 
7 A11 3α-Hydroxy-5β-cholanate C24H40O3 376.297 
7 A12 Protoporphyrin C34H34N4O4 562.258 
7 B1 Heptanoic acid C7H14O2 130.099 
7 B2 Retinol C20H30O 286.229 
7 B3 Menaquinone C31H40O2 444.302 
7 B4 Elaidic Acid C18H34O2 282.255 
7 B5 Estradiol-17α C18H24O2 272.177 
7 B6 Myristic acid C14H28O2 228.208 
7 B7 Cholesteryl oleate C45H78O2 650.60 
7 B8 Rosmarinic acid C18H16O8 360.084 
7 B9 Glyceryl tripalmitate C51H98O6 806.736 
7 B10 Reichstein substance S C21H30O4 346.214 
7 B11 Taurolithocholate C26H45NO5S 506.291 
7 B12 Palmitoleic acid C16H30O2 254.224 
7 C1 Palmitate C16H32O2 256.24 
7 C2 3,3',5'-Triiodothyronine C15H12I3NO4 650.79 
7 C3 Sphinganine C18H39NO2 301.298 
7 C4 Lanosterol C30H50O 426.386 
7 C5 Lauric acid C12H24O2 200.177 
7 C6 Arachidic acid C20H40O2 312.302 
7 C7 Erucic acid C22H42O2 338.318 
7 C8 Deoxycholate C24H40O4 414.274 
7 C9 4-Methyl-2-oxo-pentanoic acid C6H10O3 334.094 
7 C10 Leukotriene B4 C20H32O4 336.23 
7 C11 Heptadecanoate C17H34O2 270.255 
7 C12 Glyceryl trimyristate C45H86O6 722.6424 
7 D1 Linoleate C18H32O2 280.24 
7 D2 Sphingomyelin C41H83N2O6P 730.598 
7 D3 Cholesta-5,7-Dien-3β-ol C27H44O 384.339 
7 D4 Thyroxine C15H11I4NO4 776.686 
7 D5 Bis(2-Ethylhexyl)phthalate C24H38O4 390.277 
7 D6 Gamma-Linolenic acid C18H30O2 278.224 
7 D7 Ω-Hydroxydodecanoic acid C12H24O3 216.172 
7 D8 Methyl jasmonate C13H20O3 224.141 
7 D9 L-α-Phosphatidylcholine C42H80NO8P 766.082 
7 D10 Hexadecanol C16H34O 242.26 
7 D11 Dimethylbenzimidazole C9H10N2 146.084 
7 D12 Retinoate C20H28O2 300.208 
7 E1 Indole C8H7N 117.057 
7 E2 Cholate C24H40O5 408.287 
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7 E3 Phylloquinone C31H46O2 450.349 
7 E4 Cholesteryl palmitate C43H76O2 624.584 
7 E5 Quinoline C9H7N 129.057 
7 E6 Docosahexaenoic acid C22H32O2 328.24 
7 E7 Diethyl 2-methyl-3-oxosuccinate C9H14O5 202.084 
7 E8 Retinyl Palmitate C36H60O2 524.459 
7 E9 1-Naphthylamine C10H9N 143.073 





7 E12 Phenylpyruvate C9H8O3 186.029 
7 F1 Trans-Cinnamate C9H8O2 148.052 
7 F2 Oleate C18H34O2 282.255 
7 F3 Stearate C18H36O2 284.271 
7 F4 β-Carotene C40H56 536.438 
7 F5 25-Hydroxycholesterol C27H46O2 402.349 
7 F6 Nervonic Acid C24H46O2 366.349 
7 F7 Desmosterol C27H44O 384.339 
7 F8 Deoxycorticosterone acetate C23H32O4 372.23 
7 F9 1-Oleoyl-rac-glycerol C21H40O4 356.292 
7 F12 α-Tocopherol C29H50O2 430.381 
7 F11 Rac-Glycerol 1-myristate C17H34O4 302.245 
7 F12 Tricosanoic acid C23H46O2 354.349 
7 G1 Coenzyme Q10 C59H90O4 863.343 
7 G2 Cortisone C21H28O5 360.193 
7 G3 Decanoate C10H20O2 172.146 
7 G4 Corticosterone C21H30O4 346.214 
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Compound name Mass RT 
Polarity 
+VE -VE 
(S)-Nicotine 162.1157 1.00 x 





10-Hydroxydecanoate 188.1412 7.69 x x 





1-Methyladenosine 281.1124 2.72 x x 
1-Naphthylamine 143.0735 9.30 x 
 1-Oleoyl-rac-glycerol 356.2927 12.21 x x 
2,3-Dihydroxybenzoate 154.0266 3.23 
 
x 
2,4-Dihydroxyacetophenone 152.0474 5.26 x x 
2,4-Dihydroxypteridine 164.0334 1.14 x x 
2,4-Dihydroxypyrimidine-5-carboxylic acid 156.0171 0.91 x x 
2,5-Dihydroxybenzoate 154.0266 2.54 
 
x 
25-Hydroxycholesterol 402.3498 12.05 x 
 2-Aminophenol 109.0528 0.97 x 
 2'-Deoxyadenosine 251.1018 1.49 x x 
2'-Deoxycytidine 5'-diphosphate 387.0233 0.89 
 
x 
2'-Deoxyguanosine 267.0968 1.38 x x 
2'-Deoxyguanosine 5'-diphosphate 427.0294 0.94 
 
x 
2'-Deoxyguanosine 5'-monophosphate 347.0631 0.83 x x 
2-Hydroxy-4-(methylthio)butyric acid 150.0351 2.75 x x 
2-Hydroxybutyric acid 104.0473 1.45 
 
x 
2-Hydroxyphenylacetic acid 152.0473 4.26 x x 
2-Hydroxypyridine 95.0371 1.34 x 
 2-Methylglutaric acid 146.0579 2.98 x x 
2-Methylmaleate 130.0266 1.17 x x 
2-Oxoadipate 160.0372 0.86 x x 
2-Quinolinecarboxylic acid 173.0477 3.82 x 
 3-(2-Hydroxyphenyl)propanoate 166.063 5.32 x x 
3-(4-Hydroxyphenyl)lactic acid 182.0579 2.93 
 
x 
3-(4-Hydroxyphenyl)pyruvic acid 180.04 2.77  x 
3,3,5-Triiodothyronine 650.79 7.94 x x 
3,4-Dihydroxybenzoate 154.0266 2.21 x x 
3,4-Dihydroxyphenyl glycol 170.0579 0.94 
 
x 
3,4-Dihydroxyphenylacetate 168.0423 2.74 
 
x 
3',5'-Cyclic AMP 329.0525 1.32 x x 
3,5-Diiodo-L-thyronine 524.8934 6.76 x x 
3,5-Diiodo-L-tyrosine 432.8672 4.45 x x 
3-Amino-4-hydroxybenzoic acid 153.0426 0.97 x x 
3-Amino-5-hydroxybenzoic acid 153.0426 0.99 x x 
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3-Hydroxy-3-methylglutarate 162.0528 1.22 x x 
3-Hydroxyanthranilate 153.0426 2.49 x x 
3-Hydroxybenzaldehyde 122.0368 4.15 
 
x 
3-Hydroxybenzoate 138.0317 3.75 
 
x 
3-Hydroxybutanoic acid 104.0473 4.28 x 
 3-Hydroxykynurenine 224.0797 0.91 
 
x 
3-Hydroxyphenylacetate 152.0473 3.92 x x 
3-Methoxy-4-hydroxymandelate 198.0528 1.40 
 
x 
3-Methoxy-L-tyrosine 211.0845 1.36 x x 
3-Methoxytyramine 167.0946 1.55 x 
 3-Methyglutaric acid 146.0579 2.97 x x 
3-Methyl-2-Oxindole 147.0684 6.08 x 
 3-Methyl-2-oxovaleric acid 130.063 2.99 
 
x 
3-Nitro-L-tyrosine 226.059 2.23 x x 
3-α,11-β,17-α,21-Tetrahydroxy-5-α-pregnan-
20-one 
366.2406 7.44 x x 
3-α-Hydroxy-5β-cholanate 376.2977 11.58 
 
x 
4-Acetamidobutanoate 145.0739 1.34 x x 
4-Aminobenzoate 137.0477 2.33 x 
 4-Coumarate 164.0473 4.61 
 
x 
4-Hydroxy-2-quinolinecarboxylic acid 189.0426 3.30 
 
x 
4-Hydroxybenzaldehyde 122.0368 3.75 x x 
4-Hydroxybenzoate 138.0317 3.12 
 
x 
4-Hydroxyphenylacetic acid 152.0473 3.59 x x 
4-Methyl-2-Oxo-pentanoic acid 130.063 3.12 
 
x 
4-Methyl-2-Oxovaleric acid 130.063 3.23 
 
x 
4-Methylcatechol 124.0524 4.49 
 
x 
4-Pyridoxate 183.0532 1.31 x x 
4-Quinolinecarboxylic acid 173.0477 1.40 x x 
5'-Deoxyadenosine 251.1018 2.49 x x 
5-Hydroxyindoleacetate 191.0582 3.27 x x 
5-Hydroxy-L-tryptophan 220.0848 1.24 
 
x 
5'-Methylthioadenosine 297.0896 3.67 x x 
5-Oxo-D-proline 129.0426 0.90 x x 
5-Oxo-L-proline 129.0426 0.90 x x 
6-Carboxyhexanoate 160.0736 4.18 x x 
6-Hydroxydopamine 169.0739 8.08 x x 
6-Hydroxynicotinate 139.0269 1.27 
 
x 
Acetoacetate 102.0317 0.95 
 
x 
Acetoin 88.0524 9.57 x x 
Adenosine 2',3'-cyclic monophosphate 329.0525 0.93 x x 
Adenosine 3',5'-cyclic monophosphate 329.0525 1.32 x 
 Adipic Acid 146.0579 2.93 x x 
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Aniline 93.0578 5.61 
 
x 
Anthranilate 137.0477 4.28 x x 
Arachidic acid 312.3028 13.04 
 
x 
Azelaic acid 188.1049 6.46 x x 
Benzoic acid 122.0368 5.64 
 
x 
Biliverdin 582.2478 9.94 x x 
Biotin 244.0882 4.36 x x 
Bis(2-Ethylhexyl)phthalate 390.277 12.98 x 
 Butanoate 88.0524 4.96 x x 
Caffeate 180.0423 3.84 x x 
Caffeine 194.0804 4.16 x 
 Caprylic Acid 144.115 12.38 x 
 Catechol 110.0368 2.75 x x 
Chenodeoxycholate 392.2927 10.98 
 
x 
Cholate 408.2876 10.34 
 
x 
Cholesta-5,7-dien-3β-ol 384.3392 12.00 x 
 Cholesteryl acetate 428.3654 13.21 x 
 Cholesteryl oleate 650.6002 13.37 x 
 Citramalate 148.0372 1.05 x x 
Citrate 192.027 0.80 x x 
Corticosterone 346.2144 8.34 
 
x 
Cortisol 362.2093 7.72 x x 
Cortisol 21-acetate 404.2199 8.47 
 
x 
Cortisone 360.1937 7.44 
 
x 
D-AMP 331.0682 0.83 x 
 Decanoate 172.1463 10.35 x x 
Deoxycholate 392.2927 11.05 
 
x 
Desmosterol 384.3392 13.16 x 
 Dethiobiotin 214.1317 5.29 x x 
Dihydrofolate 443.1553 3.81 x x 
Dihydroxymandelic acid 184.0372 0.84 x x 
Dimethylbenzimidazole 146.0844 4.43 x x 
DL-Kyneurenine 208.0848 1.67 x x 
Docosahexaenoic acid 328.2402 12.18 
 
x 
Dopamine 153.079 0.80 x x 
D-Pantothenic acid 219.1107 2.73 x x 
D-Tryptophan 204.0899 2.82 x x 
Elaidic acid 282.2559 12.51 
 
x 
Erucic acid 338.3185 13.10 
 
x 
Ethyl 3-indoleacetate 203.0946 7.91 x 
 Ethylmalonic acid 132.0423 1.95 
 
x 
Ferulate 194.0579 5.15 x x 
Flavin adenine dinucleotide 785.1571 3.92 x x 
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Folic acid 441.1397 3.89 x x 
Formyl-L-methionyl peptide 177.046 2.71 x x 
Fumarate 116.011 0.87 
 
x 
Linoleic acid 278.2246 11.95 x 
 Glyceryl trimyristate 722.6424 13.32 x 
 Glycocholate 465.309 9.68 x x 
Guanosine 283.0917 1.19 x x 
Guanosine 3',5'-cyclic monophosphate 345.0474 1.14 x x 
Guanosine 5'-monophosphate 363.058 0.89 x x 
Heptadecanoate 270.2559 12.56 
 
x 
Heptanoic acid 130.0994 11.10 x 
 Hippurate 179.0582 3.67 x x 
Homogentisate 168.0423 1.62 x x 
Homovanillate 182.0579 4.19 
 
x 
Hydroquinone 110.0368 2.54 
 
x 
Hypoxanthine 136.0385 0.85 x x 
Indole-3-acetaldehyde 159.0684 2.43 x x 
Indole-3-acetamide 174.0793 4.21 x x 
Indole-3-acetate 175.0633 5.53 x x 
Indole-3-acetic acid 175.0633 5.53 x x 
Indole-3-ethanol 161.0841 5.60 x 
 Indoxyl sulfate 213.0096 2.48 
 
x 
Inosine 268.0808 1.19 x x 
Itaconate 130.0266 1.77 x x 
Lanosterol 426.3862 13.46 x 
 Lauric acid 200.1776 11.25 x x 
Lauroylcarnitine 343.2723 9.61 x x 
Leucine 131.0946 1.26 x x 
Leukotriene B4 336.2301 11.38 x x 
Linoleate 280.2402 12.21 x x 
Lipoamide 205.0595 6.40 x 
 L-Isoleucine 131.0946 1.17 x x 
L-Kynurenine 208.0848 1.67 x x 
L-Methionine 149.051 0.84 x x 
L-Phenylalanine 165.079 2.05 x x 
L-Tryptophan 204.0899 2.82 x x 
L-Tryptophanamide 203.1059 2.44 x x 
L-Tyrosine 181.0739 0.92 x x 
Lumichrome 242.0804 6.51 x x 
L-α-Phosphatidylcholine 757.5622 13.55 x x 
Mandelic Acid 152.0473 3.10 
 
x 
Melatonin 232.1212 5.60 x x 




Mercaptopyruvate 119.9881 1.99 
 
x 
Meso-tartaric acid 150.0164 0.91 
 
x 
Methyl indole-3-acetate 189.079 6.97 x 
 Methyl jasmonate 224.1412 8.79 x 
 Methyl vanillate 168.0423 4.74 
 
x 
Methylmalonate 118.0266 1.04 
 
x 
Mevalolactone 148.0736 1.20 x x 
Mono-methyl glutarate 146.0579 3.64 x x 
Myristic acid 228.2089 11.89 x 
 N,N-Dimethyl-1,4-phenylenediamine 136.10 1.04 x 
 N-6-(δ-2-Isopentenyl)-adenine 203.1171 5.99 x x 
N-Acetyl-DL-glutamic acid 189.0637 1.27 x x 
N-Acetyl-DL-methionine 191.0616 3.26 x x 
N-Acetyl-D-tryptophan 246.1004 5.19 x x 
N-Acetyl-L-alanine 131.0582 1.13 x x 
N-Acetyl-L-cysteine 163.0303 1.37 x x 
N-Acetyl-L-leucine 173.1052 5.06 x x 
N-Acetyl-L-phenylalanine 207.0895 5.14 x x 
N-Acetylserotonin 218.1055 3.64 x x 
Nervonic Acid 366.3498 13.44 
 
x 
Nicotinamide 122.048 1.00 x 
 Nicotinate 123.032 0.89 x x 
Nonanoate 158.1307 10.75 x x 
Norleucine 131.0946 1.33 x x 
Oleate 282.2559 12.47 
 
x 
Palmitate 256.2402 12.36 x x 
Palmitoleic acid 254.2246 12.04 
 
x 
Paraxanthine 180.0647 3.24 x 
 Petroselinic acid 282.2559 12.5 
 
x 
Phenethylamine 121.0891 2.62 x 
 Phenyl acetate 136.0524 3.97 
 
x 
Phenylacetic acid 136.0524 2.93 
 
x 
Phenylethanolamine 137.0841 1.55 x 
 Phenylpyruvate 164.0473 3.55 
 
x 
Phylloquinone 450.3498 11.72 x 
 Propenoate 72.0211 4.88 
 
x 
Protoporphyrin 562.258 12.41 
 
x 
Pterin 163.0494 1.10 x x 
Purine 120.0436 1.09 x x 
Pyridine-2,3-dicarboxylate 167.0219 0.83 x x 
Pyridoxal 167.0582 0.86 
 
x 
Pyridoxal 5'-phosphate 247.0246 1.08 x x 
Pyridoxine 169.0739 0.86 x x 
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Pyrrole-2-carboxylate 111.032 2.79 
 
x 
Pyruvic aldehyde 72.0211 2.20 
 
x 
Quinoline 129.0578 9.00 x 
 Rac-glycerol 1-myristate 302.2457 11.57 x x 
Reichstein's substance S 346.2144 8.43 
 
x 
Resorcinol monoacetate 152.0473 5.25 x x 
Retinoate 300.2089 12.10 
 
x 
Riboflavin 376.1383 4.88 
 
x 
Rosmarinic acid 360.0845 5.81 
 
x 
S-(5'-Adenosyl)-L-homocysteine 384.1216 1.01 x x 
Salicylamide 137.0477 4.10 x x 
Salicylate 138.0317 4.99 x x 
Selenomethionine 191.0015 0.97 
 
x 
Serotonin 176.095 1.27 x 
 S-Hexyl-glutathione 391.1777 7.11 x x 
Sphinganine 301.2981 11.03 x x 
Sphingomyelin 730.5989 13.65 x x 
Stearate 284.2715 12.73 
 
x 
Suberic acid 174.0892 5.39 x x 
Succinic acid 118.0266 1.01 
 
x 
Taurolithocholate 483.3018 10.32 
 
x 
Theobromine 180.0647 2.75 x 
 Theophylline 180.0647 3.37 x x 
Thiopurine S-methylether 166.0313 4.19 x x 
Thymidine 242.0903 2.17 x x 
Thymidine 5'-monophosphate 322.0566 0.93 x x 
Thymine 126.0429 1.26 
 
x 
Thyrotropin releasing hormone 362.1703 1.02 x x 
Thyroxine 776.6867 8.70 x x 
Trans-aconitate 174.0164 0.98 x x 
Trans-cinnamaldehyde 148.0524 6.97 
 
x 
Trans-cinnamate 148.0524 6.94 x x 
Trans-cyclohexane-1,2-diol 116.0837 3.29 x 
 Tricosanoic acid 354.3498 13.59 
 
x 
Tryptamine 160.10 3.20 x 
 Tyramine 137.0841 1.07 x 
 Uridine 244.0695 0.93 x x 
Xanthine 152.0334 0.90 x x 
Xanthosine 284.0757 1.55 x x 
Xanthurenic acid 205.0375 2.91 x x 
α-Hydroxyisobutyric acid 104.0473 1.41 
 
x 
α-Tocopherol 430.3811 11.65 x 
 β-Carotene 536.4382 13.93 x x 
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Supplementary Table 2.2. Method 1 accurate mass retention time data 
from the analysis of mass spectrometry metabolite library of standards. 
Supplied by IROA Technologies, LLC. Product information provided by 
Sigma-Aldrich (Version PD, MAM 09/15-1). RT – retention time; +VE – 









































Ω-Hydroxydodecanoic acid 216.1725 9.02 x x 
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Compound name Mass RT 
Polarity 
+VE -VE 
(2-Aminoethyl)phosphonate 125.02 1.25 x x 
(R)-Malate 134.02 1.58 x x 
(R,R)-Tartaric acid 150.02 1.46 
 
x 
(S)-Dihydroorotate 158.03 1.61 x x 
(S)-Malate 134.02 1.58 x x 





565.37 13.32 x x 
10-Hydroxydecanoate 188.14 9.27 x x 
1-Aminocyclopropane-1-carboxylate 101.05 1.30 x 
 




179.09 2.15 x x 
1-Methyladenosine 281.11 4.39 x x 
1-Naphthylamine 143.07 10.71 x 
 
1-Oleoyl-rac-glycerol 356.29 14.02 
 
x 
2,3-Dihydroxybenzoate 154.03 6.26 
 
x 
2,4-Dihydroxyacetophenone 152.05 3.22 x x 
2,4-Dihydroxypteridine 164.03 2.86 x x 
2,4-Dihydroxypyrimidine-5-carboxylic acid 156.02 2.22 x 
 
2,5-Dihydroxybenzoate 154.03 4.67 
 
x 
2,5-Dimethylpyrazine 108.07 9.74 x 
 
2-Amino-2-methylpropanoate 103.06 1.35 x 
 
2-Aminophenol 109.05 2.16 x 
 
2-Deoxyadenosine 251.1 3.40 x 
 
2-Deoxycytidine 5-monophosphate 307.06 1.57 
 
x 
2-Deoxy-D-Glucose 164.07 1.43 x x 
2-Deoxyguanosine 267.1 3.22 x 
 
2-Deoxyguanosine 5-monophosphate 347.06 2.21 x x 
2-Deoxyuridine 5-mono-phosphate 308.04 2.04 x x 
2-Hydroxy-4-(methylthio)butyric acid 150.04 4.92 x x 
2-Hydroxybutyric acid 104.05 3.13 
 
x 
2-Hydroxyphenylacetic acid 152.05 6.00 x x 
2-Hydroxypyridine 95.037 3.11 x 
 
2-Methylglutaric acid 146.06 4.74 x x 
2-Methylmaleate 130.03 2.84 x x 
2-Oxoadipate 160.04 2.08 
 
x 
2-Quinolinecarboxylic acid 173.05 5.75 x x 
3-(2-Hydroxyphenyl)propanoate 166.06 7.09 
 
x 
3-(4-Hydroxyphenyl)lactic acid 182.06 4.75 
 
x 
3-(4-Hydroxyphenyl)pyruvic acid 180.04 5.69  x 
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3,3,5-Triiodothyronine 650.79 9.38 x 
 
3,4-Dihydroxybenzoate 154.03 4.31 x x 
3,4-Dihydroxy-L-phenylalanine 197.07 1.77 x 
 
3,4-Dihydroxyphenyl glycol 170.06 2.23 
 
x 
3,4-Dihydroxyphenylacetate 168.04 4.43 x x 
3,5-Cyclic AMP 329.05 3.47 x x 
3,5-Diiodo-L-thyronine 524.89 8.32 x x 
3,5-Diiodo-L-tyrosine 432.87 6.17 x x 
3-Amino-4-hydroxybenzoic acid 153.04 2.43 x x 
3-Amino-5-hydroxybenzoic acid 153.04 2.43 x x 
3-Aminoisobutanoate 103.06 1.29 x 
 
3-Dehydroshikimate 172.04 1.82 
 
x 
3-Hydroxy-3-methylglutarate 162.05 2.89 x x 
3-Hydroxyanthranilate 153.04 4.62 x x 
3-Hydroxybenzaldehyde 122.04 6.10 
 
x 
3-Hydroxybenzoate 138.03 5.70 x x 
3-Hydroxybenzyl Alcohol 124.05 4.70 
 
x 
3-Hydroxybutanoic acid 104.05 5.77 x x 
3-Hydroxykynurenine 224.08 2.19 x x 
3-Hydroxyphenylacetate 152.05 5.69 x x 
3-Methoxy-4-hydroxymandelate 198.05 3.22 x x 
3-Methoxy-L-tyrosine 211.08 3.13 x x 
3-Methoxytyramine 167.09 3.20 x 
 
3-Methyglutaric acid 146.06 4.71 x x 
3-Methyl-2-oxindole 147.07 7.84 x 
 
3-Methyl-2-oxovaleric acid 130.06 5.09 
 
x 
3-Methyladenine 149.07 1.70 x 
 
3-Methylhistamine 125.1 1.26 x 
 
3-Nitro-L-tyrosine 226.06 4.06 x x 
3-Sulfino-L-alanine 153.01 1.39 x 
 
3-Ureidopropionate 132.05 1.72 x x 
3-α,11-β,17-α,21-Tetrahydroxy- 5-α-
pregnan-20-one 
366.24 9.17 x x 
3α,12α-Dihydroxy-5β-cholanate 392.29 13.74 x x 
3α-Hydroxy-5β-cholanate 376.3 13.73 x x 
4-Acetamidobutanoate 145.07 3.14 x x 
4-Aminobenzoate 137.05 4.41 x x 
4-Coumarate 164.05 6.68 x 
 
4-Guanidinobutanoate 145.09 1.49 
 
x 
4-Hydroxy-2-quinolinecarboxylic acid 189.04 5.31 x x 
4-Hydroxy-3-methoxyphenylglycol 184.07 3.73 x x 
4-Hydroxybenzaldehyde 122.04 5.84 x x 




4-Hydroxy-L-phenylglycine 167.06 1.37 x 
 
4-Hydroxy-L-proline 131.06 1.46 x x 
4-Hydroxyphenylacetic acid 152.05 5.31 x x 
4-Imidazoleacetic acid 126.04 1.29 x x 
4-Methyl-2-oxo-pentanoic acid 130.06 5.15 x x 
4-Methyl-2-oxovaleric acid 130.06 5.36 
 
x 
4-Methylcatechol 124.05 6.41 
 
x 
4-Pyridoxate 183.05 3.22 x x 
4-Quinolinecarboxylic acid 173.05 3.23 x x 







5-Aminopentanoate 117.08 5.33 x 
 
5-CMP 323.05 1.59 x x 
5-Deoxyadenosine 251.1 4.13 x x 
5-Hydroxyindoleacetate 191.06 5.02 x x 
5-Hydroxy-L-tryptophan 220.08 3.08 x x 
5-Hydroxymethyluracil 142.04 1.74 
 
x 
5-Methylcytosine hydrocloride 125.06 1.39 x 
 
5-Methylthioadenosine 297.09 5.34 x x 
5-Oxo-D-proline 129.04 2.13 x x 
5-Oxo-L-proline 129.04 2.12 x x 
5-Valerolactone 100.05 7.14 
 
x 
6-Carboxyhexanoate 160.07 5.90 x x 
6-Deoxy-L-galactose 164.07 1.57 x x 
6-Hydroxynicotinate 139.03 3.24 x x 
Acetoacetate 102.03 2.19 
 
x 
Acetoin 88.052 1.34 x 
 
Adenine 135.05 1.64 x x 
Adenine hydrochloride hydrate 135.05 1.69 x x 
Adenosine 267.1 3.22 x x 
Adenosine 2,3-cyclic monophosphate 329.05 2.70 x x 
Adenosine 3,5-cyclic monophosphate 329.05 3.47 x x 
Adenosine 3,5-diphosphate 427.03 1.64 x 
 
Adenosine 5-diphosphoribose 559.07 1.65 x 
 
Adenosine 5-monophosphate 347.06 1.82 x x 
Adenosine-5-diphosphoglucose 589.08 1.65 x x 
Adipic acid 146.06 4.62 x x 
Allantoin 158.04 1.36 
 
x 
Allose 180.06 1.35 x x 
Amylose 370.15 10.28 x 
 
Aniline 93.058 7.33 
 
x 




Arabinose 150.05 1.38 
 
x 
Arachidic acid 312.3 14.30 x x 
Ascorbate 176.03 1.61 x 
 
Azelaic acid 188.1 8.12 x x 
Benzaldehyde 106.04 9.37 x 
 
Benzoic acid 122.04 7.54 
 
x 
Benzylamine 107.07 3.05 x 
 
Biliverdin 582.25 11.34 x 
 
Biotin 244.09 5.98 
 
x 
Bis(2-ethylhexyl)phthalate 390.28 13.51 x x 
Bis(3-aminopropyl)amine 131.14 1.41 x 
 
Butanal 72.058 8.76 x 
 
Caffeate 180.04 6.17 x x 
Caffeine 194.08 5.97 x 
 
Catechol 110.04 4.70 x 
 
Chenodeoxycholate 392.29 12.20 x x 
Cholate 408.29 11.61 x x 
Cholesteryl acetate 428.37 12.49 x 
 
Cis-4-hydroxy-D-proline 131.06 1.29 x x 
Citramalate 148.04 2.41 x x 
Citrate 192.03 1.92 
 
x 
Citrulline 175.1 1.29 x x 
Corticosterone 346.21 9.90 x 
 
Cortisol 362.21 9.27 x x 
Cortisol 21-acetate 404.22 9.98 x x 
Creatine 131.07 1.32 x 
 
Creatine phosphate 211.04 1.42 x x 
Creatinine 113.06 1.21 x x 
Cyclopentanone 84.058 8.16 x 
 
Cytidine 243.09 1.45 x x 
Cytidine 2,3-cyclic monophosphate 305.04 1.48 x x 
Cytidine 5-diphosphocholine 488.11 1.32 x x 
Cytosine 111.04 1.44 x 
 
D-(-)-3-Phosphoglyceric acid 185.99 1.57 x 
 
D-(-)-Arabinose 150.05 1.37 
 
x 
D-(+)-Cellobiose 342.12 1.39 x x 
D-(+)-Galacturonic acid 194.04 1.34 
 
x 
D-(+)-Raffinose 504.17 1.45 x x 
D-(+)-Trehalose 342.12 1.37 x x 
D-Alanine 89.048 1.42 x 
 
D-AMP 331.07 2.19 x x 
D-Aspartate 133.04 1.28 x x 




Dehydro-L-(+)-ascorbic acid dimer 174.02 1.37 x x 
Deoxycarnitine 145.11 1.30 x 
 
Deoxycholate 392.29 12.29 x 
 
Deoxycorticosterone acetate 372.23 11.26 x 
 
Deoxycytidine 227.09 1.58 x x 
Deoxyribose 134.06 8.91 x 
 
Dethiobiotin 214.13 6.93 
 
x 
D-Fructose 6-phosphate 260.03 1.40 x x 
D-Galactose 180.06 1.33 x x 
D-Gluconate 196.06 1.36 x x 
D-Glucono-1,5-lactone 196.06 1.36 x x 
D-Glucosamine 6-phosphate 259.05 1.22 x x 
D-Glucose 6-phosphate 260.03 1.39 x x 
D-Glucuronic acid 194.04 1.33 x x 
D-Glucuronolactone 194.04 1.32 x x 
D-Glyceric acid 106.03 1.46 
 
x 
D-Gulonic acid g-lactone 196.06 1.35 
 
x 
Diacetyl 86.037 9.48 x 
 
Dihydrofolate 443.16 5.33 x x 
Dihydroxyacetone phosphate 170 1.43 x x 
Dihydroxymandelic acid 184.04 1.94 x x 
Dimethylbenzimidazole 146.08 6.05 x 
 
D-Lactose 342.12 1.33 x x 
DL-Kyneurenine 208.08 3.51 x x 
DL-Normetanephrine 183.09 1.61 x 
 
D-Lyxose 150.05 1.37 x x 
D-Mannosamine 179.08 1.27 x x 
D-Mannose 6-phosphate 260.03 1.32 x x 
Docosahexaenoic acid 328.24 13.29 x x 
Dopamine 153.08 1.66 x x 
D-Pantothenic acid 219.11 4.34 x x 
D-Psicose 180.06 1.40 x x 
D-Ribose 150.05 1.41 x x 
D-Ribose 5-phosphate 230.02 1.41 x 
 
D-Saccharic acid 210.04 1.42 x 
 
D-Sorbitol 182.08 1.35 x x 
D-Tagatose 180.06 1.36 x x 
D-Tryptophan 204.09 4.60 x x 
D-Xylose 150.05 1.37 x x 
Elaidic acid 282.26 13.64 x x 
Adrenaline 183.09 1.38 x x 
Erucic acid 338.32 14.35 
 
x 
Erythritol 122.06 1.37 x x 
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Estradiol-17α 272.18 9.97 
 
x 
Ethyl 3-indoleacetate 203.09 9.50 x 
 
Ethylmalonic acid 132.04 3.83 x x 
Ferulate 194.06 7.04 
 
x 
Flavin adenine dinucleotide 785.16 5.97 x x 
Folic acid 441.14 5.43 x x 
Formyl-L-methionyl peptide 177.05 4.55 x 
 
Fumarate 116.01 2.12 
 
x 
Galactarate 210.04 1.35 
 
x 
Galactitol 182.08 1.32 x x 
Linoleic acid 278.22 13.51 x x 
Gluconic acid 196.06 1.37 x 
 
Glucosaminate 195.07 1.25 x x 
Glutathione 307.08 1.80 
 
x 
Glyceraldehyde 90.032 1.40 x 
 
Glycerate 106.03 2.27 
 
x 
Glycerol 92.047 1.42 x 
 
Glycerol 2-phosphate 172.01 1.45 x x 
Glyceryl trimyristate 722.64 14.64 x 
 
Glycine 75.032 1.23 x 
 
Glycocholate 465.31 11.04 x x 
Glyoxylic acid 74.0 1.49 
 
x 
Guaiacol 124.05 10.49 x 
 
Guanidinoacetate 117.05 1.39 x 
 
Guanine 151.05 1.72 x 
 
Guanosine 283.09 2.98 
 
x 
Guanosine 3,5-cyclic monophosphate 345.05 3.46 x x 
Guanosine 5-diphospho-D-mannose 605.08 1.75 x x 
Guanosine 5-diphosphoglucose 605.08 1.83 x x 
Guanosine 5-monophosphate 363.06 1.88 x x 
Heptadecanoate 270.26 13.71 
 
x 
Hexadecanol 242.26 12.6 x 
 
Hippurate 179.06 5.48 x x 
Homocysteine 135.04 1.41 x 
 
Homocystine 268.06 1.42 x x 
Homogentisate 168.04 3.54 
 
x 
Homoserine 119.06 1.27 x x 
Homovanillate 182.06 5.89 
 
x 
Hydroquinone 110.04 4.67 
 
x 
Hydroxypyruvate 104.01 1.44 x 
 
Hypotaurine 109.02 1.28 x x 
Hypoxanthine 136.04 2.07 x x 
Indole-3-acetaldehyde 159.07 4.66 x x 
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Indole-3-acetamide 174.08 6.04 x x 
Indole-3-acetate 175.06 7.27 
 
x 
Indole-3-acetic acid 175.06 7.27 
 
x 
Indole-3-ethanol 161.08 5.94 
 
x 
Indole-3-pyruvic acid 203.06 6.00 x 
 
Indoxyl sulfate 213.01 5.03 
 
x 
Inosine 268.08 2.96 x x 
Inosine 5-monophosphate 348.05 1.95 x x 
Inosine 5-phosphate 348.05 1.93 x x 
Isocitric acid 192.03 1.63 x x 
Itaconate 130.03 3.44 x x 
L-Alanine 89.048 1.26 x 
 
L-Allothreonine 119.06 1.29 x x 
Lanosterol 426.39 14.08 
 
x 
L-Arabitol 152.07 1.36 x x 
L-Asparagine 132.05 1.25 x x 
L-Aspartate 133.04 1.28 x x 
Lauric acid 200.18 12.52 x x 
Lauroylcarnitine 343.27 10.93 x x 
L-Carnitine 161.11 1.23 x x 
L-Cystathionine 222.07 1.21 x x 
L-Cysteic acid 169 1.38 x x 
L-Cysteine 121.02 1.35 x 
 
L-Cystine 240.02 1.23 x x 
Leucine 131.09 2.74 x x 
L-Glutamic acid 147.05 1.30 x 
 
L-Glutamine 146.07 1.26 x x 
L-Homocysteine thiolactone 117.02 1.34 x 
 
Linoleate 280.24 13.38 
 
x 
Lipoamide 205.06 8.16 x 
 
L-Isoleucine 131.09 2.55 x x 
L-Kynurenine 208.08 3.50 x x 
L-Methionine 149.05 1.85 x x 
L-Methionine sulfoximine 180.06 1.25 x x 
L-Norvaline 117.08 1.71 x x 
L-Phenylalanine 165.08 3.88 x x 
L-Pipecolic acid 129.08 1.68 x 
 
L-Proline 115.06 1.40 x 
 
L-Rhamnose 164.07 1.47 
 
x 
L-Serine 105.04 1.25 x x 
L-Sorbose 180.06 1.35 x x 
L-Threonine 119.06 1.29 x x 
L-Tryptophan 204.09 4.60 x x 
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L-Tryptophanamide 203.11 4.05 x x 
L-Tyrosine 181.07 2.17 x x 
Lumichrome 242.08 8.31 x 
 
L-Valine 117.08 1.65 x x 
Maleamate 115.03 1.87 x 
 
Maleic Acid 116.01 2.01 
 
x 
Maleimide 97.016 1.87 x 
 
Malonate 104.01 1.71 
 
x 
Maltose 342.12 1.38 x x 
Mandelic acid 152.05 4.85 x x 
Mannitol 182.08 1.35 x x 
Mannose 180.06 1.35 x x 
Melatonin 232.12 7.33 x x 
Melibiose 342.12 1.34 x x 
Mercaptopyruvate 119.99 1.99 
 
x 
Meso-tartaric acid 150.02 1.44 
 
x 
Methyl indole-3-acetate 189.08 7.25 x 
 
Methyl jasmonate 224.14 10.21 x x 
Methyl vanillate 168.04 6.54 
 
x 
Methyl β-D-galactoside 194.08 1.56 x x 
Methylguanidine 73.064 1.25 x 
 
Methylmalonate 118.03 1.86 x 
 
Mevalolactone 148.07 2.69 
 
x 
Mono-ethyl malonate 104.01 1.61 x 
 
Mono-methyl glutarate 146.06 5.29 x x 
Myoinositol 180.06 1.29 x x 
Myristic acid 228.21 13.08 
 
x 
N,N-Dimethyl-1,4-phenylenediamine 136.1 2.31 x 
 
N-6-(δ2-isopentenyl)-adenine 203.12 7.91 
 
x 
N-Acetyl-D-galactosamine 221.09 1.44 x 
 
N-Acetyl-D-glucosamine 221.09 1.44 x x 
N-Acetyl-DL-glutamic acid 189.06 2.26 x x 
N-Acetyl-DL-methionine 191.06 5.05 x x 
N-Acetyl-DL-serine 147.05 1.67 x x 
N-Acetyl-D-mannosamine 221.09 1.39 x x 
N-Acetyl-D-tryptophan 246.1 7.02 x x 
N-Acetylglycine 117.04 1.78 
 
x 
N-Acetyl-L-alanine 131.06 2.58 x x 
N-Acetyl-L-aspartic acid 175.05 1.89 x x 
N-Acetyl-L-cysteine 163.03 3.11 x x 
N-Acetyl-L-leucine 173.11 6.75 
 
x 
N-Acetyl-L-phenylalanine 207.09 6.90 
 
x 
N-Acetylneuraminate 309.11 1.47 x x 
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N-Acetylputrescine 130.11 1.37 x 
 
N-Acetylserotonin 218.11 5.38 x x 
Nicotinamice adeninine dinucleotide 663.11 1.76 x x 
N-Amidino-L-aspartate 175.06 1.33 x x 
N-Formylglycine 103.03 1.56 x x 
Nicotinamide 122.05 2.39 x 
 
Nicotinamide hypoxanthine dinucleotide 664.09 1.91 x x 
Nicotinamide mononucleotide 334.06 1.40 x 
 
Nicotinate 123.03 2.11 x x 
N-Methyl-D-aspartic acid 147.05 1.32 x 
 
N-Methyl-L-glutamate 161.07 1.35 x x 
Nonanoate 158.13 12.28 x 
 
Noradrenaline 169.07 1.23 x x 
Norleucine 131.09 2.78 x x 
N-α-Acetyl-L-asparagine 174.06 1.61 x x 
N-α-Acetyl-L-lysine 188.12 1.37 
 
x 
O-Acetyl-L-serine 147.05 1.43 x 
 
Octopamine 153.08 1.39 x 
 
Oleate 282.26 13.10 x x 
O-Phospho-L-serine 185.01 1.36 x 
 
O-Phosphorylethanolamine 141.02 1.25 x x 
Orotate 156.02 1.75 
 
x 
Orotic acid 156.02 1.76 x x 
O-Succinyl-L-homoserine 219.07 1.76 x x 
Palatinose 342.12 1.40 x x 
Palmitate 256.24 13.52 x x 
Palmitoleic acid 254.22 13.2 
 
x 
Paraxanthine 180.06 5.03 x 
 
Pentanoate 102.07 9.49 x 
 
Petroselinic acid 282.26 13.11 x x 
Phenethylamine 121.09 4.16 x 
 
Phenol 94.042 9.82 x 
 
Phenyl acetate 136.05 3.97 
 
x 
Phenylacetaldehyde 120.06 9.94 x 
 
Phenylacetic acid 136.05 4.75 
 
x 
Phenylethanolamine 137.08 3.02 x 
 
Phospho(enol)pyruvic acid 167.98 1.47 x x 
Phosphocholine 183.07 1.30 x x 
Phosphonoacetate 139.99 1.60 
 
x 
Phylloquinone 450.35 12.56 x 
 
Picolinic acid 123.03 1.79 x 
 
Pipecolate 129.08 1.69 x 
 




Protoporphyrin 562.26 13.69 x x 
Pterin 163.05 2.83 x x 
Purine 120.04 2.75 x 
 
Pyridine-2,3-dicarboxylate 167.02 2.12 x x 
Pyridoxal 167.06 1.84 
 
x 
Pyridoxal 5-phosphate 247.02 2.76 x x 
Pyridoxine 169.07 1.79 x x 
Pyrrole-2-carboxylate 111.03 4.71 
 
x 
Pyruvic aldehyde 72.021 2.20 
 
x 
Quinate 192.06 1.47 x x 
Quinoline 129.06 6.05 x 
 
Rac-glycerol 1-myristate 302.25 13.53 x x 
Reichstein's substance S 346.21 9.98 x x 
Resorcinol monoacetate 152.05 7.94 
 
x 
Retinoate 300.21 13.2 x x 
Retinol 286.23 9.02 x 
 
Ribitol 152.07 1.36 x x 
Riboflavin 376.14 6.50 x x 
Rosmarinic acid 360.08 7.35 x x 
S-(5-Adenosyl)-L-homocysteine 384.12 2.53 x x 
Salicylamide 137.05 6.08 x x 
Salicylate 138.03 6.91 x x 
Sarcosine 89.048 1.30 x x 
S-Carboxymethyl-L-cysteine 179.03 1.43 x x 
Selenocystamine 235.95 1.91 
 
x 
Selenomethionine 191 2.18 
 
x 
Serotonin 176.1 1.56 x 
 
S-Hexyl-glutathione 391.18 8.77 x x 
Shikimate 174.05 1.65 
 
x 
Sn-Glycerol 3-phosphate 172.01 1.43 x x 
Sorbate 112.05 9.28 
 
x 
Spermine 202.22 1.50 x 
 
Sphinganine 301.3 12.21 x x 
Sphingomyelin 730.6 14.01 
 
x 
Stachyose 666.22 1.39 x x 
Stearate 284.27 13.88 
 
x 
Suberic acid 174.09 7.10 x x 
Succinic acid 118.03 2.39 
 
x 
Sucrose 342.12 1.44 x x 
Taurine 125.01 1.27 x x 
Taurolithocholate 483.3 11.95 x x 
Theobromine 180.06 4.55 x 
 
Theophylline 180.06 5.23 x x 
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Thiamine monophosphate 344.07 1.22 x 
 
Thiamine pyrophosphate 424.04 1.42 x x 
Thiopurine-s-methylether 166.03 6.12 
 
x 
Thiourea 76.01 1.46 
 
x 
Thymidine 242.09 3.96 x x 
Thymidine 5-monophosphate 322.06 2.80 x 
 
Thymidine-5-diphospho-α-D-glucose 564.08 2.25 x x 
Thymine 126.04 3.05 x x 
Thyrotropin releasing hormone 362.17 2.12 x 
 
Thyroxine 776.69 10.13 x 
 
Trans-4-Hydroxyproline 131.06 1.44 x x 
Trans-Aconitate 174.02 2.55 
 
x 
Trans-Cinnamaldehyde 148.05 8.74 x x 
Trans-Cinnamate 148.05 8.69 x 
 
Trans-Cyclohexane-1,2-diol 116.08 5.22 x 
 
Trigonelline 137.05 1.40 x x 
Tryptamine 160.1 5.90 
 
x 
Tyramine 137.08 2.29 x 
 
Uracil 112.03 1.81 x x 
Urate 168.03 1.90 
 
x 
Uridine 244.07 2.26 x x 
Uridine 5-diphosphogalactose 566.06 1.64 x x 






Uridine 5-diphospho-N-acetylglucosamine 607.08 1.70 
 
x 
Uridine-5-monophosphate 324.04 1.73 x x 
Urocanate 138.04 1.61 x x 
Xanthine 152.03 2.27 x x 
Xanthosine 284.08 3.49 x x 
Xanthurenic acid 205.04 5.03 x 
 
Xylitol 152.07 1.36 x x 
α-Aminoadipate 161.07 1.38 x x 
α-D-Galactose 1-phosphate 260.03 1.33 x x 
α-D-Glucose 180.06 1.34 x x 
α-D-Glucose 1-phosphate 260.03 1.40 x x 
α-Hydroxyisobutyric acid 104.05 3.20 
 
x 
α-Ketoglutaric acid 146.02 1.67 
 
x 
β-Alanine 89.048 1.24 
 
x 
β-Carotene 536.44 13.81 x x 
Βine 117.08 1.33 x x 
Ω-Hydroxydodecanoic acid 216.17 10.52 x x 
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Supplementary Table 2.3. Method 2 accurate mass retention time data 
from the analysis of mass spectrometry metabolite library of standards. 
Supplied by IROA Technologies, LLC. Product information provided by 
Sigma-Aldrich (Version PD, MAM 09/15-1). RT – retention time; +VE – 


























Compound name Mass RT 
Polarity 
+VE -VE 
(2-Aminoethyl)phosphonate 125.024 8.48 x 
 
(R)-Malate 134.022 4.51 
 
x 
(S)-Dihydroorotate 158.033 4.71 
 
x 









691.515 4.23 x x 
10-Hydroxydecanoate 188.141 1.70 
 
x 





179.095 4.42 x x 
1-Methyladenosine 281.112 6.18 x x 
1-Oleoyl-rac-glycerol 356.293 1.64 x 
 
2,3-Dihydroxybenzoate 154.027 1.73 
 
x 
2,4-Dihydroxypteridine 164.033 4.15 
 
x 
2,4-Dihydroxypyrimidine-5-carboxylic acid 156.017 3.86 
 
x 
2,5-Dihydroxybenzoate 154.027 1.73 
 
x 
2-Amino-2-methylpropanoate 103.063 6.19 x 
 
2-Aminophenol 109.053 1.74 x x 
2-Deoxyadenosine 251.102 4.99 x x 
2'-Deoxyadenosine 5'-triphosphate 251.102 4.64 
 
x 
2-Deoxycytidine 5-monophosphate 307.057 8.51 x x 
2-Deoxyguanosine 267.097 5.95 x x 
2-Deoxyguanosine 5-monophosphate 347.063 8.63 x x 
2-Deoxyuridine 5-mono-Phosphate 308.041 8.35 
 
x 
2-Hydroxy-4-(methylthio)butyric acid 150.035 1.73 
 
x 
2-Hydroxybutyric acid 104.047 2.15 
 
x 
2-Hydroxyphenylacetic acid 152.047 1.72 
 
x 
2-Hydroxypyridine 95.0371 5.63 
 
x 
2-Methylmaleate 130.027 4.0 
 
x 
2-Oxoadipate 160.037 3.78 
 
x 
2-Quinolinecarboxylic acid 173.048 1.70 x 
 
3-(2-Hydroxyphenyl)propanoate 166.063 1.81 x 
 
3-(4-Hydroxyphenyl)lactic acid 182.058 1.75 
 
x 
3-(4-Hydroxyphenyl)pyruvic acid 180.04 3.80  x 
3,3,5-Triiodothyronine 650.79 4.92 x x 
3,4-Dihydroxybenzoate 154.027 1.76 
 
x 
3,4-Dihydroxy-L-phenylalanine 197.069 6.67 x x 
3,4-Dihydroxyphenyl glycol 170.058 4.07 
 
x 
3,4-Dihydroxyphenylacetate 168.042 1.74 
 
x 




3,5-Diiodo-L-thyronine 524.893 5.00 x 
 
3,5-Diiodo-L-tyrosine 432.867 5.58 x x 
3-Amino-4-hydroxybenzoic acid 153.043 1.74 x x 
3-Amino-5-hydroxybenzoic acid 153.043 1.75 x 
 
3-Aminoisobutanoate 103.063 5.34 x 
 
3-Dehydroshikimate 172.037 4.15 
 
x 
3-Hydroxy-3-methylglutarate 162.053 3.88 
 
x 
3-Hydroxyanthranilate 153.043 1.72 x x 
3-Hydroxybenzaldehyde 122.037 1.55 
 
x 
3-Hydroxyphenylacetate 152.047 1.74 x 
 
3-Methoxy-4-hydroxymandelate 198.053 3.54 
 
x 
3-Methoxy-L-tyrosine 211.085 6.14 x x 
3-Methoxytyramine 167.095 3.51 x 
 
3-Methyglutaric acid 146.058 1.73 
 
x 
3-Methyl-2-oxindole 147.068 1.71 
 
x 
3-Methyl-2-oxovaleric acid 130.063 1.64 
 
x 
3-Methyladenine 149.07 4.79 x 
 
3-Methylhistamine 125.095 6.78 x 
 
3-Nitro-L-tyrosine 226.059 5.87 x x 
3-Ureidopropionate 132.054 4.50 x 
 
3α,12α-Dihydroxy-5β-cholanate 392.293 1.50 x 
 
4-Acetamidobutanoate 145.074 3.63 
 
x 
4-Aminobenzoate 137.048 1.70 x 
 
4-Aminobutanoate 103.063 5.40 x x 
4-Coumarate 164.047 1.72 
 
x 
4-Guanidinobutanoate 145.085 4.96 x x 
4-Hydroxy-2-quinolinecarboxylic acid 189.043 5.02 x x 
4-Hydroxy-L-proline 131.058 6.98 x x 
4-Hydroxyphenylacetic acid 152.047 1.73 x 
 
4-Imidazoleacetic acid 126.043 5.33 x 
 
4-Methyl-2-oxo-pentanoic acid 130.063 1.74 
 
x 
4-Methyl-2-oxovaleric acid 130.063 1.64 
 
x 
4-Methylcatechol 124.052 1.78 
 
x 
4-Quinolinecarboxylic acid 173.048 2.0 x x 




338.063 8.76 x x 
5-Aminolevulinic acid 131.058 5.48 x 
 
5-Aminopentanoate 117.079 5.02 x 
 
5-Cytidine monophosphate 323.052 8.77 
 
x 
5-Deoxyadenosine 251.102 4.64 x x 
5-Hydroxyindoleacetate 191.058 1.73 x x 
5-Hydroxy-L-tryptophan 220.085 6.27 x x 
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5-Hydroxymethyluracil 142.038 4.99 
 
x 
5-Methylcytosine hydrocloride 125.059 5.52 x 
 
5-Methylthioadenosine 297.09 4.47 x x 
5-Oxo-D-proline 129.043 4.14 x x 
5-Oxo-L-proline 129.043 4.14 x x 
5-Valerolactone 100.052 1.70 x 
 
6-Carboxyhexanoate 160.074 1.72 x x 
6-Deoxy-L-galactose 164.069 5.77 x 
 
6-Hydroxynicotinate 139.027 4.30 x x 
Adenine 135.055 4.48 x x 
Adenine hydrochloride hydrate 135.055 5.23 
 
x 
Adenosine 267.097 5.37 x x 
Adenosine 2,3-cyclic monophosphate 329.053 7.67 x x 
Adenosine 3,5-cyclic monophosphate 329.053 7.80 x x 
Adenosine 5-diphosphoribose 559.071 11.44 x x 
Adenosine 5-monophosphate 347.063 8.63 x x 
Adenosine-5-diphosphoglucose 589.082 11.10 
 
x 
Adipic acid 146.058 1.73 
 
x 
Agmatine sulfate 130.122 6.93 x 
 
Allantoin 158.044 5.49 
 
x 
Allose 180.063 6.62 
 
x 
Aniline 93.0578 5.04 x 
 
Anthranilate 137.048 1.69 x 
 
Arabinose 150.053 6.11 x x 
Arachidic Acid 312.303 8.26 x 
 
Azelaic acid 188.105 1.71 
 
x 
Bilirubin 584.264 2.08 x 
 
Biliverdin 582.248 4.48 x 
 
Biotin 244.088 3.73 x x 
Bis(3-aminopropyl)amine 131.142 8.76 x 
 
Cadaverine 102.116 6.96 x 
 
Caffeate 180.042 1.73 x x 
Caffeine 194.08 1.66 x 
 
Carnosine 226.107 7.98 x x 
Catechol 110.037 1.76 
 
x 
Chenodeoxycholate 392.293 1.72 
 
x 
Cholate 408.288 1.75 x 
 
Cis-4-Hydroxy-D-proline 131.058 6.91 x x 
Citramalate 148.037 4.34 
 
x 
Citrulline 175.096 7.46 x x 
Coenzyme Q10 862.684 8.74 x 
 
Corticosterone 346.214 1.65 x x 
Cortisol 362.209 1.71 x 
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Cortisol 21-acetate 404.22 1.63 x x 
Cortisone 360.194 1.70 x x 
Creatine 131.07 5.84 x 
 
Creatinine 113.059 4.99 x x 
Cys-Gly 178.041 8.55 x 
 
Cytidine 243.086 6.46 x x 
Cytidine 2,3-cyclic mono-phosphate 305.041 8.07 x x 
Cytidine 5-diphosphocholine 488.107 9.39 x x 
Cytosine 111.043 5.84 x 
 
D-(+)-Cellobiose 342.116 7.88 x x 
D-(+)-Galacturonic acid 194.043 7.12 
 
x 
D-(+)-Glucosamine 179.079 7.55 x 
 
D-(+)-Raffinose 504.169 8.65 x x 
D-(+)-Trehalose 342.116 8.10 x x 
D-Alanine 89.0477 6.32 x x 
D-AMP 331.068 8.59 x x 
D-Aspartate 133.038 7.28 x x 
Decanoate 172.146 1.64 x 
 
Deoxycarnitine 145.11 3.55 x 
 
Deoxycholate 392.293 1.73 
 
x 
Deoxycytidine 227.091 6.10 
 
x 
D-Fructose 6-phosphate 260.03 9.30 x x 
D-Galactose 180.063 7.04 
 
x 
D-Gluconate 196.058 6.83 
 
x 
D-Glucono-1,5-lactone 196.058 6.81 
 
x 
D-Glucosamine 6-phosphate 259.046 9.45 
 
x 
D-Glucuronic acid 194.043 6.80 
 
x 
D-Glucuronolactone 194.043 6.77 
 
x 
D-Glyceric acid 106.027 4.33 
 
x 
Diethanolamine 105.079 5.77 x 
 
Diethyl 2-methyl-3-oxosuccinate 202.084 1.70 x 
 
Dihydroxymandelic acid 184.037 4.34 
 
x 
Dimethylbenzimidazole 146.084 1.78 
 
x 
DL-5-Hydroxylysine 162.10 8.31 x x 
D-Lactose 342.116 8.06 
 
x 
DL-Kyneurenine 208.085 5.79 x 
 
D-Lyxose 150.053 5.59 x 
 
D-Mannosamine 179.079 7.18 x 
 
D-Mannose 6-phosphate 260.03 9.47 x x 
Dopamine 153.079 5.23 x x 
D-Ornithine 132.09 8.19 
 
x 
D-Pantothenic acid 219.111 3.98 x x 
D-Ribose 150.053 4.99 x 
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D-Sorbitol 182.079 6.63 
 
x 
D-Tagatose 180.063 6.32 x 
 
D-Tryptophan 204.09 5.67 x x 
D-Xylose 150.053 5.57 x 
 
Elaidic acid 282.256 1.64 x 
 
Epinephrine 183.09 5.23 x x 
Flavin adenine dinucleotide 785.157 11.46 
 
x 
Folic acid 441.14 5.98 x x 
Formyl-L-methionyl peptide 177.046 3.44 
 
x 
Galactitol 182.079 6.74 
 
x 
Linoleic acid 278.225 1.70 x 
 
Gluconic acid 196.058 6.95 
 
x 
Glucosaminate 195.074 8.31 x x 
Glutathione 307.084 7.05 x x 
Glycerate 106.027 4.31 
 
x 
Glycocholate 465.309 4.48 x x 
Guanidinoacetate 117.054 6.21 x 
 
Guanine 151.049 6.06 x 
 
Guanosine 283.092 6.39 x x 
Guanosine 3,5-cyclic monophosphate 345.047 8.28 x x 
Guanosine 5-diphosphoglucose 605.077 12.95 
 
x 
Hippurate 179.058 1.72 x 
 
Histamine 111.08 7.09 x 
 
Homocystine 268.055 8.25 x x 
Homogentisate 168.042 1.78 
 
x 
Homoserine 119.058 6.98 x x 
Hypotaurine 109.02 7.23 x 
 
Hypoxanthine 136.039 5.12 x x 
Indole-3-acetaldehyde 159.068 5.62 
 
x 
Indole-3-acetamide 174.079 1.70 x 
 
Indole-3-acetic acid 175.063 1.70 x 
 
Indole-3-pyruvic acid 203.058 1.70 x 
 
Indoxyl sulfate 213.01 4.22 
 
x 
Inosine 268.081 5.74 x x 
Inosine 5'-phosphate 348.047 9.02 x 
 
L-2,6-Diaminoheptanedioate 190.095 8.8 x x 
L-Alanine 89.0477 6.38 x 
 
L-Allothreonine 119.058 6.99 
 
x 
L-Anserine 240.122 7.57 x x 
L-Arabitol 152.069 6.04 
 
x 
L-Arginine 174.112 7.98 x x 
L-Asparagine 132.054 7.50 x x 
L-Aspartate 133.038 7.27 x x 
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Lauroylcarnitine 343.272 1.71 x x 
L-Carnitine 161.105 4.49 x 
 
L-Cystathionine 222.067 8.80 x x 
L-Cysteic acid 169.005 8.23 x x 
L-Cystine 240.024 8.99 x x 
Leucine 131.095 5.42 x 
 
L-Glutamic acid 147.053 6.95 x x 
L-Glutamine 146.069 7.31 x x 
L-Histidine 155.07 8.08 x 
 
L-Histidinol 141.09 7.33 x x 
L-Homocysteine thiolactone 117.025 4.61 x 
 
Lipoamide 205.06 1.64 x 
 
L-Isoleucine 131.095 5.59 x x 
L-Kynurenine 208.085 5.79 x 
 
L-Lysine 146.106 8.10 x x 
L-Lysine monohydrochloride 146.106 8.08 x x 
L-Methionine 149.051 6.06 x 
 
L-Methionine sulfoximine 180.057 7.59 x x 
L-Norvaline 117.079 5.84 x 
 
L-Ornithine 132.09 8.06 x x 
L-Phenylalanine 165.079 5.68 x x 
L-Phosphatidylcholine 757.562 4.37 x 
 
L-Pipecolic acid 129.079 6.29 x 
 
L-Proline 115.063 6.31 x 
 
L-Serine 105.043 7.37 x x 
L-Sorbose 180.063 6.43 
 
x 
L-Threonine 119.058 6.98 
 
x 
L-Tryptophan 204.09 5.68 x x 
L-Tryptophanamide 203.106 4.60 x 
 
L-Tyrosine 181.074 6.26 x x 
Lumichrome 242.08 1.80 x x 
L-Valine 117.079 6.01 x 
 
Maleic acid 116.011 4.17 
 
x 
Maltose 342.116 7.63 x x 
Mandelic acid 152.047 1.72 
 
x 
Mannitol 182.079 6.66 
 
x 
Mannose 180.063 6.52 
 
x 
Melatonin 232.121 1.65 x 
 
Melibiose 342.116 8.33 x x 
Methyl indole-3-acetate 189.079 1.71 x 
 
Methyl vanillate 168.042 1.69 
 
x 
Methyl β-D-galactoside 194.079 5.37 x x 
Methylmalonate 118.027 3.72 x x 
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Mono-methyl glutarate 146.058 1.72 
 
x 
Myoinositol 180.063 8.22 
 
x 
N(Pai)-Methyl-L-histidine 169.085 7.64 x 
 
N,N-Dimethyl-1,4-phenylenediamine 136.10 1.70 x 
 
N1-Acetylspermine 244.226 8.53 x 
 
N-6-(δ2-isopentenyl)-adenine 203.117 1.74 x x 
N-Acetyl-D-galactosamine 221.09 6.15 
 
x 
N-Acetyl-D-glucosamine 221.09 6.24 
 
x 
N-Acetyl-DL-glutamic acid 189.064 4.40 x x 
N-Acetyl-DL-methionine 191.062 2.85 
 
x 
N-Acetyl-DL-serine 147.053 4.39 
 
x 
N-Acetyl-D-mannosamine 221.09 6.19 
 
x 
N-Acetyl-D-tryptophan 246.10 3.56 x x 
N-Acetylglycine 117.043 3.75 
 
x 
N-Acetyl-L-alanine 131.058 3.34 
 
x 
N-Acetyl-L-aspartic acid 175.048 4.54 
 
x 
N-Acetyl-L-cysteine 163.03 3.49 
 
x 
N-Acetyl-L-leucine 173.105 1.72 x x 
N-Acetyl-L-phenylalanine 207.09 1.71 
 
x 
N-Acetylneuraminate 309.106 7.02 x x 
N-Acetylputrescine 130.111 5.28 x 
 
Nicotinamide adenine dinucleotide 663.109 9.73 x 
 
N-Amidino-L-aspartate 175.059 6.40 x x 
N-Formylglycine 103.027 3.75 
 
x 
Nicotinamide 122.048 3.51 x 
 
Nicotinamide hypoxanthine dinucleotide 664.093 10.13 x x 
Nicotinamide mononucleotide 334.057 8.37 x 
 
Nicotinate 123.032 2.79 x x 
N-Methyl-D-aspartic acid 147.053 6.82 x x 
N-Methyl-L-glutamate 161.069 6.58 x x 
Noradrenaline 169.074 6.07 
 
x 
Norleucine 131.095 5.31 x 
 
N-α-Acetyl-L-asparagine 174.064 4.88 x x 
N-α-Acetyl-L-lysine 188.116 6.06 x x 
Nε, Nε, Nε -Trimethyllysine 188.153 7.38 x x 
O-Acetyl-L-serine 147.053 6.37 x 
 
Orotic acid 156.017 6.46 
 
x 
O-Succinyl-L-homoserine 219.074 6.37 x 
 
Palatinose 342.116 7.76 x x 
Paraxanthine 180.065 3.53 x 
 
Petroselinic acid 282.256 1.64 x 
 
Phenylpyruvate 164.047 1.65 
 
x 
Phospho(enol)pyruvic acid 167.982 8.46 x 
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Phosphocholine 183.066 8.26 x 
 
Phylloquinone 450.35 1.71 x 
 
Pipecolate 129.079 6.25 x 
 
Protoporphyrin 562.258 3.57 x x 
Pterin 163.049 5.23 x 
 
Purine 120.044 4.13 x x 
Pyridoxal 167.058 4.32 
 
x 
Pyridoxal 5-phosphate 247.025 7.52 x x 
Pyridoxamine 168.09 6.66 x 
 
Pyridoxine 169.074 5.0 x x 
Quinate 192.063 6.06 
 
x 
Quinoline 129.058 1.65 x 
 
Reichstein's substance S 346.214 1.65 x x 
Resorcinol monoacetate 152.047 1.51 
 
x 
Retinoate 300.209 1.50 x 
 
Retinyl palmitate 524.459 1.56 x 
 
Ribitol 152.069 5.88 
 
x 
Riboflavin 376.138 5.60 x x 
Rosmarinic acid 360.085 4.17 x x 
S-(5-Adenosyl)-L-homocysteine 384.122 7.66 x x 
S-(5-Adenosyl)-L-methionine 398.137 8.36 x 
 
Salicylate 138.032 1.70 
 
x 
Sarcosine 89.0477 6.47 x x 
S-Carboxymethyl-L-cysteine 179.025 6.99 x 
 
Selenocystamine 235.945 6.95 x 
 
Selenomethionine 191.002 5.99 x 
 
Serotonin 176.095 4.51 x 
 
S-Hexyl-glutathione 391.178 5.82 x x 
Shikimate 174.053 4.99 
 
x 
Spermidine 145.158 8.63 x 
 
Spermine 202.216 9.70 x 
 
Sphinganine 301.298 1.73 x 
 
Sphingomyelin 730.599 4.75 x 
 
Stachyose 666.222 9.38 x x 
Suberic acid 174.089 1.72 
 
x 
Succinic acid 118.027 3.61 
 
x 
Sucrose 342.116 7.63 x x 
Taurine 125.015 6.79 x x 
Taurolithocholate 483.302 5.04 x x 
Theophylline 180.065 3.40 
 
x 
Thiamine monophosphate 344.071 8.35 x 
 
Thiopurine S-methylether 166.031 1.73 x x 




Thymidine 5-monophosphate 322.057 8.08 
 
x 
Thymidine-5'-diphospho-α-D-glucose 564.076 12.53 
 
x 
Thymine 126.043 3.85 
 
x 
Thyrotropin releasing hormone 362.17 6.49 x x 
Thyroxine 776.687 5.00 
 
x 
Trans-4-Hydroxyproline 131.058 7.00 x x 
Trans-Aconitate 174.016 4.44 
 
x 
Trans-Cinnamate 148.052 1.70 x 
 
Tryptamine 160.1 1.74 x 
 
Tyramine 137.084 3.42 x 
 
Uracil 112.027 4.05 
 
x 
Urate 168.028 6.62 x x 
Uridine 244.07 5.11 
 
x 
Uridine 5-diphosphogalactose 566.055 12.95 
 
x 








Uridine 5-diphospho-N-acetylglucosamine 607.082 12.06 
 
x 
Uridine-5-monophosphate 324.036 9 x x 
Urocanate 138.043 4.88 
 
x 
Vitamin B12 1354.57 7.65 x x 
Xanthine 152.033 5.45 x x 
Xanthosine 284.076 5.96 x x 
Xanthurenic acid 205.038 5.18 x x 
Xylitol 152.069 5.96 
 
x 
α-Aminoadipate 161.069 6.65 x x 
α-D-Galactose 1-phosphate 260.03 9.61 x x 
α-D-Glucose 180.063 6.87 
 
x 
α-D-Glucose 1-phosphate 260.03 9.5 
 
x 
β-Alanine 89.0477 6.1 x 
 
Βine 117.079 6.03 x 
 




Supplementary Table 2.4. Method 3 accurate mass retention time data 
from the analysis of mass spectrometry metabolite library of standards. 
Supplied by IROA Technologies, LLC. Product information provided by 
Sigma-Aldrich (Version PD, MAM 09/15-1). RT – retention time ; +VE – 








Acetyl-tyrosine1 9.3 √   <0.0001 
-Glutamyl-tyrosine1 16 √   <0.0001 
2,5-Dihydroxybenzaldehyde1     14.1  √ <0.0001 
Hydroxynitisinone5 100+ √   <0.0001 
 
Supplementary Table 2.5. Non-AMRT urinary metabolite changes 
identified post-nitisinone. Fold changes (FC’s) for patients with AKU are 
indicated in brackets and were calculated from raw peak area. Compounds 
were identified by theoretical accurate mass match <10 ppm. Bold text 
indicates change observed in human and mouse data. Metabolic pathway 
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Background: The homogentisic acid-lowering therapy nitisinone is being 
evaluated for the treatment of Alkaptonuria (AKU) at the National Centre for 
AKU. Beyond hypertyrosinaemia the wider metabolic consequences of its 
use are largely unknown. The aim of this work was to evaluate the impact of 
nitisinone on the serum metabolome of patients with AKU after 12 and 24 
months of treatment. 
Materials and methods: Deproteinised serum from 25 patients with AKU 
(mean age±SD 51.1±14.9 y, 12 male) was analysed using the 1290 Infinity II 
LC system coupled to a 6550 QTOF-MS (Agilent, Cheadle, UK). Raw data 
were processed using a batch targeted feature extraction algorithm and an 
accurate mass retention time database containing 469 intermediary 
metabolites (mw 72-785). Matched entities (± 10ppm theoretical accurate 
mass and ± 0.3 min retention time window) were filtered based on their 
frequency and variability (<25 % CV) in group QC samples, and repeated 
measures statistical significance analysis with Benjamini-Hochberg false 
discovery rate adjustment was used to assess changes in metabolite 
abundance.  
Results: 8 metabolites increased in abundance (log2 fold change 2.1-15.2, 
p<0.05); 7 of 8 entities were related to tyrosine metabolism, and 13 
decreased in abundance (log2 fold change 1.5-15.5, p<0.05); including 
entities related to tyrosine (n=2); tryptophan (n=3); xanthine (n=2) and citric 
acid cycle metabolism (n=2).  
Conclusions: Evaluation of the serum metabolome of patients with AKU 
showed a significant difference in the abundance of several metabolites 
following treatment with nitisinone, including a number that have not been 









Alkaptonuria (AKU, OMIM 203500) is a rare autosomal recessive disorder of 
tyrosine metabolism resulting from a defect in homogentisate-1,2-
dioxygenase (HGD, E.C.1.12.11.5), which leads to a marked increase in the 
circulating concentration of homogentisic acid (HGA) (Phornphutkul et al., 
2002). The pathological hallmark of AKU is ‘ochronosis’, which is a 
consequence of the deposition of a dark pigment in connective tissue, mainly 
cartilage, which alters its physico-mechanical properties. The exact 
composition and structure of this pigment is unknown, but is known to result 
from the accumulation of HGA (Figure S3.1) (Ranganath et al., 2013). 
 
Treatment options for AKU are conservative in large focusing on supportive 
and palliative measures (Ranganath et al., 2013). The HGA lowering agent 
nitisinone (Figure S3.1) has been shown to completely prevent ochronosis in 
AKU mice (Preston et al., 2014) and is being evaluated as a potential 
treatment in AKU patients (Phornphutkul et al., 2002; Suwannarat et al., 
2005; Introne et al., 2011; Ranganath et al., 2016; Milan et al., 2017; 
Ranganath et al., 2018); it is however not without its own challenges as it is 
well documented to result in significant hypertyrosinaemia in AKU 
(Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne et al., 2011; 
Olsson et al., 2015; Ranganath et al., 2016; Milan et al. 2017; Ranganath et 
al., 2018; Davison et al., 2018a; Davison et al., 2018b; Davison et al., 2018c) 
and hereditary tyrosinaemia type 1 (HT1) (Lindstedt et al., 1992; Lock, 2017; 
van Ginkel et al., 2017). The consequences of this are largely unknown in 
AKU; in HT1 it has been suggested this may contribute to the 
neurodevelopmental delay that is frequently observed in children treated with 
nitisinone (McKiernan et al., 2015). Several mechanisms have been 
proposed for this including altered metabolism of the monoamine 
neurotransmitters (Thimm et al., 2011). Davison et al. (2018b; 2018c) 
demonstrated in a cohort of AKU patients that nitisinone therapy resulted in 
altered urinary excretion of dopaminergic and serotoninergic neurotransmitter 
metabolites. However, these findings are limited as they are not a direct 
reflection of neurotransmitter metabolism in the central nervous system. A 
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recent study in an animal model of HT1 suggested that the disease itself and 
not treatment with nitisinone is likely to be responsible for slower learning and 
altered behavior in mice (Hillgartner et al., 2016). 
 
Recently, changes in the urine metabolome of an AKU mouse model and 
patients with AKU treated with nitisinone were reported (Norman et al., 
2019a). This study demonstrated novel changes in the tyrosine metabolic 
pathway, and unexpectedly in tryptophan and purine metabolism. While 
these changes in the urine metabolome provide insight into how nitisinone 
alters metabolism, one may postulate that changes observed in the serum 
are more relevant as they are a more direct reflection of internal 
homeostasis. Gertsman et al. (2015a) reported on the impact of nitisinone 
therapy on the serum metabolome of patients with AKU. In addition to the 
expected decrease in HGA and increase in tyrosine, significant increases in 
N-acetyl-L-tyrosine and -glutamyltyrosine were also observed. In a separate 
publication (Gertsman et al., 2015b) in the same cohort of patients, novel 
disturbances in tryptophan metabolism were reported. 
 
Herein for the first time we report the impact of nitisinone (2 mg daily) therapy 
on the serum metabolome in the largest cohort of AKU patients to date over 
a 2 year period at the National AKU Centre (NAC) in the UK. 
 
 
3.3 Materials and methods 
 
3.3.1 Reagents 
Water for mobile phases was purified in-house (DIRECT-Q 3UV Millipore 
water purification system). Methanol, acetonitrile and isopropanol were 
purchased from Sigma Aldrich (Dorset, UK). Formic acid and ammonium 
formate were obtained from Biosolve, (Netherlands) and Fisher Scientific 
(Germany), respectively. All reagents were LC-MS grade. N-Acetyl-L-tyrosine 
was purchased from Sigma Aldrich, UK. 
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3.3.2 Patients and serum sample collection 
3.3.2.1 Ethical Approval 
Data collection and sample analyses at the NAC has approval from the Royal 
Liverpool and Broadgreen University Hospital Trusts Audit Committee (Audit 
no. ACO3836), this approval includes the use of patient data and biological 
material for metabolomics evaluation. As data and samples were collected as 
part of the clinical service, ethical approval was not required. Patients are 
informed verbally and through patient information leaflets about the clinical 
and research activities of the NAC and are informed that data may be used 
for publication. For a detailed protocol see Milan et al. (2017). 
 
3.3.2.2 Sample collection 
Serum samples (S-monovette, Sarstedt, Germany) were collected from 
patients after an overnight fast (≥8 h). Patients’ dietary intake of protein was 
managed through a 7-day food diary by a combination of lower protein in diet 
and phenylalanine/tyrosine-free meal exchanges. Samples were centrifuged 
at 1500 ×g for 10 min at 4 °C; and then deproteinised with perchloric acid (60 
% 5.8 M; 1:10, perchloric acid:serum), vortexed and centrifuged at 1500 ×g 
for 10 min. Supernatant was stored at -20 °C until analysis. 
 
3.3.2.3 Patient and quality control sample preparation 
Patient samples were prepared by diluting 150 µL serum with 450 µL 
deionized water (DIRECT-Q 3UV Millipore water purification system). Diluted 
samples were then transferred into a 96 well plate which was then agitated 
on a plate shaker (MTS 2/4m IKA, Germany) at 600 rpm for 10 min. 
 
Patient group quality control (QC) samples were produced by adding 50 µL 
of each patient sample into a single pool. In total 4 group QC pools were 
made [(i) baseline, (ii) 12 months, (iii) 24 months and (iv) overall – containing 
serum from all patients and visits; this acted as a system QC]. QC samples 
were prepared as per patient samples. 
  
The analytical sequence of samples was performed as per published 
guidance (Vorkas et al., 2015). Each run commenced with 20 replicate 
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injections of the overall pooled sample to condition the system. The order of 
individual samples was randomised computationally. Pooled samples were 
interspersed throughout the analytical sequence every tenth injection.  
 
3.3.3 Analytical method 
3.3.3.1 Chromatographic conditions 
Liquid chromatography (LC) was performed on an Agilent 1290 Infinity II LC 
system. An Atlantis dC18 column (3.0 x 100 mm, 3 µm, Waters, UK) was 
maintained at 60 °C with a flow rate of 0.4 mL/min. Mobile phases were (A) 
water and (B) methanol both containing 5 mmol/L ammonium formate and 
0.1 % formic acid. The elution gradient started at 5 % mobile phase B at 0-1 
min increasing linearly to 100 % B by 12 min, held at 100 % B until 14 min, 
returning to 95 % A for 5 min to recondition the column. Injection volume was 
1 µL. 
  
3.3.3.2 Quadrupole time-of-flight mass spectrometry (QTOF-MS) 
conditions 
An Agilent 6550 QTOF-MS equipped with a dual jet stream electrospray 
ionisation source was operated in 2 GHz mode, over the mass range of 50-
1700, in negative and positive polarities. A reference mass correction 
solution was continually infused at a flow rate of 0.5 mL/min via an external 
isocratic pump (Agilent, Cheadle, UK) for constant mass correction (see 
section 3.7 Supplementary material for additional details of QTOF-MS 
operating parameters and composition of reference ion solution). 
  
3.3.3.3 Metabolite identification, data quality control and statistical 
analyses 
Metabolite identification was carried out using an established accurate mass 
retention time (AMRT) database to match chemical entities (Norman et al., 
2019a). The database included theoretical accurate mass, measured 
retention time, and empirical formula. This was modified to include N-acetyl-
L-tyrosine, -glutamyl-tyrosine and indole-3-lactate (I-3-L). AMRT data for N-
acetyl-L-tyrosine were verified following the analysis of an analytical 
standard. AMRT data for -glutamyl-tyrosine and I-3-L were based on the 
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elution time associated with theoretical monoisotopic mass of each 
compound and were not verified using an analytical standard. Data quality 
control and statistical analysis were performed using the MassHunter 
software suite (Agilent, Cheadle, UK). For additional details on data quality 
control and statistical analyses see supplementary information 3.1 and 
Supplementary Figure S3.2 and S3.3.  
 
Serum samples were also analysed using 1D proton (1H) nuclear magnetic 
resonance (NMR). Data from these analyses were not included in the peer 
reviewed publication presented herein. For details of sample preparation, 
analytical methodology, data analysis, results and discussion see Appendix 1 





Twenty-five patients [13 female, mean age (±standard deviation) 55.3(15.3) 
years (range 22-75); 12 male, mean age 44.2(15.8) years (range 22-70)] 
were included at baseline and after treatment with nitisinone at 12 and 24 
months. 
 
Raw data from LC-QTOF-MS analysis showed that retention time and 
accurate mass ranges were 1.15-13.93 min and 75.0318-730.5955 Da, in 
positive and 1.03-14.67 min and 75.0318-722.6247 Da in negative polarity, 
respectively. Principal component analysis and associated loading plots in 
positive and negative polarities are depicted in Figure 3.1. Clear separation 
between the AMRT matched profiles of AKU patients pre- and post-nitisinone 
therapy was observed in component 2 in positive polarity. Negative polarity 
shows poor separation in comparison. Quantitative statistical analysis was 
performed to further evaluate changes in metabolite abundance following 




Figure 3.1. Principal component analysis to assess the effect of nitisinone therapy on metabolite profiles in serum 
samples collected from AKU patients. Baseline (no treatment) – blue circle; 12 months (2 mg daily nitisinone) – green circle and 
24 months (2 mg daily nitisinone) – red circle. PCA plots (A) in positive and (C) negative polarity. Loadings plots (B) and (D) show 
the respective contributions of individual metabolites to components 1 and 2 in positive and negative polarity, respectively.  
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151/469 and 249/469 metabolites were aligned across all samples in positive 
and negative polarities (for matched compounds see Table S3.2 and 
Supplementary Figure S3.4), respectively at baseline, and after nitisinone 
treatment at 12 and 24 months. After filtering entities based on their 
frequency and variability across replicate injections of pooled QC samples 
from each experimental group, 123 and 209 entities were retained from 
positive and negative polarity profiling experiments, respectively. Of these, 60 
and 121 respectively, were shown to be significantly different (p<0.05) 
following nitisinone therapy. Those with a log2 fold change (FC) >2 at 12 and 
or 24 months are summarised in Table 3.1. Applying this cut-off, 8 (6.5 %) 












Glycocholate4 12.7 12.7 <0.001  
 
Succinic acid6 11.4 11.4 <0.001  
 
-Ketoglutaric acid6 10.0 10.0 <0.001   
Trans-4-hydroxyproline4 15.5 15.5 <0.001  
 
Homoserine4 12.5 12.5 <0.001  
 
Mevalolactone4 10.7 10.7 <0.001  
 
L-Allothreonine4 11.8 11.8 0.02  
 
Trigonelline2 12.8 12.8 <0.001   
4-Quinolinecarboxylic acid2 8.3 8.3 <0.001  
 
Indole-3-lactate2 2.1 2.3 <0.001   
4-Hydroxyphenylacetic acid1 4.2 5.4 <0.001 
 
 
Benzaldehyde1 6.9 6.9 <0.001  
 
Homogentisate1 4.0 5.0 <0.001  
 
4-Hydroxybenzaldehyde1 14.4 14.4 <0.001 
 
 
N-Acetyl-L-tyrosine1 15.5 15.2 <0.001 
 
 
-L-Glutamyl-L-tyrosine1 3.2 3.0 <0.001 
 
 
3-(4-Hydroxyphenyl)lactic acid1 6.4 6.4 <0.001 
 
 
L-Tyrosine1 2.7 2.7 <0.001 
 
 
Mandelic acid1 12.6 12.0 <0.001 
 
 
Inosine3 10.8 10.8 <0.001  
 
Uridine7 2.1 1.5 <0.001  
 
 
Table 3.1. Serum metabolite changes identified post-nitisinone therapy 
at 12 and 24 months in patients with AKU using an in-house AMRT 
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database. Abundance expressed as log2 fold change (FC) compared to 
baseline (pre-nitisinone treatment). Log2 FC included if >2 at 12 and or 24 
months; p value <0.05 deemed significant. Metabolic pathway affected 
denoted by a number: 1 – tyrosine metabolism; 2 – tryptophan metabolism; 3 
– purine metabolism; 4 – other metabolic processes; 6 – citric acid 
metabolism; 7 – pyrimidine metabolism. 
 
 
Nine (43 %) of the 21 metabolites that were affected following treatment with 
nitisinone relate to tyrosine metabolism. Many of the other metabolites that 
had altered abundance following nitisinone therapy did not follow a clear 






Over the last 2 decades there have been several reports on the use of 
nitisinone to treat AKU. Its inhibition of HPPD (Figure S3.1) has been shown 
to dramatically reduce the circulating concentration of HGA (Phornphutkul et 
al., 2002; Suwannarat et al., 2005; Introne et al., 2011; Ranganath et al., 
2016; Milan et al., 2017; Ranganath et al., 2018), but leads to marked 
hypertyrosinaemia (Phornphutkul et al., 2002; Suwannarat et al., 2005; 
Introne et al., 2011; Olsson et al., 2015; Ranganath et al., 2016, Milan et al., 
2017; Ranganath et al., 2018; Davison et al. 2018a; Davison et al., 2018b; 
Davison et al., 2018c). Beyond hypertyrosinaemia there is very little reported 
on the biochemical consequences of nitisinone therapy. Herein we report the 
impact of nitisinone therapy on the serum metabolome, using LC-QTOF-MS 
and a validated strategy to identify metabolites using an AMRT database 
developed in-house (Norman et al., 2019a). This study is unique as it 
includes the largest cohort of patients with AKU to date, taking a 2 mg daily 
dose of nitisinone over 24 months. In addition, as it is based on the analysis 
of serum it is a better reflection of the impact of nitisinone on internal 
homeostasis. 
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This study confirms previous reports that nitisinone treatment in AKU results 
in a marked reduction in serum HGA and increase in tyrosine. In addition, a 
significant increase in 3-(4-hydroxyphenyl)lactic (HPLA) was observed. This 
marked increase in HPLA is also an expected consequence of nitisinone 
therapy (Gertsman et al., 2015a). Unexpectedly 3-(4-hydroxyphenyl)pyruvic 
acid (HPPA), the metabolite immediately proximal to the site of action of 
nitisinone, was not increased (Figure S3.1). There is an equilibrium between 
HPPA and HPLA (Figure S3.1) and it is possible that the reason for only 
observing a significant increase in HPLA is that the sample conditions (e.g. 
pH) shifted the equilibrium position to favour its formation. Moreover it is not 
known whether HPPA is a labile metabolite and thus may have degraded. A 
similar pattern where HPLA was the predominant metabolite has been 
previously reported (Norman et al., 2019a), in a study that reported on the 
urine metabolome of patients with AKU treated with nitisinone; a 84 and 16 
fold (raw FC) increase in HPLA and HPPA were reported, respectively. 
 
Marked increases in the tyrosine conjugates N-acetyl-L-tyrosine and -
glutamyl-tyrosine were also observed. The log2 FC observed was very similar 
for tyrosine and -glutamyl-tyrosine, but that of N-acetyl-L-tyrosine was 
markedly higher. The latter suggests that an equilibrium shift between 
tyrosine and N-acetyl-L-tyrosine may exist, but not for tyrosine and -
glutamyl-tyrosine. Norman et al. (2019a) showed that urinary tyrosine was 
significantly higher than N-acetyl-L-tyrosine and -glutamyltyrosine in a 
cohort of AKU patients on 2 mg daily of nitisinone supporting that an 
equilibrium shift between tyrosine and tyrosine conjugates exists. In contrast, 
Gertsman et al. (2015a) reported a proportional increase in plasma tyrosine, 
N-acetyl-L-tyrosine and -glutamyl-tyrosine following nitisinone suggesting 
there is no equilibrium shift. While direct comparisons between the 
magnitudes of FC cannot be made as herein we report log2 FC, the 
proportions of metabolites are clearly different between the 2 studies. This 
may be due to the small number of patients in the study reported by 
Gertsman et al. (2015a) and that a 2 mg dose was used only in our study. 
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Nonetheless our findings support that non-traditional metabolic pathways are 
active in the face of tyrosine excess. 
 
The elevated -glutamyl-tyrosine suggests that glutathione metabolism and 
the redox state of cell (Griffith et al., 1979; Zhang et al., 2009) are altered 
following treatment with nitisinone. This is of particular importance to AKU as 
elevated HGA is thought to lead to a pro-oxidant environment where ‘soluble 
melanins’ are formed (Davison et al., 2016). Increasing evidence to support 
HGA induced oxidative stress has been reported in vitro in serum (Braconi et 
al., 2011) and cellular models (Braconi et al., 2010), and in patients with AKU 
(Millucci et al., 2014). For a recent review on oxidative stress and its 
contribution to the mechanisms of the ochronotic process see Braconi et al. 
(2015). One may postulate that treatment with nitisinone reduces the burden 
on the glutathione cycle improving glutathione availability. In turn this may 
enable transfer of the glutamyl moiety from glutathione to tyrosine, via the 
action of -glutamyl-transpeptidase (Griffith et al., 1979; Zhang et al., 2009) 
to form -glutamyl-tyrosine. Interestingly, this study also revealed a marked 
decrease in the citric acid cycle metabolites α-ketoglutaric and succinic acid, 
the keto acids of α-ketoglutarate and succinate, following nitisinone. In this 
study glutamine and glutamatic acid did not change, thus one may 
hypothesise that glutamate (not measured) formed from glutamine is 
preferentially converted to glutathione and not α-ketoglutaric and succinic 








Figure 3.2. Proposed mechanism for the formation of -glutamyl-
tyrosine in AKU following nitisinone therapy. Entities in red and blue 
represent an increase and decrease in metabolite abundance, respectively. 




The significance of increased N-acetyl-L-tyrosine is unknown, but has been 
reported in serum (Gertsman et al., 2015a) and urine (Norman et al., 2019a) 
of AKU patients treated with nitisinone. It has also been observed in the urine 
of patients with hereditary tyrosinaemia type 2 (OMIM 276600) (Macsai et al., 
2001). One may postulate that N-acetyl-L-tyrosine represents a more efficient 
way to eliminate the excess tyrosine from the body as it is more water soluble 
than tyrosine. Interestingly N-acetyl-L-tyrosine has also been reported as an 
additive to foodstuffs given to patients on nutritional support (Hoffer et al., 
2003). 
  
4-Hydroxyphenylacetic (HPA) and 4-hydroxybenzaldehyde (4-HBA) were 
increased and benzaldehyde decreased following treatment with nitisinone; 
these have not been previously reported in the serum metabolome of 
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patients with AKU following nitisinone treatment. HPA has been reported in 
urine following treatment with nitisinone (Norman et al., 2019a). 4-HPA is 
generated from gut microbiota (Liu et al., 2016); one may hypothesise that 
the increase observed herein resulted from less oxidative stress following 
nitisinone, which increased microbiotic metabolism. This is the first report in 
humans, but has been seen previously observed in a rat model of oxidative 
stress (Liu et al., 2016). 
 
The increase in HBA has been reported in the urine of patients with AKU 
following nitisinone (Norman et al., 2019a), but the decrease in benzaldehyde 
has never been observed. The significance of both entities is uncertain. 4-
HBA is a naturally occurring compound that originates from the saprophytic 
perennial Gastrodia elata (Kang et al., 2017). Recent studies have reported 
the therapeutic effects of benzaldehydes in a number of areas including 
wound healing, cancer, vascular disease, and renal disease (Lee et al., 2010; 
Moon et al., 2012; Kong et al., 2014; Lee et al., 2014). In the context of AKU 
the significance of 4-HBA and benzaldehyde are unknown and require further 
investigation. One may speculate that they relate to the benzoquinones, 
proposed as intermediates in the formation of ochronotic pigment observed in 
AKU (Norman et al., 2019a). 
  
Mandelic acid was also increased following treatment with nitisinone, which 
has been reported previously (Norman et al., 2019a). The significance of this 
is uncertain, but urinary elevation has previously been observed in patients 
with PKU on a phenylalanine restricted diet (Rampini et al., 1974). 
 
The ‘off target effects’ of any drug are essential when considering its 
suitability in treating a patient (Lynch et al., 2017). Nitisinone therapy in AKU 
and HT1 have long been associated with altered tyrosine metabolism, and so 
can be considered a ‘targeted effect’. More recently off targets effects of 
nitisinone have been reported due to its impact on tryptophan metabolism. A 
decrease in 5-hydroxyindoleacetic acid (serotonin metabolite) has been 
reported in the cerebrospinal fluid and urine of patients with HT1 (Thimm et 
al., 2011) and AKU (Davison et al., 2018b; Davison et al., 2018c), 
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respectively. Serum tryptophan itself has been shown not to change following 
treatment with nitisinone (Davison et al., 2018a); in contrast urinary 
tryptophan has been shown to decrease (Norman et al., 2019a). These 
differences may be explained by the fact that tryptophan is highly protein 
bound (~90-95 %) (Cervenka et al., 2017) and measurement in serum 
reflects total tryptophan and urinary tryptophan reflects free tryptophan. The 
biologically active fraction is the free fraction, which is not typically measured 
in serum, and the majority is metabolized via the kynurenine pathway 
(Cervenka et al., 2017). Herein I-3-L, 4-quinolinecarboxylic acid and 
trigonelline were the only tryptophan-related metabolites that were changed 
following nitisinone. The significance of the latter 2 metabolites is uncertain, 
but reinforces that downstream metabolism of kynurenine and niacin may be 
altered following nitisinone treatment. Gertsman et al. (2015b) also 
demonstrated an increase in plasma I-3-L, but additionally indole-3-pyruvate 
(I-3-P). It has been proposed that the increased activity in the indole pyruvate 
pathway results from tryptophan aminotransferase having a higher affinity for 
tryptophan in the presence of keto acids (e.g. HPPA) (Lees et al., 1973). The 
reason for not observing I-3-P is uncertain, however one may speculate that 
I-3-L and not I-3-P was increased due to reaction conditions favoring its 
formation. In addition, differences may in part be explained by different 
approaches to sample preparation, chromatographic and mass spectrometry 
conditions, patient cohorts and nitisinone doses used. In addition a separate 
study showed urinary xanthurenic acid, and L-kynurenine and indoxyl-sulfate 
were increased and decreased following nitisinone therapy, respectively 
(Norman et al., 2019a) The significance of these changes are unknown. 
 
Beyond tryptophan metabolism there are limited reports on the off-target 
effects of nitisinone on the metabolome. Herein we have shown that trans-4-
hydroxyproline decreases significantly following treatment. This is of 
particular relevance to AKU as it suggests that there may be decreased 
collagen breakdown. This requires further investigation as previous authors 
(Taylor et al., 2017) have demonstrated a very low cartilage turnover state in 
AKU patients. In contrast, a different study reported that cartilage 
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degradation, as well as bone resorption markers were elevated in AKU 
patients compared to controls (Genovese et al., 2015). 
 
In addition, significant decreases were observed in the purine and pyrimidine 
precursor’s inosine and uridine, respectively. In a previous study decreased 
excretion of the purine metabolites adenine and allantoin were reported in 
urine from AKU patients and an AKU mouse treated with nitisinone (Norman 
et al., 2019a). Patients included in this study and previous (Norman et al., 
2019a) were not on uric acid-lowering medication, however were on a 
protein-restricted diet which may contribute to this change. A plausible 
explanation for the observations in serum and in urine may also relate to 
changes in the oxidative state of the cell. Allantoin has previously been 
suggested as a marker of oxidative stress (Marrocco et al., 2017), one may 
postulate that the decreases observed in purine and pyrimidine metabolites 
are a reflection of reduced oxidative stress in the face of lower HGA 
concentrations (Marrocco et al., 2017). 
 
Four unrelated entities were also shown to be decreased following nitisinone 
therapy; glycocholate, homoserine, mevalolactone and allothreonine. The 
reasons for this remain of unknown significance and requires further 
investigation. 
 
It is important to highlight several limitations in this study. Firstly, while the 
number of patients included in this study is the largest reported to date, 
metabolites identified need validating in a larger cohort of patients. Moreover, 
an untreated group of AKU patients would provide greater credibility that the 
findings presented herein are a consequence of nitisinone therapy.  In 
addition, while we believe the AMRT database used in this study is 
comprehensive, the targeted evaluation of the serum metabolome precludes 
the identification of novel changes in metabolites. Furthermore, the use of 
non-selective sample preparation to gain broad coverage of the metabolome 
may have limited metabolite detection if present at a low concentration or if 





Evaluation of the impact of nitisinone treatment on the serum metabolome of 
patients with AKU revealed a number of novel changes including a number 
that are not directly related to the tyrosine metabolic pathway. Some of these 
changes can be explained by the impact of nitisinone therapy on the cellular 
redox state and the wider impact of metabolites on enzyme activity. Further 
work is required to provide greater insight into the changes observed in the 

























3.7 Supplementary material 
 
3.7.1 Quadrupole time of flight mass spectrometer operating 
conditions 
Capillary and fragmentor voltages were 4000 V and 380 V, respectively. 
Desolvation gas temperature was 200 °C with flow rate at 15 L/min. The 
sheath gas temperature was 300 °C with flow rate at 12 L/min and nebulizer 
pressure was 40 psi and nozzle voltage 1000 V. Data acquisition rate was 3 
spectra/s. 
 
3.7.2 Preparation of reference mass correction solution  
Reference mass correction solution was prepared in 95:5 methanol:water 
containing 5 mmol/L purine (CAS No. 120-73-0), 100 mmol/L trifluoroacetic 
acid ammonium salt (TFA, CAS No. 3336-58-1) and 2.5 mmol/L hexakis(1H, 
1H, 3H-tetrafluoropropoxy)phosphazine (HP-0921, CAS No. 58943-98-9) 
(Agilent, Cheadle, UK).  
 
Reference ions monitored were: purine (m/z 121.0509) and HP-0921 (m/z 
922.0098) (positive polarity) and TFA (m/z 112.9856), purine (m/z 119.0363) 
and HP-0921 (HP-0921 + formate adduct: m/z 966.0007) (negative polarity). 
 
3.7.3 Data acquisition and handling parameters 
Data were acquired using Acquisition (Build 06.00, Agilent, Cheadle, UK). 
Quality checks and processing of raw data files (Agilent ‘.d’ files) were 
performed with Qualitative Analysis software (Build 07.00, Agilent, Cheadle, 
UK). 
 
Extracted ion chromatograms of reference masses were performed to check 
mass accuracy remained <5 ppm throughout the run and that the reference 
ion signal did not drop out during the chromatographic run. In addition, to 
check chromatographic reproducibility binary pump pressure curves for 
injections across each analytical sequence were overlaid. Mass accuracy 
and chromatographic reproducibility were acceptable for all experiments 
performed. 
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Profiling sample data acquired were mined for signals representing AMRT 
database compounds using ‘targeted feature extraction’ with Profinder 
software (Build 08.00, Agilent, Cheadle, UK). Targeted feature extraction 
uses the molecular formulae from the AMRT database to extract and group 
spectral signals (i.e. adducts, isotopes and multimers) that correspond to 
individual database compounds. Feature extraction employed a window of 
theoretical accurate mass ±10 ppm and database retention time ±0.3 min. 
Allowed species were: H+, Na+ and NH4
+ (positive polarity) and H- and CHO2
- 
(negative polarity). Dimers were allowed for both polarities. Charge state 
range was 1-2. 
 
3.7.4 Data quality control and statistical analysis 
Quality control filters were applied to entities obtained from targeted feature 
extraction in each profiling experiment. Entities were retained if present in at 
least 2 samples per experimental group. Data files were then exported from 
Profinder as ‘.CEF’ files as a whole batch for each profiling experiment and 
imported to Mass Profiler Professional (MPP) software (Build 14.5, Agilent, 
Cheadle, UK). 
  
In MPP sample data files were scaled to the median of all samples and 
chemical entities were filtered based on the data from injection of QC pooled 
samples. Entities were first filtered based on frequency, and retained if 
observed in 100 % of replicate injections for at least 1 sample group pool. 
Further filtering was then based on variability, and entities were retained if 
peak area coefficient of variation remained <25 % across replicate injections 
for each sample group pool. 
  
Statistical analyses performed in MPP were based on compound signal 
intensity, expressed as total peak area. Profiles were compared at 12 and 24 
months on 2 mg daily nitisinone with pre-nitisinone profiles by 1-way 
repeated measures ANOVA with Benjamini-Hochberg false-discovery rate 
adjustment. Log2 FC was calculated pairwise between all groups within each 
dataset, and this was based on raw peak area data. Changes were deemed 
significant if asymptotic p value was <0.05. Principal component analysis 
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employing a 4 component model were also performed on each filtered 





































Figure S3.1.Tyrosine metabolic pathway. Highlighted are: (i) the metabolic 
fate of tyrosine in health, (ii) site of the enzyme defect observed in AKU, 
homogentisate 1,2-dioxygenase (HGD, EC 1.13.11.5) and HT1, 
fumarylacetoacetate hydrolase (FAH, EC 3.7.1.2), and (iii) the site where 






Figure S3.2. Work flow for processing of raw data from LC-QTOF-MS 
analysis using the Agilent MassHunter software suite (Agilent, Cheadle, 














Figure S3.3. Representative data from quality checks performed on data 
acquired from LC-QTOF-MS analysis of serum samples in positive and 
negative polarities (each analytical sequence consisted of 125 
samples). (A) Overlaid binary pump pressure curves, (B) Overlaid reference 
ion signal in positive polarity and (C) Overlaid reference ion signal in negative 
polarity, extracted ion chromatograms of reference masses were performed 
to check mass accuracy remained <5 ppm throughout the run. Reference ion 
signal is present during the analytical runs in both polarities, in negative 
polarity the greatest suppression of signal occurred at 1.5 min. Ion 




Figure S3.4. Number of accurate mass retention time (AMRT) matches 
obtained from processing raw LC-QTOF-MS data. AMRT matches 
obtained using the batch targeted feature extraction algorithm (Build 08.00, 
Agilent, Cheadle, UK), and subsequent entities retained following quality 
control filtering and statistical analysis in positive (+VE) and negative (-VE) 












3.7.6 Supplementary Tables 
 
 
Table S3.1. Summary of accurate mass and retention time data for 
metabolites that make up in-house AMRT database used in this study. 
These can be found at https://doi.org/10.6084/m9.figshare.c.4378235.v2. 
This study adapted this library to include the additional metabolites below. 
The accurate mass and retention time of compounds in bold italics are 
based on elution time associated with theoretical monoisotopic mass and 
were not verified with an analytical standard
Metabolite name Empirical formula Mass 
Retention time 
(min) 
N-Acetyl-L-tyrosine C9H11NO3 223.0844 4.81 
-Glutamyl-tyrosine C14H18N2O6 310.1164 3.81 
Indole-3-lactate C11H11NO3 205.0738 6.66 
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Compound matched to AMRT database 
Polarity 
Positive Negative 
(R)-Malate  x X 





1-Aminocyclopropane-1-carboxylate  x x 







2-Deoxy-D-glucose  x x 
2-Deoxyuridine 5-mono-phosphate  
 
x 
2-Hydroxybutyric acid  
 
x 
2-Methylglutaric acid  x 
 2-Quinolinecarboxylic acid  x 
 3-(4-Hydroxyphenyl)lactic acid 
 
x 
3,4-Dihydroxyphenylacetate  x 
 3-Amino-4-hydroxybenzoic acid  
 
x 












3-Methoxy-L-tyrosine  x x 
3-Methoxytyramine  x x 
3-Methyglutaric acid  x 









3-Ureidopropionate  x x 




4-Hydroxy-2-quinolinecarboxylic acid  x 
 4-Hydroxy-3-methoxyphenylglycol  
 
x 
4-Hydroxybenzaldehyde  x 
 4-Hydroxy-L-proline  x x 
4-Hydroxyphenylacetic acid  
 
x 
4-Imidazoleacetic acid  
 
x 
4-Methyl-2-oxo-pentanoic acid  
 
x 
4-Pyridoxate  x x 
4-Quinolinecarboxylic acid  
 
x 




5-Hydroxy-L-tryptophan  x x 
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5-Methylthioadenosine  x x 
5-Oxo-D-proline  x x 
5-Oxo-L-proline  x x 
6-Carboxyhexanoate  x 
 6-Deoxy-L-galactose  x x 
N-acetyl-L-tyrosine x 
 Adenine  
 
x 
Adenine hydrochloride hydrate  
 
x 
Adenosine 5-monophosphate  
 
x 










Azelaic acid  x x 









Bis(2-ethylhexyl)phthalate  x x 







Cholesteryl acetate  x x 
Cis-4-hydroxy-D-proline  x x 
Citrate  x 




Cortisol  x x 
Cortisol 21-acetate  
 
x 
Creatine  x x 













D-(+)-Galactosamine  x x 
D-(+)-Galacturonic acid  x x 










Dehydroascorbate  x 
 Deoxycarnitine  x 










D-Fructose-6-phosphate  x x 










D-Glucose-6-phosphate  x x 
D-Glucuronic acid  x x 
D-Glucuronolactone  x x 
D-Glyceric acid  
 
x 
D-Gulonic acid--lactone  
 
x 














D-Mannosamine  x x 
D-Mannose 6-phosphate  x x 
Docosahexaenoic acid  
 
x 
D-Ornithine  x x 
D-Pantothenic acid  x x 







D-Sorbitol  x x 
D-Tagatose  x x 




Adrenaline  x x 
Erythritol  x x 
Ethylmalonic acid  
 
x 
Galactitol  x x 
Glutamyl-tyrosine* x 
 Linoleic acid 
 
x 






Glyceraldehyde  x x 
Glycerol  x x 
Glycerol 2-phosphate  x x 
Glyceryl trimyristate  
 
x 
Glycine  x x 
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Homoserine  x x 
Homovanillate  x x 
Hypotaurine  x x 




Indole-3-acetate  x x 
Indole-3-acetic acid  x x 
Indole-3-lactate* x 
 Indole-3-pyruvic acid  
 
x 
Inosine  x x 




L-Allothreonine  x x 
L-Arabitol  x x 
L-Arginine  x x 










L-Carnitine  x x 
L-Cystathionine  x 
 L-Cystine  x x 
Leucine  x 
 L-Glutamic acid  x x 
L-Glutamine  x x 




L-Isoleucine  x x 
L-Kynurenine  x x 
L-Lysine  x x 
L-Lysine monohydrochloride  x x 
L-Methionine  x x 
L-Norvaline  x x 
L-Ornithine  x x 
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L-Phenylalanine  x 
 L-Pipecolic acid  x x 
L-Proline  x x 
L-Rhamnose  x x 
L-Serine  x x 
L-Sorbose  x x 
L-Threonine  x x 
L-Tryptophan  x x 
L-Tyrosine  x x 




Maleic acid  x 
 Maltose  
 
x 
Mandelic acid  x x 
Mannitol  x x 




Methyl jasmonate  x 









Myo-inositol  x x 







N-Acetyl-DL-glutamic acid  x x 
N-Acetyl-DL-methionine  x x 







N-Acetylglycine  x x 
N-Acetyl-L-alanine  x x 
N-Acetyl-L-aspartic acid  x x 










Nicotinamide  x x 
Nicotinamide mononucleotide  
 
x 




Norleucine  x 























Palmitoleic acid  
 
x 













Phosphocholine  x 
 Phylloquinone  
 
x 
Pipecolate  x x 
Pyridoxal  x x 




Reichstein substance S  
 
x 
























Sphingomyelin  x 
 Suberic acid  x x 






Taurine  x x 
Theobromine  x x 
Theophylline  x x 













Trigonelline  x x 
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Uracil  x x 
Urate  x x 
Uridine  x x 
Urocanate  x x 




Xanthurenic acid  
 
x 
Xylitol  x x 
α-Aminoadipate  x x 
α-D-Galactose 1-phosphate  x x 
α-D-Glucose  x x 
α-D-Glucose 1-phosphate  x x 




Βine  x x 




Table S3.2. Summary of metabolites that were aligned and matched 
across all samples at baseline, and after nitisinone treatment at 12 and 
24 months. Metabolites were aligned using Profinder software (Build 08.00, 
Agilent, Cheadle, UK); a targeted feature extraction was used to align profiled 
experimental data with data in the accurate mass and retention time (AMRT) 
database containing 469 intermediary metabolites. Metabolites aligned and 
matched in both negative (n=249) and positive (n=151) polarities are 
detailed. Feature extraction employed a window of theoretical accurate mass 
± 10 ppm and retention time ± 0.30 min. Allowed species were: H+, Na+ and 
NH4
+ for positive polarity; and H- and CHO2
- for negative polarity. Dimers 
were allowed for both polarities. Charge state range was 1-2. * – accurate 
mass and retention time of compounds are based on elution time associated 
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Background on Alkaptonuria (AKU) and the rationale for evaluating the serum 
metabolome following treatment with nitisinone in patients with AKU is not 
presented herein as this is comprehensively covered in the introduction of 
Chapter 3. This study differs only in that the analytical technique used for 
sample analysis was 1D 1H nuclear magnetic resonance (NMR). 
 
Increasingly it is recognized that a metabolomic study is defined by the 
capability and limitations of the analytical methodologies employed, therefore 
the use of a single analytical methodology may hinder this and provide an 
incomplete biological picture (Marshall et al., 2017). As NMR and mass 
spectrometry based methodologies are complementary their combination is 
likely to improve the overall quality of a study and enhance the coverage of 
the metabolome, moreover it is more likely that the structural elucidation of 
unknown metabolites is possible (Marshall et al., 2017). It is for this reason 




3A.2 Materials and methods 
 
3A.2.1 Patients and serum sample collection 
Serum samples (S-monovette, Sarstedt, Germany) used were those that 
were collected from AKU patients that provided samples for LC-QTOF-MS 
analysis (see Chapter 3). Following centrifugation of samples at 1500 ×g for 
10 min at 4 °C, and prior to acidification (see section 3.3.2.2) an aliquot of 
serum (non-acidified) was made and stored at -20 °C until analysis. 
 
For demographic details of the patients included in this analysis see Chapter 
3. In brief, paired samples from 25 patients were analysed from baseline 




3A.2.2 NMR methodology 
3A.2.2.1 Sample preparation for 1H NMR 
Stored serum aliquots were thawed immediately prior to NMR sample 
preparation. 100 μL of each serum sample had 100 μL of deuterated buffer 
(200 mmol/L sodium phosphate buffer pH 7.4 and 100 mmol/L sodium azide) 
added to it and was vortexed for 20 s and centrifuged at 12,000 g for 1 min at 
4 °C. 180 μL of the sample mixture then was transferred to 3 mm (outer 
diameter) NMR tubes (Bruker, UK) for acquisition. 
 
3A.2.2.2 NMR acquisition and spectral processing 
1D proton Carr-Purcell-Meiboom-Gill (1D 1H CPMG, vendor supplied 
cpmgpr1d) NMR spectra were acquired at 700 MHz using a Bruker Avance III 
HD 700 MHz NMR spectrometer fitted with a 5 mm triple resonance 
cryoprobe and a chilled sample jet auto-sampler. Samples were referenced 
to anomeric 1H of glucose at 5.24 ppm. 1H NMR spectra had spectral widths 
of 17.16 ppm, 4 s relaxation delay, 32 scans with 4 dummy scans collected 
into 73 k data points (3.067 s acquisition time). Spectral acquisition was 
automated via iconNMR (Bruker, UK) following calibration of the 
spectrometer temperature, which was calibrated to 37 °C (± 0.1 °C) via a 
methanol thermometer (Ammann et al., 1982). 3D shimming was also 
performed on a quality control sample of sucrose, and the spectrometer 
optimised to offset for water suppression on a single representative serum 
sample. All spectra were zero filled to 128 k data points with exponential line 
broadening of 0.3 Hz applied before fourier transformation. Spectra were 
automatically phased, referenced and baseline corrected in Topspin using 
vendor supplied automated routines (Version 3.5, Bruker, UK). 
 
3A.2.2.3 Spectral data quality control, metabolite annotation and 
identification 
Figure 3A.1 summarises the main steps taken after raw data were acquired. 
Serum metabolites in the 1H NMR spectra were examined in Topspin by 
overlaying all spectra to assess (i) the shape and width of the glucose 
reference peak (5.24 ppm, line width measured at half peak height) (ii) that 
the baseline was flat without curvature or sine wiggle, (iii) that signal to noise 
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was as expected compared to a representative spectrum, (iv) that water 
suppression was good (i.e. narrow water signal between 0.2 and 0.4 ppm 
wide and no baseline distortion beyond this range and (v) phasing was good 
throughout spectra as recommended best practice in the metabolomics 





Figure 3A.1. Summary of data handling and statistical analysis 




Spectra were annotated using Chenomx (Version 8.2, Canada) by importing 
2 representative spectra from the different treatment groups (pre- and post-
nitisinone) into Chenomx. Acquired spectral data were fitted to the reference 
data to enable metabolite identification (Chenomx contains 328 metabolites). 
Identification enabled metabolite peak shift boundaries to be established. 
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These were then used to produce a pattern file. Metabolite peaks without an 
identity were labelled as ‘unknown’. The pattern file was used to generate a 
variable width 1D bucket table using AMIX (Version 3.9.14, Bruker, UK).  
Spectra were bucketed according to spectral features or peaks; all peaks 
both annotated and unknown were included in the bucket table. 
 
Spectra were subjected to a quality control filter prior to statistical analysis by 
characterization of the glucose reference peak with spectra excluded that did 
not satisfy line width or baseline requirements in the spectral bucketing 
software AMIX. 
 
To ensure spectral buckets did not overlap small windows from the entire 
spectrum were reviewed visually using tameNMR (https://github.com/PGB-
LIV/tameNMR). TameNMR does this by superimposing the bucket table 
boundaries onto NMR spectra, 8 representative NMR spectra were used 
(pre- and post-nitisinone treatment).  
 
Spectra were prepared for statistical analysis by normalizing each spectrum 
using the probabilistic quotient normalisation (PQN) method (Kohl et al., 
2012). The bucket table was imported into MetaboAnalyst (Version 4.0, 
https://www.metaboanalyst.ca) for statistical analysis in the format of a .csv 
file as a peak intensity table. No data filtering was applied to the data set as it 
contained <5000 features. Data were log transformed, and underwent Pareto 
scaling (mean-centered and divided by the square root of the standard 
deviation of each variable). Statistical analysis included principal component 
analysis (PCA), and a 1-way ANOVA which was used to assess significant 
differences in metabolite patterns observed at 12 and 24 months compared 
to baseline following treatment with nitisinone. An adjusted p-value 
(Benjamini Hochberg, false discovery rate corrected) cutoff of 0.05 and a log2 







Following NMR spectral data quality checks, 6 out of 75 samples were 
excluded from the data analysis. In total, 23/25 patients were included at 
baseline; 21/25 patients at 12 months and 24/25 patients at 24 months. All 
spectra included were manually aligned to glucose (5.24 ppm, see Figure 
3A.2 for an example) before any statistical analysis. Figure 3A.3 shows 
representative aligned NMR spectra from a patient pre-nitisinone, and at 12 
and 24 months after 2 mg daily nitisinone treatment. The most visible 
changes observed between the spectra are in the aromatic region highlighted 





Figure 3A.2. NMR spectra showing spectral alignment to glucose at 5.24 
ppm. Spectra from the analysis of serum samples are depicted (A) AKU 
patient pre-nitisinone, (B) AKU patient after 12 months of nitisinone treatment 





Figure 3A.3. Representative 1D 1H NMR spectra from the analysis of 
serum taken from a patient. (A) Pre-nitisinone, (B) 12 months after 
nitisinone treatment and (C) 24 months after nitisinone treatment. The largest 




In order to determine statistical and FC differences in NMR serum metabolite 
profiles a pattern file was made (see Supplementary material –  Appendix 
Supplementary Table 3.1 for information contained in the pattern file) using 
representative NMR spectra (8 serum samples – 4 pre-nitisinone and 4 post-
nitisinone). In total 119 spectral shifts were included in the pattern file, this 
corresponded to 37 metabolites matched in Chenomx, 15/37 metabolites had 
multiple spectral shifts. In addition there were 27 unknown chemical shifts, 
which relate to a maximum of 27 metabolites assuming 1 spectral shift 
relates to 1 metabolite. Figure 3A.4 shows the images generated using 
tameNMR to check spectral boundaries did not overlap in the pattern file.  
 
All spectra generated from the analysis of all serum samples included in this 
study were aligned with the pattern file to generate a bucket table containing 
metabolite signal intensities for statistical analysis. PCA and associated loads 
(Figure 3A.5) show clear separation between samples collected at baseline, 




Figure 3A.4. TameNMR screen shots showing spectral boundaries used 
for individual metabolite spectral shifts in 8 representative serum 
samples from patients with AKU at baseline, 12 and 24 months. (A) 9.5-
7.4 ppm; (B) 7.5-5.5 ppm; (C) 5.5-4.9 ppm; (D) 4.5-2.5 ppm and (E) 2.5-0.5 
ppm. In total there were 119 metabolite boundaries across the entire 
spectrum. Note there are no metabolite boundaries between 4.9-4.5 ppm as 




Figure 3A.5. Summary of statistical analysis of serum samples at 
baseline (pre-nitisinone, n=23), 12 months (n=21) and 24 months (n=24) 
following nitisinone treatment. (A) PCA and (B) Loadings associated with 
PCA. All labelled metabolites were deemed significant when baseline 
samples were compared to samples collected 12 and 24 months following 
nitisinone treatment. Metabolites in bold text had a log2 FC >2. 
 
 
The majority of metabolite signals from the NMR analysis causing this 
separation were from tyrosine, specifically tyrosine 18 (at 7.2 ppm) and 
tyrosine 12 (6.9 ppm) (Figure 3A.6). Both signals showed a log2 FC increase 
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>2 (p values <0.05, Table 3A.1). Several unknown metabolite signals and 
desaminotyrosine are annotated in Figure 3A.5, but showed a log2 FC <2. 
The identity of the unknown metabolites was not determined as they were not 
significantly different. Of note, HGA was not observed in any samples from 





Figure 3A.6. 1H NMR spectra from the analysis of serum taken from a patient (A) Pre-nitisinone and (B) 24 months after 
nitisinone treatment. In this figure the expected spectral shifts for tyrosine are highlighted (based on Chenomx library). The 5 shifts 
highlighted by purple rings on chemical structures srelate to the aromatic ring (7.2 and 6.9 ppm), amide group (3.9 ppm) and the 
alkyl groups (3.2 and 3.0 ppm). This figure shows the specific region of 0-8 ppm; x-axis relates to the spectral shift in ppm and the y-
axis the intensity of the signal. 
Metabolite 









7.82E-26 2.7 1.03E-28 2.8 
Tyrosine 
(tyrosine 12) 
1.03E-25 2.7 1.29E-28 2.7 
 
Table 3A.1. Serum metabolite changes identified post-nitisinone therapy 
at 12 and 24 months in patients with AKU using an in-house pattern file. 
Abundance expressed as log2 FC compared to baseline (pre-nitisinone 






The results presented herein were generated from 1D 1H NMR experiments, 
which were performed in conjunction with LC-QTOF-MS analysis (Davison et 
al., 2019b). The NMR data were not included in the peer reviewed publication 
presented in the main body of Chapter 3 and are included as an appendix for 
completeness.  
  
This is the first study to evaluate the serum metabolome of patients with AKU 
following treatment with nitisinone, using NMR. The only other report of using 
NMR in the context of AKU relates to the diagnosis of AKU being made by 
NMR urinalysis (Yamaguchi et al., 1986). As alluded to earlier the reason for 
using NMR in conjunction with LC-QTOF-MS was to maximise the coverage 
of the metabolome with a view to providing a more complete biological 
picture, and a structural identity in unknown entities that appear to change 
significantly following nitisinone therapy. 
 
In total 119 metabolite spectral signals were identified in the serum samples 
analysed in this study, which corresponded to 37 matched metabolites in 
Chenomx (15 metabolites had multiple spectral shifts) and 27 unknown 
spectral shifts relating to a maximum of 27 metabolites, if it is assumed that 
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each metabolite had a single spectral shift. This is typical of NMR based 
metabolomic experiments in native serum where typically ~30 metabolites 
can be expected to be observed (Psychogios et al., 2011). This is 
significantly lower than the number of metabolites matched using LC-QTOF-
MS (see Chapter 3); 151 and 249 metabolites matched in positive and 
negative polarity, respectively. One of the reasons for this is that NMR is 
limited to detecting the most abundant metabolites (typically ≥1 micomolar). 
In contrast, mass spectrometry is able to measure femtomolar to attomolar 
concentrations, has significantly better resolution due to chromatographic 
separation and a greater dynamic range (~103–104). However, quantification 
is limited by ion suppression and when used in combination with liquid 
chromatography there are additional sources of complexity and error with 
mobile and stationary phases (Marshall et al., 2017). 
 
Another potential problem with NMR lies in the approach used to fit 
metabolite signals to patterns as many 1H signals overlap (Markley et al., 
2017). In this study the impact of this was limited as standardised conditions 
and data collection protocols were used. Probabilistic fitting of data can 
further reduce the impact of this (Ravanbakhsh et al., 2015).  
 
The data presented herein confirms the significant hypertyrosinaemia that is 
known to occur following nitisinone therapy (Phornphutkul et al., 2002; 
Suwannarat et al., 2005; Introne et al., 2011; Ranganath et al., 2016; Milan et 
al., 2017; Davison et al., 2018a; Davison et al., 2018b; Davison et al., 
2018b), and is the first report of this using NMR. No HGA signals were 
observed in the data set, which is surprising as 1H NMR reference spectra 
(600 MHz, 50 mmol/L in water, pH 7.0) on the Human Metabolome Database 
(http://www.hmdb.ca) show clear shifts at 3.47, 6.71, 6.81 ppm. There are 
several potential reasons for this, including sample preservation; HGA is 
known to be labile and sample acidification with perchloric acid is 
recommended (Hughes et al., 2015). However, samples used in this set of 
experiments were not acidified due to the detrimental impact it would have on 
sample pH (pH 7.4 required for NMR analysis). Whilst HGA in the sample 
may have degraded to some extent, it is unlikely it would not be observed at 
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all as it is present in serum at 20-30 µmol/L pre-nitisinone therapy 
(Phornphutkul et al., 2002; Introne et al., 2011; Ranganath et al., 2016; Milan 
et al., 2017).  
 
Secondly the concentration of HGA may also have been grossly 
underestimated in serum due to it binding to serum proteins (Bell et al., 1988; 
Nicholson et al., 1989; Chatham et al., 1999; Nagana Gowda et al., 2014). 
High protein concentrations can also result in reduced transverse relaxation 
(T2) times for metabolite signals and facilitate exchange between protein 
bound and free metabolites, which result in broadened NMR peaks and poor 
quantitative accuracy (Nagana Gowda et al., 2015). 
  
Despite NMR not providing additional information on changes in identified 
metabolite abundance in this study it is a technique that is firmly entrenched 
in metabolomic studies. The advantages include minimal sample handling 
without the need for chromatography, that it is easily quantitative, and 





This is the first study to evaluate the serum metabolome of patients with AKU 
following treatment with nitisinone using NMR, and confirms the presence of 
hypertyrosinaemia following treatment with nitisinone. This study highlights 
the challenges associated with the analysis of serum samples that have not 
undergone clean up prior to NMR analysis. Further identification of unknown 
serum metabolites present in the clinical samples is required to exploit all 












number Left Right 
8.47 8.46 Formate 1 
8.213 8.186 Unknown 2 
7.898 7.851 Unknown 3 
7.85 7.83 Unknown 4 
7.82 7.8 Histidine 5 
7.739 7.644 Unknown 6 
7.448 7.409 Phenylalanine 7 
7.3893 7.374 Overlap1/phenylalanine 8 
7.3739 7.363 Overlap2/phenylalanine 9 
7.3629 7.347 Overlap3/phenylalanine 10 
7.3469 7.3191 Phenylalanine 11 
7.22 7.178 Tyrosine 12 
7.166 7.1298 Desaminotyrosine 13 
7.0842 7.055 Histidine 14 
7.05 7.0195 Unknown 15 
7.0194 6.996 Unknown 16 
6.9959 6.923 Unknown 17 
6.9223 6.8802 Tyrosine 18 
6.8801 6.75 Desaminotyrosine/n-acetyltyrosine 19 
5.362 5.253 Mobile-lipid 20 
5.253 5.226 Glucose 21 
5.219 5.1671 Fucose 22 
4.9161 4.9055 4-Hydroxy-3-methoxymandelate 23 
4.3317 4.2225 Unknown 24 
4.1888 4.1461 Fucose 25 
4.1436 4.1363 Glutarate 26 
4.1361 4.1262 Lactate/glutarate 27 
4.1261 4.0922 Lactate 28 
4.0918 4.064 Fucose 29 
4.065 4.0514 Creatinine 30 
4.02 3.9991 Amino acid-α-backbone 31 
3.9992 3.9807 Amino acid-α-backbone 32 
3.9803 3.9701 Unknown 33 
3.9699 3.9544 Galactitol 34 
3.9551 3.9291 Tyrosine 35 
3.929 3.9258 Unknown 36 
3.9206 3.9084 Glucose 37 
3.9083 3.8876 Glucose 38 
3.8878 3.8704 Unknown 39 
3.8677 3.8524 Glucose 40 
3.8524 3.82 Glucose 41 
3.8149 3.8059 Unknown 42 
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3.8046 3.7954 Fucose 43 
3.7953 3.7558 Alanine/glucose 44 
3.7559 3.7199 Glucose 45 
3.7199 3.7 Unknown 46 
3.699 3.6292 Amino acid-α-backbone 47 
3.6275 3.6032 Valine 48 
3.5971 3.5767 Amino acid-α-backbone 49 
3.5763 3.5642 Glycine 50 
3.5637 3.5284 Glucose 51 
3.529 3.4555 Glucose 52 
3.4553 3.4465 Unknown 53 
3.4456 3.3859 Glucose 54 
3.3858 3.3783 3,4-Dihydroxybenzeneacetate 55 
3.376 3.365 Unknown 56 
3.3648 3.3259 Unknown 57 
3.3083 3.2786 N-carbamoyl-alanine 58 
3.2782 3.2393 Glucose 59 
3.2378 3.209 Tyrosine 60 
3.208 3.19 Tyrosine 61 
3.189 3.1722 Tyrosine 62 
3.1721 3.1548 N-nitrosodimethylamine 63 
3.1547 3.1332 Malonate 64 
3.1246 3.1052 Cis-aconitate 65 
3.0833 3.0746 Unknown 66 
3.0745 3.0684 Unknown 67 
3.0684 3.0634 Unknown 68 
3.0633 3.057 Unknown 69 
3.057 3.0536 Unknown 70 
3.0535 3.047 Tyrosine/creatinine 71 
3.0469 3.0427 Tyrosine/creatine-phosphate 72 
3.0426 3.032 Tyrosine/creatine 73 
3.031 3.0 Tyrosine 74 
2.9959 2.9485 Asparagine 75 
2.9484 2.9283 Asparagine 76 
2.9252 2.8846 Unknown 77 
2.8737 2.8603 Asparagine 78 
2.86 2.8477 Asparagine 79 
2.8475 2.8298 Methyl-guanidine 80 
2.8297 2.8123 Unknown/acetyltyrosine 81 
2.812 2.77 Mobile-lipid 82 
2.769 2.7357 Mobile-lipid 83 
2.7355 2.7104 Sarcosine 84 
2.7104 2.69 Unknown 85 
2.6899 2.68 Unknown 86 
2.679 2.658 Citrate 87 
2.6565 2.6281 Unknown/n-carbomoylaspartate 88 
2.5776 2.5437 Citrate 89 
2.5435 2.5137 Citrate 90 
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2.5125 2.4859 Glutamine 91 
2.4857 2.4399 Glutamine/n-carbamoylaspartate 92 
2.3893 2.3809 3-Hydroxyisovalerate 93 
2.3809 2.34 Glutamate 94 
2.339 2.3109 Unknown 95 
2.3108 2.2566 Valine 96 
2.2564 2.2401 Mobile-lipid 97 
2.24 2.1884 Mobile-lipid 98 
2.1883 2.1 Glutamine/glutamic acid 99 
2.0992 2.0708 Mobile-lipid/glycoprotein 100 
2.07 2.0297 Mobile-lipid/proline 101 
2.0295 1.9404 Unknown 102 
1.9363 1.9024 Acetate 103 
1.7727 1.63 Leucine 104 
1.62 1.53 Mobile-lipid 105 
1.507 1.46 Alanine 106 
1.44 1.389 Biotin 107 
1.38 1.32 Lactate 108 
1.3198 1.2182 Mobile-lipid 109 
1.2181 1.206 Unknown 110 
1.205 1.18 Fucose 111 
1.1799 1.0652 Unknown 112 
1.0651 1.031 Valine 113 
1.026 1.0065 Isoleucine 114 
1.0063 0.985 Valine 115 
0.985 0.95 Leucine 116 
0.9498 0.92 Isoleucine 117 
0.919 0.8605 Mobile-lipid 118 
0.8604 0.8 Mobile-lipid 119 
 
Appendix Supplementary Table 3.1. Pattern file generated in Amix for 
serum samples obtained from AKU patients pre and post treatment with 
nitisinone. Metabolite names were assigned based on matches from 
Chenomx (Version 8.2, Canada), which contains 328 metabolites. 
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Background: Alkaptonuria (AKU) is a rare inherited disorder of tyrosine 
metabolic pathway. Our group is evaluating the use of the homogentisic acid 
lowering agent nitisinone in patients with AKU. A major biochemical 
consequence of this treatment is hypertyrosinaemia. Herein we report the 
concentration of 20 serum amino acids over a 36-month period pre- and 
post-treatment with nitisinone. 
Materials and methods: Fasting serum samples were collected at baseline 
(pre-nitisinone), 3 (2 mg nitisinone every other day), 6, 12, 24 and 36 (2 mg 
nitisinone daily) months. Amino acids were measured using the Biochrom-30 
high performance liquid chromatography cation exchange system with 
ninhydrin detection.  
Results: Fifty patients [21 female, mean age (±standard deviation) 
54.1(15.6) years (range 25-75); 29 male, mean age 49.3(11.6) years (range 
22-70 years)] were included. Following treatment mean tyrosine 
concentrations increased 7-8 fold (baseline 69.8 µmol/L; 3 months 670.7 
µmol/L; 6 months: 666.4 µmol/L; 12 months 692.9 µmol/L; 24 months 649.4 
µmol/L; 36 months 724.8 µmol/L, p<0.001 for all visits compared to baseline). 
At baseline mean phenylalanine, aspartic acid and arginine concentrations 
were outside the normal reference range. Following treatment the ratios of 
phenylalanine:tyrosine, phenylalanine:large neutral amino acids, 
arginine:branched chain amino acids and branched chain:aromatic amino 
acids decreased (p<0.05), and the tyrosine:large neutral amino acid ratio 
increased (p<0.0001).  
Conclusions: Marked hypertyrosinaemia was observed following treatment 
with nitisinone. Noteworthy changes were also observed in the ratio of 
several amino acids following treatment with nitisinone suggesting that the 
availability of amino acids for neurotransmitter biosynthesis, and liver function 







Alkaptonuria (AKU, OMIM 203500) is a rare autosomal recessive disorder of 
the tyrosine metabolic pathway, resulting from a congenital deficiency in the 
enzyme homogentisate-1,2-dioxygenase (HGD, E.C.1.12.11.5). AKU occurs 
1 in 250 000 of the general population (Phornphutkul et al., 2002), but in 
certain countries it is observed more commonly; for instance in Slovakia it is 
estimated to occur in 1 in 19 000 of the population (Milch, 1960; Zatkova, 
2011).  
 
One of the major metabolic implications of AKU is that the circulating 
concentration of homogentisic acid (HGA) significantly increases.  This 
pathognomonic finding is thought to be causally responsible for a number of 
abnormalities observed in the disease. These include spondyloarthropathy, 
characterised by progressive kyphoscoliosis and impaired spinal and thoracic 
mobility, as well as renal and prostate stones, aortic valve stenosis, 
osteoporosis, fractures, and ruptures of tendons, ligaments and muscle 
(Ranganath et al., 2013). 
 
Supportive medical management of AKU is the mainstay of treatment and 
includes a low protein diet, analgesia and arthroplasty (Ranganath et al., 
2013). A newer unlicenced treatment for AKU is the drug nitisinone, a 
competitive reversible inhibitor of the enzyme 4-hydroxyphenylpyruvate 
dioxygenase (HPPD, E.C. 1.13.11.27). It reduces the formation of HGA and 
thus has the potential to prevent or slow the complications observed in 
patients with AKU. Previous studies (Phornphutkul et al., 2002; Suwannarat 
et al., 2005; Introne et al., 2011; Ranganath et al., 2016; Milan et al., 2017) 
have demonstrated the clear biochemical impact of nitisinone treatment, all 
demonstrating a >94 % reduction in urinary HGA. However, none have 
shown improvement in clinical parameters. This may be for several reasons, 
including: (1) AKU is a slow progressive disorder and thus study duration 
may not have been not long enough to demonstrate improvement, (2) the 
optimal dose of nitisinone may not used and (3) clinical outcomes measured 
may not have been appropriate.   
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At the National Alkaptonuria Centre (NAC) in Liverpool nitisinone is being 
used off licence (patients are given 2 mg of nitisinone daily, off-licence) for 
treatment of AKU for all patients in the UK, as it is recognised that nitisinone 
is a potential treatment for this debilitating disease. At the NAC it has also 
been demonstrated in a real life setting that this treatment can reduce urinary 
HGA by 94 % (Milan et al., 2017). 
 
In contrast, nitisinone is already licenced for the treatment of hereditary 
tyrosinaemia type 1 (HT1, OMIM 276700) and has proved to be a very 
efficacious mode of treatment (McKiernan, 2013; McKiernan et al., 2015).  
 
One of the major metabolic consequences of treating patients with nitisinone 
in AKU and HT1 is that circulating tyrosine concentrations markedly increase 
(Lindstedt et al., 1992; Phornphutkul et al., 2002; Suwannarat et al., 2005; 
Introne et al., 2011; McKiernan et al., 2015; Olsson et al., 2015; Ranganath 
et al., 2016; van Ginkel et al., 2016; van Ginkel et al., 2017; Milan et al., 
2017).  
 
Hypertyrosinaemia has been observed in patients with AKU that attend the 
NAC in Liverpool and during the Suitability Of Nitisinone In Alkaptonuria 1 
(SONIA-1) clinical trial (Ranganath et al., 2016), which evaluated the efficacy 
of different daily doses of nitisinone over a 4 week period.  Beyond this there 
is nothing reported on the wider impact of nitisinone on amino acid 
metabolism. 
 
For many years there has been keen interest in amino acid metabolism in 
health and disease, beyond the traditional setting of inborn errors of 
metabolism.  This is because amino acids are not only basic metabolites, but 
are also key regulators in many metabolic pathways.  Examples of areas 
studied include cognitive function and Alzheimer’s disease (Ravaglia et al., 
2004), gastroesophogeal cancer (Crotti et al., 2017), diabetes (Bi et al., 
2017) and aortic dissection (Wang et al., 2017).  
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In addition, while there have been several studies evaluating serum and 
plasma amino acid concentrations both in men and women of a variety of 
ages (Armstrong et al., 1973a; Armstrong et al., 1973b; Armstrong et al., 
1973c; Rudman et al., 1989; Caballero et al.,1991; Sarwar et al., 1991; Chan, 
1999; Pitkänen et al., 2003; Kouchiwa et al., 2012; Davison et al., 2015), 
none have reported fasting serum amino acid concentrations in patients with 
AKU pre- and post-nitisinone therapy.  
 
For the first time, this longitudinal survey reports the concentration of 
essential amino acids (valine, leucine, isoleucine, threonine, methionine, 
tryptophan, phenylalanine, lysine and histidine) and non-essential amino 
acids (aspartic acid, asparagine, glutamic acid, glutamine, alanine, glycine, 
cystine, arginine, tyrosine, serine, and proline) in patients that have attended 
the NAC with AKU pre- and post-nitisinone therapy over a 36 month period. 
 
 
4.3 Materials and methods 
 
4.3.1 Patients  
4.3.1.1 Protocol for patients that attend the NAC for treatment with 
nitisinone 
The protocol for treatment at the NAC is that patients with confirmed AKU are 
commenced on a 2 mg dose of nitisinone, on alternative days for the first 3 
months, which is then increased to 2 mg daily thereafter.  Assessments are 
repeated on an annual basis to monitor response to therapy.  Nitisinone is 
given off licence to investigate its safety and efficacy. It is hypothesised that if 
HGA levels are reduced before the onset of overt ochronosis, this might 
prevent or stop the development of the debilitating features observed in AKU. 
 
Inclusion criteria are that individuals must have the diagnosis of AKU; are 
residents of England or Scotland, and over the age of 16 years.  Confirmed 
diagnosis of AKU is based upon increased urinary excretion of HGA (urine 
HGA excretion in healthy volunteers has been demonstrated to be <2.92 
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µmol/day (Davison et al., 2015)) and is mandatory for referral to the NAC.  
Exclusion criteria are individuals must not be pregnant and or lactating. All 
patients are provided with written information about the scope of the Centre 
and the assessments they will receive.  All patients at the NAC have 
biochemical measurements with clinical assessments performed at baseline, 
day 4 (2 days post-nitisinone), 3 months, 6 months and 12 months, with 
annual monitoring thereafter.   
 
4.3.1.2 Ethical Approval 
Data collection and analyses at the NAC has approval from the Royal 
Liverpool and Broadgreen University Hospital Trust Audit Committee (Audit 
no. ACO3836).  This is not a clinical trial and therefore ethical approval was 
not required.  Data obtained is following standard clinical assessments during 
the course of providing a service upon referral to the NAC.  Patients are 
informed verbally and through patient information leaflets about the activities 
of the NAC.  Patients are also explicitly informed that data may be used for 
publication and within the NAC patient information leaflet the following 
paragraph is included: 
“We could publish results from the study but if we do, we will make sure that 
you cannot be identified in anyway.  All data used for publicity or for other 
research purposes will ensure total anonymity.  Please let us know when you 
are visiting the NAC that you understand and have no objections to this.” No 
patient has objected to the use of their data.   
 
4.3.1.3 Subjects included in the study  
To date (November 2017), 62 patients with AKU have been enrolled at the 
NAC for treatment with nitisinone.  
 
Twelve of the 62 patients were excluded from this survey; 7 were Welsh 
patients and therefore funding was not available for treatment with nitisinone; 
3 patients were on nitisinone prior to enrolment at the NAC and 2 patients 
were not receiving a standard nitisinone treatment regimen due to corneal 
keratopathy (Khedr et al., 2018). 
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Fifty patients [21 female, mean age (±standard deviation) 54.1(15.6) years 
(range 25-75); 29 male, mean age 49.3(11.6) years (range 22-70 years)] 
were included in this 36 month longitudinal survey reporting the biochemical 
data obtained from monitoring 20 serum amino acids. This is an on-going 
service and at the time of preparing this manuscript results were not available 
for all 50 patients at each time point, apart from baseline. Serum amino acid 
results are included from baseline (pre-nitisinone), 3 (2 mg nitisinone every 
other day), 6 (2 mg nitisinone daily), 12 (2 mg nitisinone daily), 24 (2 mg 
nitisinone daily) and 36 (2 mg nitisinone daily) months. Results are not 
included after baseline in all patients as individuals have attended the NAC 
for different durations and not all patients have attended planned visits to the 
NAC. 
 
4.3.2 Analytical Methods 
4.3.2.1 Sample collection  
Serum samples were collected from patients (S-monovette, Sarstedt, 
Germany), centrifuged (10 min at 3000 rpm) and stored at -20 °C until 
analysis. All serum samples were collected following an overnight fast (at 
least 8 h). Patients’ dietary intake of protein was not restricted during this 
study. 
 
4.3.2.2 Measurement of serum amino acids 
Serum amino acid concentrations were determined using the Biochrom 30 
high performance liquid chromatography cation exchange system with 
ninhydrin detection (Biochrom, Cambridge, UK). Amino acids were applied to 
the high pressure PEEK column packed with Ultrapac 8 cation exchange 
resin (Biochrom, Cambridge). The conditions of the analytical column were 
altered using a series of lithium buffers [lithium Buffer 1 (Biochrom, product 
code: 80-2038-15); lithium buffer 2 (Biochrom, product code: 80-2038-16); 
lithium Buffer 3 (Biochrom, product code: 80-2099-83); lithium Buffer 4 
(Biochrom 80-2097-18); lithium Buffer 5 (Biochrom, product code 80-2037-
69); lithium regeneration buffer 6 (Biochrom, product code: 80-2038-20)].  
Altering buffer composition over the 150 min analytical run increases pH until 
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the iso-ionic point of the different amino acids are reached, facilitating elution 
of amino acids from the analytical column.  
 
Detection was achieved using a post column reaction system, the eluent 
being mixed with an ultra ninhydrin solution in a ratio of 2:1 (Biochrom, 
product code: 80-2117-64) and heated to 135 °C. The ninhydrin amino acid 
complex was monitored at 2 wavelengths to detect amino and imino acids. 
Amino acids underwent a reaction with ninhydrin (triketohydrindene) to form 
a specific blue/purple colour complex with an absorbance maximum at  
570 nm (monitored in channel A). The intensity of the reaction product was 
proportional to the amino acid concentration. Imino acids do not have free 
amino groups so do not react in the same way, but form a yellow coloured 
complex with an absorbance maximum at 440 nm. Their absorbance was 
monitored on channel B.  
 
4.3.2.3 Calibration and internal standards 
Calibration was performed using a series of aqueous standards purchased 
from Sigma (Dorset, UK) [amino acids basic standard (product code: A6282); 
amino acids acidic/neutral standard (product code: A6407); glutamine 
(product code: G8540)]. Stock calibrations standards were made to 2.0 
mmol/L, except glutamine which was made to 2.5 mmol/L. All working 
calibrator concentrations were then diluted with loading buffer (Biochrom, 
product code: 80-2038-70) to a final concentration of 100 µmol/L, except for 
cystine which was 50 µmol/L. The diluted working calibrator also contained 
the internal standards S-2-amino-ethyl-L-cystine hydrochloride (product code: 
A2636) and norleucine (product code: N6877) at a final concentration of 200 
µmol/L and 5-sulphosalicylic acid at a final concentration of 91.7 mmol/L. 
 
4.2.3.4 Internal quality control 
ClinCheck® plasma control (level 1) for amino acids was used as internal 
quality control material (Recipe, Germany). This contained all amino acids 
measured, apart from cystine, which was purchased from Sigma (Dorset, 
UK) to make in-house internal quality control material. Inter-assay coefficient 
of variation for all 20 amino acids was <4 %; this is detailed below as mean 
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amino acid concentration (µmol/L) (±standard deviation), coefficient of 
variation (%). Aspartic acid: 12 (0.5), 3.9; threonine: 109.3 (1.9), 1.8; serine: 
96.7 (1.5), 1.5; asparagine: 45 (1.1), 2.3; glutamic acid: 98 (1.2), 1.3; 
glutamine: 408.9 (9.1), 2.2; glycine: 185.3 (3.0), 1.6; alanine: 405.9 (8.6), 2.1; 
valine: 233.2 (5.1), 2.2; cystine: 13.2(0.3), 2.4; methionine: 27.9 (0.9), 3.1; 
isoleucine: 76.8 (2.3), 3.0; leucine: 139.4 (3.1), 2.2; tyrosine: 68.3 (1.7), 2.5; 
phenylalanine: 78.1 (1.8), 2.3; lysine: 171.8 (3.0), 1.7; histidine: 73.5 (1.7), 
2.3; tryptophan: 53.5 (1.0), 1.8; arginine: 30.4 (0.8), 2.8; proline: 236.2 (3.7); 
3.7. 
 
4.2.3.5 Sample preparation  
100 μL of calibrator/serum/internal quality control material was mixed with 
100 μL of a solution containing sulfosalicylic acid (183.4 mmol/L) to 
precipitate proteins and internal standards (S-2-amino-ethyl-L-cystine 
hydrochloride and norleucine both at 100 µmol/L). Samples were then put in 
the fridge at 4 °C for 1 h, and then centrifuged at 13 000 rpm for 10 min. 60 
µL of supernatant was injected onto the analytical column for analysis. 
 
4.2.3.6  Data Analysis and calculations 
Amino acid concentrations were calculated off-line using EZCHrom Elite 
software (Build 3.2.1 Agilent, USA). All statistical analysis were performed 
using Graphpad Instat (Version 3.10, 2009, CA, USA) and Analyse It for 
Microsoft Excel (Version 2.20 Analyse-it Software, Ltd, Leeds, UK).  
Kolmogorov-Smirnov testing was performed to assess if serum amino 
concentrations were normally distributed. For non-parametric data a Kruskal-
Wallis test with a Dunn's multiple comparisons post-hoc test was used to 
assess significant differences in serum amino acid concentrations pre- and 
post-treatment with nitisinone. For parametric data a 1-way ANOVA with 
Tukey post-hoc was applied. A p value <0.05 was deemed significant. 
 
4.2.3.7 Amino acid ratios  
All amino acid concentrations used in calculations were in µmol/L. Ratios 
were calculated to assess dietary adequacy of protein intake (calculation a) 
(Antener et al., 1981); to predict phenylalanine, tyrosine, and arginine 
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availability to the brain for neurotransmitter synthesis (calculations b-d) 
(Lieberman, 1999; Ravaglia et al., 2004) and to assess liver metabolism, 
hepatic functional reserve and the severity of liver damage (calculation e) 
(Fisher et al., 1976). 
 
(a) Phenylalanine to tyrosine = [phenylalanine]/[tyrosine] 
 
(b) Tyrosine to large neutral amino acids ([tyrosine]:[LNAA]) =  
[tyrosine]/([tyrosine] + [phenylalanine] + [tryptophan] + [leucine] + 
[isoleucine] +[valine]) 
 
(c) Phenylalanine to large neutral amino acids ([phenylalanine]:[LNAA]) = 
[phenylalanine]/([tyrosine] + [phenylalanine] + [tryptophan] + [leucine] 
+ [isoleucine] +[valine]) 
 
(d) Arginine to branched chain amino acids ([arginine]:[BCAA]) = 
[arginine]/([leucine] + [isoleucine] +[valine]) 
 
(e) Branched chain amino acids to aromatic amino acids ([BCAA]:[AAA]) 





4.3.1 Serum amino acid concentrations pre-nitisinone treatment 
Table 4.1 summarises mean (±standard deviation) fasting serum amino acid 
concentrations from all patients included in this longitudinal survey. Fifty 
patients had amino acids measured at baseline (Table 4.1). After baseline 
amino acids were not measured in all patients as individuals have attended 
the NAC for different durations and not all patients attended planned visits to 
the NAC.  
 
Mean amino acid concentrations were within the normal reference range at 
baseline (pre-nitisinone treatment) apart from phenylalanine, aspartic acid, 
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arginine and cystine (Table 4.1). The latter being the only amino acid below 
the lower reference range, despite there being a large spread of 
concentrations. All other amino acids detailed were outside the upper 
reference range. Following treatment with nitisinone these amino acids did 
not change significantly over the 36 month period studied. 
 
4.3.2 Impact of nitisinone treatment on serum amino acid 
concentrations 
Mean serum tyrosine and tryptophan concentrations were within the normal 
reference range pre-nitisinone treatment, and phenylalanine was marginally 
outside the normal reference range (Table 4.1). Following treatment with  
2 mg nitisinone, every other day (3 month visit) and daily (all visits after 3 
month), tyrosine concentrations increased to 7-8 fold (p<0.001, at all visits).  
 
Phenylalanine and tryptophan concentrations were not significantly different 
over the 36 month period studied when compared to baseline. Phenylalanine 
concentrations did however show an increasing concentration. 
 
Several amino acid ratios were calculated (calculations a-e) (Table 4.1). All 
amino acid ratios were within the normal range pre-nitisinone treatment, 
except the phenylalanine to tyrosine ratio, which was increased. Following 
treatment with nitisinone all amino acid ratios showed a significant decrease 
(see Table 4.2 for p values, all were <0.05), apart from the tyrosine to LNAA 

















Phenylalanine (30-76)E,1 87.42 (13.9) 84.4 (18.3) 91.5 (22.5) 94.5 (13.5) 92.9 (13.6) 97.6 (15.0) 
Tyrosine (29-92)1 69.8 (15.7) 670.7 (155.0) 666.4 (162.3) 692.9 (119.8) 649.4 (183.6) 724.8 (116.8) 
Tryptophan (40-79)E,1 51.8 (11.5) 50.9 (9.9) 48.5 (11.9) 48.1 (11.1) 51.1 (10.2) 53.5 (14.7) 
Glutamine (326-800)2 571.2 (108.0) 476.2 (79.4) 495.1 (81.1) 527.6 (86.0) 525.4 (77.8) 469.4 (103.5) 
Asparagine (30-70)2 72.1 (15.1) 64.7 (14.6) 65.3 (17.9) 69.2 (11.0) 61.3 (11.8) 61.4 (9.1) 
Aspartic acid (2-5)3 39.8 (9.7) 38.2 (10.9) 37.9 (9.9) 38.1 (6.7) 39.5 (8.7) 45.4 (17.0) 
Glutamic acid (26-151)3 128.9 (40.4) 129.2 (56.6) 141.1 (63.5) 151.8 (37.4) 137.5 (32.4) 149.5 (49.2) 
Cystine (36-61)4 11.1 (9.3) 6.9 (4.6) 8.3 (8.4) 9.6 (9.1) 13.9 (9.1) 15.7 (13.5) 
Methionine (10-41)E,4 25.5 (6.6) 21.8 (4.5) 23.7 (5.9) 25.8 (5.4) 24.4 (4.3) 25.2 (5.3) 
Glycine (120-436)5 316.7 (77.6) 299.5 (60.6) 330.5 (61.6) 343.2 (63.2) 329.9 (75.1) 332.6 (74.4) 
Isoleucine (20-91)E,5 69.7 (17.6) 63.2 (15.5) 64.5 (15.7) 64.8 (12.1) 66.6 (13.5) 72.5 (18.0) 
Leucine (44-169)E,5 148.8 (27.8) 132.1 (28.4) 137.1 (30.7) 139.4 (21.6) 139.7 (20.7) 134.6 (33.1) 
Proline (66-330)5 204.3 (89.6) 183.3 (76.3) 207.9 (108.9) 180.4 (63.5) 182.3 (53.3) 182.5 (75.8) 
Valine (79-313)E,5 240.4 (43.4) 222.9 (44.6) 226.7 (45.4) 234.2 (36.0) 241.9 (40.2) 250.3 (52.7) 
Alanine (112-529)5 462.0 (96.9) 444.8 (92.0) 485.1 (124.8) 427.8 (83.3) 448.5 (82.6) 450.6 (79.5) 
Histidine (43-111)E,6 84.1 (12.3) 85.0 (12.8) 86.7 (16.5) 80.7 (9.5) 85.2 (11.7) 79.3 (10.0) 
Lysine (66-242)E,6 191.3 (32.2) 180.5 (33.8) 180.45 (38.8) 177.8 (27.9) 183.8 (28.0) 185.6 (27.4) 
Arginine (14-102)6 105.2 (23.4) 113.9 (31.1) 116.2 (26.9) 98.1 (13.8) 96.6 (15.9) 108.2 (18.0) 
Serine (69-206)7 162.3 (28.7) 149.8 (21.9) 155.5 (29.6) 161.3 (18.6) 157.9 (30.5) 162.4 (25.6) 
Threonine (43-218)E,7 132.2 (27.5) 114.5 (25.5) 112.7 (27.0) 112.5 (21.3) 113.4 (23.6) 124.5 (27.8) 
Phenylalanine:tyrosine  
(0.80-1.0) 
1.28 (0.21) 0.13 (0.04) 0.13 (0.03) 0.14 (0.03) 0.16 (0.1) 0.13 (0.04) 
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Table 4.1. Mean serum amino acid concentrations (mean(±standard deviation), µmol/L) in patients attending the NAC over 
a 36 month period. All samples were collected in a fasted state (overnight fast >8 h). Baseline – refers to pre-nitisinone therapy; 3 
months patients received 2 mg nitisinone every other day; after 3 months patients received 2 mg nitisinone daily. Aromatic1; amidic2; 
acidic3; sulphur containing4; aliphatic5; basic6; hydroxylic7; essentialE amino acids. Amino acid reference ranges were determined in-
house. Amino acid ratio reference ranges were adopted from Antener et al. (1981); Lieberman, 1999; Ravaglia et al. (2004); 
Kouchiwa et al. (2012). LNAA – large neutral amino acids; BCAA – branched chain amino acids; AAA – aromatic amino acid.  
Tyrosine:LNAA (0.0-0.14) 0.10 (0.01) 0.55 (0.07) 0.54 (0.10) 0.54 (0.05) 0.52 (0.09) 0.54 (0.06) 
Phenyalanine:LNAA (0.09-0.13) 0.13 (0.01) 0.07 (0.01) 0.07 (0.02) 0.07 (0.01) 0.08 (0.02) 0.07 (0.01) 
Arginine:BCAA (0.16-0.23) 0.23 (0.05) 0.27 (0.07) 0.27 (0.07) 0.23 (0.04) 0.22 (0.05) 0.24 (0.04) 
BCAA/AAA (Fishers ratio)  
(2.7-3.5) 
2.93 (0.37) 0.56 (0.14) 0.71 (0.86) 0.56 (0.09) 0.71 (0.49) 0.56 (0.13) 
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4.3.3 Amino acid concentrations showing differences after nitisinone 
treatment started 
Table 4.2 summarises significant differences in amino acid concentrations 
that were observed between visits after nitisinone treatment was started. 
Apart from tyrosine, the amino acids asparagine and glutamine showed 
significant decreases in concentration post nitisinone treatment at 24 and 36 
months (p=0.004), and 3, 6 and 36 months respectively (p<0.0001). 
 
Amino acid p value 
Change in amino acid 
concentration observed 
compared to baseline 
Change      
observed 
Asparagine 0.004 24 and 36 months Decrease 
Glutamine <0.0001 3, 6 and 36 months Decrease 
Tyrosine <0.0001 3, 6, 12, 24 and 36 months Increase 
Phenylalanine:tyrosine  <0.0001 3, 6, 12, 24 and 36 months Decrease 
Tyrosine:LNAA  <0.0001 3, 6, 12, 24 and 36 months Increase 







 BCAA/AAA           
(Fishers Ratio) 
<0.0001 3, 6, 12, 24 and 36 months Decrease 
 
Table 4.2. Serum amino acid concentrations that were significantly 
different in patients attending the NAC over a 36 month period. Baseline 
– refers to pre-nitisinone therapy; 3 months patients received 2 mg nitisinone 
every other day; after 3 months patients received 2 mg nitisinone daily. LNAA 
– large neutral amino acids; BCAA – branched chain amino acids; AAA – 





Herein for the first time we report the concentration of 20 serum amino acids 
over 36 month period in a large cohort of patients with AKU before and after 
treatment with nitisinone. This highly unique longitudinal survey examines the 
impact of AKU and its treatment on amino acid metabolism in a real life 
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healthcare setting. Traditionally the focus has been on the tyrosine metabolic 
pathway when studying AKU, and several reports have shown that patients 
treated with nitisinone have marked hypertyrosinaemia (Phornphutkul et al., 
2002; Suwannarat et al., 2005; Introne et al., 2011; Olsson et al., 2015; 
Ranganath et al., 2016; Milan et al., 2017). In line with previous authors we 
too observed a significant increase in serum tyrosine following treatment with 
nitisinone. This occurs because nitisinone is a reversible competitive inhibitor 
of HPPD, and essentially creates a new metabolic defect up-stream of its site 
of action. The biochemical pattern observed is that which is seen in type 3 
hereditary tyrosinaemia (OMIM 276710), so called ‘pseudo-type 3 
tyrosinaemia’. 
 
Recently Milan et al. (2017) reported tyrosine concentrations in patients 
treated with nitisinone over a 24 month period. In contrast, this longitudinal 
survey reports the concentration of 20 serum amino acids, not just tyrosine 
over a 36 month period to establish the wider impact of treatment with 
nitisinone on amino acid metabolism. Moreover data presented herein is in a 
larger cohort of patients. 
 
Concerns exist over the impact of hypertyrosinaemia, as tyrosine is 
transported across the blood brain barrier and may result in high brain 
tyrosine concentrations (Thimm et al., 2011), and thus increased dopamine 
(DP) concentrations in cerebrospinal fluid (CSF) as tyrosine is its precursor. 
A previous study has demonstrated an increase in homovanillic acid (DP 
metabolite) concentrations in CSF (Thimm et al., 2011), which suggests that 
DP metabolism may be altered. Moreover animal studies have also shown a 
direct neurotoxic effect of tyrosine, including oxidative stress (Macedo et al., 
2013) and altering DNA repair (Da Pra et al., 2014).    
 
Changes in the other aromatic amino acids were fairly unremarkable. Serum 
tryptophan remained within the normal reference range over the 36 month 
period. Previous studies in patients with HT1 treated with nitisinone, and in 
animal models have suggested that hypertyrosinaemia observed following 
treatment may reduce the biosynthesis of serotonin, and thus be responsible 
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for altered cognitive function and behavioral problems observed in HT1 (De 
Laet et al., 2011; Thimm et al., 2012; Masurel-Paulet et al., 2013; Bendadi et 
al., 2014; van Ginkel et al., 2016). Evidence of this is sparse and only 1 small 
study has reported decreased CSF concentrations of 5-hydroxyindole acetic 
acid (serotonin metabolite) (Thimm et al., 2011). Mechanisms that have been 
proposed suggest: (1) that tyrosine may inhibit tryptophan hydroxylase 
activity, which is the rate limiting step in serotonin metabolism and (2) 
tyrosine may compete for transport into the central nervous system via a 
common large neutral amino acid transporter (LAT-1) and thus reduce 
tryptophan uptake required for serotonin biosynthesis (Hillgartner et al., 
2016). It is reassuring that tryptophan did not change following nitisinone in 
the present data set.  
 
Phenylalanine showed an increasing trend over the period studied. This is in 
contrast to reports in patients with HT1 that have shown reduced 
concentrations of phenylalanine following nitisinone therapy (Daly et al., 
2012; van Vliet et al., 2014). While HT1 patients are on a protein restricted 
diet it is still thought that nitisinone itself may be the cause of the lower 
phenylalanine observed. The underlying mechanism for this is not fully 
understood (Harding et al., 2014). It has been postulated that 
hypertyrosinaemia may also reduce phenylalanine uptake into the brain due 
to competition for the LAT-1 (van Ginkel et al., 2016). This supposition may 
be supported as a significant increase in the ratio calculated in equation b 
(tyrosine to large neutral amino acids), and significant decrease in the ratios 
calculated in equations c-d (phenylalanine to LNAA; arginine to BCAA) were 
observed after nitisinone treatment implying that amino acid availability to the 
brain may be reduced, with the exception of tyrosine. The ratios are 
proposed to be a more reliable measure of the availability of tyrosine, 
phenylalanine and arginine to the brain instead of individual amino acid 
concentrations (Lieberman, 1999; Ravaglia et al., 2004).  
 
While the significant decrease in the ratios implies a reduced availability of 
the detailed amino acids to the brain for neurotransmitter synthesis it does 
not fit with the serum concentrations of phenylalanine observed in the current 
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survey. However the concentration of phenylalanine in serum does not 
necessarily reflect that which is seen in CSF.  
 
Of note pre-nitisinone therapy, the phenylalanine to tyrosine ratio was 
increased compared to the normal reference range (Antener et al., 1981). 
The reason for this is uncertain, as typically this ratio is monitored to assess 
the flux of phenylalanine to tyrosine and the adequacy of protein intake. One 
may postulate that phenylalanine hydroxylase activity may be reduced, thus 
causing a mild increase in the ratio. Reduced enzyme activity has been 
reported in individuals with increased inflammation (Wannemacher et al., 
1976). As AKU is a chronic disease process it is possible that inflammatory 
processes are altered, however this was not assessed. Another possibility is 
that the increase in phenylalanine is an artefact; however this is unlikely as 
samples were centrifuged immediately and stored at -20 °C until they were 
analysed.  
 
Following the commencement of nitisinone treatment the BCAA to AAA ratio 
significantly decreased, suggesting that following treatment liver function was 
altered. However this is potentially misleading as tyrosine is in such vast 
quantities in AKU following treatment with nitisinone and is not related to liver 
function; consequently one cannot use this ratio reliably to make an 
assessment of liver function. Prior to starting treatment the BCAA to AAA 
ratio was within the normal range indicating that patients had normal liver 
function. 
 
A number of changes were observed in several amino acids over the course 
of this longitudinal survey, but none appear to be related to treatment with 
nitisinone and are not consistent at all-time points evaluated. It is thought that 
these findings are likely to reflect the natural fluctuation one would observe in 
amino acids, and no reliable conclusions can be drawn from these data. 
  
Of particular interest were the mean amino acid concentrations (Table 4.1) 
that were outside the normal reference range independent of nitisinone 
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therapy. Specifically cystine was below the lower reference range and 
arginine and aspartic acid concentrations were higher.  
 
Decreases in cystine can be observed due to haemolysis, delayed separation 
and or platelet/leukocyte contamination (Perry et al., 1969; Bowron et al., 
2012). As discussed previously samples were separated immediately from 
cells and stored before analysis at -20 °C, thus eliminating this as a 
mechanism for the low cystine concentrations observed. One may postulate 
that the low cystine observed is a result of its reaction with glutathione, via 
glutathione-cystine transhydrogenase activity to form cysteine as part of the 
body’s defence against oxidative stress. The rationale for this is that AKU is 
accompanied by increased oxidative stress (Davison et al., 2016), which in 
part, results from the benzoquinone polymers that are produced from the 
high concentrations of HGA observed in AKU. Cysteine was not measured in 
this longitudinal survey, but should be evaluated to assess the validity of this 
hypothesis. The elevated arginine concentrations cannot be explained and 
require further investigation. 
 
Decreases in asparagine and glutamine were observed following treatment 
with nitisinone. It has been proposed that increases in aspartic acid and 
glutamic acid can be observed from the deamination of asparagine and 
glutamine, respectively, due to delayed separation and haemolysis (Perry et 
al., 1969, Bowron et al., 2012). Herein samples did not visually appear to be 
haemolysed, however no haemolytic indices were measured so this cannot 
be completed excluded as a contributory factor. Moreover samples were 
separated immediately from cells and stored before analysis at -20 °C. One 
possibility for the decrease in glutamine is that the proposed increased 
oxidative stress observed in AKU results in the increased formation of 
glutamate (not measured) from glutamine. Glutamate is the precursor for 
glutathione, which is essential for maintaining the redox state of the cell 
(Davison et al., 2016). Glutamic acid did not increase post nitisinone 
treatment and thus supports this supposition. 
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If deamination of asparagine to aspartic acid was the cause of increased 
aspartic acid in this survey one would have expected lower concentrations of 
asparagine to be observed, which was not the case. The significance of this 




Significant hypertyrosinaemia has been demonstrated following treatment 
with the HGA lowering drug nitisinone. The implications of the 
hypertyrosinaemia are in large unknown. However in this longitudinal survey 
it has been demonstrated that amino acid ratios have been significantly 
altered suggesting that the availability of amino acids for neurotransmitter 























4.6 Declaration and acknowledgements 
 
Preparation and analysis of serum samples for amino acids was performed 
by Andrew Davison and Elizabeth Smith (Department of Clinical 
Biochemistry, Alder Hey Children’s Hospital, Liverpool, UK). All data analysis 
performed by Andrew Davison. 
 
Jean Devine (Department of Clinical Biochemistry, Liverpool Clinical 
Laboratories, Royal Liverpool Hospital, Liverpool, UK) processed all serum 
samples from patients attending the NAC. 
 





Assessment of the effect of once daily nitisinone therapy on 
24 hour urinary metadrenalines and 5-hydroxyindole acetic 
acid excretion in patients with alkaptonuria after 4 weeks of 
treatment  
 
Davison AS1,2, Norman BP2, Milan AM1,2, Hughes AT1,2, Khedr M1,2, 
Rovensky J,3 Gallagher JA2, Ranganath LR1,2 
 
Department of Clinical Biochemistry and Metabolic Medicine, Liverpool 
Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, 
Liverpool, UK1; Musculoskeletal Biology I, Institute of Ageing and Chronic 
Disease, University of Liverpool, Liverpool, UK2; National Institute of 















Published in:  




Background: One of the major metabolic consequences of using nitisinone 
to treat patients with Alkaptonuria (AKU) is that circulating tyrosine 
concentrations increase. As tyrosine is required for the biosynthesis of 
catecholamine neurotransmitters it is possible that their metabolism is altered 
as a consequence. Herein we report the 24 h urinary excretion of 
normetadrenaline (NMA), metadrenaline (MA), 3-methoxytyramine (3-MT) 
(catecholamine metabolites) and 5-hydroxyindole acetic acid (5-HIAA, 
metabolite of serotonin) in a cohort of AKU patients before and after 4 weeks 
of treatment with nitisinone.  
Materials and methods: 24 h urinary excretion of NMA, MA, 3-MT, and 5-
HIAA were determined by liquid chromatography tandem mass spectrometry. 
Inter-assay coefficient of variation was <10 % for all analytes measured, at all 
concentrations tested.  
Results: Urine samples were assayed at baseline (pre-nitisinone, n=36) and 
4 weeks later; 7 received no nitisinone (4 male, mean age (±SD) 46.3 (16.4) 
years) and 29 received a daily dose of nitisinone [1 mg (n=7, 6 male, mean 
age 45.9 (10.9) years), 2 mg (n=8, 5 male, mean age 43.9 (13.7) years), 4 
mg (n=8, 5 male, mean age 47.3 (10.7) years) and 8 mg (n=6, 4 male, mean 
age 53.8 (8.3) years)]. 3-MT concentrations increase significantly (p<0.01, at 
all doses) following nitisinone therapy, but not in a dose dependent manner. 
NMA concentrations decreased (p<0.05, at all doses) following nitisinone 
therapy at all doses. 5-HIAA concentrations decreased following nitisinone 
therapy, and were significantly lower at a daily dose of 8 mg only (p<0.05).  
Conclusions: This study shows that catecholamine and serotonin 










Alkaptonuria (AKU, OMIM 203500) is a rare autosomal recessive disorder of 
tyrosine metabolism (Figure 5.1 (A)) resulting from a congenital lack in the 
enzyme homogentisate-1,2-dioxygenase (HGD, E.C.1.12.11.5). It occurs in 1 
in 250 000 of the general population (Phornphutkul et al., 2002), however in 
certain countries it is observed more commonly; for instance in Slovakia it is 
estimated to occur in 1 in 19 000 of the population (Milch, 1960; Zatkova, 
2011). One of the major biochemical consequences of AKU is that the 
circulating concentration of homogentisic acid (HGA) significantly increases. 
HGA is central to the pathophysiology of the disease and is thought to be 
responsible for a number of abnormalities including spondyloarthropathy, 
characterised by progressive kyphoscoliosis and impaired spinal and thoracic 
mobility, as well as renal and prostate stones, aortic valve stenosis, 
osteoporosis, fractures, and ruptures of tendons, ligaments and muscle 
(Ranganath et al., 2013). 
 
Supportive medical management of AKU includes a low protein diet, 
analgesia and arthroplasty (Ranganath et al., 2013). An additional HGA 
lowering therapy is nitisinone (Figure 5.1 (A)), a competitive reversible 
inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD, E.C. 
1.13.11.27). Its action reduces the accumulation of HGA and thus has the 
potential to prevent or slow the complications observed in patients with AKU. 





Figure 5.1. (A) Tyrosine metabolic pathway – highlighting the site of the enzyme defect observed in alkaptonuria and 
hereditary tyrosinaemia type 1, and the site of action of nitisinone; (B) Catecholamine metabolic pathway showing the 
formation of metadrenalines and (C) Tryptophan metabolic pathway – highlighting the proposed site tyrosine inhibits 
tryptophan hydroxylase activity. TyH – tyrosine hydroxylase; AADC – aromatic acid decarboxylase; COMT – catechol-O-methyl 
transferase; MAO – monoamine oxidase; TPH – tryptophan hydroxylase.
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In contrast nitisinone is already licenced for the treatment of hereditary 
tyrosinaemia type 1 (HT1, OMIM 276700) and has proved to be a very 
efficacious mode of treatment (McKiernan, 2013).  
 
One of the major metabolic consequences of treating patients with nitisinone 
in AKU and HT1 is that circulating tyrosine concentrations increase 
significantly (Lindstedt et al., 1992; Suwannarat et al., 2005; Introne et al., 
2011; McKiernan et al., 2015; Olsson et al., 2015; Ranganath et al., 2016; 
Milan et al., 2017). As tyrosine is the metabolic substrate required for the 
biosynthesis of catecholamine neurotransmitters (adrenaline (Ad), 
noradrenaline (NA) and dopamine (DP)) (Figure 5.1 (B)) it is possible that 
they may be altered during the 4 week treatment trial with nitisinone.  
 
Hypertyrosinaemia is observed in patients with AKU that attend the National 
AKU Centre in Liverpool (patients are given 2 mg of nitisinone daily, off-
licence) and during the Suitability Of Nitisinone In Alkaptonuria 1 (SONIA-1) 
clinical trial (Ranganath et al., 2016), which evaluated the efficacy of different 
daily doses of nitisinone over a 4 week period.  
 
Significant elevations in serum and cerebrospinal fluid tyrosine 
concentrations have also been a documented consequence of nitisinone 
treatment in HT1 (Thimm et al., 2011). In patients with HT1 it is believed that 
the supraphysiological concentrations of tyrosine may be responsible for the 
reduced intelligence quotient and cognitive function observed (Masurel-
Paulet et al., 2008; De Laet et al., 2011; Thimm et al., 2012; Bendadi et al., 
2014; Mckiernan et al., 2015).  
 
The impact of hypertyrosinaemia on neurotransmitter metabolism (Figures 
5.1 (B) and (C)) in patients with AKU following nitisinone therapy has not 
been previously reported. Herein we report the 24 h urinary excretion of 
normetadrenaline (NMA), metadrenaline (MA) and 3-methoxytyramine (3-
MT) (catecholamine metabolites) and 5-hydroxyindole acetic acid (5-HIAA) 
(metabolite of serotonin) in patients before and during the 4 week treatment 
trial with nitisinone.  
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5.3 Materials and methods 
 
5.3.1 Subjects  
All urine samples were from subjects included in the SONIA-1 clinical trial 
(Trial registration number EudraCT number: 2012-005340-24. Registered at 
ClinicalTrials.gov: NCTO1828463). 24 h urine samples were collected into 
2.5 L bottles containing 30 mL of 5N H2SO4; aliquots were stored away from 
bright light at -80 °C. Urine samples analysed in this study were from 
baseline (pre-nitisinone, n=36) and 4 weeks following no treatment (n=7) or a 
daily dose of nitisinone [1 mg (n=7), 2 mg (n=8), 4 mg (n=8) and 8 mg (n=6)]. 
No patients included in this study had renal impairment (eGFR >60 
mL/min/1.73 m2 in all cases). Completeness of 24 h urine collection was 
assessed by measurement of urine creatinine (Jaffe reaction, Roche 
Diagnostics, Germany) all patients had urine creatinine concentrations within 
the normal reference range (9.0-18.0 µmol/24 h, in house reference range). 
 
5.3.2 Analytical methods 
5.3.2.1 Urine metadrenalines 
The concentrations of urinary NMA, MA and 3-MT were determined by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) (Banks et al., 
2014). 1 mL of urine underwent acid hydrolysis (5 M HCl) at 100 °C for 30 
min. 50 µL of hydrolysate was diluted in 2 mL of deionised water containing 
deuterated internal standards (d3-NMA, 0.11 µmol/L, d3-MA 0.10 µmol/L and 
d4-3-MT 0.12 µmol/L. CDN Isotopes, Essex) and loaded onto the solid phase 
extraction plate (30 mg Evolute-SCX, Biotage, Hengoed). 20 µL of extract 
was injected onto a C18 phenyl-hexyl column (4.6 x 100 mm, 2.6 µm, 
Phenomenex, Cheshire) using a Waters Acquity UPLC separations module 
coupled to a Xevo TQS tandem mass spectrometer. Initial conditions of 
90:10 water:methanol with 0.1 % formic acid (v/v) increased linearly to 40:60 
over 2 min, returning to starting conditions by 4 min. In-house calibration 
standards and commercial quality controls materials (Recipe ClinChek, 
Germany) were used. Calibrator concentrations were 0-46.8 µmol/L for NMA; 
0-24.8 µmol/L for MA and 0-27.7 µmol/L for 3-MT. Interassay coefficient of 
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variation for NMA, MA and 3-MT were 4.6, 4.7 and 7.2 % at 1.7, 0.8 and 1.6 
µmol/L, respectively. 
 
5.3.2.2 Urine 5-HIAA 
The concentration of urinary 5-HIAA was determined by LC-MS/MS. Samples 
were diluted (20 µL urine in 2 mL) in deionised water containing a deuterated 
internal standard (d5-5-HIAA, 0.34 µmol/L, CDN Isotopes, Essex). 20 µL of 
the diluted urine sample was injected onto an Atlantis dC18 column (3.0 x 100 
mm, 3.0 µm, Waters, Milford) using a Waters Alliance 2795 separations 
module coupled to a Waters Quattro Premier XE tandem mass spectrometer. 
Initial conditions of 95:5 water:methanol with 0.1 % formic acid (v/v) and 2 
mmol/L ammonium acetate, increased linearly to 5:95 over 2 min, returning 
to starting conditions by 4 min. Commercial calibration standards (3.6-356 
µmol/L, Chromsystems, Germany) and quality controls materials (Recipe 
ClinChek, Germany) were used. Interassay coefficient of variation was 7.2 % 
for 5-HIAA at 26.2 µmol/L. 
 
5.3.2.3 Serum tyrosine and phenylalanine 
The concentration of serum tyrosine and phenylalanine were determined by 
LC-MS/MS, for details see Hughes et al. (2015). Tyrosine concentrations 
were previously reported in the SONIA-1 clinical trial (Ranganath et al., 
2016).  
 
In this study data from only 36 of 40 subjects from the SONIA-1 clinical were 
included. Serum tyrosine and phenylalanine concentrations presented herein 
are from subjects that had urine samples analysed for urinary NMA, MA,  
3-MT and 5-HIAA. All serum samples were collected from patients after an 
overnight fast (at least 8 h). Patients’ dietary intake of protein was not 
restricted during this study, nor was it monitored. 
 
5.3.3 Statistical Analysis 
All statistical analysis were performed using Graphpad Instat (Version 3.10, 
2009). Kolmogorov-Smirnov testing was performed to assess if urinary NMA, 
MA, 3-MT and 5-HIAA concentrations and serum tyrosine concentrations 
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were normally distributed. Unpaired 2-tailed student t-test was used to 
assess significant differences in urinary metabolites pre- and post-treatment 





Forty patients were included in the SONIA-1 study (Ranganath et al., 2016). 
Urine samples from 36 of these patients were available for inclusion in this 
study. Of the 36 patients 7 patients received no treatment with nitisinone (4 
male, mean age (±SD) 46.3 (16.4) years) and 29 patients received a daily 
dose of nitisinone [1 mg (n=7, 6 male, mean age 45.9 (10.9) years), 2 mg 
(n=8, 5 male, mean age 43.9 (13.7) years), 4 mg (n=8, 5 male, mean age 
47.3 (10.7) years) and 8 mg (n=6, 4 male, mean age 53.8 (8.3) years)].  
 
Urinary 3-MT concentrations increased significantly (p≤0.01, at all doses) 
following daily nitisinone therapy. This occurred at all doses, but not in a dose 
dependent manner. In contrast urinary NMA concentrations decreased 
(p≤0.03, at all doses) following nitisinone therapy. Urinary MA concentrations 





Figure 5.2. Urinary metadrenaline concentrations in patients with AKU 
before and after 4 weeks of treatment with nitisinone. At 4 weeks there 
were 5 treatment groups – no treatment (n=7); treatment with 1 mg nitisinone 
daily (n=7); treatment with 2 mg nitisinone daily (n=8); treatment with 4 mg 
nitisinone daily (n=8) and treatment with 8 mg nitisinone daily (n=6). (A) 3-
MT; (B) MA and (C) NMA. --- = indicates upper limit of normal urine reference 
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range for 3-MT <1.4 µmol/24h; MA <1.3 µmol/24h; NMA <3.0 µmol/24h; - = 
95 % confidence notched outlier boxplot; + = outlier; o=individual patient 
concentrations. Significance testing compared metadrenalines before and 
after a 4 week trial of nitisinone, *p≤0.01; **p≤0.03; p value <0.05 deemed 
significant. NTBC – nitisinone. 
 
 
Of interest a large proportion of patients had NMA (reference range <3.0 
µmol/24 h), MA (reference range <1.3 µmol/24 h) and 3-MT (reference range 
<1.4 µmol/24 h) concentrations outside of the normal reference range pre- 
nitisinone therapy. Following nitisinone therapy NMA concentrations were 
within the normal reference range in all but 1 patient, however 3-MT 
concentrations were outside of the reference range in all patients. MA 
concentrations remained unchanged overall post nitisinone therapy, although 
there was less of a spread of concentrations observed.  
 
5-HIAA concentrations decreased following nitisinone therapy (Figure 5.3), 
and were significantly lower at a daily dose of 8 mg (p<0.05) only. 5-HIAA 
concentrations were within the normal reference range (reference range <50 
µmol/24 h) in the majority of patients pre- (7/36 patients had elevated 5-
HIAA) and post (2/8 patients receiving no nitisinone and 1/7 patients 







Figure 5.3. Urinary 5-HIAA concentrations in patients with AKU before 
and after 4 weeks of treatment with nitisinone. At 4 weeks there were 5 
treatment groups – no treatment (n=7); treatment with 1 mg nitisinone daily 
(n=7); treatment with 2 mg nitisinone daily (n=8); treatment with 4 mg 
nitisinone daily (n=8) and treatment with 8 mg nitisinone daily (n=6).--- = 
indicates upper limit of normal urine reference range for 5-HIAA, <50 
µmol/24h; - = 95 % confidence notched outlier boxplot; + = outlier; 
o=individual patient concentrations. Significance testing compared 5-HIAA 
concentrations before and after a 4 week trial of nitisinone, ***p<0.05. p value 
<0.05 deemed significant. NTBC – nitisinone.  
 
 
Fasting serum tyrosine concentrations increased significantly following 
treatment with nitisinone at all doses (p<0.0001). There were also 
significantly higher tyrosine concentrations observed between subjects 
receiving 1 mg nitisinone versus 8 mg nitisinone (p<0.05) and subjects 
receiving 2 mg nitisinone versus 8mg nitisinone (p<0.05), thus indicating a 
dose dependent increase in serum tyrosine concentrations following 
nitisinone. Mean (± standard deviation) concentrations were 59 (±10) µmol/L 
and 750 (±140) µmol/L pre- and post-nitisinone therapy (Figure 5.4), 




Figure 5.4. Serum tyrosine concentrations in patients with AKU before 
and after 4 weeks of treatment with nitisinone. At 4 weeks there were 5 
treatment groups – no treatment (n=7); treatment with 1 mg nitisinone daily 
(n=7); treatment with 2 mg nitisinone daily (n=8); treatment with 4 mg 
nitisinone daily (n=8) and treatment with 8 mg nitisinone daily (n=6). --- = 
indicates normal serum reference range for tyrosine, 30-87 µmol/L; - = 95 % 
confidence notched outlier boxplot; + = outlier; o=individual patient 
concentrations. Significance testing compared tyrosine concentrations before 
and after a 4 week trial of nitisinone, and tyrosine concentrations in patients 
that received different doses of nitisinone at 4 weeks of therapy (brackets 
compare 1 mg vs. 8 mg nitisinone, and 2 mg vs. 8 mg nitisinone), **** 
p<0.0001; ***p<0.05. p value <0.05 deemed significant. NTBC – nitisinone. 
 
 
Serum phenylalanine concentrations were not significantly different following 
a 4 week trial of nitisinone (p>0.05 at all doses) and were within the normal 
reference range (30-76 µmol/L, in-house reference range). Mean (±standard 
deviation) phenylalanine concentrations were 57.1 µmol/L (7.9) (pre-
nitisinone, n=36); 55.7 (17.8) µmol/L (no nitisinone, n=7); 53.0 (6.0) µmol/L (1 
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mg nitisinone, n=7); 51.6 (13.0) µmol/L (2 mg nitisinone, n=8); 53.8 (12.2) 





Significant hypertyrosinaemia following nitisinone therapy has been 
previously reported in AKU (Suwannarat et al., 2005; Introne et al., 2011; 
Olsson et al., 2015; Ranganath et al., 2016; Milan et al., 2017). To date there 
are no reports on the impact this may have on closely related metabolic 
pathways that require tyrosine as a substrate, including the biosynthesis of 
the catecholamine neurotransmitters (Figure 5.1 (B)).  
 
Much of the literature focuses on hypertyrosinaemia following nitisinone 
therapy in patients with HT1. It is believed that the supraphysiological 
concentrations observed may contribute to neurodevelopmental delay 
(Masurel-Paulet et al., 2008; De Laet et al., 2011; Thimm et al., 2012; 
Bendadi et al., 2014; Mckiernan et al., 2015). It is estimated that up to 35 % 
of children treated with nitisinone have learning difficulties (McKiernan et al., 
2015). It is not known whether this may also be related to nitisinone 
treatment itself or low phenylalanine concentrations, presenting with acute 
liver disease or an intrinsic effect of HT1. 
 
Several mechanisms for neurodevelopmental delay have been postulated. 
These include: increased transport of tyrosine into the brain; decreased 
transport of other neutral amino acids into the brain (specifically tryptophan, 
the precursor of serotonin); increased central nervous system (CNS) DP; 
decreased CNS serotonin, oxidative damage from δ-aminolevulinic acid and 
succinylacetone modification of neuronal proteins (Thimm et al., 2011; 
Harding et al., 2014; Hillgartner et al., 2016).  
 
It has also been suggested that altered serotonin metabolism may be due to 
direct inhibition of tryptophan hydroxylase (TPH, EC 1.14.16.4) activity by 
tyrosine (Figure 5.1 (C)), which leads to a reduced biosynthesis of serotonin 
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(Thimm et al., 2011). TPH is the rate limiting step in the biosynthesis of 
serotonin.  
 
As it has been suggested that hypertyrosinaemia may have an impact on 
neurodevelopmental delay in HT1 concern exists around the use of nitisinone 
in AKU, which is currently not licenced for treatment of this disorder. While 
the dose prescribed to patients with AKU is much lower than those with HT1 
(2 mg daily at the National Centre for AKU (NAC) in Liverpool versus 0.5-2.5 
mg/kg per day in HT1) the concentration of serum and urine tyrosine 
observed following nitisinone therapy is similar.  
 
Herein for the first time we report the impact of nitisinone on the urinary 
excretion of the NMA, MA and 3-MT, and 5-HIAA, which serve as surrogate 
markers for catecholamine and serotonin neurotransmitter biosynthesis, 
respectively (Figures 5.1 (B) and (C)). Urinary metabolites were measured as 
collecting urine is non-invasive and is the primary route for neurotransmitter 
elimination.  
 
The marked increase in 3-MT and decreased NMA excretion post nitisinone 
therapy indicates that nitisinone therapy alters the metabolism of 
catecholamines as the concentration of their respective O-methylated 
metabolites are altered when compared to pre-treatment concentrations.  
 
The metabolism of catecholamine neurotransmitters is complex (Figure 5.1 
(B)) and they have multiple origins, including the sympathetic nerves, adrenal 
medulla, brain and mesenteric organs (for detailed overview see Eisenhofer 
et al., 2004). It has been demonstrated that the concentration of monoamine 
neurotransmitters in urine are dependent on plasma concentration and 
uptake via organic cation transporters in the kidney (Eisenhofer et al., 1996; 
Graefe et al., 1997). However it is also essential to consider the degree to 
which renal neurotransmitter synthesis can contribute to the urinary 
concentrations. In the kidneys DP is produced via the uptake and 
decarboxylation of circulating dihydroxyphenylalanine (DOPA), and not just 
from the filtration of circulating DP (Eisenhofer et al., 2004).  
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In this study 3-MT was shown to increase significantly post nitisinone 
therapy. 3-MT is a direct metabolite of DP and thus may reflect increased 
circulating DP concentrations and or synthesis in the kidney. It is proposed 
that the latter is highly likely as the tyrosine load delivered to the kidney 
increased significantly post nitisinone therapy. This was reported in the 
SONIA-1 dosing study (Ranganath et al., 2016) and shown in the data 
presented herein where mean serum tyrosine concentrations increased 
significantly (p<0.0001) after a 4 week treatment with nitisinone therapy 
(reference range 30-87 µmol/L, Davison et al., 2015). The increased tyrosine 
load delivered to the kidney may provide a substrate for DOPA synthesis and 
thus the subsequent decarboxylation of DOPA to DP may lead to the 
consequent increase in 3-MT observed.  
 
The elevated serum tyrosine concentrations observed post nitisinone therapy 
was accompanied by a significant dose dependent decrease in urinary 
excretion of HGA, across the studied dose interval of 1–8 mg. The 8 mg dose 
resulted in a mean reduction of 24 h urinary HGA excretion of  
98.8 % compared with baseline (Ranganath et al., 2016). Serum 
phenylalanine concentrations were not affected by the marked increase in 
tyrosine following a 4 week trial with nitisinone, indicating that tyrosine has an 
alternative metabolic fate. 
 
The impact of hypertyrosinaemia on serum tryptophan concentrations were 
not evaluated in this short term dose evaluation study as it was not included 
in the original study design. However it has been shown at the NAC in 
Liverpool that serum tryptophan concentrations do not change following a 2 
mg daily dose of nitisinone (Davison et al., 2018a). The authors postulate 
that serum tryptophan concentrations will not be altered at a higher dose of 
nitisinone as marked hypertyrosinaemia is observed at all doses of nitisinone 
evaluated. Further work is required to confirm this. 
 
In this study tissue concentrations of tyrosine were not determined to assess 
whether they correlate with serum and urine concentrations. Further work 
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into this area is required to help understand the pathophysiology of AKU at a 
tissue level. 
 
Previously Thimm et al. (2011) reported tyrosine and homovanillic acid 
(dopamine metabolite) concentrations in the CSF of 3 patients with HT1 
during long-term treatment with nitisinone. In this small study tyrosine 
concentrations were markedly increased in the CSF and plasma, as 
expected. However homovanillic acid concentrations were within the normal 
reference range, suggesting that there is no alteration in DP metabolism in 
the CNS. This supports the postulate that the increased urinary 3-MT 
observed in this study is a consequence of increased tyrosine load being 
delivered to the kidney. It is also important to consider that dietary 
constituents have been shown to influence urinary concentrations of 3-MT 
and thus represent 1 peripheral source of DP metabolites (de Jong, 2009).  
 
In this study dietary components rich in biogenic amines were not restricted 
or documented. However as the data presented herein show an increase in 
3-MT in all patients following a 4 week treatment with nitisinone it is believed 
that diet alone is not solely responsible for the increase in 3-MT observed. 
 
The parallel decrease in NMA suggests that there may be a reduction in the 
synthesis of NA as a consequence of nitisinone therapy. While there is 
limited information available on the exact contribution of central and 
peripheral output to urinary excretion of neurotransmitters Graefe et al. 
(1997) demonstrated that a significant proportion of urinary NA and Ad stems 
from circulation. In this study one may postulate the observed decrease in 
NMA may be a consequence of reduced sympathetic nerve excitation as 
subjects are less depressed or anxious, as they are on treatment for AKU. 
Previous studies (Roy et al.,1986a; Roy et al., 1986b; Grossman et al., 1999; 
Hughes et al., 2004) have evaluated the urinary concentration of NA and Ad 
in subjects with depression, demonstrating that urinary concentrations of NA 
and Ad were significantly higher in subjects with depression compared to 
controls. It is not surprising that MA concentrations were not significantly 
different post nitisinone therapy as Ad is produced by the adrenal gland and 
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not the sympathetic nervous system, mesenteric organs or the kidney 
(Eisenhofer, 2004). The reduced variability of MA concentrations observed 
following a 4 week trial of nitisinone is of unknown significance and is unlikely 
to reflect a change in diet, this requires further investigation. 
 
Another possibility is that there is an alteration in inflammatory signalling 
following nitisinone therapy. Elenkov et al. (2000) demonstrated that Ad and 
NA can inhibit the production of pro-inflammatory cytokines (i.e. interleukin-2, 
tumour necrosis factor-α, and interferon-) and stimulate the production of 
anti-inflammatory cytokines (i.e. interleukin-10 and transforming growth 
factor-β). It is postulated that altering these pathways may cause a selective 
suppression of T helper-1 cells and cellular immunity, and enhancement of T 
helper-2 cell activity and a shift toward humoral immunity. 
 
While changes in urinary concentrations of NA, Ad and their respective 
metabolites were not evaluated in this study, one can postulate that they may 
be altered as a consequence of changes in the inflammatory processes 
observed following nitisinone therapy.  
 
The decrease in 5-HIAA excretion at a daily dose of 8 mg only, suggests that 
there is a dose dependent effect of nitisinone therapy. This supports that 
serotonin metabolism is altered following treatment with nitisinone. Thimm et 
al. (2011) also reported alterations in serotonin metabolism in patients with 
HT1 treated with nitisinone. This study showed a decrease in CSF 5-HIAA 
concentrations following nitisinone therapy.  
 
It is proposed that the decrease in CSF 5-HIAA occurred as increased 
tyrosine concentrations compete with tryptophan (serotonin precursor) via a 
neutral amino acid transporter across the blood-brain barrier, thus reducing 
tryptophan availability for intracerebral serotonin synthesis (Pratt et al., 
1982).  
 
In addition it has been hypothesised that elevated tyrosine may inhibit 
tryptophan hydroxylase activity (Figure 5.2 (C)), the rate limiting step for 
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serotonin metabolism (Thimm et al., 2011). Although this study was small 
and analysis was performed in CSF it has been shown that urinary analysis 
of serotonin and 5-HIAA reflect parallel changes in immunoreactivity in the 
dorsal raphe nucleus, demonstrating a positive correlation between CNS 
serotonergic activity and urinary serotonin concentrations (Lynn-Bullock et 





For the first time alterations in monoamine neurotransmitter metabolism have 
been reported in patients with AKU following nitisinone therapy. Specifically 
increased urinary 3-MT (dopaminergic neurotransmitter metabolite), and 
decreased NMA (NA neurotransmitter metabolite) and 5-HIAA 
(serotoninergic neurotransmitter metabolite) concentrations. The exact 
mechanism(s) causing these changes are not known and further work is 
required to elucidate this, and to establish whether these observations truly 
reflect changes in CNS monoamine neurotransmitter metabolism or 
contributions from peripheral or renal metabolism. 
 
Moreover it is recognised that these data are based on a short term dosing 
study and it is necessary to assess whether these changes would be 
observed in patients on long term therapy with nitisinone and to see if 
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Background: Concerns exist over hypertyrosinaemia that is observed 
following treatment with nitisinone. It has been suggested that tyrosine may 
compete with tryptophan for uptake into the central nervous system, and or 
inhibit tryptophan hydroxylase activity reducing serotonin production. At the 
National Alkaptonuria (AKU) Centre nitisinone is being used off-licence to 
treat AKU, and there is uncertainty over whether hypertyrosinaemia may alter 
mood. Herein results from clinical and biochemical assessments of 
depression in patients with AKU before and after treatment with nitisinone are 
presented.  
Materials and methods: 63 patients were included pre-nitisinone treatment, 
of these 39 and 32 patients were followed up 12 and 24 months after 
treatment. All patients had Beck’s Depression Inventory-II (BDI-II) 
assessments (scores can range from 0-63, the higher the score the more 
severe the category of depression), and where possible urinary monoamine 
neurotransmitter metabolites and serum aromatic amino acids were 
measured as biochemical markers of depression.  
Results: Mean (±standard deviation) BDI-II scores pre-nitisinone, and after 
12 and 24 months were 10.1(9.6); 9.8(10.0) and 10.5(9.9) (p>0.05, all visits). 
Paired scores (n=32), showed a significant increase at 24 months compared 
to baseline 10.5(9.9) vs. 8.6 (7.8) (p=0.03). Serum tyrosine increased at least 
6-fold following nitisinone (p<0.0001, all visits), and urinary 3-
methoxytyramine (3-MT) increased at 12 and 24 months (p<0.0001), and 5-
hydroxyindole acetic acid (5-HIAA) decreased at 12 months (p=0.03). 
Conclusions: BDI-II scores were significantly higher following 24 months of 
nitisinone therapy in patients that were followed up, however the majority of 
these patients remained in the minimal category of depression. Serum 
tyrosine and urinary 3-MT increased significantly following treatment with 
nitisinone. In contrast urinary 5-HIAA did not decrease consistently over the 
same period studied. Together these findings suggest nitisinone does not 
cause depression despite some observed effects on monoamine 




Alkaptonuria (AKU, OMIM 203500) is a rare autosomal recessive disorder of 
the tyrosine metabolic pathway, occurring 1 in 250 000 of the general 
population (Phornphutkul et al., 2002). It results from a congenital deficiency 
in the enzyme homogentisate 1,2-dioxygenase (HGD, E.C.1.12.11.5). One of 
the major biochemical consequences of AKU is that the circulating 
concentration of homogentisic acid (HGA) significantly increases despite 
significant renal excretion. It is proposed that circulating HGA is responsible 
for a number of the complications which are observed, for a detailed review 
see Ranganath et al. (2013). The psychological impact of this painful and 
debilitating musculoskeletal disease has never been reported. Katon et al. 
(2002) reported that patients with chronic medical illness, such as diabetes, 
stroke, cancer and heart disease have a high prevalence of major depressive 
illness.  
 
Assessing patients’ psychological state before and after treatment is 
important as judgments can be made about whether treatment will result in a 
change in mood or depression. This is highly relevant when considering 
patients with AKU that are being treated with nitisinone, a competitive 
inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD, E.C. 1.13.11.27).  
This is because it results in marked hypertyrosinaemia (Suwannarat et al., 
2005; Introne et al., 2011; Olsson et al., 2015; Ranganath et al., 2016; Milan 
et al., 2017; Davison et al., 2018a). This has also been reported in patients 
with hereditary tyrosinaemia type 1 (HT1, OMIM 276700) treated with 
nitisinone (Lindstedt et al., 1992; McKiernan et al., 2013; McKiernan et al., 
2015; van Ginkel et al., 2016; van Ginkel et al., 2017).  
 
The metabolic fate of these supraphysiological tyrosine concentrations is 
unknown. It has been reported that it can cause corneal keratopathy (Khedr 
et al., 2018). In addition it is known that tyrosine is the precursor for the 
biosynthesis of the neurotransmitter dopamine (DP), which plays a role in 
mood.  
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In HT1 it is estimated that 35 % of children have neurodevelopmental delay 
(McKiernan et al., 2015). Several mechanisms have been postulated, 
including: increased transport of tyrosine into the brain; decreased transport 
of other neutral amino acids into the brain (specifically tryptophan, the 
precursor of serotonin); increased central nervous system (CNS) DP; 
decreased CNS serotonin, oxidative damage from δ-aminolevulinic acid and 
succinylacetone (the toxic metabolites in HT1) or modification of neuronal 
proteins (Thimm et al., 2011; Harding et al., 2014; Hillgartner et al., 2016). It 
has also been suggested that altered serotonin metabolism may be due to 
direct inhibition of tryptophan hydroxylase (TPH; EC 1.14.16.4) activity by 
tyrosine, which leads to a reduced biosynthesis of serotonin (Thimm et al., 
2011).  
 
Due to the possibility that hypertyrosinaemia may have an impact on 
neurodevelopment in HT1, concerns exist around its off licence use in 
patients with AKU. Therapy is currently commenced when patients are ≥16 
years old so they are less likely to suffer the same neurodevelopmental 
delay. Therefore the focus is on whether changes in neurotransmitter 
metabolism may affect mood and result in depression.  
 
The impact of hypertyrosinaemia on neurotransmitter metabolism in patients 
with AKU following nitisinone therapy has been previously reported (Davison 
et al., 2018b). Catecholamine neurotransmitter metabolites 3-
methoxytyramine (3-MT, DP metabolite) and normetadrenaline (NMA) 
(noradrenaline (NA) metabolite) were shown to increase and decrease 
significantly following nitisinone therapy, respectively. The urinary serotonin 
metabolite 5-hydroxyindole acetic acid (5-HIAA) was shown to decrease 
following nitisinone therapy, but the decrease was only significant at the 
highest daily dose of 8 mg. These biochemical data were however limited in 
that this was a short term dosing study that did not report any psychometric 




Herein for the first time we report BDI-II scores as a self-reporting measure of 
depression (Beck et al., 1961; Beck et al., 1996) in patients with AKU, pre-
nitisinone and at 12 and 24 months of nitisinone therapy. In addition urinary 
monoamine metabolites of catecholamine and serotonin neurotransmitters 
and associated serum aromatic amino acids tyrosine, phenylalanine and 
tryptophan are reported in a sub-group of patients.  
 
 
6.3 Materials and methods  
 
6.3.1 Patients 
6.3.1.1 Protocol for patients that attend the National Alkaptonuria 
Centre (NAC) for treatment with nitisinone 
The protocol for treatment at the NAC is that patients with confirmed AKU are 
commenced on a 2 mg dose of nitisinone, on alternative days for the first 3 
months, which is then increased to 2 mg daily thereafter. Assessments are 
repeated on an annual basis to monitor response to therapy.   
 
Inclusion criteria for treatment with nitisinone are that individuals must have 
the diagnosis of AKU; must be a resident of England or Scotland, and be 
over the age of 16 years. Confirmed diagnosis of AKU is based upon 
increased urinary HGA excretion [urine HGA in healthy volunteers has been 
demonstrated in the order of <2.92 µmol/day (Davison et al., 2015)] and 
mandatory for referral to the NAC. Exclusion criteria are individuals must not 
be pregnant and or lactating. Nitisinone is used in an off-licence setting to 
investigate its safety and efficacy in the treatment of this rare disease.  All 
patients are provided with written information about the scope of the Centre 
and the assessments they will receive. All patients at the NAC have 
biochemical measurements and clinical assessments which are performed at 
baseline, day 4 (2 days post-nitisinone), 3 months, 6 months and 12 months; 




6.3.1.2 Ethical Approval 
Data collection and analyses at the NAC has approval from the Royal 
Liverpool and Broadgreen University Hospital Trusts Audit Committee (Audit 
no. ACO3836). As data were collected as part of the clinical service ethical 
approval was not required. Data is obtained following standard clinical 
assessments upon referral to the NAC. Patients are informed verbally and 
through patient information leaflets about the activities of the NAC. Patients 
are also explicitly informed that data may be used for publication and within 
the NAC patient information leaflet. 
 
6.3.1.3 Subjects included in the study  
Sixty-three patients [26 female, mean age (±standard deviation) 51.3(16.8) 
years (range 18-75); 37 male, mean age 47.6(13.9) years (range 16-70)] 
were included at baseline in this 24 month longitudinal survey reporting the 
BDI-II data.  
 
BDI-II data were also included at 12 (n=39) and 24 (n=32) months following  
2 mg daily nitisinone. Twenty-four and 31 of the 63 patients included at 
baseline were not included at 12 and 24 months, respectively. Five patients 
were excluded as they were not resident of England or Scotland. The 
remaining 19 and 26 patients did not have follow-up visits at 12 and 24 
months respectively, either because they did not attend or because they had 
not attended the NAC for long enough for follow-up visits at the point of data 
collection. 
 
24 h urine samples for measurement of monoamine metabolites were 
collected into 2.5 L bottles containing 30 mL of 5 N H2SO4; aliquots were 
stored away from bright light at -20 °C. Urine samples were from baseline 
(pre-nitisinone), 3 months (2 mg nitisinone every other day), 6 months (2 mg 
nitisinone daily), 12 months (2 mg nitisinone daily) and 24 months (2 mg 
nitisinone daily). No patients included in this study had renal impairment 
(eGFR >60 mL/min/1.73 m2 in all cases). Completeness of 24 h urine 
collection was assessed by measurement of urine creatinine (Jaffe reaction, 
Roche Diagnostics, Germany) and all patients had urine creatinine 
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concentrations within the normal reference range (9.0-18.0 µmol/24 h, in-
house reference range). 
 
Serum samples (S-monovette, Sarstedt, Germany) were collected from 
patients at the same visits as urine samples. Samples were centrifuged (10 
min at 3000 rpm) and stored at -20 °C until analysis. All serum samples were 
collected following an overnight fast (at least 8 h). Patients’ dietary intake of 
protein was managed through a 7 day food diary by a combination of lower 
protein in diet and phenylalanine/tyrosine free meal exchanges. 
 
6.3.2 Methods 
6.3.2.1 Beck’s depression inventory-II 
BDI-II (Beck et al., 1961; Beck et al., 1996) is a self-scored questionnaire that 
includes 21 items; each has 4 alternative statements ranked in order of 
severity from 0-3. The questionnaire evaluates a number of emotions 
including: mood, pessimism, sense of failure, self-dissatisfaction, guilt, 
punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, 
social withdrawal, insomnia, and loss of appetite. Conventional cut-offs are 
0–13 for minimal depression, 14-19 for mild depression, 20-28 for moderate 
depression and 29-63 for severe depression, with a maximum score of 63. In 
this study all BDI-II assessments were carried out by the same practitioner. 
 
6.3.2.2 Urine metadrenalines 
The concentrations of urinary NMA, metadrenaline (MA) and 3-MT were 
determined by liquid chromatography tandem mass spectrometry (LC-
MS/MS) as previously described by Davison et al. (2018b). 20 µL of sample 
extract was injected onto a C18 phenyl-hexyl column (4.6 x 100 mm, 2.6 µm, 
Phenomenex, Cheshire) using a Waters Acquity UPLC separations module 
coupled to a Xevo TQS tandem mass spectrometer. Initial conditions of 
90:10 water:methanol with 0.1 % formic acid (v/v) increased linearly to 40:60 
over 2 min, returning to starting conditions by 4 min. Commercial calibration 
standards (Chromsystems, Munich) and quality control materials (Recipe 
ClinChek, Germany) were used. Calibrator concentrations were 0-46.8 
µmol/L for NMA; 0-24.8 µmol/L for MA and 0-27.7 µmol/L for 3-MT. 
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Interassay coefficient of variation for NMA, MA and 3-MT were 4.6, 4.7 and 
7.2 % at 1.7, 0.8 and 1.6 µmol/L, respectively. 
 
6.3.2.3 Urine 5-HIAA 
The concentration of urinary 5-HIAA was also determined by LC-MS/MS as 
previously reported by Davison et al. (2018b). 20 µL of diluted urine sample 
was injected onto an Atlantis dC18 column (3.0 x 100 mm, 2.6 µm, Waters, 
Milford) using a Waters Alliance 2795 separations module coupled to a 
Waters Quattro Premier XE tandem mass spectrometer. Initial conditions of 
95:5 water:methanol with 0.1 % formic acid (v/v) and 2 mmol/L ammonium 
acetate, increased linearly to 5:95 over 2 min, returning to starting conditions 
by 4 min. Commercial calibration standards (3.6-356 µmol/L, Chromsystems, 
Germany) and quality control materials (Recipe ClinChek, Germany) were 
used. Interassay coefficient of variation was 7.2 % for 5-HIAA at 26.2 µmol/L. 
 
6.3.2.4 Serum amino acids 
Serum amino acid concentrations were determined as previously reported by 
Davison et al. (2018a). In brief, analyses were performed using the Biochrom 
30 high performance liquid chromatography cation exchange system with 
ninhydrin detection (Bichrom, Cambridge, UK).  
 
Calibration was performed using a series of aqueous standards purchased 
from Sigma (Dorset, UK) [amino acids basic standard (product code: A6282); 
amino acids acidic/neutral standard (product code: A6407)].  
 
100 μL of calibrator/serum/internal quality control material was mixed with 
100 μL of a solution containing sulfosalicylic acid (183 mmol/L) to precipitate 
proteins and internal standards (S-2-amino-ethyl-L-cystine hydrochloride and 
norleucine both at 100 µmol/L). Samples were then refrigerated at 4 °C for  
1 h, centrifuged at 13 000rpm for 10 min and 60 µL of supernatant injected 
onto the analytical column for analysis. Commercial internal quality control 
material was used (Recipe, Clinchek, Germany). Interassay coefficient of 
variation for tyrosine, phenylalanine and tryptophan were 2.5, 1.8 and 1.0 % 
at 68.3, 78.1 and 53.5 μmol/L, respectively. 
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6.3.2.5 Data analysis and calculations 
Amino acid concentrations were calculated off-line using EZCHrom Elite 
software (Build 3.2.1 Agilent, USA). NMA, MA, 3-MT and 5-HIAA 
concentrations were calculated using MassLynx software (Version 4.1, 
Waters, USA). 
 
All statistical analyses were performed using Graphpad Instat (Version 3.10, 
2009, CA, USA) and Analyse-It for Microsoft Excel (Version 2.20 Analyse-it 
Software, Ltd, Leeds, UK).  
 
Kolmogorov-Smirnov testing was performed to assess if data were normally 
distributed. Spearmans rank correlation was used to assess if data were 
correlated. Wilcoxon matched-pairs signed-ranks test (2-tailed) was used to 
assess significant differences pre- and post-treatment with nitisinone in 
patients that were followed up. Mann Whitney unpaired test (2 tailed) was 






Sixty-three patients completed BDI-II questionnaires at baseline pre-
nitisinone treatment and 39 patients at 12 months following 2 mg daily of 
nitisinone treatment. Thirty-two of these patients also completed 
questionnaires at 24 months following 2 mg daily of nitisinone treatment.  
Mean (± standard deviation) BDI-II scores at baseline (n=63), 12 (n=39) and 
24 (n=32) months were 10.1(9.6); 9.8 (10.0) and 10.5 (9.9). Mean scores 





Figure 6.1. Beck’s depression inventory-II data box plot at baseline (pre-
nitisinone, n=39), and at 12 (n=39) and 24 months (n=32) (2 mg 
nitisinone daily). BDI-II scoring: minimal depression (0-13 points); mild 
depression (14-19 points); moderate depression (20-28 points); severe 
depression (29-63 points). Significance testing compared BDI-II scores at 
each visit. p value <0.05 was deemed significant. BDI-II scores were highly 
correlated at baseline and 12 months (rs=0.80, p<0.0001), baseline and 24 
months (rs=0.99, p<0.0001), and 12 and 24 months (rs=0.74, p<0.0001). 
This supports that BDI-II scores did not change significantly in the majority of 
patients over the 24 month period studied. 
 
 
A number of patients were followed up and so paired data were also 
analysed. Paired BDI-II scores were available in 39 patients at baseline and 
12 months, scores were not significantly different (p=0.30). Thirty-two of the 
39 patients also had BDI-II scores at 24 months (mean (±standard deviation) 
10.5 (9.9) vs 8.6 (7.8), which were significantly higher compared to baseline 
(p=0.03). There was no significant difference between BDI-II scores at 12 
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and 24 months (p=0.48). BDI-II scores were not significantly different 
between male and female patients pre- and post nitisinone treatment at 
baseline (n=24 and n=15, p=0.56), 12 months (n=24 and n=15, p=0.82) and 
24 months (n=18 and n=14, p>0.99). 
 
At baseline 74.6 % (47/63) of patients had minimal depression. A similar 
proportion of patients that commenced nitisinone had minimal depression at 
12 (30/39) and 24 months (23/32). At baseline the percentage of mild, 
moderate and severe depression was 11.1; 9.5 and 4.8 %, respectively. At 
12 months a greater proportion of patients were classified as having severe 
depression (10.8 %, 4/39). At 24 months the proportion of patients with 
severe depression reduced to 6.3 % (2/32).  
 
Table 6.1 shows the changes that were observed in the BDI-II classification 
of patients over the 24 month period studied. Six patients moved to a more 
severe category, and 2 patients moved to a less severe BDI-II category at 12 
months. The biggest change in category was observed in patients moving 
from the moderate to severe category (2/7 patients). At 24 months 5 patients 
moved to a more severe BDI-II category and 3 to a less severe BDI-II 
category. The biggest change in category was in patients moving from the 
minimal to mild category (3/8). 
 
BDI-II score category change 
Baseline  
to 12 months 
12 to 24  
months 
Minimal to mild 1 3 
Minimal to moderate 1 1 
Minimal to severe 1 0 
Mild to moderate 1 1 
Moderate to severe 2 0 
Mild to minimal 2 1 
Severe to moderate 0 1 
Severe to minimal 0 1 
 
Table 6.1. Beck’s depression inventory-II category changes observed 
between baseline (pre-nitisinone), 12 and 24 months (2 mg nitisinone 
daily). BDI-II scoring: minimal depression (0-13 points); mild depression (14-
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19 points); moderate depression (20-28 points); severe depression (29-63 




All patients had their medications reviewed at each visit. At baseline, 6 of the 
63 patients were on anti-depressants/mood stabilising agents. Agents 
included: citalopram, venlafaxine, olanzapine and duloxetine. Three of these 
patients had BDI-II scores recorded at 12 and 24 months. Two of the 3 
patients moved from the minimal to the moderate depression category. 
 
Five patients were excluded from the 12 and 24 BDI-II data analysis as they 
were not residents of England or Scotland, which meant they did not receive 
nitisinone treatment. They still had BDI-II assessments at 12 and 24 months, 
so effectively acted as a control group. One of these patients showed 
deterioration in BDI-II category at 24 months from minimal to mild.  
 
In addition review of medications revealed that 35 of 63 patients (56 %) were 
on at least 1 pain relief agent (15 patients on 1 agent; 10 patients on 2 
agents; 8 patients on 3 agents and 2 patients on 4 agents). Oral medications 
included: tramadol, co-codamol, morphine sulphate, dihydrocodeine, aspirin, 
paracetamol, naproxen, co-dydramol, diclofenac, amitriptyline, pregabalin, 
gabapentin, and buprenorphine. Fentanyl, morphine, lidocaine and 
buprenorphine patches were also recorded. Patients that were followed up 
remained on the agents documented at baseline. 
 
6.4.2 Urine monoamine metabolites 
Urinary monoamine metabolites were measured in a sub-group of patients 
that had BDI-II testing carried out. This was because urine samples were not 
available in all patients. Urinary NMA, MA and 3-MT (Figure 6.2(A-C)) were 
measured at baseline (n=33), 3 months (n=29), 12 months (n=31) and 24 
months (n=32). Urinary 5-HIAA (Figure 6.2(D)) was measured at the same 
time points but only in 21 patients.   
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MA concentrations were significantly lower at 3 months when compared to 
baseline concentrations (p=0.04). At the 3 month time point MA 
concentrations were all within the normal reference range and there was less 
of a spread of concentrations. At baseline, 12 and 24 months not all MA 
concentrations were within the normal reference range (Figure 6.2(A)). 
Interestingly the same pattern was observed in NMA concentrations; 
however no significant difference were observed between visits (Figure 
6.2(B)). 
 
3-MT results were significantly higher at 12 and 24 months following 2 mg 
daily of nitisinone treatment when compared to baseline and 3 month 
concentrations (2 mg nitisinone every other day) (p<0.0001) (Figure 6.2(C)). 
At baseline and 3 months 3-MT concentrations were within the normal 
reference range in the majority of patients; in contrast at 12 and 24 months 3-
MT concentrations were outside the normal reference range in the majority of 
patients.  
 
5-HIAA concentrations were significantly lower at 12 months when compared 
to baseline (p=0.03). Only 1 patient had 5-HIAA concentrations outside the 
normal reference range (in-house reference range <50 µmol/24 h), and this 
was at 3 months (Figure 6.2(D)).  
 
As monoamine metabolites are related to catecholamine and serotonin 
neurotransmitters they were correlated with BDI-II scores. At baseline, 12 
and 24 months BDI-II scores were not correlated with NMA, MA, 3-MT, or 5-




Figure 6.2. Urinary monoamine metabolite concentrations in patients 
with AKU. This includes samples at baseline (pre-nitisinone) (n=32 for 
metadrenalines, n=21 for 5-HIAA) and after treatment at 3 (n=29 for 
metadrenalines, n=21 for 5-HIAA), 12 (n=31 for metadrenalines, n=21 for 5-
HIAA) and 24 (n=32 for metadrenalines, n=21 for 5-HIAA) months (2 mg 
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nitisinone daily). (A) MA; (B) NMA; (C) 3-MT and (D) 5-HIAA. --- = indicates 
upper limit of normal urine reference range for NMA <3.0 µmol/24 h; MA <1.3 
µmol/24 h; 3-MT <1.4 µmol/24 h; 5-HIAA <50 µmol/24 h - = 95 % confidence 
notched outlier boxplot; + = outlier; o=individual patient concentrations. 
Significance testing compared monoamine concentrations before and after 
treatment at each visit. p value <0.05 was deemed significant 
 
 
6.4.3 Serum amino acids 
Serum phenylalanine, tyrosine and tryptophan were measured at baseline, 3, 
12 and 24 months. Herein the concentrations of these aromatic amino acids 
are only included where patients also had BDI-II assessments at baseline 
and at follow up. This was to assess if changes in amino acid concentration 
were observed following nitisinone treatment.  
 
Serum tyrosine (Figure 6.3 (A)) was within the normal reference range (29-92 
μmol/L) in all patients (n=30) before nitisinone treatment. Tyrosine 
significantly increased (p<0.0001) following treatment with nitisinone at 3 
months (n=28), 12 months (n=27) and 24 months (n=28). Serum 
concentrations increased 6-7 times the upper reference range on 2 mg every 
other day and daily. There were no significant differences in tyrosine 




Figure 6.3. Serum amino acid concentrations in patients with AKU. This 
includes samples at baseline (pre-nitisinone) (n=30) and after treatment at 3 
(n=28), 12 (n=27) and 24 (n=28) months (2 mg nitisinone daily). (A) Tyrosine; 
(B) Phenylalanine and (C) Tryptophan. --- = indicates the normal serum 
reference range for tyrosine 29-92 µmol/L; phenylalanine 30-76 µmol/L and 
tryptophan 40-79 µmol/L. Significance testing compared serum aromatic 
amino acid concentrations before and after treatment at each visit. p value 
<0.05 was deemed significant. 
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Phenylalanine concentrations showed a slight increasing trend (mean 
baseline phenylalanine=86.1 µmol/L (n=30) and mean 24 month (n=28) 
phenylalanine=91.7 µmol/L, (Figure 6.3(B)). Significant difference were 
observed between baseline and 12 months (n=27) (p=0.02). Interestingly 
phenylalanine concentrations were outside the upper end of the normal 
reference range (30-76 µmol/L) in >73 % of patients across all visits. 
 
In contrast serum tryptophan concentrations did not significantly change from 
baseline (n=30) following nitisinone therapy at 3 (n=28), 12 (n=27) or 24 
months (n=28), and concentrations remained within the normal reference 
range (40-79 µmol/L) in the >80 % of patients across all visits (Figure 6.3(C)). 
 
The aromatic amino acids tyrosine, tryptophan and phenylalanine were 
correlated with BDI-II scores (Table 6.2) as all 3 amino acids play a key role 
in neurotransmitter biosynthesis. A weak positive correlation was observed 




Baseline 12 months 24 months 
Correlation 
coefficient (rs)  
(95 % CI) 
p value 
Correlation 
coefficient (rs)   
(95 % CI) 
p value 
Correlation 
coefficient (rs)  
(95 % CI) 
p value 
BDI-II vs. NMA (n=25)* 0.39 (0 to 0.68) 0.05 -0.18 (-0.55 to 0.25) 0.41 -0.05 (-0.44 to 0.36) 0.82 
BDI-II vs. MA (n=25)* 0.26 (-0.15 to -0.59) 0.21 -0.23(-0.59 to 0.20) 0.28 0.02 (-0.38 to 0.42) 0.86 
BDI-II vs. 3-MT (n=25)* 0.25(-0.16 to -0.59) 0.22 -0.02 (-0.43 to 0.39) 0.91 0.04 (-0.37 to 0.32) 0.90 
BDI-II vs. 5-HIAA (n=20)** 0.05 (-0.41 to 0.50) 0.81 -0.20 (-0.59 to 0.27) 0.39 -0.12 (-0.60 to 0.41) 0.65 
BDI-II vs. Phenylalanine (n=30)*** 0.23 (-0.14 to 0.55) 0.21 0.41 (0.03 to 0.68) 0.06 0.12 (-0.27 to 0.46) 0.55 
BDI-II vs. Tyrosine (n=30)*** 0.41 (0.06 to 0.67) 0.02
# 0.03 (-0.35 to 0.40) 0.88 0.13 (-0.25 to 0.48) 0.49 
BDI-II vs. Tryptophan (n=30)*** -0.08 (-0.43 to 0.29) 0.68 0.06 (-0.33 to 0.44) 0.76 -0.25 (-0.59 to 0.17) 0.24 
 
Table 6.2. Correlations between Beck’s depression inventory-II scores and (1) Monoamine neurotransmitter metabolites 
and (2) Aromatic amino acids at baseline (pre-nitisinone) and at 12 and 24 months (2 mg nitisinone daily). *=24 patients at 
24 months with BDI-II and metadrenaline results; **=15 patients at 24 months with BDI-II and 5-HIAA results. ***=27 patients at 12 
months and 28 patients at 24 months; # = significance, p value <0.05 was deemed significant. CI – confidence interval; 5-HIAA – 5-





Currently nitisinone is being evaluated off licence at the NAC in Liverpool for 
treatment of AKU. Concerns exist over its use, in particular there is a focus 
on whether the hypertyrosinaemia may alter neurotransmitter metabolism 
and thus lead to altered mood or depression. Herein we report BDI-II scores 
as a self-reporting measure of depression before and after treatment with 
nitisinone, along with biochemical markers associated with depression. 
 
6.5.1 Beck’s depression inventory-II 
Mean BDI-II scores were not significantly different pre- and post-nitisinone 
treatment at 12 and 24 months, and the majority of patients were in the 
minimal depression category. This is the least severe category for depressive 
symptom scores.  
 
Interestingly BDI-II scores were shown to be significantly higher when paired 
data were compared at baseline and 24 months (n=32, p=0.03); mean scores 
were 8.6 and 10.5, respectively. It is important to note that despite this the 
majority of patients still fell into the least severe category for depression. This 
significant increase was not observed when comparing baseline and 12 
month results. Moreover there were no significant differences observed with 
respect to gender although mean BDI-II scores were higher in men. The 
increase in BDI-II scores observed may reflect natural variation in the scores 
generated in a self-reporting questionnaire, it is important to recognise that 
while BDI-II assessments are widely accepted in medical practice due to the 
ease of implementation and cost effectiveness they are challenging to use in 
medically ill patients as the presence of somatic symptoms in physical 
disease can mislead their score interpretation (Wang et al., 2013). Patients 
included in this study have chronic pain, as confirmed by 56 % of patients 
being on 1 or more pain relieving agents. It is highly likely this will have 
influenced BDI-II scores, but as all patients remained on medications for the 
duration of the study, data are not biased. 
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A small proportion of patients changed BDI-II category; in the first 12 months 
6 of 8 patients moved into a more severe category and 2 of 8 to a less severe 
category. The greatest changes were in patients moving from the moderate 
to severe (n=2), and mild to minimal (n=2) categories. These changes are 
probably not attributable to the effect of nitisinone directly, but are more likely 
a reflection of the variation seen in a self-reporting questionnaire and the 
impact of living with a chronic painful musculoskeletal disease and its 
associated comorbidities. At 24 months the same number of patients moved 
category, 5 of 8 moving into a more severe category and 3 of 8 improving. 
The biggest changes were observed in the movement from the minimal to 
mild category (n=3). Interestingly 2 of 3 patients that showed improvements 
in category moved from severe to moderate and minimal categories, 
respectively.  
 
In all of the BDI-II questionnaires carried out 9.5, 7.6 and 9.3 % of patients 
were taking antidepressants at baseline, 12 and 24 months. The prevalence 
of patients taking anti-depressants in this study is very similar to reported 
national patterns (Olfson et al., 2009). It is surprising that such a small 
proportion of patients were taking anti-depressants given the chronic pain 
and debilitation symptoms these patients have. This is likely to be a reflection 
that the majority of patients were not depressed and thus medication was not 
required, and a large proportion of patients were on pain relief medication. 
This is in contrast to a study that examined depression in patients with a 
similarly debilitating disease, osteoarthritis where in patients over the age of 
65 years (n=1425), 23.1 % were taking anti-depressant medication (Gleicher 
et al., 2011).  
 
Patients that were taking anti-depressant medication were not excluded from 
the data as they represent the typical population and were believed not to 
skew the data. Two patients taking antidepressant medications changed 
category, but this is not believed to be due to the effect of nitisinone.  
 
In this longitudinal survey 5 patients were excluded from the data analysis at 
12 and 24 months as they did not receive nitisinone. By definition these 
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patients acted as a ‘control group’, mean BDI scores were 10.6 and 10.8 at 
12 and 24 months, respectively. This is very similar to those patients 
receiving nitisinone (9.8 and 10.5 at 12 and 24 months, respectively) and 
thus while this is a small group it supports that nitisinone is not having a 
detrimental impact on mood. 
  
6.5.2 Urinary monoamine metabolites and serum amino acids 
In patients where urine and serum samples were available urinary 
monoamine metabolites and serum aromatic amino acids were measured to 
assess if treatment with nitisinone affected their concentrations. This is of 
particular importance because the aromatic amino acids are precursors to 
the catecholamine and serotonergic neurotransmitters, and urinary 
monoamine metabolites are a biochemical reflection of peripheral 
neurotransmitter metabolism; both have previously been shown to be altered 
in patients with depression (Roy et al., 1986a; Roy et al., 1986b; Grossman 
et al., 1999; Hughes et al., 2004).  
 
In keeping with previous (Suwannarat et al., 2005; Introne et al., 2011; 
Olsson et al., 2015; Ranganath et al., 2016; Milan et al., 2017; Davison et al., 
2018a; Davison et al., 2018b) serum tyrosine increased significantly to 
outside of the normal reference range at all visits following 2 mg nitisinone 
treatment. This marked increase resulted from the action of nitisinone, which 
is a reversible competitive inhibitor of the HPPD enzyme.  
 
The increase in tyrosine was accompanied by a small, but significant 
increase in phenylalanine concentrations when baseline was compared to 12 
months. Of note is that phenylalanine concentrations were outside the normal 
reference range (30-76 µmol/L, in-house reference range) independently of 
treatment with nitisinone. This has been previously reported by Davison et al. 
(2018b). It has been postulated that while these changes were significant, 
they may reflect normal intra-individual variation in amino acid concentration. 
It is also possible that changes result from reduced phenylalanine 
hydroxylase activity. Reduced enzyme activity has been reported in 
individuals with increased inflammation (Wannemacher et al., 1976). As AKU 
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is a chronic disease process it is possible that inflammatory processes are 
altered, however this was not assessed.  
 
Changes in serum amino acids were accompanied by a significant increase 
in the urinary DP metabolite 3-MT at 12 and 24 months, where the majority of 
patients had concentrations outside the normal reference range (<1.4 
µmol/24 h). Patients with 3-MT outside the normal reference range were also 
observed at baseline and 3 months. It is thought that this may reflect dietary 
intake of foods containing biogenic amines (De Jong et al., 2009). No 
patients with increased 3-MT at these time points were on any medications 
(including anti-depressants) known to increase 3-MT concentrations. This is 
consistent with previous findings (Davison et al., 2018b) in patients taking a 2 
mg daily dose of nitisinone.  
 
The marked increase in 3-MT excretion indicates that nitisinone therapy 
alters the metabolism of catecholamines, specifically DP. As previously 
highlighted (Davison et al., 2018b) the metabolism of catecholamine 
neurotransmitters is complex and they have multiple origins including the 
sympathetic nerves (involved peripheral metabolism), adrenal medulla, brain 
(involved in central nervous system metabolism) and mesenteric organs 
(Eisenhofer et al., 2004). It has been demonstrated that the concentration of 
monoamine neurotransmitters in urine are dependent on plasma 
concentrations and uptake via organic cation transporters in the kidney 
(Eisenhofer et al., 1996; Graefe et al., 1997). It is also important to consider 
the degree to which renal neurotransmitter synthesis can contribute to the 
urinary concentrations. 
 
Davison et al. (2018b) suggested the increase in 3-MT is highly likely to 
reflect renal synthesis as serum tyrosine concentrations increased 
significantly post nitisinone therapy. It is thought that the increased tyrosine 
load delivered to the kidney may provide a substrate for the synthesis of 
dihydroxyphenylalanine, and subsequent decarboxylation to DP may lead to 
the increase in 3-MT observed. However this rationale does not explain why 
changes in 3-MT were not observed at 3 months after nitisinone therapy 
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every other day, despite the large increase in serum tyrosine concentration. 
The explanation for this is unknown and requires further investigation.  
 
This supposition is supported by BDI-II scores not changing drastically and 
the majority of patients did not move to a more severe category of 
depression. In contrast Roy et al. (1986b) showed that the urinary metabolite 
of DP, dihydroxyphenylacetic acid was significantly lower in patients with 
depression, and suggested that this finding shows dysregulation of the 
sympathetic nervous system in depression. 
 
Urinary MA was significantly lower between baseline and 3 months following 
nitisinone treatment, but not at 12 and 24 months. This is in contrast to 
previous (Davison et al., 2018b) where no significant changes were observed 
following nitisinone treatment. This study however showed that urinary MA 
concentrations were less variable following nitisinone treatment (Davison et 
al., 2018b). The lack of significantly lower MA concentrations across all visits 
suggests this finding is not due to nitisinone therapy and may reflect variation 
in dietary intake (de Jong et al., 2009).  
 
While there were no significant differences observed in urinary NMA 
concentrations following treatment; at 3 months urinary excretion also 
showed less variation compared to all other visits. As this is not a consistent 
finding at other visits it is of unknown significance and requires further 
investigation. Previously Davison et al. (2018b) showed that NMA decreased 
significantly following a daily dose of nitisinone at 1-8 mg. The reason for not 
seeing this difference in the current study is unknown; the findings presented 
herein are however based on a larger cohort of patients that were followed 
up over a 24 month period and likely to be more representative of the effect 
of nitisinone on urinary NMA excretion. 
 
Previous studies (Roy et al., 1986a; Roy et al., 1986b; Grossman et al., 
1999; Hughes et al., 2004) have demonstrated that urinary concentrations of 
NA, MA and adrenaline were significantly higher in subjects with depression 
compared to controls and concluded that this reflected dysregulation of the 
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sympathetic nervous system in depression. In contrast, the majority of 
patients in our study were in the least severe category of depression, which 
supports the biochemical findings presented.  
 
Herein the mean urinary excretion of 5-HIAA decreased following treatment 
with nitisinone at all visits (only significantly lower at 12 months), suggesting 
that peripheral serotonin metabolism is altered. This however was not 
reflected in changes in BDI-II scores. In contrast Davison et al. (2018b) only 
showed a significant decrease in 5-HIAA excretion following a daily 8 mg 
dose of nitisinone. This difference may be the result of the current study 
being over a 24 month period and not 8 weeks.  
 
Thimm et al. (2011) has reported alterations in serotonin metabolism in 
patients with HT1 treated with nitisinone. This study showed a decrease in 
cerebrospinal fluid (CSF) 5-HIAA concentrations following nitisinone therapy. 
It is proposed that the decrease in CSF 5-HIAA occurred as increased 
tyrosine concentrations compete with tryptophan (serotonin precursor) via a 
neutral amino acid transporter across the blood-brain barrier, thus reducing 
tryptophan availability for intracerebral serotonin synthesis (Pratt et al., 
1982).  
 
In addition it has been hypothesised that elevated tyrosine may inhibit 
tryptophan hydroxylase activity, the rate limiting step for serotonin 
metabolism (Thimm et al., 2011). Although this study was small and analysis 
was performed in CSF it has been shown that urinary analysis of serotonin 
and 5-HIAA reflect parallel changes in immunoreactivity in the dorsal raphe 
nucleus, demonstrating a positive correlation between CNS serotonergic 
activity and urinary serotonin concentrations (Lynn-Bullock et al., 2004).  
 
6.5.3 Correlation between BDI-II scores and biochemical 
measurements 
A weak positive correlation was observed between BDI-II scores and serum 
tyrosine before nitisinone treatment. This is not unexpected as tyrosine is the 
precursor to catecholamine neurotransmitters. Following nitisinone treatment 
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and consequent hypertyrosinaemia, this correlation disappeared. This is 
likely to reflect the large rapid change in tyrosine with very little change in 
BDI-II scores. This supports the postulate that hypertyrosinaemia does not 
result in worsening mood or depression in this cohort. The significant 
increase in the ratio of tyrosine to large neutral amino acids (i.e. 
phenylalanine and tryptophan) has been previously reported following 
nitisinone treatment (Davison et al., 2018b), and it is has been hypothesised 
that hypertyrosinaemia may reduce phenylalanine and tryptophan uptake into 
the brain due to competition for the LAT-1 transporter (van Ginkel et al., 
2016), thus altering neurotransmitter metabolism. As serum amino acids 
were measured in serum, speculative inferences can only be made as 
concentrations do not necessary reflect the concentration in CSF. 
 
The lack of correlation between BDI-II scores and monoamine metabolites is 
not surprising for a number of reasons. Firstly, while urinary monoamine 
metabolites are produced by the sympathetic nervous system and adrenal 
gland, they also reflect production in the mesenteric organs and dietary 
intake thus reducing their specificity as a marker of increased 
sympathoadrenal activity. Moreover the majority of patients included herein 





BDI-II scores were significantly higher after 24 months of nitisinone treatment 
in patients that were followed up. Despite this the majority of patients 
remained in the least severe category of depression suggesting that 
nitisinone treatment does not substantially worsen mood. Independent of this 
there were significant effects on serum tyrosine concentrations and 
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Background: Nitisinone induced hypertyrosinaemia is a concern in patients 
with Alkaptonuria (AKU). It has been suggested that this may alter 
neurotransmitter metabolism, specifically dopamine and serotonin. Herein 
mass spectrometry imaging (MSI) is used for the direct measurement of 2,4-
diphenyl-pyranylium tetrafluoroborate (DPP-TFB) derivatives of monoamine 
neurotransmitters in brain tissue from a murine model of AKU following 
treatment with nitisinone. 
Materials and methods: Metabolite changes were assessed using MSI on 
DPP-TFB derivatised fresh frozen tissue sections directing analysis towards 
primary amine neurotransmitters. Matched tail bleed plasma samples were 
analysed using LC-MS/MS. Eighteen BALB/c mice were included in this 
study: HGD-/- (n=6, treated with nitisinone – 4 mg/L, in drinking water); HGD-/- 
(n=6, no treatment) and HGD+/- (n=6, no treatment). 
Results: Ion intensity and distribution of DPP-TFB derivatives in brain tissue 
for dopamine, 3-methoxytyramine, noradrenaline, tryptophan, serotonin, and 
glutamate were not significantly different following treatment with nitisinone in 
HGD -/- mice, and no significant differences were observed between HGD-/- 
and HGD+/- mice that received no treatment. Tyrosine (10-fold in both 
comparisons, p=0.003; [BALB/c HGD-/- (n=6) and BALB/c HGD+/- (n=6) (no 
treatment) vs. BALB/c HGD-/- (n=6, treated)] and tyramine (25-fold, p=0.02; 
32-fold, p=0.02) increased significantly following treatment with nitisinone. 
Plasma tyrosine and homogentisic acid increased (9-fold, p<0.0001) and 
decreased (9-fold, p=0.004), respectively in HGD-/- mice treated with 
nitisinone. 
Conclusions: Monoamine neurotransmitters in brain tissue from a murine 
model of AKU did not change following treatment with nitisinone. These 
findings have significant implications for patients with AKU as they suggest 







Alkaptonuria (AKU, OMIM 203500) is a rare bi-allelic autosomal recessive 
disorder of the tyrosine metabolic pathway, occurring 1 in 100,000-250,000 of 
the general population (Phornphutkul et al., 2002) and arises from a 
congenital deficiency in the enzyme homogentisate 1,2-dioxygenase (HGD, 
E.C.1.12.11.5) (Figure 7.1). The biochemical hallmark of AKU is that 
circulating concentrations of homogentisic acid (HGA) markedly increase, 
and it is this that is thought to be responsible for many of the complications 
observed (for a detailed review see Ranganath et al., 2013). Treatment for 
this condition is largely based on supportive and palliative measures that 
include pain relief and anti-inflammatory medications, dietary protein 
restriction and joint replacement (Ranganath et al., 2013). Currently the drug 
nitisinone, a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase 
(HPPD, E.C.1.13.11.27) (Figure 7.1), is being evaluated as a potential 
treatment (Ranganath et al., 2016; Milan et al., 2017; SONIA-2 – 
ClinicalTrials.gov Identifier: NCT01916382). This drug acts to move the 
metabolic block in the tyrosine metabolic pathway resulting in a marked 
reduction in the circulating concentration of HGA and a consequential  
significant increase in tyrosine, creating a so called ‘pseudo type-3 
Tyrosinaemia’ picture (Suwannarat et al., 2005; Introne et al., 2011; Olsson 
et al., 2015; Ranganath et al., 2016; Milan et al., 2017; Davison et al., 2018a; 
Davison et al., 2018b; Davison et al., 2018c). Hypertyrosinaemia has also 
been well documented in patients with hereditary tyrosinaemia type 1 (HT1, 
OMIM 276700) that are treated with nitisinone (Lindstedt et al., 1992; van 
Ginkel et al., 2017; Zeybek et al., 2017).  
 
The metabolic fate of these supraphysiological tyrosine concentrations is 
unknown. It has been proposed in HT1 that hypertyrosinaemia may 
contribute to the neurodevelopmental delay that is frequently observed in 
children (McKiernan et al., 2015). Several mechanisms have been proposed 
for this, including increased transport of tyrosine into the brain; decreased 
transport of other neutral amino acids into the brain (specifically tryptophan); 
increased central nervous system (CNS) dopamine (DP); decreased CNS 
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serotonin, oxidative damage from δ-aminolevulinic acid and succinylacetone 
or modification of neuronal proteins (Thimm et al., 2011; Hillgartner et al., 
2016). It has also been suggested that altered serotonin metabolism may be 
due to direct inhibition of tryptophan hydroxylase (TPH, EC.1.14.16.4) activity 





Figure 7.1. Tyrosine metabolic pathway. Highlighted are the enzyme 
defects observed in Phenylketonuria (phenylalanine hydroxylase, PAH 
E.C.1.14.16.1), AKU (homogentisate 1,2-dioxygenase, HGD E.C.1.13.11.5) 
and HT1 (fumarylacetoacetate hydrolase, FAH E.C.3.7.1.2), and the site of 
action of nitisinone inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD, 
E.C.1.13.11.27). Adapted from Davison et al. (2018b). 
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In AKU there is uncertainty about whether the hypertyrosinaemia may alter 
neurotransmitter metabolism and specifically whether this may lead to 
depression or altered cognition through the mechanisms detailed above. 
Recently Davison et al. (2018c) concluded that treatment with nitisinone is 
unlikely to cause depression in patients with AKU in a study that assessed 
urinary neurotransmitter metabolite concentrations, in a cohort of patients 
with AKU. This study did show an increase in urinary 3-methoxytyramine (3-
MT, DP metabolite) and a decrease in urinary 5-hydroxyindole acetic acid 
(serotonin metabolite) following treatment. These changes did not correlate 
with Beck's depression inventory-II scores. Similar biochemical findings were 
also reported in a study that evaluated different doses of nitisinone (0-8 mg 
daily for 4 weeks) in patients with AKU over a 4 week period (Davison et al., 
2018b). 
 
While previous studies have demonstrated that hypertyrosinaemia clearly 
results in altered peripheral metabolism of dopaminergic and serotoninergic 
neurotransmitter metabolites they are limited as they are not a direct 
reflection of neurotransmitter metabolism in the CNS, which is directly linked 
to mood and cognition. Direct measurement of neurotransmitter 
concentrations in cerebrospinal fluid and or in the brain are not feasible in 
this patient group owing to their complex musculoskeletal comorbidities. 
 
Herein for the first time we report a direct approach to assess whether 
hypertyrosinaemia effects monoamine neurotransmitter metabolism. 
Desorption electrospray ionisation mass spectrometry imaging (DESI-MSI) 
was used to measure the ion intensity and distribution of 2,4-diphenyl-
pyranylium tetrafluoroborate (DPP-TFB) derivatives of monoamine 
neurotransmitters in brain tissue from a murine model of AKU (BALB/c  
HGD-/-) (Preston et al., 2014) following treatment with nitisinone. Applying an 
imaging approach will enable us to identify whether any occurring changes 
are only appearing in certain brain sub-structures or are systemic to the 
whole brain. Chemical charge tagging of monoamine neurotransmitters 
(primary amines) with DPP-TFB was carried out as previous studies have 
demonstrated significant improvements in signal intensity compared to their 
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analysis in native brain tissue (Shariatgorji et al., 2014; Esteve et al., 2016; 
Shariatgorji et al., 2016).  
 
DESI-MSI was employed over other techniques as it allows the direct 
mapping of the distribution and localisation of multiple molecular species in a 
single experiment (Shariatgorji et al., 2014; Shariatgorji et al., 2016). This is 
in contrast to the direct measurement of individual metabolite concentrations 
in brain tissue homogenates, which gives no information on distribution and 
localisation, and more traditional indirect methods like histological, 
immunochemical and ligand based assays (de Jong et al., 2005).  
 
In addition plasma concentrations of HGA and tyrosine were measured using 
liquid chromatography tandem mass spectrometry (LC-MS/MS), to confirm 
that the murine model employed (1) had the expected biochemical phenotype 
observed in AKU (i.e. elevated HGA) and (2) hypertyrosinaemia was 
observed following treatment with nitisinone. 
 
 
7.3 Materials and methods 
 
7.3.1 Chemicals and reagents 
Triethylamine (TEA), hydroxypropylmethylcellulose, polyvinylpyrrolidone and 
perchloric acid were purchased from Sigma-Aldrich (Dorset, UK). Water, 
methanol and trifluoroacetic acid (TFA) were obtained from Merck 
(Hohenbrunn, Germany). DPP-TFB was obtained from American Custom 
Chemicals Corporation (San Diego, CA, USA). 
 
7.3.2 Animal experiments 
7.3.2.1 Protocol for treating murine AKU model with nitisinone 
A murine model of AKU was used for all experiments as described previously 
(Preston et al., 2014). Eighteen BALB/c mice (Figure 7.2) (12 HGD-/- and 6 
HGD+/-) were used in total. Six mice (HGD-/-) were administered nitisinone (4 
mg/L) through drinking water for one week, the remaining 12 mice (6 HGD-/- 
and 6 HGD+/-) received no nitisinone. All animals were housed in air 
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conditioned rooms (with a 12 h dark/light cycle) at 20 °C and 53 % humidity, 
with access to food and water ad libitum at the University of Liverpool. All 
animal experiments complied with the ARRIVE guidelines and were carried 
out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 





Figure 7.2. Summary of experimental workflow involving murine model 
of AKU. Included are mouse gender, weight and age; treatment groupings 




7.3.2.2 Collection of tail bleed samples 
Tail bleed samples were collected into Microvettes (Sarstedt, Germany) at 
baseline and after 1 week prior to culling. Whole blood samples were 
centrifuged at 1500 ×g for 10 min at 4 °C and the plasma deproteinised by 
adding 60 % 5.8 M perchloric acid (ratio 1:10, perchloric acid:plasma). 
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Samples were vortexed and centrifuged at 1500 ×g for a further 10 min. The 
supernatant was stored at -80 °C until analysis (Figure 7.2). 
 
7.3.2.3 Brain harvesting  
Brains were resected from each animal following cervical dislocation, and 
placed into a trough of dry ice cooled isopentane until any effervescence 
stopped. They were then removed using chilled forceps and wrapped in 
aluminium foil and stored at -80 °C until dissection. 
 
7.3.2.4 Brain tissue processing and derivatisation 
Frozen brain tissues were placed into plastic moulds and embedded into a 
matrix composed of 7.5 % (w/v) hydroxypropylmethylcellulose and 2.5 % 
(w/v) polyvinylpyrrolidone. Brains were divided into 3 moulds (n=6 per mould, 
2 brains from each treatment group) to allow axial (n=6), sagittal (n=6) and 
coronal (n=6) sectioning to allow spatially resolved assessment of metabolite 
changes in brain substructures. This embedding approach was chosen in 
order to ensure that all brains are treated identically as it was previously 
shown that consecutive sectioning can lead to metabolite degradation 
(Swales et al., 2018). Although it was attempted to position brains into the 
moulds in exactly same position and orientation, this approach might lead to 
slight differences in sectioning depth and position.  
 
Embedded tissues were then cut using a cryo-microtome operated at -20 °C 
(Leica CM3050S, Leica Microsystems, Wetzlar, Germany) to a thickness of 
10 μm and thaw mounted onto superfrost microscope glass slides (Thermo 
Scientific, Braunschweig, Germany). These slides were subsequently dried 
under a gentle flow of nitrogen before being stored at −80 °C until 
derivatisation and MSI analysis. 
 
Brain tissues were derivatised as previously described (Shariatgorji et al., 
2014; Shariatgorji et al., 2016) using DPP-TFB (9.2 mg DPP-TFB was 
dissolved in 7.2 mL of 75 % methanol alkalinised with 3.5 μL of TEA to obtain 
a 1.3 mg/mL derivatisation solution). This was applied using a TM sprayer 
(HTX Technologies, Chapel Hill, NC) at 75 °C in 30 passes using criss-cross 
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pattern [flow rate 80 μL/min, nitrogen flow of 10 psi, nozzle speed 1100 
mm/min]. Chemical charge tagging of primary amine functional groups with 
DPP-TFB was done to enhance signal intensity of monoamine 
neurotransmitters as their analysis has proven difficult due to their low-
ionization efficiency, spectral interferences from tissue components, ion 
suppression effects and analyte insource fragmentation (Shariatgorji et al., 
2014; Esteve et al., 2016; Shariatgorji et al., 2016). 
 
7.3.3 Analytical methods for the analysis of murine samples 
7.3.3.1 Liquid chromatography tandem mass spectrometry 
analysis of murine plasma samples 
Plasma samples from tail bleeds were analysed for tyrosine, nitisinone and 
HGA using a previously published method (Hughes et al., 2015). In brief, 
samples were analysed for all 3 analytes in a single run on an Agilent 6490 
triple quadrupole tandem mass spectrometer with Jet-Stream® electrospray 
ionization coupled with an Agilent 1290 Infinity II UHPLC pump. Separation 
was achieved on an Atlantis dC18 column (3.0 x 100 mm, 3 µm, Waters) 
maintained at 35 °C. Quantification was achieved using a matrix matched 7 
point calibration curve and 2 product ion transitions for each analyte of 
interest (HGA 167>122 and 167>108, negative polarity; tyrosine 182>136 
and 182>91; nitisinone 330>218, positive polarity).The linear measuring 
range for tyrosine, HGA and nitisinone were 60-2000; 15-500 and 0.5-10 
μmol/L, respectively. 2 μL of deproteinized sample was diluted 1:1000 with 
200 nmol/L 13C6-HGA, 500 nmol/L d4-tyrosine and 2 nmol/L 
13C6-nitisinone in 
0.1 % formic acid/deionized water. 10 μL of diluted plasma was injected onto 
the column. Data were acquired using MassHunter LC/MS Data Acquisition 
(Build 07.00).  
 
7.3.3.2 Mass spectrometry imaging of murine brain tissue 
MSI data were acquired using an OmniSpray-2D DESI ion source (Prosolia 
Inc, Indianapolis, IN, USA) mounted onto a Q-Exactive Plus mass 
spectrometer (Thermo Scientific, Bremen, Germany). A home-built DESI 
sprayer assembly was used. This was based on a previously reported design 
(Takáts et al., 2004) that was modified as previously described (Abbassi-
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Ghadi et al., 2015). The distance between the sprayer and inlet capillary was 
7 mm, the distance between sprayer and sample surface was 1.5 mm and 
the distance between inlet capillary and sample surface was <1 mm. The 
angle between the sprayer and the sample surface was set to 75 °, and the 
collection angle between inlet capillary and sample surface was 10 °. 
Methanol/water (95:5 v/v) was used as the electrospray solvent, at a flow rate 
of 1.5 μL/min, and the spray voltage was set to +4.5 kV. Solvent was 
delivered using a Dionex Ultimate3000 nLC pump (Sunnyvale, CA, USA). 
N4.8 Nitrogen (BOC, Guilldford, UK) was used as the nebulizing gas at a 
pressure of 7 bar. An S-Lens RF level of 75, capillary temperature of 320 °C 
and mass resolution of 70,000 were employed. Derivatised tissues were 
analysed in positive ion mode using a mass range of m/z 250-1000 and an 
injection time of 150 ms. All images were recorded with 100 µm spatial 
resolution resulting in a scan speed of 378.79 µm/s. Compound identities 
were assigned using exact mass only. 
 
7.3.4 Data and statistical analysis 
7.3.4.1 LC-MS/MS data  
HGA, tyrosine and nitisinone concentrations were calculated using 
MassHunter Quantitative Analysis (Build 06.00). A paired t-test was used to 
compare plasma HGA and tyrosine concentrations at baseline and 1 week 
using Graphpad Instat (Version 3.10, 2009, CA, USA). A p value <0.05 was 
deemed significant. 
 
7.3.4.2 Mass spectrometry imaging data  
MSI raw data files were initially converted into centroided .mzML files using 
MSConvert tool (ProteoWizard toolbox Version 3.0.4043) and then further 
converted into .imzML format using imzML Converter (version 1.3, Race et 
al., 2012), which were then converted to SCiLS data format for visualization 
and statistical analysis of the data in SCiLS Lab v2018b. (Bruker Daltonics, 
Bremen, Germany). 
 
All m/z values for monoamine neurotransmitters were extracted with a mass 
window of less than 0.0052 Da. Derivatisation led to the formation of a [M + 
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(DPP-TFB)]+ ion with no observable [M]2+ or [M + Na]+ ions. A peak 
corresponding to the DPP-TFB derivative was observed with a mass shift of 
+215.0855 to the exact monoisotopic mass. The differences between the 
theoretical and observed m/z values of each derivatised compound was <5 
ppm. 
 
Mean intensity and standard deviation of raw m/z signal intensity for DPP-
TFB derivatives of monoamine neurotransmitters were extracted from tissue 
regions of interest using SCiLS software (SCiLS Lab Bruker, Version 2018b). 
To compare signal intensities for extracted m/z values for all compounds an 
unpaired t-test was used; a p value <0.05 was deemed significant.  
 
 
7.4 Results  
 
7.4.1 LC-MS/MS analysis of plasma homogentisic acid and tyrosine 
Plasma HGA concentrations were markedly higher in BALB/c HGD-/- mice 
(AKU mice) at baseline compared to HGD-/+ mice (non-AKU mice). HGA 
concentrations in the HGD+/- mice were below the lower limit of the 
measuring interval for the assay. Tyrosine concentrations were similar at 
baseline between the 3 groups studied; the variation observed between the 3 
groups is thought to reflect dietary intake and normal variation in amino acid 
metabolism.  
 
Treatment of HGD-/- mice with nitisinone (mean(±standard deviation) plasma 
concentration 0.4±(0.094) µmol/L) resulted in a marked decrease in HGA (9-










(µmol/L, mean ±SD) 
Homogentisic acid                      
(µmol/L, mean ±SD) 
Baseline 1 week p value Baseline 1 week p value 
HGD-/- # 112.3 (21.9) 997.8 (112.7) <0.0001* 197.2 (87.2) 21.6 (4.3) 0.004* 
HGD-/- ## 92.8 (29.9) 77.6 (16.2) 0.096 215.7 (168.2) 158.2 (89.8) 0.18 
HGD+/- ## 66.5 (7.9) 62.6 (5.8) 0.27 <3.1 <3.1 NS 
 
Table 7.1. Plasma tyrosine and HGA concentrations at baseline and 1 
week later in a murine model of AKU. *pvalue <0.05 deemed significant. # 
– treated with nitisinone (4 mg/L); ## – no treatment; NS – no significance 
testing performed as concentrations below limit of quantification of assay. Six 
mice were in each experimental group. 
 
 
7.4.2 Mass spectrometry imaging of neurotransmitters in murine brain 
tissue 
MS images were successfully generated for all 18 murine brains included in 
this study in positive polarity. Differences in the appearance of sagittal 
images (Figure 7.3) is a reflection of the positioning of brains in the mould. All 
brains were very similar in size and were anatomically symmetrical thus the 
plane sectioned for all 6 brains in each mould was considered to be 
comparable and thus ion intensities recorded were considered representative 
of the plane of tissue sectioned. Figure 7.3 shows representative sagittal MS 
images of BALB/c mice brains from all 3 treatment groups. As previously 
described (Shariatgorji et al., 2014; Esteve et al., 2016; Shariatgorji et al., 
2016) chemical charge tagging of primary amines with DPP-TFB enabled the 
detection of DP, 3-MT, noradrenaline (NA), serotonin, tyrosine, tryptophan 
and tyramine. It is important to note that NA has the same monoisotopic 
mass as 6-hydroxydopamine (m/z 169.0738), thus chemical charge tagging 
would also theoretically generate a mass shift of +215.0855 to its exact 
monoisotopic mass. In this study it was assumed the mass shift observed at 
384.1575 was NA. This is because it has been hypothesised that 6-
hydroxydopamine is a neurotoxic metabolite of DP that is only observed in 
patients with Parkinson's disease that are treated with L-DOPA (Borah et al., 
2012). It is proposed that 6-hydroxydopamine aggravates dopaminergic 
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neurodegeneration, and it is this that forms the basis of its use in the 
generation of experimental models of Parkinson’s disease (Breese et al., 
2005).  
 
Glutamate was also detected, but it is important to note that tissue 
derivatisation is not required for this and native sections can be used 
(Shariatgorji et al., 2016). Using a derivatisation approach allowed analysis of 
all neurotransmitters in a single analytical run while the embedding approach 
ensured all tissues are treated identically at all times to minimise unequal 
degradation of neurotransmitters. Tissue drying was found to further increase 
stability (Swales et al., 2018). 
 
Comparisons of m/z ion distribution maps for each compound were made 
between the 3 groups of mice: (1) BALB/c HGD-/- (n=6, no treatment) vs. 
BALB/c HGD-/- (n=6, treated); (2) BALB/c HGD+/- (n=6, no treatment) vs. 
BALB/c HGD-/- (n=6, treated); (3) BALB/c HGD-/- (n=6, no treatment) vs. 
BALB/c HGD+/- (n=6, no treatment). It is important to note that comparisons 
made between m/z signal intensities represent a relative and not quantitative 
change in response. In agreement with previous authors (Shariatgorji et al., 
2014; Shariatgorji et al., 2016) the total signal through the brain was used to 
assess spatial changes in neurotransmitter patterns, with the exception of DP 
and 3-MT in which only the signal relating to the striatum was used. This is 
because their production is very localised and specific to this anatomical 
region of the brain. In contrast the other neurotransmitters and related 
metabolites are distributed more ubiquitously throughout the brain and so the 
total brain area was used. 
 
Tyrosine (10-fold, p=0.003; 10 fold, p=0.003; and p=0.71) and tyramine (25 
fold, p=0.02; 32 fold, p=0.02; p=0.77) showed significantly more intense 
signals in mice that received treatment with nitisinone (Figure 7.3 (A) and 
(B)). Signal intensities for tyrosine and tyramine increased in all regions of 
the brains studied. Signals were most intense in the cerebellum, cerebral 
cortex and hypothalamus for tyrosine, and the striatum and cerebellum for 
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tyramine. No differences in ion distribution or intensity were observed for the 
2 groups of mice that did not receive nitisinone treatment.  
 
DP (striatum of brain only, p=0.38, p=0.68, and p=0.47, respectively) and its 
metabolites 3-MT (striatum of brain only, p=0.67, p=0.77, and p=0.94, 
respectively) and NA (p=0.41, p=0.81, and p=0.54, respectively) did not 
change significantly following treatment with nitisinone. The intensity of the 
signal for DP and 3-MT was highest in the striatum, cortical subplate, and 
palladium (Figure 7.3 (C) and (D)). The intensity of the signal for NA (Figure 
7.3 (E)) was more dispersed than that of DP and 3-MT, and was most 
intense in the substantia nigra reticulata and ventral striatum.  
 
Serotonin (p=0.54, p=0.78, and p=0.64, respectively) and its precursor amino 
acid tryptophan (p=0.36, p=0.90, and p=0.27, respectively), and glutamate 
(p=0.89, p=0.93, and p=0.92, respectively) showed no significant differences 
between mice that received nitisinone and those that did not. The signal 
intensity for serotonin was most intense in the substantia nigra reticulata and 
ventral striatum, while its precursor tryptophan and glutamate were found in 
all brain tissues. The latter being most intense in the cerebral cortex (Figure 
7.3 (F–H)). 
 
All monoamine neurotransmitter compounds and related metabolites in the 2 
groups of mice that did not receive nitisinone treatment were not significantly 










Figure 7.3. Representative mass spectrometry images of sagittal brain 
tissue sections from the BALB/c mouse. Ion intensity maps of precursor 
ions of DPP-TFB derivatives acquired in positive ionisation mode (A) 
Tyrosine m/z 396.15814; (B) Tyramine m/z 352.16702; (C) DP m/z 
368.16238; (D) 3-MT m/z 382.18013; (E) NA m/z 384.15753; (F) Tryptophan 
m/z 419.1753; (G) Serotonin m/z 396.15854 and (H) Glutamate m/z 
362.1364. In each panel Left: sagittal brain sections from BALB/c mice:  
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HGD-/- mouse treated with nitisinone (red outline); (2) HGD-/- mouse no 
treatment (green outline) and (3) HGD+/- no treatment (yellow outline). Right: 
bar graph: y-axis – mean (± standard deviation) extracted m/z ion intensity 
for metabolite; x-axis – experimental group (n=6 in each group); ion intensity 
for DP and 3-MT from striatum only, not the whole brain section. Scale bar: 6 
mm; spatial resolution 100 μm. *p<0.05 deemed significant. Signal intensities 





To date the direct consequences of nitisinone induced hypertyrosinaemia on 
neurotransmitter metabolism in patients with AKU has not been reported. 
Herein for the first time we report the direct measurement of DPP-TFB 
derivatives of monoamine neurotransmitters in the brain tissue from a murine 
model of AKU following treatment with nitisinone, and corresponding plasma 
concentrations of HGA and tyrosine. 
  
7.5.1 LC-MS/MS analysis of plasma homogentisic acid and tyrosine 
Plasma HGA concentrations were markedly higher in BALB/c HGD-/- mice 
(AKU mice) at baseline compared to HGD-/+ mice (non-AKU mice), this was 
expected and entirely in keeping with the genotype of the mice studied 
(Preston et al., 2014). 
 
Treatment of BALB/c HGD-/- mice with nitisinone resulted in an expected 
decrease in HGA and increase in tyrosine. The changes observed occurred 
because nitisinone is a reversible competitive inhibitor of HPPD (Figure 7.1). 
These findings confirm that the mice used in this study had the biochemical 
phenotype one would expect in AKU and that hypertyrosinaemia was 
observed following treatment with nitisinone. 
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7.5.2 Mass spectrometry imaging of neurotransmitters in murine brain 
tissue 
Tyrosine and tyramine increased significantly in BALB/c HGD-/- mice treated 
with nitisinone. No changes in tyrosine or tyramine were observed in HGD-/- 
and HGD-/+ mice that received no treatment. These novel findings support 
that the changes observed were a consequence of treatment with nitisinone. 
The increase in tyrosine is likely to be the result of the 9-fold increase in 
plasma tyrosine, which through facilitated diffusion via the LAT-1 transporter 
(Mastroberardino et al., 1998) will have resulted in increased transport into 
the CNS. The large increase in tyramine was an unexpected finding, and is a 
likely consequence of the action of aromatic acid decarboxylase, which 
converts tyrosine to tyramine. The physiological role and mechanisms of 
action of this trace amine remain poorly understood in mammals. Tyramine is 
often regarded as a by-product of amino acid metabolism with no clear 
functional relevance (Ledonne et al., 2011). 
 
It is reassuring that DP did not increase itself and is likely to reflect that its 
synthesis is highly regulated. There is a major and minor route for DP 
biosynthesis (Meiser et al., 2013). The minor route involves the enzymatic 
conversion of tyrosine to tyramine via the action of aromatic acid 
decarboxyalse, tyramine is then converted to DP via cytochrome CYP2D6. 
The major route is via the enzymatic conversion of tyrosine to L-DOPA and 
then to DP via the actions of tyrosine hydroxylase and then aromatic acid 
decarboxylase. In the face of excess tyrosine and tyramine and no change in 
DP one may postulate that 1 or all of the enzymes mentioned are down 
regulated to limit DP production when it is not required. A limitation of this 
study is that enzyme activity was not measured. The increased catabolism of 
DP to NA via the enzymatic action of DP hydroxylase, or to 3-MT via the 
enzymatic action of catechol-O-methyltransferase is unlikely as no significant 
changes were observed in either of these compounds following treatment 
with nitisinone (Figure 7.3). Importantly this study did not show any changes 
in serotonin or tryptophan metabolism in HGD-/- mice following treatment with 
nitisinone, confirming that hypertyrosinaemia does not affect serotonin 
biosynthesis or metabolism in the murine model of AKU studied.  
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In addition it is reassuring that no significant changes were observed in 
neurotransmitters or their metabolites at baseline and 1 week in the HGD-/- 
and HGD-/+ mice that received no treatment, supporting that changes that 
were observed were a consequence of treatment with nitisinone. 
 
Whilst there have been no reported investigations of the impact of nitisinone 
induced hypertyrosinaemia on dopaminergic and serotoninergic 
neurotransmitter metabolism in AKU, the impact of nitisinone induced 
hypertyrosinaemia on neurotransmitter metabolism has been investigated in 
a mouse model of phenylketonuria (PKU) (Harding et al., 2014) and HT1 
(Hillgartner et al., 2016).  
 
Hillgartner et al. (2016) used a similar dose of nitisinone to our group and 
reported that urinary homovanillic acid (DP metabolite) increased 4-fold 
following nitisinone, but concluded that this was likely to be a reflection of 
peripheral breakdown and metabolism did not reflect changes in the CNS. In 
this study no direct measurements of DP or serotonin were made in brain 
tissue, but they concluded that slower learning and cognitive difference in the 
mice studied were caused by HT1 and not by the treatment with nitisinone. 
We have also reported an increase in a urinary DP metabolite    (3-MT) 
following nitisinone treatment in AKU patients (Davison et al., 2018b; Davison 
et al., 2018c) and are in agreement that this is likely to reflect a change in 
peripheral metabolism of catecholamines. 
 
In contrast Harding et al. (2014) used a much higher dose of nitisinone         
(4 mg/mL) than our group (4 mg/L) and as expected this led to 
hypertyrosinaemia; a 6-fold increase in mean serum tyrosine (256 μmol/L), 
and a slight but, significant increase in brain tyrosine was observed. This was 
however far less than what we observed (9-fold increase in mean plasma 
tyrosine [mean tyrosine 997 µmol/L] and 10-fold increase in tyrosine in the 
brain tissue) on a thousand times lower dose of nitisinone. This can be 
explained in large by the metabolic defect in the tyrosine metabolic pathway 
being proximal to the site of nitisinone action in PKU and distal in AKU 
(Figure 7.1). In PKU, phenylalanine cannot be converted to tyrosine and thus 
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far less accumulates as a consequence of nitisinone inhibiting HPPD, in large 
the observed increase will reflect the accumulation of dietary tyrosine.  
 
Harding et al. (2014) also observed that phenylalanine decreased by 44 % 
and DP increased by 36 % in brain tissue following nitisinone treatment. 
Herein no significant changes in DP in brain from the AKU mouse were 
observed following nitisinone. It has been proposed that the lower 
phenylalanine concentration in brain tissue reduced phenylalanine mediated 
inhibition of tyrosine hydroxylase, thus enabling DP biosynthesis (Harding et 
al., 2014). These differences are likely to be accounted for by the fact that 
Harding et al. (2014) performed analysis in brain tissue from a mouse model 
of PKU and not AKU, which have different metabolic defects.  
 
Importantly in the AKU mouse model there was no significant difference in 
brain serotonin in HGD-/- mice following treatment with nitisinone, or between 
HGD-/- and HGD+/- that received no treatment. Serotonin concentrations did 
not change in PKU animal model following treatment with nitisinone either, 
but did remain depressed in the PKU mice whether they were treated or not, 
compared to wild type mice (Harding et al., 2014). It is thought that this was 
caused by phenylalanine inhibiting the enzyme tryptophan hydroxylase, 
which regulates the rate limiting step of serotonin metabolism, and cannot be 
recovered by nitisinone treatment (Harding et al., 2014). Recently Winn et al. 
(2018) provided further support for this hypothesis in a study that showed 
that while blood phenylalanine reduction corrects DP and serotonin 
deficiencies in the CNS; it did not recover the activity of tryptophan 
hydroxylase. 
 
Herein we also showed that glutamate does not change following treatment 
with nitisinone. The reason for measuring this neurotransmitter was that the 
glutaminergic neurotransmitter system is known to have a close relationship 
with dopaminergic and serotoninergic systems (Andreou et al., 2015). 
Dysregulation of either of the latter may have resulted in a compensatory 




Treatment with nitisinone did not affect the ion distribution or intensity of the 
neurotransmitters DP, NA and serotonin in the AKU mouse brain, suggesting 
that their concentrations do not change. Neurotransmitter precursor’s 
tyrosine and tyramine were significantly increased following treatment with 
nitisinone. The significance and fate of these metabolites is unknown and 
requires further investigation. These findings have critical importance for the 
use of nitisinone in patients with AKU as they clearly demonstrate that 
nitisinone does not have a direct effect on monoamine neurotransmitter 
metabolism in the CNS of mice with AKU. If these findings translate to 
patients with AKU treated with nitisinone, one can postulate that the 
hypertyrosinaemia occurring following treatment with nitisinone does not 
affect monoamine neurotransmitter metabolism and thus is unlikely to result 
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Background: Nitisinone induced hypertyrosinaemia is well documented in 
Alkaptonuria (AKU), and there is uncertainty over whether it may contribute 
to a decline in cognitive function and or mood by altering neurotransmitter 
metabolism. The aim of this work was to evaluate the impact of nitisinone on 
the cerebrospinal fluid (CSF) metabolome in a murine model of AKU, with a 
view to providing additional insight into metabolic changes that have been 
previously reported in murine brain tissue using mass spectrometry imaging. 
Materials and methods: Experiment 1: 17 CSF samples were collected from 
BALB/c HGD-/- mice (n=8, treated with nitisinone – 4 mg/L and n=9, no 
treatment). Samples were diluted 1:1 with deionised water and 1 µL was 
analysed in both polarities using liquid chromatography quadrupole time of 
flight mass spectrometry (LC-QTOF-MS). Raw data were processed using an 
established accurate mass retention time (AMRT) database. A moderated t-
test with Benjamini-Hochberg false-discovery rate adjustment was used to 
assess changes in metabolite abundance between experimental groups.  
Experiment 2: 15 additional CSF samples were collected from BALB/c HGD-/- 
mice (n=8, treated with nitisinone – 4 mg/L, n=7, no treatment). Samples 
from each treatment group were pooled and 7.5 µL analysed directly using 
LC-QTOF-MS to assess if a greater number of monoamine metabolites not 
matched in experiment 1 could be detected. Additionally 9 monoamine 
metabolite standards were analysed in water and artificial CSF (0.1-4.0 
µmol/L) to assess the limit of detection for these compounds using LC-
QTOF-MS.  
Results: Experiment 1: 5 metabolites had a greater abundance (log2 fold 
change (FC) 3.1-13.1, 3/5 were significant p<0.05) in the mice that received 
treatment with nitisinone; 4/5 metabolites related directly to tyrosine 
metabolism and 1/5 related to tyramine metabolism.  
Experiment 2: No additional metabolites were matched using the AMRT 
database when a larger injection volume of undiluted CSF was analysed. The 
analysis of monoamine analytical standards showed 5/9 and 1/9 compounds 
were detected at 0.1 µmol/L and, 4/9 and 7/9 compounds were detected at 
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0.5 µmol/L in deionsed water and artificial CSF, respectively. One compound 
was not detected at all in artificial CSF. 
Conclusions: Evaluation of the CSF metabolome of a murine model of AKU 
showed a significant difference in the abundance of a limited number of 
metabolites. None of these have been reported in CSF from an AKU mouse 
model previously. Moreover this study confirms that some monoamine 
metabolites do not appear to be altered following nitisinone therapy, however 






























The widespread metabolic complication of nitisinone therapy in Alkaptonuria 
(AKU) (Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne et al., 
2011; Ranganath et al., 2016; Milan et al., 2017; Davison et al., 2018a; 
Sloboda et al., 2019) and hereditary tyrosinaemia type 1 (HT1) (Lindstedt et 
al., 1992; van Ginkel et al., 2016; Zeybek et al., 2017) is hypertyrosinaemia. 
 
Much of the literature available on hypertyrosinaemia relates to the clinical 
consequences that have been observed, for example corneal keratopathy 
and skin rash (Introne et al., 2011; Stewart et al., 2014; Ranganath et al., 
2016; Khedr et al., 2018; White et al., 2018). These particular side effects 
typically resolve when nitisinone is stopped or dosage is modified. A more 
contentious side effect of hypertyrosinaemia has been linked to alterations in 
neurotransmitter metabolism, specifically in HT1 where it is estimated that 
~35 % children have altered cognitive function following nitisinone therapy 
(McKiernan et al., 2015). The very limited evidence in the literature centres 
around the direct impact hypertyrosinaemia may have on catecholamine 
metabolism, specifically dopamine (DP), and the indirect impact it may have 
on serotonin metabolism (Chapter 1, Figure 1.5), respectively. The reason for 
this interest is that both DP and serotonin play a pivotal role in cognitive 
function and mood. 
 
Several mechanisms relating to hypertyrosinaemia have been proposed for 
altered neurotransmitter metabolism and include: increased transport of 
tyrosine into the brain and a consequent decrease in the transport of other 
large neutral aromatic amino acids via the large neutral amino acid 
transporter 1 (LAT-1) into the brain (i.e. tryptophan); increased DP and 
decreased serotonin in the central nervous system (CNS). It has also been 
suggested that altered serotonin metabolism may also be due to the direct 
inhibition of tryptophan hydroxylase (TPH; EC 1.14.16.4) activity (rate limiting 
step in serotonin biosynthesis) by tyrosine (Chapter 1, Figure 1.5) (Thimm et 
al., 2011; Hillgartner et al., 2016; Barone et al., 2019). 
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While these theories are credible the literature is somewhat limited. Thimm et 
al. (2011) reported low concentrations of the serotonin metabolite  
5-hydroxyindole acetic acid (5-HIAA) in cerebrospinal fluid (CSF); however 
there were only 3 patients in the study. Additionally Hillgartner et al., (2016) 
showed in a murine model that urinary homovanillic acid (HVA, DP 
metabolite) increased 4-fold following nitisinone, but concluded that this was 
likely to be a reflection of peripheral breakdown of catecholamines and did 
not reflect changes in the CNS. No direct measurements of DP or serotonin 
were made in brain tissue or CSF, and they concluded that the altered 
cognition observed was caused by HT1 and not treatment with nitisinone.  
 
More recently Barone et al. (2019) demonstrated that human tyrosine 
hydroxylase isoform 1 and human tryptophan hydroxylase 2, expressed in 
Escherichia coli (BL21), exhibited prominent substrate inhibition kinetics and 
that enzyme activity decreased at elevated tyrosine levels. This supports the 
earlier supposition, but in this study no downstream metabolites were 
measured (i.e. DP or serotonin). 
 
There is no direct evidence of altered cognition or central neurotransmitter 
metabolism in AKU patients with hypertyrosinaemia. In order to assess 
central neurotransmitter metabolism either CSF or a brain biopsy are 
required as they directly reflect neurotransmitter metabolism in the CNS. This 
is an accepted practice in the assessment of neurotransmitter disorders 
(Pearl et al., 2007), however to obtain these samples would be impractical in 
patients with AKU owing to their complex musculoskeletal comorbidities and 
unethical in the absence of clinical evidence of altered cognition or mood. 
Previous studies in patients with AKU have made assessments of 
neurotransmitter metabolism in urine and reported increased urinary 
excretion of the DP metabolite, 3-methoxytyramine (3-MT) in patients 
receiving nitisinone on a short (4 weeks, 1-8 mg) and long term (2 mg daily, 2 
years) basis (Davison et al., 2018b (Chapter 5); Davison et al., 2018c 
(Chapter 5); Norman et al., 2019a (Chapter 2)). Urinary normetadrenaline 
(NMA) was also shown to be significantly decreased in the short term study 
at all doses (1-8 mg) (Davison et al., 2018b (Chapter 5)). Both studies 
289 
concluded that the marked increase in 3-MT and decrease in NMA are likely 
to reflect altered peripheral catecholamine metabolism. This is supported by 
the finding in the long term study (Davison et al., 2018c (Chapter 6)) that no 
concurrent change in Beck’s depression inventory-II scores were observed.  
 
A recent study in a murine model of AKU using mass spectrometry imaging 
has reassuringly demonstrated that monoamine metabolite patterns in brain 
tissue did not change following treatment with nitisinone, with the exception 
of the trace amine tyramine which increased 25-fold (Davison et al., 2019a 
(Chapter 7)). This was the first direct evidence that showed DP and serotonin 
do not change following treatment with nitisinone. 
 
Herein for the first time we report the direct analysis of CSF from a murine 
model of AKU using liquid chromatography quadrupole time of flight mass 
spectrometry (LC-QTOF-MS) analysis and an established in-house accurate 
mass retention time (AMRT) database (Norman et al., 2019a; Norman et al., 
2019b (Chapter 2); Davison et al., 2019b (Chapter 3)). The rationale for 
analysing CSF is that it bathes the tissues of the CNS and may give 
additional insight into changes in neurotransmitters and their respective 
metabolites and confirm previous findings (Davison et al., 2019a, Chapter 7). 
Moreover it will allow for changes in the wider CSF metabolome to be 
assessed following treatment with nitisinone (for a detailed review on the 
translational utility of CSF in studying neuroscience see de Lange, 2013).  
 
 
8.3 Materials and methods 
 
8.3.1 Reagents 
Water for mobile phases was purified in-house (DIRECT-Q 3UV Millipore 
water purification system). Methanol, acetonitrile and isopropanol were 
purchased from Sigma Aldrich (Dorset, UK). Formic acid and ammonium 
formate were obtained from Biosolve, (Netherlands). All reagents were LC-
MS grade. 2 mL amber screw vial and 150 µL glass inserts with polymer feet 
(maximum recovery vials) were purchased from Agilent (Cheadle, UK) and 
290 
artificial CSF from Harvard apparatus (Holliston, MA). All analytical standards 
were obtained from Sigma (UK) as 1 mg/mL Cerilliant standards. These 
included catecholamine mixture (contained vanillylmandelic acid (VMA), 
homovanillic acid  (HVA), 5-HIAA, catecholamines mix I (contained 
adrenaline and noradrenaline (NA), catecholamines mix II (contained NMA 
and metadrenaline), DP and 3-MT). 
 
8.3.2 Animal experiments and CSF sample collection 
A murine model of AKU was used for all experiments as described previously 
(Preston et al., 2014). Thirty-two BALB/c HGD -/- mice (see Figure 8.1 for age 
and gender) were included in this study, 16 mice were administered 
nitisinone (4 mg/L) through their drinking water for 1 week, the remaining 16 
mice received no nitisinone. All animals were housed in air conditioned 
rooms (with a 12 h dark/light cycle) at 20 °C and 53 % humidity, with access 
to food and water ad libitum at The University of Liverpool. All animal 
experiments complied with the ARRIVE guidelines and were carried out in 
accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and 
associated guidelines, EU Directive 2010/63/EU for animal experiments.  
 
All mice were culled by carbon dioxide asphyxiation and CSF was removed 
from the cisterna magna following the puncture technique of Liu et al. (2008), 
with some modifications. The cisterna magna was exposed by dissecting skin 
and overlaying muscles. Cauterisation was used to dry up any bleeding from 
surrounding tissues. A pulled glass pipette with an internal diameter of ~0.4 
mm was attached to silicone tubing and connected to a 1 mL syringe with a 
19 g needle. The tip of the glass pipette was used to puncture the membrane 
and held still just below the membrane by 1 person. Through a double-
headed microscope a second person then used the 1 mL syringe to apply 
gentle pressure to encourage the CSF to flow up the capillary tube. Only 
clear CSF samples (i.e. non blood stained) were collected. Once collected 
CSF samples were transferred to clear Eppendorf tubes and stored at -80 °C 
until analysis. Samples were not acidified. The same glass pipette was used 






Figure 8.1. Summary of experimental workflow involving murine model 
of AKU. This includes mouse gender (♂- male; ♀- female) and mean age 
(±standard deviation); treatment groupings, and sample collection and 
storage. Experiment 1 – individual CSF sample analysis by LC-QTOF-MS. 
Experiment 2 – (A) Pooled treatment group CSF sample analysis by LC-
QTOF-MS and (B) Analysis of monoamine analytical standards to assess the 
lowest concentration which can be detected by LC-QTOF-MS.  
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8.3.4 Murine and quality control sample preparation (Experiment 1) 
Murine CSF samples were prepared by diluting 2 µL CSF with 2 µL deionized 
water (DIRECT-Q 3UV Millipore water purification system). CSF samples 
were pipetted directly into a 150 µL glass insert with polymer feet, which sat 
in a 2 mL amber screw vial (Agilent, Cheadle, UK). These vials were used to 
ensure maximal recovery of sample. Deionised water was also added directly 
to the glass insert, and mixed with the CSF sample using a pipette. The glass 
vials were centrifuged at 600 rpm for 10 min to ensure the diluted sample 
was at the bottom of the vial for sampling. 1 µL of diluted CSF was analysed 
in negative and positive polarities, respectively. 
 
As CSF sample volume was very limited (~3 µL per mouse) biological group 
QCs were not prepared. The performance of the analytical run was assessed 
using system quality control samples that were prepared in artificial CSF 
(Harvard Apparatus, Holliston, MA). These contained phenylalanine (100 
µmol/L), tyrosine (100 µmol/L), nitisinone (10 µmol/L) and succinylacetone 
(30 µmol/L). Phenylalanine, tyrosine and nitisinone were assessed in positive 
polarity and succinylacetone in negative polarity. Each analytical run (i.e. 
negative and positive polarities) commenced with 20 replicate injections of 
the system quality control sample to condition the system.  
 
The order of individual samples was randomised computationally. System 
QC samples were interspersed throughout the analytical sequence every 6th 
injection, to assess the analytical system performance. Binary pump 
pressures and reference ions were also monitored to assess the 
performance of the LC-QTOF-MS (Figure 8.2). 
 
8.3.5 Murine CSF and monoamine neurotransmitter analytical standard 
sample preparation (Experiment 2) 
8.3.5.1 (A) Murine CSF samples 
CSF samples from mice that received nitisinone (n=8) were pooled to make 1 
biological pool and CSF from mice that did not receive nitisinone (n=7) were 
pooled to make a separate biological pool. The rationale for doing this was to 
generate a large enough CSF sample volume so that CSF could be injected 
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into the LC-QTOF-MS in a larger volume and without the need for sample 
dilution, thus improving analytical sensitivity.  
 
Pooled murine CSF samples were not diluted. Each pool consisted of 20 µL 
and was pipetted directly into a 150 µL glass insert with polymer feet, which 
sat in a 2 mL amber screw vial (Agilent, Cheadle, UK). 7.5 µL of CSF from 
each biological pool was analysed in negative and positive polarity, 
respectively. 
 
8.3.5.2 (B) Monoamine neurotransmitter analytical standards 
Analytical standards deemed relevant to catecholamine and serotonin 
neurotransmitter metabolism were analysed to assess the analytical limit of 
detection by LC-QTOF-MS (Table 8.1). There is no available literature on the 
concentration of neurotransmitter metabolites in mice and so concentrations 
chosen are based on what is reported in humans (i.e. adult human  CSF 5-
HIAA reference range 67-140 nmol/L and HVA reference range 145-324 
nmol/L) (Hyland, 2008). 
 
10 µL of each 1 mg/mL Cerilliant standard (total spike volume of 50 µL) was 
added to 12.45 mL of deionised water (1 in 1250 dilution) to give standard 1 
(S1) (Table 8.1). Serial dilutions were then performed to give 3 additional 
standards S2-S4; concentrations are detailed in Table 8.1. 2 µL of standards 
S1-S4 were analysed in negative and positive polarity, respectively. This 
series of dilutions was also performed in artificial CSF to assess the impact of 














S1 S2 S3 S4 
Adrenaline 183.2 5458 4366 2018 504 101 
Noradrenaline 169.2 5910 4728 2092 523 105 
Dopamine 153.2 6528 5222 2195 548 110 
Normetadrenaline 183.1 5462 4369 2392 598 120 
Metadrenaline 197.1 5073 4058 2183 545 109 
3-MT 167.2 5980 4784 2364 591 118 
VMA 198.2 5046 4036 2611 652 131 
HVA 182.2 5489 4391 2029 507 101 
5-HIAA 191.2 5230 4184 2184 546 109 
 
Table 8.1. Summary of monoamine neurotransmitter compounds 
analysed by LC-QTOF-MS in deionised water and artificial CSF, and the 
theoretical concentrations. The concentration of all standards is in nmol/L, 
except Cerilliant standard which is in µmol/L. 5-HIAA – 5-hydroxyindole acetic 




8.3.6 Analytical method 
8.3.6.1 LC-QTOF-MS conditions 
LC-QTOF-MS conditions used for the analysis of analytical standards and 
murine CSF samples were the same as those used for the analysis of urine 
(Norman et al., 2019a (Chapter 2)) and serum samples (Davison et al., 
2019b (Chapter 3). 
 
8.3.6.2 Metabolite identification  
Metabolite identification was carried out using an established AMRT 
database to match chemical entities (Davison et al., 2019b (Chapter 3)). The 
database included theoretical accurate mass, measured retention time, and 
empirical formula. It is important to note AMRT data for -glutamyl-tyrosine 
and I-3-L were based on the elution time associated with the theoretical 
monoisotopic mass of each compound and were not verified using an 
analytical standard. Data quality control and statistical analysis were 
performed using the MassHunter software suite (Agilent, Cheadle, UK).  
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8.3.6.3 Data acquisition and handling parameters 
For additional details on data acquisition and handling parameters see 
Chapter 3 (Section 3.7 Supplementary material). 
 
Data acquired from the analysis of analytical standards were reviewed in 
Profinder (Build 08.00) as per CSF samples, as the standards analysed were 
present in the AMRT database. Raw abundance areas for the standards 
were exported from Profinder as a .csv file and data manipulated in Excel 
(Microsoft Excel, 2010) to assess linearity. The signal to noise ratios were 
determined using MassHunter Qualitative software (Build 07.00). 
 
8.3.6.4 Data quality control and statistical analysis 
Quality control filters were applied to entities obtained from targeted feature 
extraction in each profiling experiment. Entities were retained if present in at 
least 2 samples per experimental group. Data files were then exported from 
Profinder as ‘.CEF’ files as a whole batch for each profiling experiment and 
imported to Mass Profiler Professional (MPP) software (Build 14.5, Agilent, 
Cheadle, UK). 
 
In MPP sample data files were scaled to the median of all samples and 
chemical entities were filtered based on frequency. Further filtering was then 
based on variability, and entities were retained if peak area coefficient of 
variation (CV) remained <25 % across either experimental group. Previously 
filtering was based on the frequency and variability of entities in biological 
group QCs across an analytical run (Chapters 2 and 3). Due to the very 
limited sample volume in this study a different approach was used as it was 
not possible to make biological group QCs.  
 
Statistical analyses performed in MPP were based on compound signal 
intensity, expressed as total peak area. Profiles from the experimental group 
that received nitisinone were compared to the profiles that did not receive 
nitisinone using a moderated t-test with Benjamini-Hochberg false-discovery 
rate adjustment. Log2 fold change (FC) was calculated between each 
experimental group, and this was based on raw peak area data. Changes 
296 
were deemed significant if asymptotic p value was <0.05 and a log2 FC >2.0. 
Principal component analysis (PCA) employing a 4 component model was 
performed on each filtered dataset using MPP. 
 
 
8.4 Results  
 
8.4.1 Experiment 1 – Quality control and murine CSF data 
In the absence of biological group QCs only system QC samples were run 
every 6th sample. Table 8.2 demonstrates that the analytical run was 
acceptable as raw peak abundance for all metabolites were <12 % CV, and 
mean retention time (RT) and ppm error were <0.1 min and <1 ppm, 
respectively. In addition, reference ion mass calibration and binary pump 











target RT (min) 
Tyrosine (100 µmol/L) 8.8 0.69 0.07 
Phenylalanine (100 µmol/L) 2.4 0.20 0.06 
Nitisinone (10 µmol/L) 11.9 0.26 0.004 
Succinylacetone (30 µmol/L) 4.6 0.42 0.02 
 
Table 8.2. Summary of results from the analysis of quality control 
samples (n=5) throughout analytical runs. RT – retention time; CV – 





Figure 8.2. Representative data from quality checks performed on data 
acquired from LC-QTOF-MS analysis of CSF samples in positive and 
negative polarities. Each analytical sequence consisted of 30 samples.  
(A) Overlaid binary pump pressure curves, (B) and (C) Overlaid reference ion 
signal in positive polarity; (D) Overlaid TIC for quality control samples 
analysed across the analytical sequence – 1: tyrosine, 2 – phenylalanine, 3 – 
succinylacetone, 4 – nitisinone (peaks 1, 2 and 4 positive polarity and peak 3 
negative polarity); (E) and (F) Overlaid reference ion signal in negative 
polarity. Extracted ion chromatograms of reference masses were performed 
to check mass accuracy remained <5 ppm throughout the run. Reference ion 
signal is present during the analytical runs in both polarities, but shows the 
greatest suppression of signal at 1-1.5 min. This is near the column void 




174 and 106 metabolites were aligned across all CSF samples in positive 
and negative polarities (for matched compounds see Table S8.1) 
respectively, using an AMRT database. After filtering entities based on their 
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frequency and variability across the experimental groups 83 and 50 entities 
were retained from positive and negative polarity profiling experiments, 
respectively. Of these, 10 and 16 were shown to have a log2 FC>2.0 in 
positive and negative polarity, respectively of which 3 entities were 





Figure 8.3. Number of accurate mass retention time (AMRT) matches 
obtained from processing raw LC-QTOF-MS data. AMRT matches 
generated using the batch targeted feature extraction algorithm (Profinder 
Build 08.00, Agilent, Cheadle, UK), and subsequent entities retained 
following quality control filtering and statistical analysis (MPP, Build 14.5) in 






Figure 8.4. Principal component analysis to assess the effect of nitisinone therapy on metabolite profiles in CSF samples 
collected from AKU mice. Blue circle – no treatment and red circle – nitisinone therapy (4 mg/L, 7 days). PCA plots (A) in positive 
and (C) negative polarity. Loadings plots (B) and (D) show the respective contributions of individual metabolites to components 1 
and 2 in positive and negative polarity, respectively. 
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Clear separation between the AMRT matched profiles of CSF from untreated 
and nitisinone treated AKU mice (Figure 8.4) was observed in components 1 
and 2 in positive polarity. Negative polarity also showed some separation in 
components 1 and 2, but was less clear in comparison. 
 
Table 8.3 and Figure 8.5 show compounds in CSF that were significantly 
different (p<0.05 with a log2 FC >2.0) between the BALB/c HGD
-/- mice that 
did and did not receive nitisinone therapy. All 3 entities were related to 










affected Up Down 
p-Hydroxyphenylacetic acid  13.1 √  1.69E-18 Tyramine 
3-(4-Hydroxyphenyl)lactic acid 4.6 √  1.58E-11 Tyrosine 
L-Tyrosine* 3.1 √  5.90E-10 Tyrosine 
 
Table 8.3. CSF metabolite changes identified post-nitisinone therapy in 
BALB/c HGD-/- mice using an in-house AMRT database. Abundance 
expressed as log2 FC, compared to BALB/c HGD
-/- mice that did not receive 
nitisinone. Log2 FC included if abundance >2.0 and p <0.05. * – increase in 
abundance observed in positive and negative polarities. Data included 
represents the lowest Log2 FC, which was observed in negative polarity. 
 
 
The abundance of -L-glutamyl-L-tyrosine and N-acetyl-L-tyrosine was 
greater in the mice that received nitisinone, the log2 FC was 6.9 and 5.0, 
respectively (Figure 8.5). However no p value was calculated for these 2 
metabolites as the CV for raw signal abundance was >25 % in both 
experimental groups. For -L-glutamyl-L-tyrosine raw signal abundance had 
CVs of 26 and 130 % in the mice that were and were not treated with 
nitisinone, respectively. For N-acetyl-L-tyrosine raw signal abundance had 





Figure 8.5. Bar graphs showing the mean raw abundances from LC-
QTOF-MS analysis for metabolites that were matched to the AMRT 
database and had a log2 FC >2.0. Error bars represent +1 standard 
deviation of the mean raw metabolite abundance (A) Tyrosine; (B) N-Acetyl-
L-tyrosine; (C) -Glutamyl-tyrosine; (D) p-Hydroxyphenylacetic acid;                 
(E) 3-(4-Hydroxyphenyl)lactic acid. * – indicates significance, p<0.05. 
 
 
In addition to those compounds detailed in Table 8.3 and Figure 8.5, several 
other metabolites (Figure 8.3) were matched in positive and negative 
polarities, respectively with a raw abundance CV <25 % in at least 1 
experimental group. These metabolites had a log2 FC <2.0 and no significant 
differences were observed between the experimental groups. Of particular 
interest in this study were compounds related to neurotransmitter metabolism 
302 
(see Figure 8.6). Reassuringly the large neutral aromatic amino acids 
(LNAAs) tryptophan and phenylalanine, and the catecholamine metabolites 
octopamine (trace amine metabolite from tyramine), adrenaline, and 3-
methoxy-4-hydroxyphenylglycol (major metabolite of NA) were not 
significantly different in the 2 experimental groups. 
 
Other metabolites of interest related to catecholamine metabolism included 
5-HIAA, dihydroxyphenylacetic acid (DOPAC) and kynurenine. These 
however had raw signal abundance CVs of 53 and 64 %, 100 and 61 %, and 
51 and 86 % in the mice that were and were not treated with nitisinone, 
respectively. These metabolites were therefore excluded from further 
statistical analysis. Interestingly homogentisic acid (HGA) was not observed 






Figure 8.6. Bar graphs showing mean raw abundances from LC-QTOF-MS analysis for AMRT matched metabolites that are 
important in neurotransmitter metabolism. Error bars represent +1 standard deviation of the mean raw metabolite abundance. 
The abundance of these metabolites between the 2 experimental groups had a log2 FC <2.0 and there were no significant 
differences. (A) Tryptophan, (B) 5-HIAA, (C) Kynurenine, (D) Octopamine, (E) Adrenaline, (F) 3-Methoxy-4-hydroxyphenylglycol, (G) 
Phenylalanine, (H) DOPAC. It is important to note that 5-HIAA, DOPAC and kynurenine showed large variability within each 
experimental group (i.e. CV >25 %) and were excluded from further statistical analysis.
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In this study it was disappointing that the catecholamine metabolites HVA, 
DP, VMA and tyramine were not matched using the targeted feature 
extraction in Profinder or through manual extraction of chromatograms in 
MassHunter Qualitative software (Build 07.00) using the m/z of each 
metabolite in positive and negative polarity, respectively.  
 
8.4.2 Experiment 2 - Analytical standards and murine CSF data  
System performance parameters were acceptable as per experiment 1, 
reference ion signal in negative and positive polarities remained <5 ppm 
throughout the run and were present during the entire analytical runs in both 
polarities. Chromatographic binary pump pressures were very reproducible 
throughout the analytical run. 
 
8.4.2.1 (A) Murine CSF data  
176 and 107 compounds were matched in pool 1 and 2 using the AMRT 
database targeted feature extraction algorithm in positive and negative 
polarities, respectively. As only 2 samples were analysed, further filtering of 
data and statistical analysis as in experiment 1 (Figure 8.3) was not possible. 
The same entities that were observed to have an altered abundance in 
experiment 1 (Table 8.3) also had an altered abundance in experiment 2, 
confirming the findings in experiment 1. However the goal of experiment 2 
was to match low abundance compounds of interest that were not matched in 
experiment 1 due to poor sensitivity; it was hoped that MS signal for these 
compounds would be obtained by not diluting CSF samples and injecting a 
larger sample volume onto the analytical column. Unfortunately HVA, DP, 
VMA and tyramine were still not matched in this experiment using the 
targeted feature extraction in Profinder or through manual extraction of 
chromatograms in MassHunter Qualitative software. Interestingly, HGA was 






Figure 8.7. Extracted ion chromatogram of HGA in pooled CSF (negative 
polarity). Blue – mice that received no treatment and red – mice that 
received nitisinone treatment (ppm error from theoretical mass <10; RT error 
< 0.15 min from target).  
 
 
8.4.2.2 (B) Monoamine metabolite standards 
Table 8.4 summarises the linear range and signal to noise ratio for the lowest 
concentration of metabolite detected. All compounds detected showed a 
good linear response except for NA in deionsed water and DP in artificial 
CSF.  
 
5/9 and 1/9 compounds were detected at 0.1 µmol/L and, 4/9 and 7/9 
compounds were detected at 0.5 µmol/L in deionsed water and artificial CSF, 












Deionised water Artificial CSF 
Linear  
Range 




Adrenaline 0.5-4.0 0.94 60 0.5-4.0 0.96 30 
Noradrenaline 0.5-4.0 0.78 13 ND ND ND 
Dopamine 0.1-4.0 0.98 21 0.5-4.0 0.74 77 
Normetadrenaline 0.1-4.0 0.97 23 0.5-4.0 0.95 32 
Metadrenaline 0.1-4.0 0.95 21 0.5-4.0 0.94 45 
3-MT 0.1-4.0 0.98 50 0.1-4.0 0.96 15 
VMA 0.5-4.0 0.99 26 0.5-4.0 0.99 23 
HVA 0.5-4.0 0.99 6 0.5-4.0 0.99 6.7 
5-HIAA 0.1-4.0 0.96 19 0.5-4.0 0.96 37 
 
Table 8.4. Summary of the linear range for monoamine metabolites 
measurement by LC-QTOF-MS. All concentrations in µmol/L. ND – not 
detected; S:N* - signal to noise ratio at lowest standard concentration 
detected (calculated using Qualitative Analysis software (Build 07.00). 5-
HIAA – 5-hydroxyindole acetic acid; HVA- homovanillic acid; VMA – 





Hypertyrosinaemia is a universal biochemical consequence of nitisinone 
treatment in AKU (Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne 
et al., 2011; Ranganath et al., 2016; Milan et al., 2017; Davison et al., 2018a; 
Sloboda et al., 2019) and HT1 (Lindstedt et al., 1992; van Ginkel et al., 2016; 
Zeybek et al., 2017). 
 
As indicated earlier the rationale for analysing CSF from a murine model of 
AKU is that it gives a unique insight into the CNS that cannot be gained from 




The study presented herein is the first of its kind to report on the assessment 
of the CSF metabolome in a murine model of AKU. The reason for the 
paucity in the literature is likely to reflect the rarity of AKU, but also the small 
volume of CSF that can be collected from a mouse (~3 µL). The latter 
presents a significant analytical challenge in terms of sample handling (e.g. 
auto samplers attached to chromatography systems) and also that the 
metabolites of interest are present at picomolar to nanomolar concentrations. 
Moreover the technical expertise required to collect non-blood stained CSF 
from a mouse means the procedure is not frequently performed without some 
sample contamination  
 
Only 3 metabolites were shown to have significant differences in abundance 
(log2 FC >2.0, p<0.05) when the metabolite profiles from the 2 treatment 
groups were compared. All 3 of the metabolites (Figure 8.8 and Table 8.3) 
were shown to have a greater abundance in the mice that received 
nitisinone, all of which have been reported to be elevated following treatment 
with nitisinone in serum (Davison et al., 2019b, Chapter 3) and urine 
(Norman et al., 2019a, Chapter 2) in patients with AKU, and in the urine of a 
murine model of AKU (Norman et al., 2019a, Chapter 2).  
 
The increased tyrosine in CSF can be explained by the increased circulating 
concentrations observed following treatment with nitisinone as a 
consequence of its action on the HPPD enzyme. This finding is consistent 
with a previous study that showed nitisinone treatment resulted in significant 
increases in tyrosine in brain tissue from a murine model of AKU (Davison et 
al., 2019a, Chapter 7). 
 
The increased abundance of HPLA in the CSF is a curious finding as there 
are no known mechanisms for its transport into the CNS, unlike tyrosine 
which goes via the LAT-1 transporter. If HPLA transport occurred via the 
LAT-1 transporter one could speculate that due to its structural similarity to 
HGA, the latter would be present in a greater abundance in the CSF, which 
was not the case in this study as a very low abundance was observed. 
Additionally if HPLA in CSF was from contamination from the circulation then 
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HGA would also be present at a higher abundance. The fact that the liver and 
kidney are the only organs that contain all of the required enzymes for the 
entire tyrosine metabolic pathway makes the local production of HPLA 
directly from tyrosine in the CNS unlikely. It is however possible it is 
produced via an alternative pathway in the brain that is not defined, and 
requires further investigation. Bernardini et al. (2015) has however shown 
that the HGD gene is expressed in murine and human brain tissue, and 
reported that in the presence of excess HGA cultured neuronal cells produce 
ochronotic pigment and amyloid. The authors postulated that this may 
contribute to induction of neurological complications. The implications of the 
presence of HPLA in the CNS are unknown and also require further 
investigation. Elevated HPLA has been previously reported in CSF from 
children with phenylketonuria (PKU) (Antoshechkin et al., 1991) and brain 
tissue  from a rat model of PKU (Sarkissian et al., 2000). 
 
Increased N-acetyl-L-tyrosine and -glutamyl-tyrosine in CSF from mice 
treated with nitisinone was expected based on the observations previously 
reported in urine (Norman et al., 2019a (Chapter 2)) and serum (Gertsman et 
al., 2015a; Davison et al., 2019b (Chapter 3)) from AKU patients treated with 
nitisinone. The large variation in abundance in this study meant the changes 
observed were not deemed to be statistically significant, however the trend 
suggests that excess tyrosine is metabolised to N-acetyl-L-tyrosine and -
glutamyl-tyrosine following treatment with nitisinone. It is presumed that due 
to their structural similarity to tyrosine both N-acetyl-L-tyrosine and -
glutamyl-tyrosine are both transported into the CNS via the LAT-1 
transporter. Interestingly in CSF the log2 FC of these metabolites was very 
similar; in contrast in serum the increase in N-acetyl-L-tyrosine was much 
greater than that of -glutamyl-tyrosine (Davison et al., 2019b, Chapter 3).  
 
The increase in 4-hydroxyphenylacetic acid (HPA) is novel in CSF in the 
context of AKU as its origin has been reported to be that of gut microbiota 
(Liu et al., 2016), as previously postulated in serum (Davison et al., 2019b 
(Chapter 3)). Its presence in CSF cannot be explained by this and is likely to 
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reflect an increased turnover of tyramine in the brain through oxidative 
deamination via the action of monoamine oxidase (Figure 8.8). Previous 
studies have reported low HPA levels in plasma (Yu et al., 1983), urine 
(Sandler et al., 1979) and CSF (Kobayashi et al., 1982) of depressed patients 
suggesting a lower turnover of tyramine compared to control subjects.  
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Figure 8.8. Summary of metabolite differences that were observed between HGD-/- mice that received no treatment and 
HGD-/- mice that received treatment with nitisinone. Red – compounds that had a higher abundance in CSF from mice treated 
with nitisinone; blue – compounds that had a lower abundance in CSF from mice treated with nitisinone; orange – metabolites 
matched in CSF samples, but abundances were not significantly different between the 2 groups of mice; black – compounds not 
observed in samples. * - log2FC >2.0, p<0.05; ** - log2FC >2.0, p>0.05. HVA – homovanillic acid; DOPAC – dihydroxyphenylacetic 
acid; HPA – 4-hydroxyphenylacetic acid; L-DOPA – L-3,4-dihydroxyphenylalanine. 
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In a previous study Davison et al. (2019a, Chapter 7) reported a 25-fold 
increase in tyramine in brain tissue from the same murine model of AKU 
used in this study, herein tyramine was not detected in the CSF analysed in 
either group of mice. This is likely to reflect that it is present at very low 
concentrations and that CSF in a mouse is turned over rapidly (i.e. total CSF 
volume of 40 μL is turned over 12–13 times/day (Simon et al., 2016)).  
 
Dourish et al. (1982) reported p-tyramine to be present at 5.4 ng/g of mouse 
brain tissue and that it is metabolised rapidly by its conversion to HPA. In the 
previous study (Davison et al., 2019a, Chapter 7); monoamine metabolites 
were derivitised in brain tissue to enhance their detection. Interestingly 
octopamine, 1 potential product of tyramine metabolism was matched in all 
CSF samples herein and was not different between the experiment groups. 
One possible reason for this may be that tyramine in the CNS is preferentially 
metabolised to HPA as it is not biologically active, unlike tyramine and 
octopamine (Berry et al., 2007; Lindemann et al., 2008). To this end one may 
speculate that tyramine is present in the CSF following nitisinone, but is 
present below the limit of detection for LC-QTOF-MS. Previously tyramine 
has been regarded as a metabolic dead end, however evidence suggests it, 
along with other trace amines, can act as neuromodulators for monoamine 
neurotransmitters, altering the release of and uptake of serotonin, DP and NA 
(Berry et al., 2007; Lindemann et al., 2008). Several studies have therefore 
made associations between trace amines and depression, schizophrenia, 
PKU, Parkinson’s disease, Reye’s syndrome, Tourette’s syndrome, epilepsy, 
attention deficit hyperactivity disorder, and migraines (Boulton, 1980; Baker 
et al., 1993; D’Andrea et al., 2004; D’Andrea et al., 2010). 
 
Reassuringly in this study no changes in the abundance of the other large 
neutral aromatic amino acids (LNAA’s) tryptophan and phenylalanine were 
observed, suggesting that the excess tyrosine observed following nitisinone 
treatment does not compete for uptake into the CNS via the LAT-1 
transporter. This is in contrast to what has been proposed in PKU or HT1, 
where the excess of phenylalanine and tyrosine, respectively have been 
proposed to alter neurotransmitter metabolism (Thimm et al., 2011; Thimm et 
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al., 2012; Harding et al., 2014; Hillgartner et al., 2016; Pilotto et al., 2019). It 
is also unlikely that there is competition for other transporters proposed to be 
involved in the transport of LNAA’s across the blood brain barrier, such as 
SLCA19 and SLCA15 (O’Mara et al., 2006).  
 
Encouragingly MHPG (NA metabolite), adrenaline, 5-HIAA (serotonin 
metabolite), DOPAC (DP metabolite) and kynurenine (tryptophan metabolite) 
were also not significantly altered in nitisinone-treated mice. The latter 3 
metabolites did however show large variation in their respective treatment 
groups so it is important to not over interpret this trend. In contrast in a recent 
study by Pilotto et al. (2019) patients with PKU were shown to have lower 5-
HIAA concentrations in CSF compared to controls, suggesting the elevated 
phenylalanine may contribute to altered neurotransmitter metabolism. 
Moreover significant negative correlations were observed between CSF 5-
HIAA, HVA, and 5-hydroxytyrptophan and phenylalanine. In a small cohort of 
patients with HT1 lower 5-HIAA in CSF has also been reported (Thimm et al., 
2011). 
 
It is uncertain whether the high variation in abundance was a reflection of ion 
suppression due to the CSF matrix or indeed a limitation of the 
instrumentation utilised herein (i.e. not sensitive enough to measure at such 
low concentrations). Previous studies have utilised quantitative high pressure 
liquid chromatography with fluorescence or electrochemical detection 
(Ormazabal et al., 2005; Akiyama et al., 2017) for measurement of 
neurotransmitters. Furthermore monoamine metabolites have been 
derivitised using benzylamine to improve analytical sensitivity (Yoshitake et 
al., 2006). Targeted quantitative methods utilising liquid chromatography 
tandem mass spectrometry (LC-MS/MS) have also been reported which have 
superior analytical specificity and sensitivity (Kovac et al., 2014).  
 
It should be borne in mind that a major limiting factor in this unique study was 
the very limited sample volume available for analysis. This precluded sample 
clean up or concentration or indeed application of quantitative LC-MS/MS 
methodology with the use of an internal standard and matrix matched 
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calibrators. One approach adopted by previous authors (Ramautar et al., 
2012) has been to use sheathless capillary electrophoresis coupled to mass 
spectrometry which requires nanolitre injection volumes. 
 
Disappointingly DP, and its major metabolites 3-MT and HVA, and the major 
metabolite of adrenaline VMA were not detected in the samples analysed. 
The reasons for this are not known as these metabolites are likely to be 
present at similar concentrations to 5-HIAA as they are in humans and have 
a short half life (Hyland, 2008). The previous discussion around ion 
suppression from the CSF matrix and the analytical capability of the LC-
QTOF-MS are equally relevant for these metabolites. Additionally the 
analysis of a small volume of diluted sample may have impacted on their 
measurement. As samples were frozen at -80 °C immediately after collection 
it is unlikely that this is a reflection of metabolite degradation.  
 
An additional consideration with analysis of monoamine metabolites using 
the Agilent 6550 LC-QTOF-MS is the geometry of the hardware, specifically 
this model has 2 ion funnels which may predispose more ‘fragile’ metabolites 
to break up impacting on sensitivity and reproducibility. 
 
To investigate the impact of diluting CSF samples on the detection of 
metabolites additional experiments were performed (experiment 2), in which 
pooled CSF samples from respective treatment groups were analysed 
(Figure 8.1). This meant a larger sample volume was available for analysis 
and samples were not diluted. Disappointingly this strategy did not improve 
the detection of 3-MT, HVA, tyramine or VMA meaning that the impact of 
hypertyrosinaemia on DP metabolism in CSF could not be fully evaluated. It 
did however show HGA was present at low abundance in CSF and 
decreased following treatment with nitisinone (Figure 8.6). 
 
To assess whether the inability to detect some monoamine metabolites was 
related to the sensitivity of the LC-QTOF-MS method used, monoamine 
analytical standards were analysed in water and artificial CSF at appropriate 
concentrations. Tyramine was not analysed as it is known to be present at 
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low picomolar concentrations that a LC-QTOF-MS cannot measure without 
sample concentration or clean-up (experiment 2). Data showed that in a 
water matrix all monoamine metabolites studied were detected at 0.1 µmol/L 
(5/9 standards) or 0.5 µmol/L, this included HVA, 3-MT and VMA. In contrast, 
analysis in artificial CSF showed that 7/9 standards were detected at 0.5 
µmol/L, and one standard (NA) was not detected at all. Interestingly 3-MT 
was detected at 0.1 µmol/L in analytical standards in deionised water and 
artificial CSF, but not mouse CSF. The reason for this is not known and 
requires further investigation. Together these data provide support that the 
use of LC-QTOF-MS for the analysis of monoamine neurotransmitter in CSF 
without sample clean up or concentration can provide valuable but somewhat 
limited information. Further work is required to assess the impact of 
hypertyrosinaemia on both DP and serotonin related metabolites in CSF 
using a targeted quantitative method like LC-MS/MS. This will however not 
be without its own challenges due to the limited volume of CSF available 
from a mouse. An alternative animal model could also be considered, for 
example the rat where larger volumes of CSF can be obtained for analysis as 





This is the first study to report the impact of treatment with nitisinone on the 
CSF metabolome, and specifically on monoamine neurotransmitter 
metabolites using LC-QTOF-MS and an established AMRT database. This 
study shows that a small number of tyrosine related metabolites had a 
greater abundance in mice treated with nitisinone. Further work is required to 
understand the significance of these findings and the mechanisms by which 
the altered metabolite abundances occur. 
 
Moreover this study showed that LC-QTOF-MS was not able to fully evaluate 
all neurotransmitter metabolites of interest due to the limit of detection for 
these metabolites using this analytical approach.  
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(-)-Adrenaline x   
(S)-Dihydroorotate   x 
10-Hydroxycapric acid x   
12-Hydroxydodecanoic acid x   
1-Aminocyclopropane-1-carboxylic acid x   
1-methylhistidine x   
1-Naphthylamine x   
2-Amino-1-phenylethanol x   
2-Aminoisobutyric acid x   
2-Deoxy-D-ribose x   
2-Deoxyglucose x x 
2-Hydroxy-butanoic acid   x 
2-Methylglutaric acid x x 
3,4-Dihydroxybenzoic acid x   
3-Amino-4-hydroxybenzoic acid x   
3-Carboxypropyl trimethylammonium x   
3-Hydroxy-3-methyl-glutaric acid x x 
3-Hydroxyphenylacetic acid x   
3-Methoxy-4-hydroxyphenylglycol x   
3-Methyladenine x   
3-Methylglutaric acid x x 
3-Ureidopropionic acid x   
4-Acetamidobutanoate x   
4-Hydroxy-L-phenylglycine x   
3-(4-Hydroxyphenyl)lactic acid   x 
4-Pyridoxic acid x x 
5′-Deoxy-5′-(methylthio)adenosine x   
5-Hydroxyindole acetic acid x   
6-Deoxy-L-galactose x x 
Adenine x x 
Adenosine x x 
Adenosine-5'-monophosphate x x 
Adipic acid x x 
AHBA x   
Allantoin   x 
Allose x x 
Allothreonine x x 
α-L-Rhamnose   x 
α-N-Acetylglucosamine x x 
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Caffeine x   
Caldine x   
Carnitine x   
Carnosine x   
Chenodeoxycholic acid x   
Citramalic acid   x 
Citric acid   x 
Citrulline x x 
Cortexolone x   
Corticosterone x   
Creatine x   
Creatinine x   
Cytidine x x 
Cytosine x   
D-(-)-Lyxose x   
D-(+)-Cellobiose x   
D-(+)-Galacturonic acid   x 
D-(+)-Malic acid x x 
D-(+)-Mannose x x 
D-(+)-Xylose x   
D-Alanine x   
D-Aspartic acid x x 
Deoxycholic acid x   
Deoxycytidine x   
Deoxyguanosine x   
Deoxyuridine monophosphate  x   
D-Fructose-6-phosphate x x 
D-Galactose x x 
D-Glucosamine-6-phosphate x x 
D-Glucose 6-phosphate x   
D-Glucuronic acid   x 
Diacetyl x   
Diethanolamine x   
Dihydrouracil x   
Dihydroxyacetone phosphate   x 
Dihydroxyphenylacetic acid  x   
DL-3-Amino-isobutanoic acid x   
DL-α-Hydroxybutyric acid   x 
DL-Homoserine x x 
DL-pipecolic acid x   
D-Mannitol x x 
D-Mannose 6-phosphate x   
D-Ornithine x   
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D-Psicose x x 
D-Ribose x   
D-Saccharic acid x   
D-Sorbitol   x 
D-Tagatose   x 
D-Tryptophan x x 
Dulcitol x x 
Elaidic acid   x 
Erythritol x x 
Ethylmalonic acid x x 
Fumaric acid   x 
-Aminobutryic acid x   
-L-Glutamyl-L-tyrosine x   
Gluconic acid   x 
Glucuronolactone   x 
Glutamine x x 
Glyceraldehyde x   
Glycerol-2-phosphate x x 
Glyceryl phosphate x x 
Glyoxylic acid   x 
Guanine x   
Guanosine   x 
Hippuric acid x   
Histamine x   
Hypotaurine   x 
Hypoxanthine x x 
Indole-3-lactate x   
Inosine x x 
Inosine-5'-monophosphate  x   
Isocitrate x x 
Ketoleucine x   
Kynurenic acid   x 
L-(-)-Arabitol x x 
L-(-)Sorbose   x 
L-2-Aminoadipic acid x   
L-Alanine x   
L-Anserine x   
L-Arginine x   
L-Asparagine x x 
L-Aspartic Acid x x 
L-Cystine x   
L-Glutamate x   
L-Histidine x   
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Linoleic acid   x 
L-Isoleucine x x 
L-Leucine x x 
L-Lysine x x 
L-Methionine x x 
L-N-Acetyl-tyrosine x   
L-Norleucine x x 
L-Norvaline x   
L-Norvaline   x 
L-Ornithine x   
L-Phenylalanine x x 
L-Pipecolic acid x   
L-Proline x   
L-Serine x x 
L-Threonine x x 
L-Tryptophan x x 
L-Tyrosine x x 
L-Valine x x 
Maleamic acid x   
Malic acid x x 
Malonic acid   x 
Methyl N-(α-methylbutyryl)glycine x x 
Methyl-β-D-galactoside x   
Monomethyl glutaric acid x   
Myoinositol   x 
N-α-Acetyl-L-asparagine x   
N-Acetylaspartate x x 
N-Acetyl-D-galactosamine x   
N-Acetyl-DL-methionine x   
N-Acetyl-DL-serine x x 
N-Acetyl-L-alanine x x 
N-Acetyl-L-glutamic acid x x 
N-Acetylneuraminic acid x x 
N-Acetyl-β-D-mannosamine x   
N-Formylglycine   x 
N-Formylmethionine x   
Niacinamide x   
N-Methyl-D-aspartic acid x   
N-Methylhistamine x   
N-Methyl-L-glutamate x x 
Nε,Nε,Nε-Trimethyllysine x   
O-Acetylserine x   
Octopamine  x   
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O-Phosphorylethanolamine x   
Oxoglutaric acid   x 
Palmitic acid   x 
Pantothenic acid x x 
Paraxanthine x   
Petroselinic acid x   
Phosphocreatine x x 
Phosphoenol pyruvate   x 
4-Hydroxyphenylacetic acid  x x 
Pimelic acid x   
Pyridoxamine x   
Pyrocatechol x   
Pyroglutamic acid x x 
Quinic acid   x 
R-(-)-Mandelic acid x   
Ribitol x x 
Riboflavin  x   
S-(5-Adenosyl)-L-methionine x   
S-Adenosylhomocysteine x   
Salsolinol x   
Sarcosine x x 
Spermidine x   
Stearic acid   x 
Suberic acid x x 
Succinic acid   x 
Taurine x x 
Thiamine monophosphate x   
Thymidine x x 
Trigonelline x   
Uracil x x 
Uric acid   x 
Uridine x x 
Urocanic acid x   
Xanthine x x 
Xanthosine x   
Xanthurenic acid x   
Xylitol x x 
α-D-Galactose-1-phosphate x   
α-D-Glucose x x 
α-D-Glucose-1-phosphate x x 
β-Alanine   x 
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Supplementary Table S8.1. Summary of metabolites that were aligned 
and matched across samples in each experimental group. Metabolites 
were aligned using Profinder software (Build 08.00, Agilent, Cheadle, UK); a 
targeted feature extraction was used to align profiled experimental data with 
data in the accurate mass and retention time database containing 469 
intermediary metabolites. Metabolites aligned and matched in both negative 
(n=106) and positive (n=174) polarities are detailed. Feature extraction 
employed a window of theoretical accurate mass ± 10 ppm and retention 
time ± 0.30 min. Allowed species were: H+, Na+ and NH4
+ for positive polarity; 
and H- and CHO2
- for negative polarity. Dimers were allowed for both 
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The body of work presented herein is the most extensive evaluation of the 
impact of nitisinone treatment on the metabolome in humans and mice with 
Alkaptonuria (AKU) using mass spectrometry based techniques. 
 
In reference to the original aims of this work an analytical strategy has been 
established and applied for the evaluation of (i) the serum and urine 
metabolome of patients with AKU and (ii) the urine and cerebrospinal fluid 
(CSF) metabolome of mice with AKU, following treatment with nitisinone. 
Moreover the work presented herein addresses the more specific question 
regarding the impact of nitisinone induced hypertyrosinaemia on 
neurotransmitter metabolism through (i) the quantitative measurement of 
urinary monoamine neurotransmitter metabolites and their related serum 
amino acids in AKU patients, and (ii) the qualitative assessment of 
monoamine neurotransmitters in CSF and brain tissue from a murine model 
of AKU. 
 
Key findings relating to the wider impact of treatment with nitisinone on 
tyrosine metabolism (Figure 9.1), tryptophan metabolism (Figure 9.2) and 
oxidative stress (Figure 9.3) are presented, integrating findings from the 
analysis of serum and urine from AKU patients and, urine, plasma, CSF and 
brain tissue from AKU mice. One of the major observations in the studies 
performed is how a number of metabolic pathways appear to be affected as a 
consequence of nitisinone treatment that are not classically associated with 
AKU and or its treatment with nitisinone. A number of changes in the 
abundance of metabolites relate to the hypertyrosinaemia observed following 
the specific inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD, 
E.C.1.13.11.27), the enzyme proximal to the defect in homogentisate 1,2-
dioxygenase observed in AKU. 
 
Nitisinone-induced hypertyrosinaemia has been reported extensively in AKU 
(Phornphutkul et al., 2002; Suwannarat et al., 2005; Introne et al., 2011; 
Ranganath et al., 2016; Milan et al., 2017; Davison et al., 2018a; Sloboda et 
al., 2019) and has been confirmed herein in urine and serum from AKU 
patients, and plasma, urine, CSF and brain tissue from mice. This finding is 
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highly novel in mouse CSF and brain tissue. Moreover, with the exception of 
human serum (Gertsman et al., 2015a; Gertsman et al., 2015b), this is the 
first study to report this using high resolution mass spectrometry and nuclear 
magnetic resonance spectroscopy.  
 
Moreover the work presented demonstrated a significant increase in 3-(4-
hydroxyphenyl)pyruvic acid (HPPA) (urine only) and 3-(4-
hydroxyphenyl)lactic acid (HPLA) in AKU patients following treatment with 
nitisinone (Figure 9.1). This confirms previous findings (Gertsman et al., 
2015b; Milan et al., 2019), but adds to the picture because for the first time 
changes were also observed in urine and CSF (HPLA only) from AKU mice, 
which is unique to the studies presented herein. The reason for not observing 
HPPA in serum is uncertain and requires further investigation as it has been 
reported to increase following treatment with nitisinone (Gertsman et al., 
2015b; Milan et al., 2019). One may postulate that sample preparation and or 
analytical conditions may have impaired the ability to detect in HPPA. 
Moreover it is uncertain whether this metabolite is labile and thus may 
degrade.  
 
Important findings in relation to the alternative fate of tyrosine observed 
following nitisinone therapy include an increase in the abundance of  
N-acetyl-L-tyrosine and -glutamyl-tyrosine in serum and urine from AKU 
patients. These findings also confirm what has been previously reported by 
Gertsman et al. (2015a), but additionally demonstrate these changes occur in 
urine and CSF from AKU mice. Novel metabolites relating to tyrosine 
metabolism were also observed, including an increase in urinary coumarate. 
Together these metabolites demonstrate an altered route of metabolism to 
facilite the elimination or indeed detoxification of tyrosine in the body, beyond 
the conventional pathways for its catabolism and transformation to other 
biologically important molecules (i.e. thyroid hormones, catecholamines, 
melanin).  
 
Biochemical observations in urine from the studies in mouse and human 
subjects confirm that in fact peripheral catecholamine metabolism is affected 
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following treatment with nitisnone, specifically dopamine and noradrenaline 
metabolism (Figure 9.1). Interestingly all metabolites that were altered 
following treatment with nitisinone had a decreased abundance (Figure 9.1), 
except urinary tyramine, 3-methoxytyramine (3-MT) and mandelic acid, the 
latter also had an increased abundance in serum. The increase in urinary 3-
MT was observed in all AKU patients that received a daily dose of nitisinone 
(1-8 mg) in the suitability of nitisinone in AKU 1 (SONIA-1) trial and those 
patients that attend the National Centre for AKU (NAC), the latter cohort also 
showed an increase in urinary tyramine. Interestingly in the NAC cohort 
where patients had 2 mg of nitisinone every other day (i.e. up to 3 months) 
the increase in 3-MT was not observed. Changes in 3-MT and tyramine were 
not observed in serum samples collected from patients with AKU, or CSF 
samples collected from AKU mice. The exact mechanism for these urinary 
changes is not known.  
 
One may postulate the observed decrease in normetadrenaline, in the short 
term SONIA-1 dosing study may be a consequence of reduced sympathetic 
nerve excitation as subjects were less depressed or anxious, as they are on 
treatment for AKU. Previous studies (Roy et al.,1986a; Roy et al., 1986b; 
Grossman et al., 1999; Hughes et al., 2004) have evaluated the urinary 
concentration of noradrenaline and adrenaline in subjects with depression, 
demonstrating that urinary concentrations of noradrenaline and adrenaline 
were significantly higher in subjects with depression compared to controls. 
This decrease in normetadrenaline was however not observed in patients 
attending the NAC who had metadrenalines evaluated after 3 months. The 
reason for this is unknown, but may relate to the body adapting to the long 
term use of nitisinone such that this change is no longer observed. Moreover 
this was a larger cohort of AKU patients. 
 
The marked increase in urinary 3-MT and tyramine, and decrease in the 
major dopamine metabolite homovanillic acid (HVA) suggest there is an 
altered route of dopamine metabolism, the course of which was not 
elucidated in this study. The increase in mandelic acid in serum and urine, a 
metabolite of vanillylmandelic acid, supports the supposition that there is an 
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altered route of monoamine metabolism. The significance of the latter is 
unknown, but has been reported previously in patients with phenylketonuria 
(Rampini et al., 1974). 
 
It is widely accepted that the metabolism of catecholamine neurotransmitters 
is complex and they have multiple origins including the sympathetic nerves, 
adrenal medulla, brain and mesenteric organs (Eisenhofer et al., 2004), and 
are affected by dietary intake (de Jong, 2009). Importantly it has been 
demonstrated that the concentration of monoamine neurotransmitters in urine 
are dependent on plasma concentration and uptake via organic cation 
transporters in the kidney (Eisenhofer et al., 1996; Graefe et al., 1997), thus 
one may postulate that the changes observed in urine relate to alterations in 
the renal transport, and the intrarenal metabolism of tyrosine following 
treatment with nitisinone, and its respective metabolism to catecholamine 
metabolites.  
 
Beck’s depression inventory II (BDI-II) data included in this study support that 
central metabolism of monoamine metabolites is not altered in patients 
following treatment with nitisinone. This clinical assessment of mood is a 
widely accepted tool in clinical practice, and effectively is a phenotypic 
reflection of dopamine and serotonin neurotransmitter metabolism. Whilst 
BDI-II scores were marginally increased in patients followed for 24 months 
post treatment the majority of patients remained in the minimal depression 
catergory. Moreover these data were not correlated with urinary monoamine 
metabolites. 
 
Encouragingly animal studies did not demonstrate any changes in 
catecholamine neurotransmitter patterns in brain tissue following treatment 
with nitisinone. These studies did however reveal that the trace amine 
tyramine increased following nitisinone treatment. The significance of this 
novel finding is unknown and requires further investigation, previous studies 
have linked trace biogenic amines to a number of psychiatric and 
neurological disorders (Boulton, 1980; Baker et al., 1993; D’Andrea et al., 
2004; D’Andrea et al., 2010). Interstingly the increase in tyramine was not 
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observed in murine CSF, however 1 of its acidic metabolites, 4-
hydroxyphenylacetic acid (HPA) was shown to be increased; this is likely to 
reflect an increased brain turn over of tyramine. This observation also 
requires futher investigation. Additional studies should include the analysis of 
CSF and brain tissue from (1) mice that have been on nitisinone for a longer 
duration than the current study (i.e. 3-6 months) and (2) mice that have had 
long term nitisinone treatment and are then taken off it (i.e. for 1 month). This 
would establish whether the findings observed in brain tissue in this study 
were a consequence of the short term exposure to nitisinone (i.e. 
hypertyrosinaemia), and it would show if the changes observed dissappear 
when nitisinone treament is stopped. Furthermore due to the analytical 
limitations reported herein regarding the measurement of monoamine 
neurotransmitters in CSF using liquid chromatography quadrupole time of 
flight mass spectrometry (LC-QTOF-MS), an alternative more sensitive 
quantitative approach should be adopted for the analysis of these 
compounds that are present at low picomolar to nanomolar abundance (e.g. 
liquid chromatography tandem mass spectrometry, (LC-MS/MS)). 
 
A reassuring finding from the work presented herein is that the aromatic 
amino acids phenylalanine and tryptophan did not change following treament 
with nitisinone in serum from patients (Chapter 4) and CSF from mice 
(Chapter 8), supporting that hypertyrosineaemia does not alter uptake or 
metabolism of these amino acids. This is particularly important as tryptophan 
is an important substrate for the neurotransmitter serotonin. Together these 
findings discredit what calculated amino acid ratios (Lieberman, 1999; 
Ravaglia et al., 2004) suggest herein (Chapter 4) with respect to 
neurotransmitter metabolism (i.e. that amino acid availability to the brain may 
be reduced, with the exception of tyrosine). Whilst this is so treatment with 
nitisinone clearly has an impact on tryptophan metabolism as the abundance 
of several urinary and serum tryptophan metabolites were shown to decrease 
in patients following treatment with nitisinone, with the exception of 
xanthenuric acid and indole-3-lactate (I-3-L), which increased in urine and 




Figure 9.1. Summary of metabolite changes relating to tyrosine and catecholamine neurotransmitter metabolism observed 
in biological fluids analysed in patients and mice with AKU following treatment with nitisinone. Red/blue bold text – denotes 
increase/decrease in abundance in human urine and serum; red/blue non-bold text denotes increase/decrease in abundance in 
human urine; blue italicised text denotes decrease in abundance in mouse urine; * – additionally mouse brain, plasma, urine and 
CSF; ** – additionally mouse CSF; 
#
 – additionally in mouse urine; 
†
 – additionally mouse brain tissue; 
††
 – additionally mouse 
plasma; ## – only in SONIA-1 (Chapter 5); PAH – phenylalanine hydroxylase; TyH – tyrosine hydroxylase; COMT – catechol-O-
methyltransferase;  MAO – monoamine oxidase; PNMT – phenylethanolamine-N-methyltransferase; DBH – dopamine-β-
hydroxylase; AADC – aromatic L-amino acid decarboxylase; TAL – tyrosine ammonia lyase; -GT – -glutamyltranspeptidase; 
HPPD – 4-hydroxyphenylpyruvate dioxygenase; AT – acetyl transferase; L-DOPA – L-3,4-dihydroxyphenylalanine; 3-MT – 3-
methoxytyramine; DHPG – 3,4-dihydroxyphenylglycol.  
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The exact mechanism to explain these changes is uncertain and little can be 
gained from the indiscriminate use of the kynurenine to tryptophan ratio in 
urine or serum to assess changes in indole-2,3-dioxygenase activity (Badawy 
et al., 2019). To this end it is not clear whether these findings are (1) an ‘off 
target’ effect of nitisinone, (2) a consequence of nitisinone reducing 
homogentisic acid (HGA) and thus reducing oxidative stress and or (3) a 
consequence of a metabolite that increases due to the action of nitisinone 
(i.e. keto acids are thought to upregulate tryptophan amino transferase (TAT) 
activity, Figure 9.2) (Lees et al., 1973; Gertsman et al., 2015b). It is plausible 
that the latter leads to the majority of changes observed herein, as the 
increase in I-3-L observed in serum suggests that there is an increased 
metabolism of tryptophan via the mechanism proposed above. One may 
hypothesise that the down stream effect of this is that there is less surplus 
tryptophan available for metabolism via the other major metabolic routes it 
takes to produce a variety of biologically active compounds (e.g. serotonin, 
tryptamine, kynurenines, and NAD+), and as a consequence urinary excretion 
of tryptophan and a number of related metabolites is reduced.  
 
Additionally the increase in I-3-L may also relate to the reduced oxidative 
stress that has been proposed to occur as a consequence of lowering HGA 
(Braconi et al., 2010; Braconi et al., 2011; Millucci et al., 2014; Braconi et al., 
2015; Davison et al., 2016), thus leading to an increase in the activity of gut 
microbiota and increased formation of I-3-L. Interestingly a reduction in 
urinary indoxyl sulphate was observed herein, a metabolite well known to 
originate from colonic microbiota (Wikoffa et al., 2009), therefore the change 
observed is not expected. One potential reason for this maybe related to the 
increased metabolism of tryptophan to I-3-L and as a consequence there 
maybe less tryptophan available for metabolism to indoxyl sulphate. A 
reduction in indoxyl sulphate may be percieved as beneficial as it has been 
implicated as a contributor to the progression of renal and vascular disease. 
Studies have also suggested that it may also have adverse effects on bones 




The significance of the increase in urinary xanthenuric acid in AKU patients 
following treatment with nitisinone is unknown. This cannot be easily 
explained by the accumulation of metabolites proximal to xanthenuric acid as 
they are either lower or unchanged, which would not lead to its increased 
formation. Moreover this finding cannot be explained by liver disease or 
vitamin B6 deficiency, which has prevously been associated with increased 
urinary xanthenuric acid (Rossouw et al., 1978; Ueland et al., 2015).  
 
Another interesting observation was that the abundance of the urinary 
serotonin metabolite, 5-hydroxyindole acetic acid, decreased following a 8 
mg daily dose of nitisinone in the SONIA-1 study (Chapter 5). This was not 
seen in patients attending the NAC who received long term treatment with 
nitisinone (2 mg daily dose) (Chapter 6). The reason for this is unknown and 
the long term metabolic impact of this will be re-assessed in the SONIA-2 
clinical trial (ClinicalTrials.gov Identifier: NCT01916382) where patients 
received a 10 mg daily dose of nitisinone for 4 years. 
 
The rationale above is likely to be an oversimplification as tryptophan 
metabolism is complex involving the gut and liver, and is distributed into 
peripheral circulation for transport to the brain, heart, and skeletal muscle, 
where the free fraction is of biological importance (Cervenka et al., 2017). 
Moreover an important contributor to tryptophan metabolism is gut 
microbiota, which are known to generate indole compounds. The increase in 
indoles observed herein may be beneficial as they act as hydroxyl radical 
scavengers, neuroprotectants, and selective human aryl hydrocarbon 
receptor agonists attenuating inflammation (Zelante et al., 2013).  
 
The wider consequence of the changes in tryptophan metabolism are of 
unknown significance. Of relevance to the CNS, previous studies have 
shown alterations in tryptophan metabolism in stress-related depression, 
schizophrenia, Alzheimer’s and Parkinson’s diseases (Schwarcz et al., 
2017). Several kynurenine metabolites have been implicated including 
quinolinic acid, which is thought to be an important contributor to neuronal 
excitotoxicity (Stone et al., 1981; Schwarcz et al., 2017);                               
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3-hydroxykynurenine, anthranilic acid and 3-hydroxyanthranilic acid have 
also been shown to induce neuroinflammation by direct generation of free 
radical species even under physiological conditions and thus contribute to 
oxidative stress (Okuda et al., 1998). Herein none of these metabolites were 
altered; however the decrease in the urinary metabolite 4-hydroxyquinollinic 
acid may be a reflection of reduced oxidative stress following treatment with 
nitisinone. 
 
In contrast, kynurenic acid is thought to have neuroprotective properties 
through its antagonistic action on glutamate receptors (Stone et al., 1981). 
The decrease in kynurenine observed herein may appear to be detrimental 
based on this, however one may also see this as beneficial as lower 
kynurenine may mean there is less substrate for the formation of the toxic 
metabolites 3-hydroxykynurenine, anthranilic acid, and 3-hydroxyanthranilic 
acid; which as alluded to earlier can induce oxidative stress. 
 
As changes to tryptophan metabolism have been observed peripherally one 
cannot relate changes directly to the CNS, but should be mindful that 
dysregulation of kynurenine metabolism in peripheral tissues can also have a 
strong effect on the CNS, resulting in complications such as anxiety and 
depression (Cervenka et al., 2017). 
 
It has already been highlighted that some of the changes observed in the 
biological matrix studies may relate to changes in the redox state of the body 
that occur as a consequence of the reduced HGA observed following 
treatment with nitisinone (Figure 9.3). Additional changes to the abundance 
of metabolites reported herein were observed in purine metabolism (Figure 
9.3 (A)), glutathione and intermediary metabolism (Figure 9.3 (B)) and the gut 





Figure 9.2. Summary of metabolite changes relating to tryptophan and serotonin neurotransmitter metabolism observed in 
biological fluids analysed in patients and mice with AKU following treatment with nitisinone. Red/blue – denotes 
increase/decrease in abundance; bold text – refers to change in human serum; non-bold refers to human urine; *- change also 
observed in mouse urine; **– only observed in SONIA-1 study at a dose of 8 mg daily nitisinone (Chapter 5); AADC – aromatic L-
amino acid decarboxylase; AFAH – aryl-formylamine amidohydrolase; ALDH – aldehyde dehydrogenase; KAT – kynurenine 
aminotransferase; KH – kynurenine hydroxylase; MAO – monoamine oxidase; TDO – tryptophan dioxygenase; IDO – indole 
dioxygenase; TPH – tryptophan hydroxylase; KN – kynureninase; NMT – N-methyltransferase; TAT – tryptophan amino transferase 
(proposed enzyme keto acids inhibit). 
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A decrease in the abundance of several metabolites relating to purine 
metabolism were observed, principally in urine with the exception of caffeate 
which increased. Purines are derived from both endogenous metabolism and 
exogenous dietary intake, with the uric acid being the final oxidation 
production of metabolism. Increases in circulating uric acid concentrations 
are widely reported in gout, and have been correlated with cardiovascular 
disease, hypertension, and renal disease (Chen et al., 2016). It has been 
postulated that hyperuricemia contributes to the progression of 
cardiovascular disease through oxidative stress, systemic inflammation, and 
endothelial dysfunction (Borghi et al., 2016). Thus one may hypothesise that 
a reduction in metabolites may reduce oxidative stress. 
 
Patients included in this study were not on uric acid-lowering medication, 
however they were on a protein-restricted diet which may have contributed to 
the decrease in metabolite abundance observed. A more plausible 
explanation relates to changes in the oxidative state of the body. Urinary 
allantoin, which was lower following nitisinone treatement, has previously 
been suggested as a marker of oxidative stress (Marrocco et al., 2017); one 
may postulate that the decreases observed herein are a reflection of reduced 
oxidative stress in the face of lower HGA concentrations (Braconi et al., 
2010; Braconi et al., 2011; Millucci et al., 2014; Braconi et al., 2015; Davison 
et al., 2016). The decrease may also be a consequence of the increase in 
caffeate observed, which is known to inhibit the activity of xanthine oxidase 
(EC 1.17.3.2), the enzyme responsible for the metabolism of hypoxanthine 
and xanthine (Chang et al., 1994). The reason for seeing this increase in 
caffeate is unknown, but one may postulate that it may be an ‘off target’ 
effect of nitisinone. Nevertheless the increase in caffeate may be benefical to 





Figure 9.3. Summary of metabolite changes proposed to relate to 
oxidative stress observed in biological fluids analysed from patients 
and mice with AKU following treatment with nitisinone. (A) Purine 
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metabolism; (B) Glutathione and intermediary metabolism and (C) Gut 
microbiome. Red/blue text – indicates increase/decrease in abundance; bold 
text – change observed in serum from AKU patients; bold italicised – 
change observed in serum and urine from AKU patients; non bold italicised – 
change observed in AKU mouse urine; *– change also observed in AKU 
mouse urine; ** – increase observed in mouse urine; *** – decrease 
observed in serum using HPLC (Chapter 4) not LC-QTOF-MS (Chapters 3). 
XO – xanthine oxidase; IMPDH – inosine monophosphate dehydrogenase; 
AMPDH – adenosine monophosphate dehydrogenase; PDE – 
phosphodiesterase; 5-NT – 5-nucleotidase; PNP- purine nucleotide 
phosphorylase; HGPRT – hypoxanthine guanine phosphoribosyltransferase; 
ROS – reactive oxygen species; GTa – glutaminase; GS – glutamine 
synthetase; GDH – glutamate dehydrogenase; GR – glutathione reductase; 
GP – glutathione peroxidase; -GT – -glutamyltranspeptidase. 
 
 
The increase in -glutamyl-tyrosine in urine, serum and CSF from AKU 
patients and mice suggests that glutathione metabolism and the redox state 
of the cell (Griffith et al., 1979; Zhang et al., 2009) are altered following 
treatment with nitisinone (Figure 9.3 (B)). One may hypothesise that the 
reduced burden on the glutathione cycle improves glutathione availability, 
thus enabling the transfer of the glutamyl moiety from glutathione to tyrosine 
(Griffith et al., 1979; Zhang et al., 2009). Changes in the abundance of some 
citric acid metabolites were also observed in serum from AKU patients, and 
urine from AKU mice following nitisinone treatment, suggesting that 
intermediary energy metabolism is likely to be an ‘off target’ effect of 
treatment with nitisinone.  
 
Previously Hallan et al. (2017) reported on the clinical utility of measuring 
citric acid metabolites in a cohort of non-diabetic patients with chronic kidney 
disease, suggesting that their measurement in serum and urine are a direct 
reflection of citric acid cycle activity. Herein serum α-ketoglutaric, glutamine 
and succinic acid decreased in AKU patients (Figure 9.3 (B)), suggesting that 
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metabolites may be diverted to facilitate glutathione production and recycling. 
Interestingly a contradictory picture was observed in mouse urine, as  
α-ketoglutaric acid and isocitrate were increased. This relationship requires 
further investigation, but one may postulate serum is a better reflection of 
internal homeostasis, moreover the changes in mouse urine were observed 
in a random spot sample and not a complete 24 h sample, like in AKU 
patients. Further investigations are required to better understand this 
relationship as it is clear that citric acid metabolites have a key role to play in 
health and disease (Martínez-Reyes et al., 2020). 
 
The increase in HPA in serum and urine following nitisinone treatment is a 
curious finding in humans as it has not been reported to date. Unlike in the 
CSF, it is likely to originate from gut microbiota (Liu et al., 2016), and again 
one may hypothesise that the increase observed is a consequence of less 
oxidative stress following nitisinone, which increased microbiotic metabolism.  
 
The changes in 4-hydroxybenzaldehyde and benzaldehyde are highly novel 
findings and it is possible they are related to benzoquinones; one may 
postulate they are intermediates in the formation of ochronotic pigment 
observed in AKU. Interestingly recent reports have suggested that there are 
therapeutic benefits from benzaldehyde compounds (Lee et al., 2010; Moon 
et al., 2012; Kong et al., 2014; Lee et al., 2014). 
 
A number of other changes in the abundance of urinary and serum 
metabolites were observed in the studies presented here. Evaluation of their 
significance presents a significant challenge as there is no obvious or 
theoretical relation to the action of nitisinone or AKU as a disease entity. To 
this end one may postulate that many of these are ‘off target’ effects of 
nitisinone. These include glycocholate, homoserine, mevalolactone and 
allothreonine in serum from AKU patients; 5-valeroclactone, creatine, 
maleimide, N-acetylglycine in mouse urine; ethylmalonic acid,  
2-hydroxybutyric acid, L-threonine, methyl vanillate in urine from AKU 
patients and 2-hydroxy-4-(methylthio)butyric acid which was observed in 
urine from mice and AKU patients.  
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There are some confounding factors to consider in the body of data 
presented in this thesis. Firstly in relation to the impact of hypertyrosinaemia 
on neurotransmitter metabolism; analysis of serum and urine samples 
following treatment with nitisinone cannot give a direct answer to this 
question. It can however provide invaluable indirect evidence, and 
reassuringly the findings of these analyses in this study are corroborated by 
the observations from the direct analysis of CSF and brain tissue from a well 
characterised mouse model of AKU. The findings of the latter are however 
incomplete owing to the limited analytical sensitivity of the LC-QTOF-MS 
method used for the analysis of CSF. Future studies should consider the use 
of quantitative LC-MS/MS methodology as it is a more sensitive technique for 
the measurement of neurotransmitter compounds present at low picomolar to 
nanomolar concentrations. This will however be met with its own challenges 
as method validation and sample analysis will be limited by the volume of 
CSF that can be collected from mice. It is also unlikely that ethical permission 
will be sought to collect CSF from patients with AKU as they do not 
demonstrate clinical features of depression or altered mood following 
treatment with nitisinone. Also as these patients have complex 
musculoskeletal comorbidities sample collection is high risk and technically 
challenging. 
 
Secondly, whilst this is the most comprehensive evaluation of the 
metabolome reported in AKU following treatment with nitisinone additional 
work is required to provide a better understanding of the ‘off target’ effects of 
this drug. It is clear that its action in blocking the activity of HPPD has wider 
metabolic consequences beyond hypertyrosinaemia, some of which are 
surprising. Moreover the work presented herein, with the exception of urine 
samples from the SONIA-1 study, has looked at the impact of treatment with 
nitisinone in patients that have attended the NAC without simultaneously 
studying a group of AKU patients that did not receive treatment (i.e. no 
treatment control group). To this end one may speculate that some of the 
changes observed may relate to the evolution of AKU as a disease and not 
as a consequence of nitisinone treatment.  
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Additionally whilst metabolomics data were acquired using non-targeted LC-
QTOF-MS methods, data analysis was performed using a targeted feature 
extraction method. Though this method was comprehensive covering a broad 
range of metabolites it precluded from the identification of novel metabolites 
that may have been observed following treatment. Future studies should 
include the non-targeted interrogation of data.  
 
Looking to the future it is hoped that the novel findings presented herein, as 
well as its shortcomings will be addressed in the SONIA-2 clinical trial 
(ClinicalTrials.gov Identifier: NCT01916382), which was completed recently. 
This trial includes the largest cohort to date of AKU patients from Europe 
(excluding the United Kingdom), which have been randomised to receive no 
treatment or a 10 mg daily dose of nitisinone over a 4 year period. It is hoped 
that this invaluable trial and the work presented herein will improve the lives 
of patients with AKU, and that the analytical platform created through AKU for 
clinical metabolomics in Liverpool will be applied to study the metabolic basis 
of other diseases. It seems very fitting to finish by quoting Archibald Garrod 
('The Scientific Spirit in Medicine: Inaugural Sessional Address to the 
Abernethian Society', St. Bartholomew's Hospital Journal, 1912 20:19): 
 
“Nevertheless, scientific method is not the same as the scientific spirit. The 
scientific spirit does not rest content with applying that which is already 
known, but is a restless spirit, ever pressing forward towards the regions of 
the unknown, and endeavouring to lay under contribution for the special 
purpose in hand the knowledge acquired in all portions of the wide field of 
exact science. Lastly, it acts as a check, as well as a stimulus, sifting the 
value of the evidence, and rejecting that which is worthless, and restraining 
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